TREATMENT OF INFECTIONS

TRAITEMENT D'INFECTIONS

English Abstract

The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each -X0D- is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.

French Abstract

La présente invention concerne, entre autres aspects, un conjugué ou un sel pharmaceutiquement acceptable de celui-ci, ou une composition pharmaceutique comprenant ledit conjugué ou un sel pharmaceutiquement acceptable de celui-ci utilisée dans le cadre d'un procédé de prévention ou de traitement d'une infection, ledit conjugué étant insoluble dans l'eau et comprenant une fraction polymère-Z à laquelle une pluralité de fractions -L2-X0D-L1-D sont conjuguées de manière covalente, chaque -D étant indépendamment une fraction antibiotique ; chaque -L1- étant indépendamment une fraction de liaison à laquelle -D est conjugué de manière covalente et réversible ; chaque X0D- étant indépendamment soit absent, soit une liaison, et chaque -L<sp />2- étant indépendamment une liaison chimique ou une fraction d'espaceur.

Claims

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
271
Claims
1. A
conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
in a method of preventing or treating an infection, wherein said conjugate is
water-
insoluble and comprises a polymeric moiety -Z to which a plurality of
moieties -1_,2-XOD_-.- 1_
L D are covalently conjugated,
wherein
each -D is independently an antibiotic moiety;
each -Ll- is independently a linker moiety to which -D is covalently and
reversibly conjugated;
each -X D- is independently absent or a linkage; and
each -L2- is independently absent or a spacer moiety.
2. The
conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
of claim
1, wherein the infection is an infection in a body compartment.
3. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
of claim
1 or 2, wherein the infection is a joint infection.
4. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 3, wherein the infection is an infection related to
a surgical
implant.
5. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of claim 4, wherein the surgical implant is selected from the group consisting
of pins,
rods, screws, artificial joints, mesh, clips, sutures, wires, tubes,
catheters, pumps,
filters, prostheses, plates, fasteners, washers, bolts, seeds, beads, staples,
nails, shunts,
cuffs, buttons, ports, cement, fixators, stents, fillers, wax, wraps, weights,
stimulators,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
272
anchors, expanders, guidewires, fillers, polymers, film, fixators, drains,
lines and
cones.
6. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of claim 4 or 5, wherein the surgical implant is an artificial joint.
7. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 3 to 6, wherein administration occurs via intraarticular
injection
into the infected joint.
8. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 3 to 7, wherein the infected joint is a synovial joint.
9. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 8, wherein the method of preventing or treating a
joint
infection also comprises the step of preventing the formation of a biofilm or
eradicating an existing biofilm.
10. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 9, wherein -Z is a hydrogel.
11. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 10, wherein -Z is degradable.
12. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 10, wherein -Z is a hyaluronic acid-based or PEG-
based
hydrogel.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
273
13. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 12, wherein each -D is independently selected from
the
group consisting of aminoglycosides, tetracycline antibiotics, amphenicols,
pleuromutilins, macrolid antibiotics, lincosamides, steroid antibiotics,
antifolate
antibiotics, sulfonamides, topoisomerase inhibitors, quinolones,
fluoroquinolones,
nitroimidazole antibiotics, nitrofuran antibiotics, rifamycins, glycopeptides,

penicillins, cephalosporins, monobactams, beta-lactamase inhibitors, polymyxin
antibiotics, lipopeptide antibiotics, oxazolidinon, antimicrobial peptides,
porphyrins,
azole antifungals, polyenes, antiprotozoal drugs, fosfomycin, cycloserine, and

bacitracin.
14. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 13, wherein -D is daptomycin.
15. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of claim 14, wherein -LI- is connected via the primary amine of the ornithine
side
chain.
16. The conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
for use
of any one of claims 1 to 15, wherein -L1- is of formula (II):
R3 a -A-
-,-3 R 1 R i a
3 N X2
(II)
2 2a 1
R -i , - H* 0
,
wherein the dashed line indicates the attachment to a nitrogen, hydroxyl or
thiol
of -D;
-X- is selected from the group
consisting
of _c. (R4R4a)_,
-N(R4)-, -0-, _C(R4R4a)_C(R5R5a)_,
-C(R5R5a)-

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
274
C(R4R4a)-, -C(R4R4a)-N(R6)-, -N(R6)-C(R4R4a)-, -C(R4R4a)-0-, -0-C(R4R4a)-,
and -C(R7R7a)-;
X1 is selected from the group consisting of C and S(0);
-X2- is selected from the group consisting of -C(R8R8a)- and -C(R8R8a)-
C(R9R9a)-;
=X 3 =
is selected from the group consisting of =0, =S, and =N-CN;
_Ria,
_R2a, _R4, _R4a, _R5, _R5a, _R6, _R8, _R8a, _R9 and -R9a are
independently selected from the group consisting of -H and Ci_6 alkyl;
-R3 and -R3a are independently selected from the group consisting of -H and
C16
alkyl, provided that in case one of -R3 and -R3a or both are other than ¨H,
they are
connected to the nitrogen atom to which they are attached through an sp3-
hybridized carbon atom;
-R7 is selected from the group consisting of -N(R10R10a) and -NR10-(C=0)-R11;
-R7a, -R10, -ea and -R11 are independently of each other selected from the
group
consisting of -H and C1_6 alkyl;
alternatively, one or more of the pairs -Riai_R4a, _Rla/_R7a,
_R4aii_Rsa
and -R8a/-R9a form a chemical bond;
alternatively, one Or more of
the
pairs -R1/-Ria, -R2/_R2a, _R4/_R4a, _R5/_Rsa, _R8/_¨K 8a
and -R9/-R9a are joined
together with the atom to which they are attached to form a C3_10 cycloalkyl
or 3-
to 10-membered heterocyclyl;
alternatively, one or more of the pairs -R1/-R4, -R1/-R5, -R1/-R6, -R1/-R7a,
-R4/-R5, -R4/-R6, -R8/-R9 and -R2/-R3 are joined together with the atoms to
which
they are attached to form a ring A;
alternatively, R3/R3a are joined together with the nitrogen atom to which they
are
attached to form a 3- to 10-membered heterocycle;
A is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl,
tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-
membered heterobicyclyl; and
wherein -L1- is substituted with -XOD-L2- and wherein -L1- is optionally
further
substituted, provided that the hydrogen marked with the asterisk in formula
(II) is
not replaced by -X D-L2- or a substituent.
17.
A water-insoluble conjugate comprising a plurality of antibiotic moieties -D
covalently and reversibly bound to a polymeric moiety, wherein the antibiotic
moieties

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
275
are released from the polymeric moiety and wherein a single intra-articular
injection
provides a concentration of said antibiotic in the intra-articular compartment
of at least
1 g antibiotic/ml synovial fluid for at least 3 days.
18. The conjugate of claim 17, wherein the concentration in the intra-
articular
compartment is at least 10 g antibiotic/ml synovial fluid.
19. The conjugate of claim 17 or 18, wherein the concentration in the intra-
articular
compartment is at least 50 idg antibiotic/ml synovial fluid.
20. The conjugate of any one of claims 17 to 19, wherein the concentration
in the infra-
articular compartment is at least 100 lug antibiotic/ml synovial fluid.
21. The conjugate of any one of claims 17 to 20, wherein the concentration
is provided for
at least 4 days.
22. The conjugate of any one of claims 17 to 21, wherein the concentration
is provided for
at least 5 days.
23. The conjugate of any one of claims 17 to 22, wherein -D is selected
from the group
consisting of aminoglycosides, tetracycline antibiotics, amphenicols,
pleuromutilins,
macrolid antibiotics, lincosamides, steroid antibiotics, antifolate
antibiotics,
sulfonamides, topoisomerase inhibitors, quinolones, fluoroquinolones,
nitroimidazole
antibiotics, nitrofuran antibiotics, rifamycins, glycopeptides, penicillins,
cephalosporins, monobactams, beta-lactamase inhibitors, polymyxin antibiotics,
lipopeptide antibiotics, oxazolidinon, antimicrobial peptides, antimicrobial
proteins,
porphyrins, azole antifungals, polyenes, antiprotozoan drugs, fosfomycin,
cycloserine,
and bacitracin.
24. The conjugate of any one of claims 17 to 23, wherein -D is a
lipopeptide antibiotic.
25. The conjugate of any one of claims 17 to 24, wherein -D is daptomycin.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
276
26. A pharmaceutical composition comprising the conjugate of any one of
claims 17 to 25
and at least one excipient.
27. The conjugate of any one of claims 17 to 25 or the pharmaceutical
composition of
claim 26 for use as a medicament.
28. The conjugate of any one of claims 17 to 25 or the pharmaceutical
composition of
claim 26 for use in the treatment of a joint infection.
29. The conjugate of use of claim 28, wherein the joint infection is a
joint infection related
to a surgical implant.
30. The conjugate for use of claim 29, wherein the surgical implant is an
artificial joint.
31. The conjugate for use of any one of claims 28 to 30, wherein
administration occurs via
intra-articular administration.
32. A sustained-release compound or a pharmaceutically acceptable salt
thereof or a
pharmaceutical composition comprising said compound or its pharmaceutically
acceptable salt comprising a plurality of antibiotic moieties -D or antibiotic
molecules
D-H or D-OH, wherein the antibiotic moieties or molecules are released from
said
sustained-release compound and provide a concentration in the intra-articular
compartment of said antibiotic that is at least 1.1-fold above the minimal
biofilm
eradicating concentration of the respective antibiotic for at least 3 days
after a single
intra-articular injection.
33. The sustained-release compound of claim 32, wherein the concentration
is at least 1.3-
fold above the minimal biofilm eradication concentration of the respective
antibiotic
after a single intra-articular injection.
34. The sustained-release compound of claim 32 or 33, wherein the sustained-
release
compound is water-insoluble.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
277
35. The sustained-release compound of any one of claims 32 to 34, wherein -
D is selected
from the group consisting of aminoglycosides, tetracycline antibiotics,
amphenicols,
pleuromutilins, macrolid antibiotics, lincosamides, steroid antibiotics,
antifolate
antibiotics, sulfonamides, topoisomerase inhibitors, quinolones,
fluoroquinolones,
nitroimidazole antibiotics, nitrofuran antibiotics, rifamycins, glycopeptides,
penicillins, cephalosporins, monobactams, beta-lactamase inhibitors, polymyxin

antibiotics, lipopeptide antibiotics, oxazolidinon, antimicrobial peptides,
antimicrobial
proteins, porphyrins, azole antifungals, polyenes, antiprotozoal drugs,
fosfomycin,
cycloserine, and bacitracin.
36. The sustained-release compound of any one of claims 32 to 35, wherein -
D is a
lipopeptide antibiotic.
37. The sustained-release compound of any one of claims 32 to 36, wherein -
D is
daptomycin.
38. The sustained-release compound of any one of claims 32 to 37, wherein -
D is
embedded in a carrier.
39. The sustained-release compound of any one of claims 32 to 38, wherein -
D is
covalently conjugated to a carrier.
40. The sustained-release compound of any one of claims 32 to 39, wherein -
D is
reversibly and covalently conjugated to a carrier.
41. A pharmaceutical composition comprising the sustained-release compound
of any one
of claims 32 to 40 and at least one excipient.
42. The sustained-release compound of any one of claims 32 to 40 or the
pharmaceutical
composition of claim 41 for use as a medicament.
43. The sustained-release compound of any one of claims 32 to 40 or the
pharmaceutical
composition of claim 41 for use in the treatment of a joint infection.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
278
44. The sustained-release compound or the pharmaceutical composition for
use of claim
43, wherein the joint infection is a joint infection related to surgical
implants.
45. The conjugate for use of claim 44, wherein the surgical implant is an
artificial joint.
46. The conjugate for use of any one of claims 43 to 44, wherein
administration occurs via
intra-articular administration.

Description

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
1
Treatment of infections
The present invention relates among other aspects to a conjugate or a
pharmaceutically
acceptable salt thereof or a pharmaceutical composition comprising said
conjugate or its
pharmaceutically acceptable salt for use in a method of preventing or treating
an infection,
wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z
to which a
plurality of moieties -1.2-X0DL _, 1_
D are covalently conjugated, wherein each -D is
independently an antibiotic moiety; each -L1- is independently a linker moiety
to which -D is
covalently and reversibly conjugated; each -X 13- is independently absent or a
linkage and
each -L2- is independently either a chemical bond or a spacer moiety.
The growing threat of untreatable infections caused by multi-drug resistant
(MDR) pathogens
is considered amongst the most significant challenges to public health systems
worldwide. As
bacteria and fungi are found to becoming less susceptible to the treatment
with antibiotic
compounds, the risk of severe and life-threatening chronic infections
increases and challenges
today's standard of care that suffers from a relative gap in therapeutic
innovations.
Recently, new studies have revealed the ability of relevant pathogens to
aggregate as coherent
clusters of bacterial cells embedded in a matrix of proteins and mucus, a so-
called biofilm. It
has been shown that bacterial biofilms can form preferably on foreign
surfaces, such as
implants and (necrotic) tissue, or can be embedded in host material. Biofilms
exhibit an
extreme resistance to antibiotics, and a high capacity to evade the host
defense. The
eradication of mature biofilm requires magnitudes higher antibiotic drug
levels with
concentrations 500 to 1000x above the minimal inhibitory concentration (MIC)
for planktonic
bacteria. However, often the required bactericidal concentration to defeat
biofilm cannot
reliably be achieved in all tissues when the drug is given by intravenous (IV)
or oral route.
The relative toxicity of antibiotic compounds, their short half-life and
potentially low
vascularization at the site of infection require a new therapeutic strategy to
ensure successful
antimicrobial treatment (Bjarnsholt T. et al., Nature Reviews Drug Discovery
2013:791-808).
Given the huge impact on patient morbidity and mortality, and the significant
health-
economic burden of chronic infections, it is a surprising fact that more
effective treatment
options aiming at biofilm eradication have not yet been developed.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
2
For example, the shortcomings of the current anti-infectives therapy can be
observed with the
treatment of prosthetic joint infections (PJI) following a total or partial
joint replacement
surgery (arthroplasty). PJI of the hip and knee result in significant
morbidity and mortality
when they do occur. Current management consists of a combination of either
single- or two-
stage exchange of the prosthesis and/or exchange of polymer components with IV
antibiotics
(4-6 weeks) and intraoperative debridement of the joint prior to
reimplantation. However,
failure rate, morbidity, and expense associated with current management are
high, especially
if the infection involves resistant pathogens and/or osteomyelitis. PJI
represent a high
economic burden with US$ >5 billion annual cost and a predicted increase in
the incidence
rate (Anthony et al., Infectious Diseases: Research and Treatment 2015:8 17-
23).
Several attempts of localized anti-infective treatments are known in the
field, however,
surprisingly little progress has been made to improve the rate of prosthetic
infections or treat
the infected joints. Most commonly used preparations consist of poly(methyl
methacrylate)
(PMM) cements that contain 5-10% (m/m) of antibiotic compound or combinations
of
antibiotic compounds in the powder mix. Often, cements are used for the
fixation of the
implant to the bone during arthroplasty. During two-stage revision surgery,
cements are
inserted as a spacer, before re-implantation of the secondary orthopedic
device. When applied
during the surgical procedure, they transiently release certain quantities of
the antibiotic
ingredient (Joseph et al., Journal of the American Academy of Orthopedic
Surgeons
2003:11(1) 38-47).
However, antibiotic cement mixtures exhibit significant shortcomings that may
explain why a
real breakthrough in the clinical management of biofilm related infections has
not yet been
achieved. For example, little reliability of antibiotic elution has been
reported, with release
rates in the range of hours or many months making the treatment success
somewhat
unpredictable (Patti et al., Orthopedics 211:34(3) 210-218). Upon elution,
changes in the
mechanical properties of cements were observed causing substantial risk of
implant loosening
and the need for revision surgery. A prolonged elution of sub-therapeutic
doses of the
antibiotic compound are reported to promote bacterial drug resistance
(Hinarejos et al., World
Journal of Orthopedics 2015:6(11) 877-885). Given the relative chemical
instability of
antibiotic compounds, such as vancomycin, daptomycin, gentamicin, tobramycin
and others,
exposure to high temperature as occurring during preparation of cement
mixtures or
physiological conditions quickly degrades commonly used antibiotic compounds
and thus

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
3
substantially impacting their efficacy (Bistolfi et al., ISRN Orthopedics
Volume 2011 1-8
(2011)). As the cements represent permanent foreign surfaces, they exhibit an
intrinsic risk
for the formation of novel biofilms and thereby delaying cure of the
infections or worsening
of symptoms (Bertazzoni et al., Anaerobe 2011:17(6) 380-383). Furthermore, as
low amount
of antibiotics below bactericidal levels are released at later time points,
the risk of formation
of antibiotic resistant biofilm strains exists, which potentially can worsen
the therapeutic
outcome. Recently, antibiotic impregnated PMM cement spacers have been
associated with
renal failure and allergic reactions (Runner et al., Arthroplasty Today
2017:4(1) 51-57).
Amongst the most relevant downsides of commonly used cements is their non-
degradability,
requiring surgical procedure for removal and the risk of providing a surface
for biofilm
formation.
Currently, there is no product approved or on the market that offers better
therapeutic success
by overcoming the insufficiencies described above.
In summary, there is a need for a more efficacious treatment of infections.
It is an object of the present invention to at least partially overcome the
above-described
shortcomings.
This object is achieved with a conjugate or a pharmaceutically acceptable salt
thereof or a
pharmaceutical composition comprising said conjugate or its pharmaceutically
acceptable salt
for use in a method of preventing or treating an infection, wherein said
conjugate is water-
insoluble and comprises a polymeric moiety -Z to which a plurality of moieties
-L2-xoD_Li_D
are covalently conjugated,
wherein
each -D is independently an antibiotic moiety;
each -LI- is independently a linker moiety to which -D is covalently and
reversibly
conjugated;
each -X D- is independently absent or a linkage; and
each -L2- is independently absent or a spacer moiety.
This object is also achieved with a water-insoluble conjugate or a
pharmaceutically acceptable
salt thereof or a pharmaceutical composition comprising said conjugate or its

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
4
pharmaceutically acceptable salt comprising a plurality of antibiotic moieties
-D covalently
and reversibly bound to a polymeric moiety, wherein the antibiotic moieties
are released from
the polymeric moiety and wherein a single intra-articular injection provides a
concentration of
said antibiotic in the intra-articular compartment of at least 1 1,1g
antibiotic/ml synovial fluid
for at least 3 days.
This object is also achieved with a sustained-release compound or a
pharmaceutically
acceptable salt thereof or a pharmaceutical composition comprising said
compound or its
pharmaceutically acceptable salt comprising a plurality of antibiotic moieties
-D or antibiotic
molecules D-H or D-OH, wherein the antibiotic moieties or molecules are
released from said
sustained-release compound and provide a concentration in the intra-articular
compartment of
said antibiotic that is at least 1.1-fold above the minimal biofilm
eradicating concentration of
the respective antibiotic for at least 3 days after a single intra-articular
injection.
The present inventors were able to identify the concentration of antibiotics
required to
eradicate biofilms (minimal biofilm eradication concentration, MBEC) formed by
pathogens
that lead to infections, in particular to infections in body compartments,
such as for example
in joints and in particular to joint infections related to surgical implants.
Surprisingly, the
longer the exposure to antibiotics the lower the concentration required to
eradicate the biofilm
of a given pathogen. This unexpected observation was made when biofilm was
exposed to
constant daptomycin, a cyclic lipopeptide antibiotic, over one, three and five
days. The
concentrations of daptomycin required to fully eradicate biofilm are
representative of drug
levels that can be achieved following release from the conjugates of the
present invention. To
our knowledge, this is the first time that data demonstrate that the MBEC of,
for example,
daptomycin is much lower when biofilm is exposed to a given antibiotic for
multiple days. It
was thus concluded that continuous release of an antibiotic is advantageous to
the eradication
of a biofilm and therefore to the treatment of joint infections as compared to
one or more
bolus injections of the respective antibiotic.
Within the present invention the terms are used having the meaning as follows.
As used herein, the term "antibiotic" refers to an antimicrobial drug for the
prevention or
treatment of bacterial infections, which either kills or inhibits growth of
bacteria. The term
also refers to drugs having antiprotozoal and antifungal activity.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
As used herein, the term "biofilm" refers to a plurality of microorganisms,
such as
microorganisms selected from the group consisting of bacteria, archaea,
protozoa, fungi and
algae, such as to a plurality of bacteria, embedded within an extracellular
matrix that is
5 composed of extracellular polymeric substances, such as polysaccharides,
proteins and DNA,
and said extracellular matrix may comprise material from the surrounding
environment, such
as blood components. Biofilms may form on living and non-living surfaces and
may comprise
one or more species of microorganism. It is known that during the ageing
process of a biofilm
it becomes increasingly difficult to eradicate it, because not only do
individual cells form
tighter bonds with the surface, but the extracellular matrix also provides a
protective
environment that restricts access of the antibiotics to the microorganisms.
As used herein the terms "compartment" and "body compartment" are used
synonymously
and refer to any particular space in the body comprising a diffusion barrier
impeding the
exchange of solutes with the surrounding tissue. Such space may also be
artificially
introduced by, for example, an implant. This space may be fluid, solid or may
contain a gas
phase or may be any combination thereof. It is understood that said solutes
may comprise
pharmacologically active compounds. The terms "compartment" and "body
compartment"
also refer to body structures that are separated by membranes, sheaths,
linings, fascia and
other connective tissue, bones, cartilage, or any combination thereof
As used herein, the term "water-insoluble" refers to a compound, such as a
conjugate of the
present invention, of which less than 1 g can be dissolved in one liter of
water at 20 C to form
a homogeneous solution. Accordingly, the term "water-soluble" refers to a
compound of
which 1 g or more can be dissolved in one liter of water at 20 C to form a
homogeneous
solution.
As used herein, the term "sustained release" refers to the property of a
compound, such as the
conjugates of the present invention, to release a drug, such as one or more
antibiotic, with a
release half-life of at least 1 day.
It is understood that the conjugates of the present invention are prodrugs.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
6
As used herein the term "prodrug" refers to a drug moiety reversibly and
covalently
connected to a specialized protective group through a reversible prodrug
linker moiety which
is a linker moiety comprising a reversible linkage with the drug moiety and
wherein the
specialized protective group alters or eliminates undesirable properties in
the parent molecule.
This also includes the enhancement of desirable properties in the drug and the
suppression of
undesirable properties. The specialized non-toxic protective group may also be
referred to as
"carrier". A prodrug releases the reversibly and covalently bound drug moiety
in the form of
its corresponding drug. In other words, a prodrug is a conjugate comprising a
drug moiety,
which is covalently and reversibly conjugated to a carrier moiety via a
reversible linker
moiety, which covalent and reversible conjugation of the carrier to the
reversible linker
moiety is either directly or through a spacer. The reversible linker may also
be referred to as
"reversible prodrug linker". Such conjugate may release the formerly
conjugated drug moiety
in the form of a free drug, in which case the reversible linker or reversible
prodrug linker is a
traceless linker.
As used herein, the term "free form" of a drug means the drug in its
unmodified,
pharmacologically active form.
As used herein the term "spacer" refers to a moiety that connects at least two
other moieties
with each other.
As used herein, the term "reversible", "reversibly", "degradable" or
"degradably" with regard
to the attachment of a first moiety to a second moiety means that the linkage
that connects
said first and second moiety is cleavable under physiological conditions,
which physiological
conditions are aqueous buffer at pH 7.4 and 37 C, with a half-life ranging
from one day to
three month, such as from one day to two months, such as from one day to one
month. Such
cleavage is non-enzymatically. Accordingly, the term "stable" with regard to
the attachment
of a first moiety to a second moiety means that the linkage that connects said
first and second
moiety exhibits a half-life of more than three months under physiological
conditions.
As used herein, the term "reagent" means a chemical compound, which comprises
at least one
functional group for reaction with the functional group of another chemical
compound or
drug. It is understood that a drug comprising a functional group is also a
reagent.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
7
As used herein, the term "moiety" means a part of a molecule, which lacks one
or more
atom(s) compared to the corresponding reagent. If, for example, a reagent of
the formula
"H-X-H" reacts with another reagent and becomes part of the reaction product,
the
corresponding moiety of the reaction product has the structure "H-X-" or "-X-"
, whereas
each "-" indicates attachment to another moiety. Accordingly, a drug moiety,
such as an
antibiotic moiety, is released from a reversible linkage as a drug, such as an
antibiotic drug.
It is understood that if the chemical structure of a group of atoms is
provided and if this group
of atoms is attached to two moieties or is interrupting a moiety, said
sequence or chemical
structure can be attached to the two moieties in either orientation, unless
explicitly stated
otherwise. For example, a moiety "-C(0)N(R1)-" can be attached to two moieties
or
interrupting a moiety either as "-C(0)N(RI)-" or as "-N(R1)C(0)-". Similarly,
a moiety
0
_"NVNz
0
can be attached to two moieties or can interrupt a moiety either as
0
_"NVNz
0 0
or as
The term "substituted" as used herein means that one or more -H atom(s) of a
molecule or
moiety are replaced by a different atom or a group of atoms, which are
referred to as
"substituent".
As used herein, the term "substituent" in certain embodiments refers to a
moiety selected
from the group consisting
of
halogen, -CN, -COORx I , -OR', -C(0)R'', -C(0)N(Rx1R) I a), -5(0)2N(Rx 1RxIa),
-S(0)N(Rx1Rx1a), _s(0)2Rxl, _s(0)Rxl, _N(Rxl)s(0)2N(RxI1RxI)
) SRxi, -N(Rx1Rx1a), -NO2,
-0C(0)R'', -N(Rxi)c(o)Rxia, _N(Rxi)s(0)2Rxia, _N(Rxi)s(0)Rxia, _N Rx
(i )C(0)0Rxia,
-N(Rxi)C(0)N(RxlaR)
xl,bµ OC(0)N(Rx 1RxIa),
1 C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl;
wherein -T , C1-50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
substituted with one or

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
8
more -Rx2, which are the same or different and wherein C1_50 alkyl, C2_50
alkenyl, and C2_50
alkynyl are optionally interrupted by one or more groups selected from the
group consisting
of -T -, -C(0)0-, -0-, -C(0)-, -C(0)N(Rx3)-, -S(0)2N(Rx3)-, -S(0)N(Rx3)-, -
S(0)2-,
-S(0)-, -N(Rx3)S(0)2N(R)(3a)-, -S-, -N(Rx3)-, -0C(OR(3)(R)(3a)-, -
N(Rx3)C(0)N(R)(3a)-,
and -0C(0)N(Rx3)-;
_Rxla, --Kxlb
are independently of each other selected from the group consisting
of -H, -T , C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T , C1_50
alkyl, C2_50 alkenyl,
and C2_50 alkynyl are optionally substituted with one or more -Rx2, which are
the same or
different and wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are
optionally interrupted by
one or more groups selected from the group consisting of -T -, -C(0)0-, -0-, -
C(0)-,
-C(0)N(Rx3)-, -S(0)2N(Rx3)-, -S(0)N(Rx3)-; -S(0)2-, -S(0)-, -
N(Rx3)S(0)2N(R)3a)-, -S-,
-N(Rx3)-, -0C(OR)(3)(Rx3a)-, -N(R)(3)C(0)N(R)(3a)-, and -0C(0)N(Rx3)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, and 8-
to 11-membered
heterobicyclyl; wherein each T is independently optionally substituted with
one or more -Rx2,
which are the same or different;
each -Rx2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -C 0 ORx4, -0R'4, -C(0)R'4, -C(0)N(Rx4R)(4a), -S(0)2N(Rx4R)(4a), -
S(0)N(Rx4R)(4a),
-S(0)2R'4, -S(0)R'4, , -N(Rx4)S(0)2N(Rx4aR)4b.) _ 4
SRx , -N(Rx4R)(4a.), NO2, -0C(0)R'4,
-N(Rx4)C(0)Rx4a, -N(Rx4)S(0)2Rx4a,
-N(Rx4)S(0)Rx4a, -N(Rx4)C(0)0Rx4a,
-N(Rx4)C(0)N(Rx4aRx4b), OC(0)N(Rx4Rx4a), and C1_6 alkyl; wherein C1,6 alkyl is
optionally
substituted with one or more halogen, which are the same or different;
each -Rx3, -Rx3a, _Rx4, _Rx4a,
K
is independently selected from the group consisting of -H
and C1_6 alkyl; wherein C1_6 alkyl is optionally substituted with one or more
halogen, which
are the same or different.
In certain embodiments a maximum of 6 -H atoms of an optionally substituted
molecule are
independently replaced by a substituent, e.g. 5 -H atoms are independently
replaced by a
substituent, 4 -H atoms are independently replaced by a substituent, 3 -H
atoms are

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
9
independently replaced by a substituent, 2 -H atoms are independently replaced
by a
substituent, or 1 -H atom is replaced by a substituent.
As used herein the term "crosslinker" refers to a moiety that is a connection
between different
elements of a hydrogel, such as between two or more backbone moieties or
between two or
more hyaluronic acid strands.
As used herein, the term "hydrogel" means a hydrophilic or amphiphilic
polymeric network
composed of homopolymers or copolymers, which is insoluble due to the presence
of
hydrophobic interactions, hydrogen bonds, ionic interactions and/or covalent
chemical
crosslinks. The crosslinks provide the network structure and physical
integrity.
As used herein the term "about" in combination with a numerical value is used
to indicate a
range ranging from and including the numerical value plus and minus no more
than 25% of
said numerical value, such as no more than plus and minus 20% of said
numerical value or
such as no more than plus and minus 10% of said numerical value. For example,
the phrase
"about 200" is used to mean a range ranging from and including 200 +/- 25%,
i.e. ranging
from and including 150 to 250; such as 200 +/- 20%, i.e. ranging from and
including 160 to
240; such as ranging from and including 200 +/-10%, i.e. ranging from and
including 180 to
220. It is understood that a percentage given as "about 50%" does not mean
"50% +/- 25%",
i.e. ranging from and including 25 to 75%, but "about 50%" means ranging from
and
including 37.5 to 62.5%, i.e. plus and minus 25% of the numerical value which
is 50.
As used herein, the term "polymer" means a molecule comprising repeating
structural units,
i.e. the monomers, connected by chemical bonds in a linear, circular,
branched, crosslinked or
dendrimeric way or a combination thereof, which may be of synthetic or
biological origin or a
combination of both. The monomers may be identical, in which case the polymer
is a
homopolymer, or may be different, in which case the polymer is a
heteropolymer. A
heteropolymer may also be referred to as a "copolymer" and includes, for
example,
alternating copolymers in which monomers of different types alternate,
periodic copolymers,
in which monomers of different types are arranged in a repeating sequence;
statistical
copolymers, in which monomers of different types are arranged randomly; block
copolymers,
in which blocks of different homopolymers consisting of only one type of
monomers are
linked by a covalent bond; and gradient copolymers, in which the composition
of different

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
monomers changes gradually along a polymer chain. It is understood that a
polymer may also
comprise one or more other moieties, such as, for example, one or more
functional groups.
The term "polymer" also relates to a peptide or protein, even though the side
chains of
individual amino acid residues may be different. It is understood that for
covalently
5
crosslinked polymers, such as hydrogels, no meaningful molecular weight ranges
can be
provided.
As used herein, the term "polymeric" refers to a reagent or a moiety
comprising one or more
polymers or polymer moieties. A polymeric reagent or moiety may optionally
also comprise
10 one or more other moieties, which in certain embodiments are selected from
the group
consisting of:
= C1_50 alkyl, C2_50 alkenyl, C2_50 alkynyl, C3_10 cycloalkyl, 3- to 10-
membered
heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl,
indanyl,
and tetralinyl; and
= linkages selected from the group comprising
I I I I I i I i I I I i
O , ¨S __________________ : , ¨N--, ¨H\1---, ¨S¨S, N=N¨,
1 1
R
OR NR 0 NR 0 0
i I i i I I ,
-c , c-r, -ic-i, -c-h, ¨C-0 , ¨10¨C¨N-1
I 1 '
0 R
R 0 S 11
i I i i I I , i I I i
I
N¨C¨, ¨N¨C-1\1I 1
¨, ¨N¨C-1\1¨ , and
R
0 R IN I
R RIa ) ___
a
I ,
0 S;
wherein
dashed lines indicate attachment to the remainder of the moiety or reagent,
and
-R and -Ra are independently of each other selected from the group consisting
of -H,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl, 2-
methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-
dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl; and
which moieties and linkages are optionally further substituted.
The person skilled in the art understands that the polymerization products
obtained from a
polymerization reaction do not all have the same molecular weight, but rather
exhibit a

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
11
molecular weight distribution. Consequently, the molecular weight ranges,
molecular weights,
ranges of numbers of monomers in a polymer and numbers of monomers in a
polymer as used
herein, refer to the number average molecular weight and number average of
monomers, i.e.
to the arithmetic mean of the molecular weight of the polymer or polymeric
moiety and the
arithmetic mean of the number of monomers of the polymer or polymeric moiety.
Accordingly, in a polymeric moiety comprising "x" monomer units any integer
given for "x"
therefore corresponds to the arithmetic mean number of monomers. Any range of
integers
given for "x" provides the range of integers in which the arithmetic mean
numbers of
monomers lies. An integer for "x" given as "about x" means that the arithmetic
mean numbers
of monomers lies in a range of integers of x +/- 25%, such as x +/- 20% or
such as x +/- 10%.
As used herein, the term "number average molecular weight" means the ordinary
arithmetic
mean of the molecular weights of the individual polymers.
As used herein, the term "PEG-based" in relation to a moiety or reagent means
that said
moiety or reagent comprises PEG. Such PEG-based moiety or reagent comprises at
least 10%
(w/w) PEG, such as at least 20% (w/w) PEG, such as at least 30% (w/w) PEG,
such as at least
40% (w/w) PEG, such as at least 50% (w/w), such as at least 60 (w/w) PEG, such
as at least
70% (w/w) PEG, such as at least 80% (w/w) PEG, such as at least 90% (w/w) PEG,
or such as
at least 95% (w/w) PEG. The remaining weight percentage of the PEG-based
moiety or
reagent may be other moieties, such as those selected from the group
consisting of:
= C1_50 alkyl, C2_50 alkenyl, C2_50 alkynyl, C3_10 cycloalkyl, 3- to 10-
membered
heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl,
indanyl,
and tetralinyl; and
= linkages selected from the group consisting of

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
12
I I
OR NR 0 NR 0 0
,
, ,
0 R
0
õ
'
and
0 R
I I I I
Ra
Ra
0 S
wherein
dashed lines indicate attachment to the remainder of the moiety or reagent,
and
-R and -Ra are independently of each other selected from the group consisting
of -H,
and C1_6 alkyl; and
which moieties and linkages are optionally further substituted.
The terms "poly(alkylene glycol)-based", "poly(propylene glycol)-based" and
"hyaluronic
acid-based" are used accordingly.
The term "interrupted" means that a moiety is inserted between two carbon
atoms or ¨ if the
insertion is at one of the moiety's ends ¨ between a carbon or heteroatom and
a hydrogen
atom.
As used herein, the term "C1_4 alkyl" alone or in combination means a straight-
chain or
branched alkyl moiety having 1 to 4 carbon atoms. If present at the end of a
molecule,
examples of straight-chain or branched C1_4 alkyl are methyl, ethyl, n-propyl,
isopropyl, n-
butyl, isobutyl, sec-butyl and tert-butyl. When two moieties of a molecule are
linked by the
Ci_4 alkyl, then examples for such C1_4 alkyl groups are -CH2-, -CH2-CH2-,
-CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-. Each hydrogen of a Ci_4 alkyl
carbon
may optionally be replaced by a substituent as defined above. Optionally, a
C1_4 alkyl may be
interrupted by one or more moieties as defined below.
As used herein, the term "C1_6 alkyl" alone or in combination means a straight-
chain or
branched alkyl moiety having 1 to 6 carbon atoms. If present at the end of a
molecule,
examples of straight-chain and branched C1_6 alkyl groups are methyl, ethyl, n-
propyl,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
13
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl,
2,2-dimethylpropyl,
n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl
and 3,3-
dimethylpropyl. When two moieties of a molecule are linked by the Ci_6 alkyl
group, then
examples for such C1_6 alkyl groups are -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-
CH2-,
-CH(C2H5)- and -C(CH3)2-. Each hydrogen atom of a C1_6 carbon may optionally
be replaced
by a substituent as defined above. Optionally, a C1_6 alkyl may be interrupted
by one or more
moieties as defined below.
Accordingly, "C1_10 alkyl", "C1_20 alkyl" or "C1_50 alkyl" means an alkyl
chain having 1 to 10,
1 to 20 or 1 to 50 carbon atoms, respectively, wherein each hydrogen atom of
the CI-10, CI-20
or C1_50 carbon may optionally be replaced by a substituent as defined above.
Optionally, a
C1_10 or C1-50 alkyl may be interrupted by one or more moieties as defined
below.
As used herein, the term "C2_6 alkenyl" alone or in combination means a
straight-chain or
branched hydrocarbon moiety comprising at least one carbon-carbon double bond
having 2 to
6 carbon atoms. If present at the end of a molecule, examples are -CH=CH2,
-CH=CH-CH3, -CH2-CH=CH2, -CH=CHCH2-CH3 and -CH=CH-CH=CH2. When two
moieties of a molecule are linked by the C2_6 alkenyl group, then an example
for such C2_6
alkenyl is -CH=CH-. Each hydrogen atom of a C2_6 alkenyl moiety may optionally
be
replaced by a substituent as defined above. Optionally, a C2_6 alkenyl may be
interrupted by
one or more moieties as defined below.
Accordingly, the terms "C2_10 alkenyl", "C2_20 alkenyl" or "C2_50 alkenyl"
alone or in
combination mean a straight-chain or branched hydrocarbon moiety comprising at
least one
carbon-carbon double bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms,
respectively.
Each hydrogen atom of a C2_10 alkenyl, C2_20 alkenyl or C2_50 alkenyl group
may optionally be
replaced by a substituent as defined above. Optionally, a C2_10 alkenyl, C2-20
alkenyl or C2-50
alkenyl may be interrupted by one or more moieties as defined below.
As used herein, the term "C2_6 alkynyl" alone or in combination means a
straight-chain or
branched hydrocarbon moiety comprising at least one carbon-carbon triple bond
having 2 to 6
carbon atoms. If present at the end of a molecule, examples are -CCH, -CH2-
CCH,
CH2-CH2-CCH and CH2-CC-CH3. When two moieties of a molecule are linked by the
alkynyl group, then an example is Each hydrogen atom of a C2_6 alkynyl
group may

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
14
optionally be replaced by a substituent as defined above. Optionally, one or
more double
bond(s) may occur. Optionally, a C2_6 alkynyl may be interrupted by one or
more moieties as
defined below.
Accordingly, as used herein, the term "C2_10 alkynyl", "C2_20 alkynyl" and
"C2_50 alkynyl"
alone or in combination means a straight-chain or branched hydrocarbon moiety
comprising
at least one carbon-carbon triple bond having 2 to 10, 2 to 20 or 2 to 50
carbon atoms,
respectively. Each hydrogen atom of a C2_10 alkynyl, C2_20 alkynyl or C2_50
alkynyl group may
optionally be replaced by a substituent as defined above. Optionally, one or
more double
bond(s) may occur. Optionally, a C2_10 alkynyl, C2_20 alkynyl or C2_50 alkynyl
may be
interrupted by one or more moieties as defined below.
As mentioned above, a C1_4 alkyl, C1_6 alkyl, Ci_io alkyl, C1_20 alkyl, C1_50
alkyl, C2_6 alkenyl,
C2_10 alkenyl, C2_20 alkenyl, C2_50 alkenyl, C2_6 alkynyl, C2-10 alkynyl,
C2_20 alkenyl or C2-50
alkynyl may optionally be interrupted by one or more moieties which may be
selected from
the group consisting of
I I I I
OR NR 0 NR 0 0
I , I I I I
, ,
I
OR
0
I I I I i I I
¨hN¨C¨N¨, and ¨1\1\
0 Ra Ra
0
S-1¨

wherein
dashed lines indicate attachment to the remainder of the moiety or reagent;
and
-R and -Ra are independently of each other selected from the group consisting
of -H
and C 1_6 alkyl.
As used herein, the term "C3_10 cycloalkyl" means a cyclic alkyl chain having
3 to 10 carbon
atoms, which may be saturated or unsaturated, e.g. cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl.
Each hydrogen

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
atom of a C3_10 cycloalkyl carbon may be replaced by a substituent as defined
above. The term
"C3_10 cycloalkyl" also includes bridged bicycles like norbornane or
norbornene.
The term "8- to 30-membered carbopolycyclyl" or "8- to 30-membered
carbopolycycle"
5 means a cyclic moiety of two or more rings with 8 to 30 ring atoms, where
two neighboring
rings share at least one ring atom and that may contain up to the maximum
number of double
bonds (aromatic or non-aromatic ring which is fully, partially or un-
saturated). In one
embodiment a 8- to 30-membered carbopolycyclyl means a cyclic moiety of two,
three, four
or five rings. In another embodiment a 8- to 30-membered carbopolycyclyl means
a cyclic
10 moiety of two, three or four rings.
As used herein, the term "3- to 10-membered heterocycly1" or "3- to 10-
membered
heterocycle" means a ring with 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms that may
contain up to the
maximum number of double bonds (aromatic or non-aromatic ring which is fully,
partially or
15 un-saturated) wherein at least one ring atom up to 4 ring atoms are
replaced by a heteroatom
selected from the group consisting of sulfur (including -S(0)-, -S(0)2-),
oxygen and nitrogen
(including =N(0)-) and wherein the ring is linked to the rest of the molecule
via a carbon or
nitrogen atom. Examples for 3- to 10-membered heterocycles include but are not
limited to
aziridine, oxirane, thiirane, azirine, oxirene, thiirene, azetidine, oxetane,
thietane, furan,
thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline,
oxazole,
oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole,
isothiazoline, thiadiazole,
thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine,
imidazolidine, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine,
sulfolane, pyran,
dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine,
pyrimidine,
piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine,
tetrazolidine, diazepane,
azepine and homopiperazine. Each hydrogen atom of a 3- to 10-membered
heterocyclyl or 3-
to 10-membered heterocyclic group may be replaced by a substituent.
As used herein, the term "8- to 11-membered heterobicycly1" or "8- to 11-
membered
heterobicycle" means a heterocyclic moiety of two rings with 8 to 11 ring
atoms, where at
least one ring atom is shared by both rings and that may contain up to the
maximum number
of double bonds (aromatic or non-aromatic ring which is fully, partially or un-
saturated)
wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom
selected from
the group consisting of sulfur (including -S(0)-, -S(0)2-), oxygen and
nitrogen (including

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
16
=N(0)-) and wherein the ring is linked to the rest of the molecule via a
carbon or nitrogen
atom. Examples for an 8- to 11-membered heterobicycle are indole, indoline,
benzofuran,
benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole,
benzimidazole,
benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline,
dihydroquinoline,
tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline,
tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine and
pteridine. The term 8-
to 11-membered heterobicycle also includes Spiro structures of two rings like
1,4-dioxa-8-
azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
Each hydrogen
atom of an 8- to 11-membered heterobicyclyl or 8- to 11-membered heterobicycle
carbon may
be replaced by a substituent.
Similary, the term "8- to 30-membered heteropolycycly1" or "8- to 30-membered
heteropolycycle" means a heterocyclic moiety of more than two rings with 8 to
30 ring atoms,
such as of three, four or five rings, where two neighboring rings share at
least one ring atom
and that may contain up to the maximum number of double bonds (aromatic or non-
aromatic
ring which is fully, partially or unsaturated), wherein at least one ring atom
up to 10 ring
atoms are replaced by a heteroatom selected from the group of sulfur
(including
-S(0)-, -S(0)2-), oxygen and nitrogen (including =N(0)-) and wherein the ring
is linked to the
rest of a molecule via a carbon or nitrogen atom.
It is understood that the phrase "the pair R'/R' is joined together with the
atom to which they
are attached to form a C3_10 cycloalkyl or a 3- to 10-membered heterocycly1"
in relation with a
moiety of the structure
Rx
RY
means that Rx and RY form the following structure:
,
=
R
,
wherein R is C3_10 cycloalkyl or 3- to 10-membered heterocyclyl.
It is also understood that the phrase "the pair Rx/RY is joint together with
the atoms to which
they are attached to form a ring A" in relation with a moiety of the structure

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
17
Rx Ry
means that Rx and RY form the following structure:
A
As used herein, "halogen" means fluoro, chloro, bromo or iodo. In certain
embodiments
halogen is fluoro or chloro.
As used herein the term "alkali metal ion" refers to Nat, 1( , Lit, Rb+ and
Cs. In certain
embodiments "alkali metal ion" refers to Nat, K+ and Li+
As used herein the term "alkaline earth metal ion" refers to Mg2+, Ca2+, Sr2+
and Ba2+. In
certain embodiments an alkaline earth metal ion is Mg2+ or Ca2 .
As used herein, the term "functional group" means a group of atoms which can
react with
other groups of atoms. Exemplary functional groups are carboxylic acid,
primary amine,
secondary amine, tertiary amine, maleimide, thiol, sulfonic acid, carbonate,
carbamate,
hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric
acid,
phosphonic acid, haloacetyl, alkyl halide, acryloyl, aryl fluoride,
hydroxylamine, disulfide,
sulfonamides, sulfuric acid, vinyl sulfone, vinyl ketone, diazoalkane,
oxirane, and aziridine.
In case the conjugates of the present invention comprise one or more acidic or
basic groups,
the invention also comprises their corresponding pharmaceutically or
toxicologically
acceptable salts, in particular their pharmaceutically utilizable salts. Thus,
the conjugates of
the present invention comprising acidic groups can be used according to the
invention, for
example, as alkali metal salts, alkaline earth metal salts or as ammonium
salts. More precise
examples of such salts include sodium salts, potassium salts, calcium salts,
magnesium salts
or salts with ammonia or organic amines such as, for example, ethylamine,
ethanolamine,
triethanolamine, amino acids, and quarternary ammonium salts, like
tetrabutylammonium or
cetyl trimethylammonium. Conjugates of the present invention comprising one or
more basic

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
18
groups, i.e. groups which can be protonated, can be present and can be used
according to the
invention in the form of their addition salts with inorganic or organic acids.
Examples for
suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid,
sulfuric acid,
nitric acid, methanesulfonic acid, p-toluenesulfonic acid,
naphthalenedisulfonic acids, oxalic
acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid,
formic acid, propionic
acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic
acid, fumaric acid,
maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid,
ascorbic acid,
isonicotinic acid, citric acid, adipic acid, trifluoroacetic acid, and other
acids known to the
person skilled in the art. For the person skilled in the art further methods
are known for
converting the basic group into a cation like the alkylation of an amine group
resulting in a
positively-charge ammonium group and an appropriate counterion of the salt. If
the
conjugates of the present invention simultaneously comprise acidic and basic
groups, the
invention also includes, in addition to the salt forms mentioned, inner salts
or betaines
(zwitterions). The respective salts can be obtained by customary methods,
which are known to
the person skilled in the art like, for example by contacting these prodrugs
with an organic or
inorganic acid or base in a solvent or dispersant, or by anion exchange or
cation exchange
with other salts. The present invention also includes all salts of the
conjugates of the present
invention which, owing to low physiological compatibility, are not directly
suitable for use in
pharmaceuticals but which can be used, for example, as intermediates for
chemical reactions
or for the preparation of pharmaceutically acceptable salts.
The term "pharmaceutically acceptable" means a substance that does not cause
harm when
administered to a patient and in certain embodiments means approved by a
regulatory agency,
such as the EMA (Europe) and/or the FDA (US) and/or any other national
regulatory agency
for use in animals, such as for use in humans.
As used herein, the term "excipient" refers to a diluent, adjuvant, or vehicle
with which the
therapeutic, such as a drug or prodrug, is administered. Such pharmaceutical
excipient may be
sterile liquids, such as water and oils, including those of petroleum, animal,
vegetable or
synthetic origin, including but not limited to peanut oil, soybean oil,
mineral oil, sesame oil
and the like. Water is a preferred excipient when the pharmaceutical
composition is
administered orally. Saline and aqueous dextrose are preferred excipients when
the
pharmaceutical composition is administered intravenously. Saline solutions and
aqueous
dextrose and glycerol solutions are preferably employed as liquid excipients
for injectable

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
19
solutions. Suitable pharmaceutical excipients include starch, glucose,
lactose, sucrose,
mannitol, trehalose, gelatin, malt, rice, flour, chalk, silica gel, sodium
stearate, glycerol
monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene,
glycol, hyaluronic
acid, propylene glycol, water, ethanol and the like. The pharmaceutical
composition, if
desired, can also contain minor amounts of wetting or emulsifying agents, pH
buffering
agents, like, for example, acetate, succinate, tris, carbonate, phosphate,
HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-
morpholino)ethanesulfonic acid),
or may contain detergents, like Tween, poloxamers, poloxamines, CHAPS, Igepal,
or amino
acids like, for example, glycine, lysine, or histidine. These pharmaceutical
compositions can
.. take the form of solutions, suspensions, emulsions, tablets, pills,
capsules, powders, sustained-
release formulations and the like. The pharmaceutical composition can be
formulated as a
suppository, with traditional binders and excipients such as triglycerides.
Oral formulation
can include standard excipients such as pharmaceutical grades of mannitol,
lactose, starch,
magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
Such
compositions will contain a therapeutically effective amount of the drug or
drug moiety,
together with a suitable amount of excipient so as to provide the form for
proper
administration to the patient. The formulation should suit the mode of
administration.
The term "peptide" as used herein refers to a chain of at least 2 and up to
and including 50
amino acid monomer moieties, which may also be referred to as "amino acid
residues", linked
by peptide (amide) linkages. The amino acid monomers may be selected from the
group
consisting of proteinogenic amino acids and non-proteinogenic amino acids and
may be D- or
L-amino acids. The term "peptide" also includes peptidomimetics, such as
peptoids, beta-
peptides, cyclic peptides and depsipeptides and covers such peptidomimetic
chains with up to
and including 50 monomer moieties.
As used herein, the term "protein" refers to a chain of more than 50 amino
acid monomer
moieties, which may also be referred to as "amino acid residues", linked by
peptide linkages,
in which preferably no more than 12000 amino acid monomers are linked by
peptide linkages,
such as no more than 10000 amino acid monomer moieties, no more than 8000
amino acid
monomer moieties, no more than 5000 amino acid monomer moieties or no more
than 2000
amino acid monomer moieties.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
As used herein the term "micelle" means an aggregate of amphiphilic molecules
dispersed in
a liquid colloid. In aqueous solution a typical micelle forms an aggregate
with the hydrophilic
moiety of the surfactant molecules facing the surrounding solvent and the
hydrophobic moiety
of the surfactant molecule facing inwards, also called "normal-phase micelle".
"Invers
5 micelles" have the hydrophilic moiety facing inwards and the hydrophobic
moiety facing the
surrounding solvent.
As used herein the term "liposome" refers to a vesicle, preferably a spherical
vesicle, having
at least one lipid bilayer. Preferably, liposomes comprise phospholipids, even
more preferably
10 phosphatidylcholine. The term "liposome" refers to various structures
and sizes, such as, for
example, to multilamellar liposome vesicles (MLV) having more than one
concentric lipid
bilayer with an average diameter of 100 to 1000 nm, small unilamellar liposome
vesicles
(SUV) having one lipid bilayer and an average diameter of 25 to 100 nm, large
unilamellar
liposome vesicles (LUV) having one lipid bilayer and an average diameter of
about 1000 um
15 and giant unilamellar vesicles (GUV) having one lipid bilayer and an
average diameter of 1 to
100 um. The term "liposome" also includes elastic vesicles such as
transferosomes and
ethosomes, for example.
As used herein the term "aquasome" refers to spherical nanoparticles having a
diameter of 60
20 to 300 nm that comprise at least three layers of self-assembled
structure, namely a solid phase
nanocrystalline core coated with an oligomeric film to which drug molecules
are adsorbed
with or without modification of the drug.
As used herein the term "ethosome" refers to lipid vesicles comprising
phospholipids and
.. ethanol and/or isopropanol in relatively high concentration and water,
having a size ranging
from tens of nanometers to micrometers.
As used herein the term "LeciPlex" refers to positively charged phospholipid-
based vesicular
system which comprises soy PC, a cationic agent, and a bio-compatible solvent
like PEG 300,
PEG 400, diethylene glycol monoethyl ether, tetrahydrofurfuryl alcohol
polyethylene glycol
ether or 2-pyrrolidoneor N-methyl-2-pyrrolidone.
As used herein the term "niosome" refers to unilamellar or multilamellar
vesicles comprising
non-ionic surfactants.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
21
As used herein the term "pharmacosome" refers to ultrafine vesicular, micellar
or hexagonal
aggregates from lipids covalently bound to biologically active moieties.
As used herein the term "proniosome" refers to dry formulations of surfactant-
coated carrier
which on rehydration and mild agitation gives niosomes.
As used herein the term "polymersome" refers to an artificial spherical
vesicle comprising a
membrane formed from amphiphilic synthetic block copolymers and may optionally
comprise
an aqueous solution in its core. A polymersome has a diameter ranging from 50
nm to 5 m
and larger. The term also includes syntosomes, which are polymersomes
engineered to
comprise channels that allow certain chemicals to pass through the membrane
into or out of
the vesicle.
As used herein the term "sphingosome" refers to a concentric, bilayered
vesicle in which an
aqueous volume is entirely enclosed by a membranous lipid bilayer mainly
composed of
natural or synthetic sphingolipid.
As used herein the term "transferosome" refers to ultraflexible lipid vesicles
comprising an
aqueous core that are formed from a mixture of common polar and suitable edge-
activated
lipids which facilitate the formation of highly curved bilayers which render
the transferosome
highly deformable.
As used herein the term "ufasome" refers to a vesicle comprising unsaturated
fatty acids.
In general, the terms "comprise" or "comprising" also encompasses "consist of'
or
"consisting of'.
In a first aspect the present invention relates to a conjugate or a
pharmaceutically acceptable
salt thereof or a pharmaceutical composition comprising said conjugate or its
pharmaceutically acceptable salt for use in a method of preventing or treating
an infection,
wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z
to which a
plurality of moieties -L2-X01130_ -DL1 are covalently conjugated,
wherein

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
22
each -D is independently an antibiotic moiety;
each -LI- is independently a linker moiety to which -D is covalently and
reversibly
conjugated;
each -X 13- is independently absent or a linkage; and
each -L2- is independently absent or a spacer moiety.
The present invention also relates to the conjugates of the first embodiment
per se.
In a second aspect the present invention relates to a water-insoluble
conjugate or a
.. pharmaceutically acceptable salt thereof or a pharmaceutical composition
comprising said
conjugate or its pharmaceutically acceptable salt comprising a plurality of
antibiotic
moieties -D covalently and reversibly bound to a polymeric moiety, wherein the
antibiotic
moieties are released from the polymeric moiety and wherein a single intra-
articular injection
provides a concentration of said antibiotic in the intra-articular compartment
of at least 1 tig
antibiotic/ml synovial fluid for at least 3 days.
In the third aspect the present invention relates to a sustained-release
compound or a
pharmaceutically acceptable salt thereof or a pharmaceutical composition
comprising said
compound or its pharmaceutically acceptable salt comprising a plurality of
antibiotic
moieties -D or antibiotic molecules D-H or D-OH, wherein the antibiotic
moieties or
molecules are released from said sustained-release compound and provide a
concentration in
the intra-articular compartment of said antibiotic that is at least 1.1-fold
above the minimal
biofilm eradicating concentration of the respective antibiotic for at least 3
days after a single
intra-articular injection.
In certain embodiments the sustained-release compound of the third aspect of
the present
invention is water-soluble.
In certain embodiments such water-soluble sustained-release compound of the
third
embodiment comprises C8_24 alkyl moiety or a polymeric moiety to which the
plurality of
antibiotic moieties are covalently and reversibly connected. If the water-
soluble sustained
release compound of the third embodiment comprises a polymeric moiety it is
preferably
selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl
cholins,
poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy)
polymers,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
23
poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides),
poly(aspartamides),
poly(butyric acids), poly(glycolic acids), polybutylene terephthalates,
poly(caprolactones),
poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides),
poly(esters),
poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl
phosphates),
poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates),
poly(hydroxyethyl-
oxazolines), poly(hydroxymethacrylates),
poly(hydroxypropylmethacrylamides),
poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines),
poly(iminocarbonates),
poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides),
poly(methacrylates),
poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters),
poly(oxazolines),
poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl
alcohols), poly(vinyl
amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones,
celluloses, carbomethyl
celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans,
dextrins, gelatins,
hyaluronic acids and derivatives, functionalized hyaluronic acids, mannans,
pectins,
rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches
and other
carbohydrate-based polymers, xylans, and copolymers thereof
In certain embodiments such polymeric moiety is PEG. In certain embodiments
such
polymeric moiety is hyaluronic acid.
In certain embodiments the sustained-release compound of the third aspect is
water-insoluble.
In such case the sustained-release compound is preferably selected from the
group consisting
of crystals, nanoparticles, microparticles, nanospheres and microspheres.
In certain embodiments the plurality of antibiotic moieties in the compounds
of the third
aspect is covalently conjugated to or embedded into a carrier. In certain
embodiments the
plurality of antibiotic moieties is reversibly and covalently conjugated to
the carrier. In certain
embodiments the carrier is water-insoluble. In certain embodiments such water-
insoluble
carrier degrades into soluble degradation products after no more than 4 months
after
administration to the infected joint, such as after no more than 3 months,
such as after no
more than 2 months. This degradability reduces the risk that the polymeric
carrier provides a
new artificial surface for biofilm formation.
In certain embodiments the sustained-release compound of the third aspect is a
crystal
comprising the plurality of antibiotic moieties.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
24
In certain embodiments the sustained-release compound of the third aspect is a
nanoparticle
comprising the plurality of antibiotic moieties.
In certain embodiments the sustained-release compound of the third aspect is a
microparticle
comprising the plurality of antibiotic moieties.
In certain embodiments the sustained-release compound of the third aspect is a
nanosphere
comprising the plurality of antibiotic moieties.
In certain embodiments the sustained-release compound of the third aspect is a
microsphere
comprising the plurality of antibiotic moieties.
In certain embodiments the sustained-release compound of the third aspect is a
vesicle
comprising the plurality of antibiotic moieties. Such vesicle may be a
micelle, liposome or
polymersome.
In certain embodiments the sustained-release compound of the third aspect is a
micelle
comprising the plurality of antibiotic moieties.
In certain embodiments the sustained-release compound of the third aspect is a
liposome
comprising the plurality of antibiotic moieties. Such liposome may be selected
from the group
consisting of aquasomes; non-ionic surfactant vesicles, such as niosomes and
proniosomes;
cationic liposomes, such as LeciPlex; transfersomes; ethosomes; ufasomes;
sphingosomes;
and pharmacosomes.
In certain embodiments the sustained-release compound of the third aspect is a
polymersome
comprising the plurality of antibiotic moieties.
The antibiotic moieties -D or antibiotic molecules D-H or D-OH of the third
aspect of the
present invention are as described elsewhere herein.
In certain embodiments the sustained-release compound of the third aspect
comprises the
plurality of antibiotic moieties non-covalently embedded in a water-insoluble
polymer. In

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
certain embodiments such water-insoluble polymer comprises a polymer selected
from the
group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic
acids),
poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers,
poly(amides),
poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides),
poly(butyric
5 acids), poly(glycolic acids), polybutylene terephthalates,
poly(caprolactones),
poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides),
poly(esters),
poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl
phosphates),
poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates),
poly(hydroxyethyl-
oxazolines), poly(hydroxymethacrylates),
poly(hydroxypropylmethacrylamides),
10 poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines),
poly(iminocarbonates),
poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides),
poly(methacrylates),
poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters),
poly(oxazolines),
poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl
alcohols), poly(vinyl
amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones,
celluloses, carbomethyl
15 celluloses, hydroxypropyl methylcelluloses, chitins, chitosans,
dextrans, dextrins, gelatins,
hyaluronic acids and derivatives, functionalized hyaluronic acids, mannans,
pectins,
rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches
and other
carbohydrate-based polymers, xylans, and copolymers thereof.
20 In certain embodiments the sustained-release compound of the third
aspect comprises the
plurality of antibiotic moieties non-covalently embedded in poly(lactic-co-
glycolic acid)
(PLGA).
In certain embodiments the sustained-release compound of the third aspect
comprises the
25 plurality of antibiotic moieties covalently and reversibly conjugated to
a polymer.
The conjugates of the first and second aspect and the compounds of the third
aspect of the
present invention release one or more types of antibiotic over an extended
period of time, i.e.
they are sustained-release conjugates. In certain embodiments the release
occurs with a
release half-life ranging between 1 day and 1 month. In certain embodiments
the release
occurs with a release half-life ranging between 1 day and 20 days. In certain
embodiments the
release occurs with a release half-life between 1 day and 15 days. In certain
embodiments the
release half-life may also range from 2 to 20 days or from 4 to 15 days. Such
continuous
release of an antibiotic is advantageous for the eradication of biofilms and
thus the treatment

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
26
of infections, such as infections in body compartments, such as for example
joint infections,
compared to one or more bolus injections of the respective antibiotic, as
discussed above.
In certain embodiments the water-insoluble conjugate of the second aspect and
the sustained-
release compound of the third aspect is a conjugate comprising a polymeric
moiety -Z to
which a plurality of moieties -1_,2-XOD_-.- 1
L -D

are covalently conjugated,
wherein
each -D is independently an antibiotic moiety;
each -L1- is independently a linker moiety to which -D is covalently and
reversibly
conjugated;
each -X D- is independently absent or a linkage;and
each -L2- is independently either a chemical bond or a spacer moiety.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
of the present
invention provides a concentration of at least 1 1,1g antibiotic/ml synovial
fluid for at least 3
days, such as for 3 days, 4 days or 5 days.
It is understood that an initial release of antibiotic from the conjugate of
the first, second or
third aspect of the present invention is required after administration to
reach an antibiotic
concentration in the intra-articular compartment of at least 1 lug antibiotic
per ml of synovial
fluid, i.e. the antibiotic concentration in the intra-articular compartment
will not immediately
after intra-articular injection be at least 1 1,1g/ml. In certain embodiments
the stated antibiotic
concentrations may be achieved 15 hours after administration. In certain
embodiments the
stated antibiotic concentrations may be achieved 18 hours after
administration. In certain
embodiments the stated antibiotic concentrations may be achieved 21 hours
after
administration. In certain embodiments the stated antibiotic concentrations
may be achieved
24 hours after administration. In certain embodiments the stated antibiotic
concentrations may
be achieved 36 hours after administration.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 5 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
27
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 25 idg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 50 idg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 75 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 100 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 150 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 200 idg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
28
concentration of at least 250 1,1g antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
.. conjugate of the first or second aspect or of the compound of the third
aspect provides a
concentration of at least 300 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 400 iõtg antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
In certain embodiments a single injection into the intra-articular compartment
of at least one
conjugate of the first or second aspect or of the compound of the third aspect
provides a
concentration of at least 500 1,1g antibiotic/ml synovial fluid for at least 3
days, such as for 3
days, 4 days or 5 days.
It is understood that if a conjugate or compound provides a certain antbiotic
concentration in
the intra-articular compartment for a certain period of time, such as for 3
days, 4 days or 5
days, that this is the minimal time period for which said concentration is
provided and that
this concentration may also be provided for a longer period of time.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.1-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.2-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
29
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.3-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.4-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.5-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect a single intra-articular
injection provide
a concentration of said antibiotic in the intra-articular compartment that is
at least 1.6-fold
above the minimal biofilm eradicating concentration of the respective
antibiotic for at least 3
days, such as for at least 4 days, at least 5 days, at least 6 days or at
least 7 days.
In certain embodiments the antibiotic molecules released from a conjugate of
the first or
second aspect or from a compound of the third aspect after a single intra-
articular injection
provide a concentration of said antibiotic in the intra-articular compartment
that is at least 1.7-
fold above the minimal biofilm eradicating concentration of the respective
antibiotic for at
least 3 days, such as for at least 4 days, at least 5 days, at least 6 days or
at least 7 days.
, 1_ _L2_, -)03_
The following sections describe embodiments of -D, _L
and -Z of the first,
second and third aspect.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments each -D is independently selected from the group
consisting of
aminoglycosides, tetracycline antibiotics, amphenicols, pleuromutilins,
macrolid antibiotics,
lincosamides, steroid antibiotics, antifolate antibiotics, sulfonamides,
topoisomerase
inhibitors, quinolones, fluoroquinolones, nitroimidazole antibiotics,
nitrofuran antibiotics,
5 rifamycins, glycopeptides, penicillins, cephalosporins, monobactams, beta-
lactamase
inhibitors, polymyxin antibiotics, lipopeptide antibiotics, oxazolidinon,
antimicrobial
peptides, antimicrobial proteins, porphyrins, azole antifungals, polyenes,
antiprotozoal drugs,
fosfomycin, cycloserine, and bacitracin.
10 In certain embodiments -D is an aminoglycoside, such as an
aminoglycoside selected from the
group consisting of streptomycin, dihydrostreptomycin, neomycin, paromomycin,
amikacin,
kanamycin, tobramycin, spectinomycin, hygromycin b, gentamicin, plazomicin,
verdamicin,
netilmicin, astromicin and sisomicin. In certain embodiments -D is amikacin.
In certain
embodiments -D is kanamycin. In certain embodiments -D is tobramycin. In
certain
15 embodiments -D is gentamicin. In another embodiment -D is plazomicin.
In certain embodiments -D is a tetracycline antibiotic, such as a tetracycline
antibiotic
selected from the group consisting of doxycycline, chloretetracycline,
tetracycline,
metacycline, minocycline, oxytetracycline and glycocyclines, such as a
glycocyclines selected
20 from the group consisting of tigecycline, omadacycline and sarecycline.
In certain
embodiments -D tetracycline. In certain embodiments -D is minocycline. In
certain
embodiments -D is oxytetracycline. In certain embodiments -D is tigecycline.
In certain
embodiments -D is omadacycline. In another embodiment -D is sarecycline.
25 In certain embodiments -D is an amphenicol, such as an amphenicol
selected from the group
consisting of chloramphenicol, thiamphenicol, azidamfenicol and florfenicol.
In certain embodiments -D is a pleuromutilin, such as a pleuromutilin selected
from the group
consisting of azamulin, lefamulin, tiamulin and valnemulin.
In certain embodiments -D is a macrolid antibiotic, such as a macrolid
antibiotic selected
from the group consisting of azithromycin, boromycin, clarithromycin,
oleandomycin,
erythromycin, roxithromycin, spiramycin, telithromycin and tylosine.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
31
In certain embodiments -D is a lincosamide, such as a lincosamide selected
from the group
consisting of clindamycin and lincomycin. In certain embodiments -D is
clindamycin.
In certain embodiments -D is a steroid antibiotic, such as fusidic acid.
In certain embodiments -D is an antifolate antibiotic, such as an antifolate
antibiotic selected
from the group consisting of trimethoprim and iclaprim.
In certain embodiments -D is a sulfonamide, such as a sulfonamide selected
from the group
consisting of sufathiazole, sulfamethoxazole, sulfadiazine and sulfamerazine.
In certain embodiments -D is a topoisomerase inhibitor, such as a
topoisomerase inhibitor
selected from the group consisting of flumequine, nalidixic acid, oxolinic
acid and pipemidic
acid. In certain embodiments -D is nalidixic acid.
In certain embodiments -D is a quinolone or fluroquinolone, such as a
quinolone or
fluroquinolone selected from the group consisting of nemonoxacin,
ciprofloxacin, ofloxacin,
norfloxacin, pefloxacin, levofloxacin, sparfloxacin, moxifloxacin,
gatifloxacin, difloxacin,
enrofloxacin, marbofloxacin, delafloxacin and nemonovobiocin. In certain
embodiments -D is
ciprofloxacin. In certain embodiments -D is levofloxacin. In certain
embodiments -D is
delafloxacin.
In certain embodiments -D is a nitroimidazole antibiotic, such as
metronidazole.
In certain embodiments -D is a nitrofuran antibiotic, such as a nitrofuran
antibiotic selected
from the group consisting of nitrofurantoin and furazolidone.
In certain embodiments -D is a rifamycin, such as rifampicin.
In certain embodiments -D is a glycopeptide, such as a glycoprotein selected
from the group
consisting of vancomycin, oritavancin, telavancin, dalbavancin and
teicoplanin. In certain
embodiments -D is vancomycin. In certain embodiments -D is oritavancin. In
certain
embodiments -D is telavancin. In another embodiment -D is dalbavancin.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
32
In certain embodiments -D is a penicillin, such as a penicillin selected from
the group
consisting of penams, penems and carbapenems. In certain embodiments such
penams are
selected from the group consisting of amoxicillin, ampicillin, carbenicillin,
ticarcillin,
temocillin, aziocillin, piperacillin, mezlocillin, mecillinam,
benzylpenicillin, cloxacillin,
dicloxacillin, flucloxacillin, oxacillin, methicillin and nafcillin. In
certain embodiments such
penems and carbapenes are selected from the group consisting of faropenem,
ertapenem,
doripenem, thiopenem, sulopenem, imipenem and meropenem. In certain
embodiments -D is
imipenem. In another embodiment -D is meropenem.
In certain embodiments -D is a cephalosporin, such as a cephalosporin selected
from the
group consisting of cefazolin, cefadroxil, cefalexin, cefradine, cefaclor,
cefamandole,
cefminox, cefotiam, cefprozil, cefuroxime, cefoxitin, cefotetan, cefmetazole,
cefixime,
ceftriaxone, ceftazidime, cefoperazone, cefpodoxime, cefdinir, cefditoren,
cefotaxime,
cefsulodin, cefteram, ceftibuten, ceftizoxime, cefepime, cefozopran,
cefpirome, ceftaroline
and ceftobiprole. In certain embodiments -D is cefazolin. In certain
embodiments -D is
cephalexin. In certain embodiments -D is ceftaroline. In certain embodiments -
D is
ceftobiprole. Cepholosporins are also known as cephamycins.
In certain embodiments -D is a monobactam, such as aztreonam.
In certain embodiments -D is a beta-lactamase inhibitor, such as a beta-
lactamase inhibitor
selected from the group consisting of sulbactam, tazobactam, clavulanic acid
and cefdinir.
In certain embodiments -D is a polymycin antibiotic, such as a polymcin
antibiotic selected
from the group consisting of colistin and polymyxin B. In certain embodiments -
D is colistin.
In certain embodiments -D is polymyxin B.
In certain embodiments -D is a lipopeptide antibiotic, such as a lipopeptide
antibiotic selected
from the group consisting of daptomycin, arylomycins and gramicidin. In
certain
embodiments -D is daptomycin. Daptomycin has the following chemical structure

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
33
H 2
0 0
, N
C0NH2 0 NH 0
0 -z 0 HO2C HN
= H
N HO2C õ
H 2 H
NH 0 C 02 H 0 00 HO NH
0
N 0
HX
0
0
NH 2 HO0
In certain embodiments -D is an oxazolidinon, such as an oxazolidinon selected
from the
group consisting of linezolid, tedizolid, esperezolid, posizolid, radezolid,
sutezolid and
cadazolid. In certain embodiments -D is tedizolid.
In certain embodiments -D is an antimicrobial peptide, such as an
antimicrobial peptide
selected from the group consisting of cationic amphipathic peptides (CAP) and
host defense
proteins (HDP). In certain embodiments such CAP is selected from the group
consisting of
omiganan pentahydrochloride and novispirin g-10. In certain embodiments such
HDP is
brilacidin.
In certain embodiments -D is an antimicrobial protein, such as lysins.
.. In certain embodiments -D is a porphyrin, such as exeporfinium chloride.
In certain embodiments -D is an azole antifungal, such as an azole antifungal
selected from
the group consisting of fluconazole, isavuconazonium sulfate, posaconazole,
itraconazole,
voriconazole, albaconazole and miconazole. In certain embodiments -D is
fluconazole. In
certain embodiments -D is voriconazole. In certain embodiments -D is
albaconazole.
In certain embodiments -D is a polyene, such as a polyene selected from the
group consisting
of amphotericin, echinocandins, flucytosine, tavaborole and triterpinoids. In
certain
embodiments an echinocandin is selected from the group consisting of
caspofungin,
micafungin, anidulafungin, cilofungin and rezafungin. In certain embodiments -
D is

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
34
amphotericin. In certain embodiments -D is caspofungin. In certain embodiments
-D is
micafungin. In certain embodiments -D is anidulafungin. In certain embodiments
-D is
cilofungin. In certain embodiments -D is rezafungin.
In certain embodiments -D is an antiprotozoal drug moiety, such as an
antiprotozoal drug
moiety selected from the list comprising eflornithine, furazolidone,
melarsoprol,
nifursemizone, ornidazole, pentamidine, pyrimethamine, quinapyramine,
tinidazole,
chlorproguanil, proguanil, atovaquone, dehydroemetine, diloxanide,
eflornithine, halofantrine,
lumefantrine, mepacrine, miltefosine, nitazoxanide, tizoxanide, pyronaridine,
suramin,
amodiaquine, chloroquine, hydroxychloroquine, primaquine, pamaquine,
tafenoquine,
mefloquine, artemether, artemisinin, artemotil, artesunate and
dihydroartemisinin.
In certain embodiments all moieties -D of a conjugate are identical. In
certain embodiments
the conjugate comprises more than one type of -D, i.e. two or more different
types of -D, such
as two different types of -D, three different types of -D, four different
types of -D or five
different types of -D. If the conjugate comprises more than one type of -D one
preferred
combination is a combination of a beta-lactamase inhibitor and an antibiotic
selected from the
group consisting of penicillins, cephalosporins and monobactam antibiotics.
Accordingly, in
certain embodiments the conjugates of the present invention may comprise a
beta-lactamase
inhibitor and a penicillin. In certain embodiments the conjugates of the
present invention may
comprise a beta-lactamase inhibitor and a cephalosporin. In certain
embodiments the
conjugates of the present invention may comprise a beta-lactamase inhibitor
and a
monobactam antibiotic. If the conjugates of the present comprise more than one
type of -D,
all -D may be connected to the same type of -LI- or may be connected to
different types
of -L1-, i.e. a first type of -D may be connected to a first type of -L1-, a
second type of -D may
be connected to a second type of -L1- and so on. Using different types of -L1-
may in certain
embodiments allow different release kinetics for different types of -D, such
as for example a
faster release for a first type of -D, a medium release for a second type of -
D and a slow
release for a third type of -D. Accordingly, in certain embodiments the
conjugates of the
present invention comprise one type of -L1-. In certain embodiments the
conjugates of the
present invention comprise two types of -1_,1-. In certain embodiments the
conjugates of the
present invention comprise three types of -1_,1-. In certain embodiments the
conjugates of the
present invention comprise four types of -LI-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments the conjugates of the present invention comprise one
type of -D and
one type of -1_,1-. In certain embodiments the conjugates of the present
invention comprise two
types of -D and two types of -1_,1-. In certain embodiments the conjugates of
the present
invention comprise three types of -D and three types of -L1-. In certain
embodiments the
5 conjugates of the present invention comprise four types of -D and four
types of -L1-.
The moiety -LI- is conjugated to -D via a functional group of -D, which
functional group is in
certain embodiments selected from the group consisting of carboxylic acid,
primary amine,
secondary amine, thiol, sulfonic acid, carbonate, carbamate, hydroxyl,
aldehyde, ketone,
10 hydrazine, isothiocyanate, phosphoric acid, phosphonic acid, acryloyl,
hydroxylamine,
sulfate, vinyl sulfone, vinyl ketone, diazoalkane, guanidine, aziridine,
amide, imide, imine,
urea, amidine, guanidine, sulfonamide, phosphonamide, phorphoramide, hydrazide
and
selenol. In certain embodiments -L1- is conjugated to -D via a functional
group of -D selected
from the group consisting of carboxylic acid, primary amine, secondary amine,
thiol, sulfonic
15 acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine,
isothiocyanate, phosphoric
acid, phosphonic acid, acryloyl, hydroxylamine, sulfate, vinyl sulfone, vinyl
ketone,
diazoalkane, guanidine, amidine and aziridine. In certain embodiments -L1- is
conjugated
to -D via a functional group of -D selected from the group consisting of
hydroxyl, primary
amine, secondary amine, amidine and carboxylic acid.
In certain embodiments -L1- is conjugated to -D via a hydroxyl group of -D.
In certain embodiments -1_,1- is conjugated to -D via a primary amine group of
-D.
In certain embodiments -L1- is conjugated to -D via a secondary amine group of
-D.
In certain embodiments -1_,1- is conjugated to -D via a carboxylic acid group
of -D.
In certain embodiments -L1- is conjugated to -D via an amidine group of -D.
The moiety -1_,1- can be connected to -D through any type of linkage, provided
that it is
reversible. In certain embodiments -1_,1- is connected to -D through a linkage
selected from the
group consisting of amide, ester, carbamate, acetal, aminal, imine, oxime,
hydrazone,
disulfide, acylguanidine, acylamidine, carbonate, phosphate, sulfate, urea,
hydrazide,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
36
thioester, thiophosphate, thiosulfate, sulfonamide, sulfoamidine,
sulfaguanidine,
phosphoramide, phosphoamidine, phosphoguanidine, phosphonamide,
phosphonamidine,
phosphonguanidine, phosphonate, borate and imide. In certain embodiments -LI-
is connected
to -D through a linkage selected from the group consisting of amide, ester,
carbonate,
carbamate, acetal, aminal, imine, oxime, hydrazone, disulfide, acylamidine and
acylguanidine.
In certain embodiments -Ll- is connected to -D through a linkage selected from
the group
consisting of amide, ester, caronate, acylamide and carbamate. It is
understood that some of
these linkages may not be reversible per se, but that in the present invention
neighboring
groups present in -L1- render these linkages reversible.
In certain embodiments -Ll- is connected to -D through an ester linkage.
In certain embodiments -L1- is connected to -D through a carbonate linkage.
In certain embodiments -Ll- is connected to -D through an acylamidine linkage.
In certain embodiments -L1- is connected to -D through a carbamate linkage.
In certain embodiments -Ll- is connected to -D through an amide linkage.
If -D is daptomycin, -L1- is in certain embodiments connected via the primary
amine of the
ornithine side chain. In certain embodiments such daptomycin is connected to -
L1- via the
primary amine of the ornithine side chain via an amide linkage.
The moiety -L1- is a linker moiety from which -D is released in its free form,
i.e. in the form
of D-H or D-OH. Such moieties are also known as "prodrug linkers" or
"reversible prodrug
linkers" and are known in the art, such as for example the reversible linker
moieties disclosed
in WO 2005/099768 A2, WO 2006/136586 A2, WO 2011/089216 Al, WO 2013/024053 Al,

WO 2011/012722 Al, WO 2011/089214 Al, WO 2011/089215 Al, WO 2013/024052 Al
and WO 2013/160340 Al, which are incorporated by reference herewith.
In certain embodiments the moiety -LI- is as disclosed in WO 2009/095479 A2.
Accordingly,
in certain embodiments the moiety -L1- is of formula (I):

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
37
R3a
X3 R1 Rla
N II
X2 X
R2/R2a I
H* 0
wherein the dashed line indicates the attachment to a nitrogen, hydroxyl or
thiol of -D;
-X- is selected from the group consisting of -C(R4R4a)-, -N(R4)-, -0-,
-C(R4R4a)-C(R5R5a)-,
-C(R5R5a)-C(R4R4a)-, -C(R4R4a)-N(R6)-,
-N(R6)-C(R4R4a)-, -C(R4R4a)-0-, -0-C(R4R4a)-, and -C(R7R7a)-,
X1 is selected from the group consisting of C and S(0);
-X2- is selected from the group consisting of -C(R8R8a)- and -C(R8R8a)-
C(R9R9a)-;
=X3 is selected from the group consisting of =0, =S, and =N-CN;
_Ria, _R2a, _R4a,
_Rsa, _ K 8a, -R9 and -R9a are independently
selected from the group consisting of -H and C1_6 alkyl;
-R3 and -R3a are independently selected from the group consisting of -H and
C1_6 alkyl,
provided that in case one or both of -R3 and -R3a are other than -H they are
connected to N to which they are attached through an sp3-hybridized carbon
atom;
-R7 is selected from the group consisting of -N(R1 R1 a) and -NR10-(C=0)-
R11;
-R7a, -R10, -R10a and -R11 are independently selected from the group
consisting of -H
and C1_6 alkyl;
alternatively, one or more of the pairs -Rlaii_R4a, _Riaii_R5a, _RI aii_R7a,
_R4aii_R5a
and -R8a/-R9a form a chemical bond;
alternatively, one or more of the pairs -R1/-R1 a, -R2/_R2a, _R4/_R4a,
_R5/_Rsa, _R8/_R8a
and -R9/-R9a are joined together with the atom to which they are attached to
form a C3_10 cycloalkyl or 3- to 10-membered heterocyclyl;
alternatively, one or more of the pairs -R1/-R4, -R1/-R5, -R1/-R6, -R1/-R7a, -
R4/-R5,
-R4/-R6, -R8/-R9 and -R2/-R3 are joined together with the atoms to which they
are attached to form a ring A;
alternatively, R3/R3a are joined together with the nitrogen atom to which they
are
attached to form a 3- to 10-membered heterocycle;
A is selected from the group consisting of phenyl; naphthyl;
indenyl; indanyl;
tetralinyl; C3_10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-
membered heterobicyclyl; and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
38
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted, provided that the hydrogen marked with the asterisk in formula
(I) is not
replaced by -X D-L2- or a substituent.
The optional further substituents of -L1- of formula (I) are as described
above.
In certain embodiments -Ll- of formula (I) is substituted with one moiety -X D-
L2-.
In certain embodiments -L1- of formula (I) is not further substituted.
It is understood that if -R3/-R3a of formula (I) are joined together with the
nitrogen atom to
which they are attached to form a 3- to 10-membered heterocycle, only such 3-
to 10-
membered heterocycles may be formed in which the atoms directly attached to
the nitrogen
are sp3-hybridized carbon atoms. In other words, such 3- to 10-membered
heterocycle formed
by -R3/-R3a together with the nitrogen atom to which they are attached has the
following
structure:
C"\ ,
N-;
#7
wherein
the dashed line indicates attachment to the rest of -L1-;
the ring comprises 3 to 10 atoms comprising at least one nitrogen; and
R# and R#4 represent an sp3-hydridized carbon atom.
It is also understood that the 3- to 10-membered heterocycle may be further
substituted.
Exemplary embodiments of suitable 3- to 10-membered heterocycles formed by -
R3/-R3a of
formula (I) together with the nitrogen atom to which they are attached are the
following:
CN ( __ \N-L
R-1\1/ _______________________ \N_,, /
N 0
and \ /

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
39
wherein
dashed lines indicate attachment to the rest of the molecule; and
-R is selected from the group consisting of -H and C1_6 alkyl.
-Li- of formula (I) may optionally be further substituted. In general, any
substituent may be
used as far as the cleavage principle is not affected, i.e. the hydrogen
marked with the asterisk
in formula (I) is not replaced and the nitrogen of the moiety
3
R \
\ i
N¨

R3a/ 1
of formula (I) remains part of a primary, secondary or tertiary amine, i.e. -
R3 and -R3a are
independently of each other -H or are connected to -N< through an sp3-
hybridized carbon
atom.
In certain embodiments -Rl of formula (I) is -H, which -H is substituted with -
X 1-L2-. In
certain embodiments -Ria of formula (I) is -H, which -H is substituted with -X
D-L2-. In
certain embodiments -R2 of formula (I) is -H, which -H is substituted with -X
D-L2-. In certain
embodiments -R2a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R3 of formula (I) is -H, which -H is substituted with -X 1-L2-.
In certain
embodiments -R3a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R4 of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R5 of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R5a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R6 of formula (I) is -H, which -H is substituted with -X 1-L2-.
In certain
embodiments -R7 of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R7a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R8 of formula (I) is -H, which -H is substituted with -X 1-L2-.
In certain
embodiments -R8a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R9 of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -R9a of formula (I) is -H, which -H is substituted with -X D-L2-.
In certain
embodiments -RI of formula (I) is -H, which -H is substituted with _x0D_L2_ .
In certain
embodiments -R" of formula (I) is -H, which -H is substituted with -X D-L2-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments -X- of formula (I) is selected from the group
consisting
of _c (R4R4a)_, _N(R4)_
and -C(R7R7a)-.
In certain embodiments -X- of formula (I) is -C(R4R4a)-.
5
In certain embodiments -X- of formula (I) is -N(R4)-.
In certain embodiments -X- of formula (I) is -C(R7R7a)-.
10 In certain embodiments -R7 of formula (I) is -NR1 -(C=0)-R11.
In certain embodiments -R7a of formula (I) is selected from -H, methyl and
ethyl.
In certain embodiments -R7a of formula (I) is -H.
In certain embodiments -R1 of formula (I) is selected from -H, methyl and
ethyl.
In certain embodiments -R1 of formula (I) is methyl. In certain embodiments -
R1 is -H.
In certain embodiments -R" of formula (I) is selected from -H, methyl and
ethyl. In certain
embodiments -R11 is -H.
_
In certain embodiments -RH of formula (I) is substituted with _xoD_c.
In certain embodiments X1 of formula (I) is C.
In certain embodiments =X3 of formula (I) is =0.
In certain embodiments -X2- of formula (I) is -C(R8R8a)-.
In certain embodiments -R8 and -R8a of formula (I) are independently selected
from the group
consisting of -H, methyl and ethyl. In certain embodiments at least one of -R8
and -R8a of
formula (I) is -H. In certain embodiments both -R8 and -R8a of formula (I) are
-H.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
41
In certain embodiments -R1 and -Ria of formula (I) are independently selected
from the group
consisting of -H, methyl and ethyl. In certain embodiments at least one of -Rl
and -Ria of
formula (I) is -H. In certain embodiments both -Rl and -Ria of formula (I) are
-H.
In certain embodiments -R2 and -R2a of formula (I) are independently selected
from the group
consisting of -H, methyl and ethyl. In certain embodiments at least one of -R2
and -R2a of
formula (I) is -H. In certain embodiments both -R2 and -R2a of formula (I) are
H.
In certain embodiments -R3 and -R3a of formula (I) are independently selected
from the group
consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-
butyl, tert-butyl, n-
pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-
methylpentyl, 2,2-
dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. In certain
embodiments at least one
of -R3 and -R3a of formula (I) is methyl. In certain embodiments both -R3 and -
R3a of formula
(I) are methyl.
In certain embodiments -D is connected to -L1- through a nitrogen by forming
an amide bond.
It is understood that the carbonyl to the left of the dashed line and the
nitrogen of -D form the
amide bond.
In certain embodiments the nitrogen that connects -D to by forming an amide
bond is
provided by a primary or secondary amine of -D.
In certain embodiments the moiety is of formula (Ia):
R3a
0
R3NX2r
H* 0
to N R
R
0
(Ia),
wherein the dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond;
_R3, _R3a, _RH), _RH and --A2_
are used as defined in formula (I); and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
42
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted, provided that the hydrogen marked with the asterisk in formula
(Ia) is not
replaced by -X D-L2- or a substituent.
The optional further substituents of -L1- of formula (Ia) are as described
above.
In certain embodiments -1_,1- of formula (Ia) is substituted with one moiety -
X D-L2-.
In certain embodiments the moiety -L1- of formula (Ia) is not further
substituted.
In certain embodiments -X2- of formula (Ia) is -C(R8R8a)-.
In certain embodiments -R8 and -R8' of formula (Ia) are independently selected
from the
group consisting of -H, methyl and ethyl. In certain embodiments at least one
of -R8 and -R8a
of formula (Ia) is -H. In certain embodiments both -R8 and -R8a of formula
(Ia) are -H.
In certain embodiments -R3 and -R3' of formula (Ia) are independently selected
from the
group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-
butyl, tert-butyl,
n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-
methylpentyl, 2,2-
dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. In certain
embodiments at least one
of -R3 and -R3' of formula (Ia) is methyl. In certain embodiments both -R3 and
-R3' of formula
(Ia) are methyl.
In certain embodiments -R1 of formula (Ia) is selected from -H, methyl and
ethyl. In certain
embodiments -R1 of formula (Ia) is methyl.
In certain embodiments -RH of formula (Ia) is selected from -H, methyl and
ethyl. In certain
embodiments -RH of formula (Ia) is -H.
In certain embodiments -R11 of formula (Ia) is substituted with -X D-L2-.
In certain embodiments the moiety -1_,1- is of formula (Ib):

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
43
R3a
0
1 ,
3 N X2 '
R I\T
I
H* 0
R1( N*
0
(Ib),
wherein
wherein the dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond;
the dashed line marked with the asterisk indicates attachment to
-R3, -R3a, -R1 and -X2- are used as defined in formula (I); and
wherein -1_,1- is optionally further substituted, provided that the hydrogen
marked with
the asterisk in formula (Ib) is not replaced by a substituent.
The optional further substituents of -LI- of formula (Ib) are as described
above.
In certain embodiments the moiety -L1- of formula (Ib) is not further
substituted.
In certain embodiments -X2- of formula (Ib) is -C(R8R8a)-.
In certain embodiments -R8 and -R8a of formula (Ib) are independently selected
from the
group consisting of -H, methyl and ethyl. In certain embodiments at least one
of -R8 and -R8a
of formula (Ib) is -H. In certain embodiments both -R8 and -R8' of formula
(Ib) are -H.
In certain embodiments -R3 and -R3a of formula (Ib) are independently selected
from the
group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-
butyl, tert-butyl,
n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-
methylpentyl, 2,2-
dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. In certain
embodiments at least one
of -R3 and -R3a of formula (Ib) is methyl. In certain embodiments both -R3 and
-R3a of
formula (Ib) are methyl.
In certain embodiments -RI of formula (Ib) is selected from -H, methyl and
ethyl. In certain
embodiments -R1 of formula (Ib) is methyl.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
44
In certain embodiments the moiety is of formula (Ic):
0
H* 0
/N./H
0
(Ic),
wherein the dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond; and
wherein -LI- is substituted with -X D-L2- and wherein is optionally
further
substituted, provided that the hydrogen marked with the asterisk in formula
(Ic) is not
replaced by -X D-L2- or a substituent.
The optional further substituents of -LI- of formula (Ic) are as described
above.
In certain embodiments -L1- of formula (Ic) is substituted with one moiety -X
D-L2-.
In certain embodiments the moiety of formula (Ic) is not further
substituted.
-D is connected to -L1- of formula (Ic) through a nitrogen of -D by forming an
amide bond. In
certain embodiments said nitrogen is provided by a primary or secondary amine
of -D.
In certain embodiments the moiety -L1- is of formula (Id):
0
H* 0
*
0 (Id),
wherein
wherein the dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
the dashed line marked with the asterisk indicates attachment to -X D-L2-; and
wherein -1_,1- is optionally further substituted, provided that the hydrogen
marked with
the asterisk in formula (Id) is not replaced by a substituent.
5 .. In certain embodiments the moiety -L1- of formula (Id) is not further
substituted.
-D is connected to -L1- of formula (Id) through a nitrogen of -D by forming an
amide bond. In
certain embodiments said nitrogen is provided by a primary or secondary amine
of -D.
10 In certain embodiments the moiety -1_,1- is of formula (le)
0
H I
H* 0
NH
0
(le),
wherein the dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond; and
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
15 substituted, provided that the hydrogen marked with the asterisk in
formula (le) is not
replaced by -X D-L2- or a substituent.
The optional further substituents of -L1- of formula (le) are as described
above.
20 In certain embodiments -1_,1- of formula (le) is substituted with one
moiety -X D-L2-.
In certain embodiments the moiety -L1- of formula (le) is not further
substituted.
-D is connected to -LI- of formula (le) through a nitrogen of -D by forming an
amide bond. In
25 certain embodiments said nitrogen is provided by a primary or secondary
amine of -D.
In certain embodiments the moiety -L1- is of formula (If):

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
46
0
NN-µ
H I
H* 0
0
(If),
wherein
the dashed line indicates the attachment to a nitrogen of -D by forming an
amide bond;
the dashed line marked with the asterisk indicates attachment to -X D-L2-; and
wherein -1_,1- is optionally further substituted, provided that the hydrogen
marked with
the asterisk in formula (If) is not replaced by a substituent.
In certain embodiments the moiety -1_,1- of formula (If) is not further
substituted.
-D is connected to -L1- of formula (If) through a nitrogen of -D by forming an
amide bond. In
certain embodiments said nitrogen is provided by a primary or secondary amine
of -D.
Another moiety -1_,1- is disclosed in WO 2016/020373 Al. Accordingly, in
certain
embodiments the moiety -L1- is of formula (II):
- - - R5
R6a R6 R4
7a R71
NI
R'
a2 _
3a T
R R 2a R2 Rla R1
0
R (II),
wherein
the dashed line indicates attachment to a primary or secondary amine or
hydroxyl
of -D by forming an amide or ester linkage, respectively;
_Rt, _Ria, _R2, _R2a, -R3 and -R3a are independently of each other selected
from the
group consisting of -H, -C(R8R8aR8b), -C(=0)R8, -C1\1, -C(=NR8)R8a,
-CR8(=CR8aR8bµ), _
CCR8 and -T;
-R4, -R5 and -R5a are independently of each other selected from the group
consisting
of -H, -C(R9R9aR9b) and -T;
al and a2 are independently of each other 0 or 1;

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
47
each -R6, - R91' are
independently of each other
selected from the group consisting of
-H,
halogen, -CN, -COOR1 ,
-C(0)R1 , -C(0)N(RioRioa), _s(0)2N(RioRioa),
-S(0)N(R1 R1 a), -S(0)2RI -S(0)R10, -N(R1 )S(0)2N(RiO1RlOb
) SR1 ,
-N(R1 R1 a), -NO2, -0C(0)R10, -N(R1 )C(0)R1
a, -N(RI )S(0)2R1 a,
-N(R10)S(0)R1'

, _N - (Ro( 0)0R1 a,
i
_N(Rio)c(o)N(RioaRiob),
-0C(0)N(R1OR)10ax -T, CI _20 alkyl, C2_20 alkenyl, and C2_20 alkynyl; wherein -
T,
C120 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally substituted with
one
or more -R11, which are the same or different and wherein C120 alkyl, C2_20
alkenyl, and C2_20 alkynyl are optionally interrupted by one or more groups
selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-, -C(0)N(R12)-,
-S(0)2N(R12)-, -S(0)N(R12)-, -S(0)2-, -S(0)-, -N(R12)S(0)2N(R12a)-,
-S-, -N(R12)-, -0C(OR12)(R12a)-, -N(R12)C(0)N(R12a)-, and -0C(0)N(R12)-;
each -R1 , -R10a, x101
is independently selected from the group consisting of -H, -T,
C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl; wherein -T, CI _20 alkyl, C2-20
alkenyl, and C2_20 alkynyl are optionally substituted with one or more -R11,
which are the same or different and wherein C120 alkyl, C2_20 alkenyl, and
C2_20
alkynyl are optionally interrupted by one or more groups selected from the
group consisting of -T-, -C(0)0-, -0-, -C(0)-, -C(0)N(R12)-, -S(0)2N(R12)-,
-S(0)N(R12)-, -S(0)2-, -S(0)-, -N(R12)S(0)2N(R12a)-, -S-, -N(R12)-,
-0C(OR12)(R12a)-, -N(R12)C(0)N(R12a)-, and -0C(0)N(R12)-;
each T is independently of each other selected from the group consisting of
phenyl,
naphthyl, indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, and 8- to 11-membered heterobicyclyl; wherein each T is
independently optionally substituted with one or more -R11, which are the same
or different;
each -R" is independently of each other selected from halogen, -CN, oxo
(=0), -COOR13, -0R13, -C(0)R13, -C(0)N(R13R13a), -S(0)2N(R13R13a),
-S(0)N(R13R13a), -S(0)2R13, -S(0)R13, -N(R13)S(0)2N(R13aRl3b), _SR' 3,
-N(R13R13a), -NO2, -0C(0)R13, -N(R13)C(0)R13a, -N(R13)S(0)2R13a,
-N(R13)S(0)R13a,
-N(R13)C(0)0R13a, -N(R13)C(0)N(R3aRi3b),
-0C(0)N(R13R13a), and C1_6 alkyl; wherein C1,6 alkyl is optionally substituted
with one or more halogen, which are the same or different;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
48
each -R12, -Ri2a, _R13, _R13a,
Ri3b is independently selected from the group consisting
of -H, and Ci_6 alkyl; wherein C1_6 alkyl is optionally substituted with one
or
more halogen, which are the same or different;
optionally, one or more of the pairs -R1/-R1a, -R2/_R2a, _R3/_R3a, _R6/_R6a,
_R7/_R7a are
joined together with the atom to which they are attached to form a C3_10
cycloalkyl or a 3- to 10-membered heterocyclyl;
optionally, one or more of the pairs -R'/-R2, -R'/-R3, -R'/-R4, -R'/-R5, -R'/-
R6,
-R1/-R7, -R2/-R3, -R2/-R4, -R2/-R5, -R2/-R6, -R2/-R7, -R3/-R4, -R3/-R5, -R3/-
R6,
-R3/-R7, -R4/-R5, -R4/-R6, -R4/-R7, -R5/-R6, -R5/-R7, -R6/-R7 are joint
together
with the atoms to which they are attached to form a ring A;
A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl;

tetralinyl; C3_10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11 -
membered heterobicyclyl; and
wherein -LI- is substituted with -X D-L2- and wherein
is optionally further
substituted.
The optional further substituents of -L1- of formula (II) are as described
above.
In certain embodiments of formula (II) is substituted with one moiety -X D-
L2-.
In certain embodiments -L1- of formula (II) is not further substituted.
Additional embodiments for -LI- are disclosed in EP1536334B1, W02009/009712A1,
W02008/034122A1, W02009/143412A2, W02011/082368A2, and US8618124B2, which
are herewith incorporated by reference in their entirety.
Further embodiments for
are disclosed in US8946405B2 and US8754190B2, which are
herewith incorporated by reference in their entirety. Accordingly, in certain
embodiments -L1- is of formula (III):
R2
R5
0
1 I I ii
m I 5
(III),
wherein

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
49
the dashed line indicates attachment to -D through a functional group of -D
selected
from the group consisting of -OH, -SH and -NH2;
m is 0 or 1;
at least one or both of -R1 and -R2 is/are independently of each other
selected from the
group consisting of -CN, -NO2, optionally substituted aryl, optionally
substituted heteroaryl, optionally substituted alkenyl, optionally substituted

alkynyl, -C(0)R3, -S(0)R3, -S(0)2R3, and -SR4,
one and only one of -R1 and -R2 is selected from the group consisting of -H,
optionally
substituted alkyl, optionally substituted arylalkyl, and optionally
substituted
heteroarylalkyl;
-R3 is selected from the group consisting of -H, optionally substituted
alkyl,
optionally substituted aryl, optionally substituted arylalkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl, -0R9
and -N(R9)2;
-R4 =
is selected from the group consisting of optionally substituted alkyl,
optionally
substituted aryl, optionally substituted arylalkyl, optionally substituted
heteroaryl, and optionally substituted heteroarylalkyl;
each -R5 is independently selected from the group consisting of -H, optionally

substituted alkyl, optionally substituted alkenylalkyl, optionally substituted
alkynylalkyl, optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted heteroaryl and optionally substituted heteroarylalkyl;
-R9 is selected from the group consisting of -H and optionally substituted
alkyl;
-Y- is absent and ¨X- is -0- or -S-; or
-Y- is -N(Q)CH2- and -X- is -0-;
Q is selected from the group consisting of optionally substituted alkyl,
optionally
substituted aryl, optionally substituted arylalkyl, optionally substituted
heteroaryl and optionally substituted heteroarylalkyl;
optionally, -R1 and -R2 may be joined to form a 3 to 8-membered ring; and
optionally, both -R9 together with the nitrogen to which they are attached
form a
heterocyclic ring; and
wherein -LI- is substituted with -X D-L2- and wherein is optionally
further
substituted.
Only in the context of formula (III) the terms used have the following
meaning:

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
The term "alkyl" as used herein includes linear, branched or cyclic saturated
hydrocarbon
groups of 1 to 8 carbon atoms, or in some embodiments 1 to 6 or 1 to 4 carbon
atoms.
5 The term "alkoxy" includes alkyl groups bonded to oxygen, including methoxy,
ethoxy,
isopropoxy, cyclopropoxy, cyclobutoxy, and similar.
The term "alkenyl" includes non-aromatic unsaturated hydrocarbons with carbon-
carbon
double bonds.
The term "alkynyl" includes non-aromatic unsaturated hydrocarbons with carbon-
carbon
triple bonds.
The term "aryl" includes aromatic hydrocarbon groups of 6 to 18 carbons,
preferably 6 to 10
carbons, including groups such as phenyl, naphthyl, and anthracenyl. The term
"heteroaryl"
includes aromatic rings comprising 3 to 15 carbons containing at least one N,
0 or S atom,
preferably 3 to 7 carbons containing at least one N, 0 or S atom, including
groups such as
pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl,
quinolyl, indolyl, indenyl, and similar.
In some instance, alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled
to the
remainder of the molecule through an alkylene linkage. Under those
circumstances, the
substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or
heteroarylalkyl,
indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or
heteroaryl moiety
and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.
The term "halogen" includes bromo, fluoro, chloro and iodo.
The term "heterocyclic ring" refers to a 4 to 8 membered aromatic or non-
aromatic ring
comprising 3 to 7 carbon atoms and at least one N, 0, or S atom. Examples are
piperidinyl,
piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as
the exemplary
groups provided for the term "heteroaryl" above.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
51
When a ring system is optionally substituted, suitable substituents are
selected from the group
consisting of alkyl, alkenyl, alkynyl, or an additional ring, each optionally
further substituted.
Optional substituents on any group, including the above, include halo, nitro,
cyano, -OR, -SR, -NR2, -OCOR, -NRCOR, -COOR, -CONR2, -SOR, -SO2R, -SONR2, -
SO2N
R2, wherein each R is independently alkyl, alkenyl, alkynyl, aryl or
heteroaryl, or two R
groups taken together with the atoms to which they are attached form a ring.
In certain embodiments -L1- of formula (III) is substituted with one moiety -X
D-L2-.
Another embodiment for -Ll- is disclosed in W02013/036857A1, which is herewith
incorporated by reference in its entirety. Accordingly, in certain embodiments
is of
formula (IV):
0 H R4
0
1 II I II
R¨S¨C ___________________
I R
I I 2 3
0 R
(IV),
wherein
the dashed line indicates attachment to -D through an amine functional group
of -D;
-R1 is selected from the group consisting of optionally substituted C1-C6
linear,
branched, or cyclic alkyl; optionally substituted aryl; optionally substituted

heteroaryl; alkoxy; and -NR52;
-R2 is selected from the group consisting of -H; optionally substituted Ci -
C6 alkyl;
optionally substituted aryl; and optionally substituted heteroaryl;
-R3 is selected from the group consisting of -H; optionally substituted C1-
C6 alkyl;
optionally substituted aryl; and optionally substituted heteroaryl;
-R4 is selected from the group consisting of -H; optionally substituted Ci -C6
alkyl;
optionally substituted aryl; and optionally substituted heteroaryl;
each -R5 is independently of each other selected from the group consisting of -
H;
optionally substituted Ci-C6 alkyl; optionally substituted aryl; and
optionally
substituted heteroaryl; or when taken together two -R5 can be cycloalkyl or
cycloheteroalkyl; and
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
52
Only in the context of formula (IV) the terms used have the following meaning:
"Alkyl", "alkenyl", and "alkynyl" include linear, branched or cyclic
hydrocarbon groups of 1-
8 carbons or 1-6 carbons or 1-4 carbons wherein alkyl is a saturated
hydrocarbon, alkenyl
includes one or more carbon-carbon double bonds and alkynyl includes one or
more carbon-
carbon triple bonds. Unless otherwise specified these contain 1-6 C.
"Aryl" includes aromatic hydrocarbon groups of 6-18 carbons, preferably 6-10
carbons,
including groups such as phenyl, naphthyl, and anthracene "Heteroaryl"
includes aromatic
rings comprising 3-15 carbons containing at least one N, 0 or S atom,
preferably 3-7 carbons
containing at least one N, 0 or S atom, including groups such as pyrrolyl,
pyridyl,
pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiszolyl, isothiazolyl,
quinolyl, indolyl,
indenyl, and similar.
The term "substituted" means an alkyl, alkenyl, alkynyl, aryl, or heteroaryl
group comprising
one or more substituent groups in place of one or more hydrogen atoms.
Substituents may
generally be selected from halogen including F, Cl, Br, and I; lower alkyl
including linear,
branched, and cyclic; lower haloalkyl including fluoroalkyl, chloroalkyl,
bromoalkyl, and
iodoalkyl; OH; lower alkoxy including linear, branched, and cyclic; SH; lower
alkylthio
including linear, branched and cyclic; amino, alkylamino, dialkylamino, silyl
including
alkylsilyl, alkoxysilyl, and arylsilyl; nitro; cyano; carbonyl; carboxylic
acid, carboxylic ester,
carboxylic amide, aminocarbonyl; aminoacyl; carbamate; urea; thiocarbamate;
thiourea;
ketne; sulfone; sulfonamide; aryl including phenyl, naphthyl, and anthracenyl;
heteroaryl
including 5-member heteroaryls including as pyrrole, imidazole, furan,
thiophene, oxazole,
thiazole, isoxazole, isothiazole, thiadiazole, triazole, oxadiazole, and
tetrazole, 6-member
heteroaryls including pyridine, pyrimidine, pyrazine, and fused heteroaryls
including
benzofuran, benzothiophene, benzoxazole, benzimidazole, indole, benzothiazole,

benzisoxazole, and benzisothiazole.
In one embodiment -L1- of formula (IV) is substituted with one moiety -X D-L2-
.
A further embodiment for -Ll- is disclosed in US7585837B2, which is herewith
incorporated
by reference in its entirety. Accordingly, in certain embodiments -L1-is of
formula (V):

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
53
Ri R2
R3
R4
(V),
wherein
the dashed line indicates attachment to -D through an amine functional group
of -D;
R1 and R2 are independently selected from the group consisting of hydrogen,
alkyl,
alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, -S03H, -SO2NHR5,
amino,
ammonium, carboxyl, P03H2, and 0P03H2;
R3, R4, and R5 are independently selected from the group consisting of
hydrogen,
alkyl, and aryl; and
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted.
Suitable substituents for formulas (V) are alkyl (such as C1_6 alkyl), alkenyl
(such as C2_6
alkenyl), alkynyl (such as C2_6 alkynyl), aryl (such as phenyl), heteroalkyl,
heteroalkenyl,
heteroalkynyl, heteroaryl (such as aromatic 4 to 7 membered heterocycle) or
halogen
moieties.
Only in the context of formula (V) the terms used have the following meaning:
The terms "alkyl", "alkoxy", "alkoxyalkyl", "aryl", "alkaryl" and "aralkyl"
mean alkyl
radicals of 1-8, preferably 1-4 carbon atoms, e.g. methyl, ethyl, propyl,
isopropyl and butyl,
and aryl radicals of 6-10 carbon atoms, e.g. phenyl and naphthyl. The term
"halogen" includes
bromo, fluoro, chloro and iodo.
In certain embodiments of formula (V) is substituted with one moiety -X D-
L2-.
In certain embodiments -L1- of formula (V) is not further substituted.
In certain embodiments -LI- is as disclosed in W02002/089789A1, which is
herewith
incorporated by reference in its entirety. Accordingly, in certain embodiments
-L1- is of
formula (VI):

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
54
Yi
L1
0 R3 R5 Y
2 :*
R4 R6
Au- -7 'R2
(VD,
wherein
the dashed line indicates attachment to -D through an amine functional group
of -D;
L1 is a bifunctional linking group,
Yi and Y2 are independently 0, S or NR7;
R2, R3, R4, R5, R6 and R7 are independently selected from the group consisting
of
hydrogen, C1_6 alkyls, C3_12 branched alkyls, C3_8 cycloalkyls, C1_6
substituted alkyls,
C3_8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1_6
heteroalkyls,
substituted C1_6 heteroalkyls, C1_6 alkoxy, phenoxy, and C1_6 heteroalkoxy;
Ar is a moiety which when included in formula (VI) forms a multisubstituted
aromatic
hydrocarbon or a multi-substituted heterocyclic group;
X is a chemical bond or a moiety that is actively transported into a target
cell, a
hydrophobic moiety, or a combination thereof,
y is 0 or 1; and
wherein -LI- is substituted with -X D-L2- and wherein is optionally further
substituted.
Only in the context of formula (VI) the terms used have the following meaning:
The term "alkyl" shall be understood to include, e.g. straight, branched,
substituted C1_12
alkyls, including alkoxy, C3_8 cycloalkyls or substituted cycloalkyls, etc.
The term "substituted" shall be understood to include adding or replacing one
or more atoms
contained within a functional group or compounds with one or more different
atoms.
Substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos,
hydroxyalkyls and
mercaptoalkyls; substtued cycloalkyls include moieties such as 4-
chlorocyclohexyl; aryls
include moieties such as napthyl; substituted aryls include moieties such as 3-
bromo-phenyl;
aralkyls include moieties such as toluyl; heteroalkyls include moieties such
as ethylthiophene;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
substituted heteroalkyls include moieties such as 3-methoxythiophone; alkoxy
includes
moieities such as methoxy; and phenoxy includes moieties such as 3-
nitrophenoxy. Halo-
shall be understood to include fluoro, chloro, iodo and bromo.
5 In certain embodiments -L1- of formula (VI) is substituted with one
moiety -X D-L2-.
In certain embodiments -1_,1- of formula (VI) is not further substituted.
In certain embodiments -L1- comprises a substructure of formula (VII)
,
¨I0 0
: /--/
¨0
10 , (VII),
wherein
the dashed line marked with the asterisk indicates attachment to a nitrogen of
-D by
forming an amide bond;
the unmarked dashed lines indicate attachment to the remainder of -L1-; and
15 wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted.
The optional further substituents of -LI- of formula (VII) are as described
above.
20 In certain embodiments -L1- of formula (VII) is substituted with one
moiety -X D-L2-.
In certain embodiments -1_,1- of formula (VII) is not further substituted.
In certain embodiments -L1- comprises a substructure of formula (VIII)
,
.\(.
-HO 0 * 0
, 0
25 (VIII),
wherein

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
56
the dashed line marked with the asterisk indicates attachment to a nitrogen of
-D by
forming a carbamate bond;
the unmarked dashed lines indicate attachment to the remainder of -L1-; and
wherein -L1- is substituted with -X D-L2- and wherein -L1- is optionally
further
substituted.
The optional further substituents of -LI- of formula (VIII) are as described
above.
In certain embodiments -L1- of formula (VIII) is substituted with one moiety -
X D-L2-.
In certain embodiments -Ll- of formula (VIII) is not further substituted.
It is understood that a moiety -12-X0D_, I-
L D is connected to Z through covalent attachment
of -L2- to -Z.
It is also understood that the phrase "-L1- is substituted with -X D-L2-"
means that -L2- is
attached to -L1- via -X D-, which is either absent or a linkage, and that the
moiety _x01130/2 is
not attached to -L1- via -L2-.
In certain embodiments all moieties -X D- are identical. In certain
embodiments a conjugate
of the present invention comprises more than one type of -X D-, such as two,
three or four
different types of -X D-.
In certain embodiments -X D- is a stable linkage, i.e -LI- and -X D-L2- are
connected through
a stable linkage.
In certain embodiments -X D- is absent, in which case the moiety -L2-)(op_LI-
is a
moiety -L2-1.1-, wherein the bond between -L2- and -Ll- is a stable bond.
In the conjugates of the present invention -L2- is absent or a spacer moiety.
In certain
embodiments -L2- does not comprise a reversible linkage, i.e. all linkages in -
L2- are stable
linkages. -1.1- is connected to -L2- via a stable linkage. -L2- is connected
to -Z via a stable
linkage.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
57
In certain embodiments -L2- is absent.
In certain embodiments -L2- is a spacer moiety.
In certain embodiments -L2- is a spacer moiety selected from the group
consisting of -T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY1)-, -S(0)2N(RY1)-, -S(0)N(RY1)-, -S(0)2-,
-S(0)-, -N(RYI)S(0)2N(RY")-,
-S-, -N(RY1)-, -0C(ORY1)(RY1a)-,
-N(RY1)C(0)N(RYla)-, -0C(0)N(RY1)-, Ci_50 alkyl, C2_50 alkenyl, and C2_50
alkynyl;
wherein -T-, C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
substituted with one or
more -RY2, which are the same or different and wherein C1_50 alkyl, C2_50
alkenyl, and C2_50
alkynyl are optionally interrupted by one or more groups selected from the
group consisting
of -T-, -C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -
S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RY1 a are independently of each other selected from the group
consisting of -H, -T,
C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T, C1_50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(RY4a)-, -N(RY4)C(0)N(RY4a)-, and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
each -RY2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -000RY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -SRY5, -N(RY5RY5a), -NO2, -
0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a,
-N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
58
-N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl
is optionally
substituted with one or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently selected from the group
consisting of -H, and C1_6 alkyl, wherein C1_6 alkyl is optionally substituted
with one or more
halogen, which are the same or different.
In certain embodiments -L2- is a spacer moiety selected from -T-, -C(0)0-, -0-
,
-C(0)-, -C(0)N(RYI)-, -S(0)2N(RYI)-,
-S(0)N(RY1)-, -S(0)2-,
-S(0)-, -N(RYI)S(0)2N(RY")-, -S-, -N(RY1)-, -0C(ORY1)(Ryla)_,
_N(Ryl)c(o)N(Ryla)_,
-0C(0)N(RY1)-, C1-50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-,
C1_20 alkyl, C2-20
alkenyl, and C2_20 alkynyl are optionally substituted with one or more -RY2,
which are the
same or different and wherein C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl
are optionally
interrupted by one or more groups selected from the group consisting of -T-, -
C(0)0-, -0-,
-C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -
N(RY3)S(0)2N(RY3a)-,
-S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
Ci_io alkyl, C2-10 alkenyl, and C2_10 alkynyl; wherein -T, C1_10 alkyl, C2_10
alkenyl, and C2-10
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein Chio alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a._,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
-RY2 is selected from the group consisting of halogen, -CN, oxo
(=0), -000RY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), SR5 -N(RY5RY5a), -NO2, -0C(0)R5, -
N(R5)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
59
C(0)RY5a, -N(RY5)S(0)2RY5a, -N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a, -
N(RY5)C(0)N(RY5aRY5b),
-0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl is optionally substituted
with one or
more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4,
-
K - RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different.
In certain embodiments -L2- is a spacer moiety selected from the group
consisting
of -T-, -C(0)0-, -0-, -C(0)-, -C(0)N(RY1)-, -S(0)2N(RY1)-, -S(0)N(RY1)-, -
S(0)2-,
-S(0)-, -N(RYI)S(0)2N(RY")-,
-S-, -N(RY1)-, -0C(ORY1)(Ryla)_,
-N(RY1)C(0)N(RY1a)-, -0C(0)N(RY1)-, Co alkyl, Co alkenyl, and C2_50 alkynyl;
wherein -T-, C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
substituted with one or
more -RY2, which are the same or different and wherein C1_50 alkyl, C2_50
alkenyl, and C2_50
alkynyl are optionally interrupted by one or more groups selected from the
group consisting
of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RY1 a are independently selected from the group consisting of -H, -
T, Ci_io alkyl, C2_10
alkenyl, and C2_10 alkynyl;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
each -RY2 is independently selected from the group consisting of halogen, and
C1_6 alkyl; and
each -RY3, -Ry3a, _Ry4, - K y4a,
- RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments -L2- is a C1_20 alkyl chain, which is optionally
interrupted by one or
more groups independently selected from -0-, -T- and -C(0)N(RY1)-; and which
Ci_20 alkyl
chain is optionally substituted with one or more groups independently selected
from -OH, -T
and -C(0)N(Ry6Ry6a) ;
wherein -RY1, -RY6, -RY6a are independently selected from the group
5 consisting of H and C1_4 alkyl and wherein T is selected from the group
consisting of phenyl,
naphthyl, indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, 8- to
11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-
membered
heteropolycyclyl.
10 In certain embodiments -L2- has a molecular weight ranging from 14 g/mol
to 750 g/mol.
In certain embodiments -L2- comprises a moiety selected from
//0
-(Z\
0
15 In certain embodiments -L2- has a chain lengths of 1 to 20 atoms.
As used herein the term "chain length" with regard to the moiety -L2- refers
to the number of
atoms of -L2- present in the shortest connection between -X '-L'- and -Z.
20 In certain embodiments -L2- is of formula (i)
0
// 0
- - n
0
(0,
wherein
the dashed line marked with the asterisk indicates attachment to -L1-;
the unmarked dashed line indicates attachment to -Z;
25 n is selected from the group consisting of 0, 1,2, 3,4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14,
15, 16, 17 and 18;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
61
m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14,
15, 16, 17 and 18; and
wherein the moiety of formula (i) is optionally further substituted.
In certain embodiments n of formula (i) is selected from the group consisting
of 3, 4, 5, 6, 7,
8, and 9. In certain embodiments n of formula (i) is 3, 4, 5, 6, or 7. In
certain embodiments n
of formula (i) is 3. In certain embodiments n of formula (i) is 4. In certain
embodiments n of
formula (i) is 5. In certain embodiments n of formula (i) is 6.
In certain embodiments m of formula (i) is selected from the group consisting
of 1, 2, 3, 4, 5,
6 or 7. In certain embodiments m of formula (i) is 1, 2, 3, 4 or 5. In certain
embodiments m of
formula (i) is 1. In certain embodiments m of formula (i) is 2. In certain
embodiments m of
formula (i) is 3. In certain embodiments m of formula (i) is 4.
In certain embodiments the moiety 1_
L is selected from the group consisting of
0
I I s
H* 0 0
0
0
0
(Ia-i),
0
H* 0 0
0
0 N
0
(Ia-ii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
62
0
I
I 11 s
H* 0
C' 0
N,.-----__s
/
0
(Ia-iii)
0
I
I 11 s
H* 0
' 0
N,.-----__s _____________________ C
/
N
0
(Ia-iv),
0
I
I
H* 0 0
N---__S CI
/
I - - 3
0
(Ib-i),
0
I
I
H* 0 0
N---__S CI
/
I - - 4
0
(Ib-ii),
0
I
I
H* 0 0
N---__S CI
/
I - - 5
2 ' *
0
(Ib-iii),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
63
0
I
I 11 s
H* 0
' 0
N -------6 s C
/
I
N - - = - -
0
0 2
(Ib-iv),
0
I
I 11 s
H* 0
C' 0
N ------- s
/
N - - =
0
(IC-1),
0
I
I
H* 0 0
N ---__S CI
/
I - - 4
3 ' *
0
(IC-ii),
0
I
I
H* 0 0
N ---__S CI
/
I - - 5
3 ' *
0
(IC-iii),
0
I
I
H* 0 0
CI
/
I- - 6 \_,¨N ,- - =
0 3
(IC-iv),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
64
I 0
I I I s
H* 0 0
0
N------7s
/
0
(Id-i),
I 0
I I I s
H* 0 0
)'.
N S __ \_.¨N0
0
(Id-ii),
I 0
I
H* 0
7() 0
/
\_____N
0
(Id-iii),
I 0
I
H* 0
7() 0
N----6¨s
/
\_____I\I
0 4
(Id-iv);
wherein
the unmarked dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond; and
the dashed line marked with the asterisk indicates attachment to -Z.
In certain embodiments the moiety -L2-X '-L'-
is of formula (ha-i). In certain embodiments
the moiety -L2-X0DL_, 1_
is of formula (ha-ii). In certain embodiments the

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
moiety -L 2A0DL_, 1_
is of formula (ha-iii). In certain embodiments the moiety -L2-xoD_Li_ is
of formula (IIa-iv). In certain embodiments the moiety -L2-X0D_, 1_
L is of formula (IIb-i). In
certain embodiments the moiety -L2-X013_-.- 1_
L
is of formula (IIb-ii). In certain embodiments the
moiety -L2_)(0D_
L1_ is of formula (IIb-iii). In certain embodiments the moiety -L2-xoD_Li_ is
5 of formula (IIb-iv). In certain embodiments the moiety -L2-X0DL_, 1_
is of formula (IIc-i). In
certain embodiments the moiety -L2-X0D_, 1_
L
is of formula (IIc-ii). In certain embodiments the
moiety -L 2A0D_, 1_
L is of formula (IIc-iii). In certain embodiments the moiety -L2-XoD_Li_ is
of formula (IIc-iv). In certain embodiments the moiety -L2-X0DL_, 1_
is of formula (lid-i). In
certain embodiments the moiety -L2-X013_ 1_
L
is of formula (lid-ii). In certain embodiments the
10 moiety -L2A013_-.- 1_
L is of formula (lid-iii). In certain embodiments the moiety -L2-XoD_Li_ is
of formula (IId-iv).
In certain embodiments -Z is degradable.
15 It was surprisingly found that it is highly advantageous to use a
degradable moiety -Z that
degrades into soluble degradation products after no more than 4 months after
administration
to the infected joint, such as after no more than 3 months, such as after no
more than 2
months. This degradability of -Z reduces the risk that the polymeric matrix
provides a new
artificial surface for biofilm formation.
In certain embodiments -Z is a hydrogel. In certain embodiments such hydrogel
is a
hydrophilic or amphiphilic polymeric network composed of homopolymers or
copolymers,
which is water-insoluble due to the presence of covalent chemical crosslinks.
It was surprisingly found that when -Z is a hydrogel, such hydrogel provides a
protective
environment for the antibiotic moieties that prevents their hydrolysis. This
effect is
particularly useful for antibiotic moieties comprising for example a lactone
moiety, such as
daptomycin, erythromycin, clarithromycin, azithromycin, boromycin,
oleandomycin,
roxithromycin, spiramycin, telithromycin, arylomycins, tylosine and linezolid,
because
lactone hydrolysis tends to lead to a loss of activity which reduces overall
treatment efficacy.
In certain embodiments the conjugate of the first or second aspect or the
compound of the
third aspect is a pre-synthesized conjugate or compound, i.e. the conjugate or
compound is
synthesized in vitro and is not formed in vivo after administration to a
patient. This is in

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
66
contrast to hydrogel conjugates that are formed in vivo upon administration to
a patient, such
as by in vivo polymerization.
In certain embodiments such hydrogel comprises a polymer selected from the
group
consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids),
poly(acrylates),
poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines),
poly(amino
acids), poly(anhydrides), poly(aspartamides), poly(butyric acids),
poly(glycolic acids),
polybutylene terephthalates, poly(caprolactones), poly(carbonates),
poly(cyanoacrylates),
poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(alkylene
glycols), such as
poly(ethylene glycols) and poly(propylene glycol), poly(ethylene oxides),
poly(ethyl
phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl
acrylates),
poly(hydroxyethyl-oxazolines),
poly(hydroxymethacrylates),
poly(hydroxypropylmethacrylamides), poly(hydroxypropyl
methacrylates),
poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids),
poly(lactic-co-
glycolic acids), poly(methacrylamides), poly(methacrylates),
poly(methyloxazolines),
poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene
glycols),
poly(siloxanes), poly(urethanes), poly(vinyl alcohols),
poly(vinyl amines),
poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses,
carbomethyl
celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans,
dextrins, gelatins,
hyaluronic acids and derivatives, functionalized hyaluronic acids, mannans,
pectins,
rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches
and other
carbohydrate-based polymers, xylans, and copolymers thereof.
In certain embodiments -Z is a poly(alkylene glycol)-based or hyaluronic acid-
based
hydrogel.
In certain embodiments -Z is a poly(propylene glycol)-based hydrogel.
In certain embodiments -Z is a PEG-based hydrogel.
In certain embodiments such PEG-based hydrogel comprise a plurality of
backbone moieties
that are crosslinked via crosslinker moieties -CLP-. Optionally, there is a
spacer
moiety -SP I - between a backbone moiety and a crosslinker moiety. In certain
embodiments
such spacer -SP I- is defined as described above for -L2-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
67
In certain embodiments a backbone moiety has a molecular weight ranging from 1
kDa to 20
kDa.
In certain embodiments a backbone moiety is of formula (pA)
B*-(A-Hyp)õ (pA),
wherein
B* is a branching core,
A is a PEG-based polymer,
Hyp is a branched moiety,
xis an integer of from 3 to 16;
and wherein each backbone moiety is connected to one or more crosslinker
moieties
and to one or more moieties -L2-, which crosslinker moieties and moieties -L2-
are
connected to Hyp, either directly or through a spacer moiety.
In certain embodiments B* of formula (pA) is selected from the group
consisting of
polyalcohol moieties and polyamine moieties. In certain embodiments B* of
formula (pA) is a
polyalcohol moiety. In certain embodiments B* of formula (pA) is a polyamine
moiety.
In certain embodiments the polyalcohol moieties for B* of formula (pA) are
selected from the
group consisting of a pentaerythritol moiety, tripentaerythritol moiety,
hexaglycerine moiety,
sucrose moiety, sorbitol moiety, fructose moiety, mannitol moiety and glucose
moiety. In
certain embodiments B* of formula (pA) is a pentaerythritol moiety, i.e. a
moiety of formula
0 0
0 0
, wherein dashed lines indicate attachment to -A-.
In certain embodiments the polyamine moieties for B* of formula (pA) is
selected from the
group consisting of an ornithine moiety, diaminobutyric acid moiety, trilysine
moiety,
tetralysine moiety, pentalysine moiety, hexalysine moiety, heptalysine moiety,
octalysine
moiety, nonalysine moiety, decalysine moiety, undecalysine moiety,
dodecalysine moiety,
tridecalysine moiety, tetradecalysine moiety and pentadecalysine moiety. In
certain

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
68
embodiments B* of formula (pA) is selected from the group consisting of an
ornithine
moiety, diaminobutyric acid moiety and a trilysine moiety.
A backbone moiety of formula (pA) may consist of the same or different PEG-
based
.. moieties -A- and each moiety -A- may be chosen independently. In certain
embodiments all
moieties -A- present in a backbone moiety of formula (pA) have the same
structure. It is
understood that the phrase "have the same structure" with regard to polymeric
moieties, such
as with regard to the PEG-based polymer -A-, means that the number of monomers
of the
polymer, such as the number of ethylene glycol monomers, may vary due to the
polydisperse
nature of polymers. In certain embodiments the number of monomer units does
not vary by
more than a factor of 2 between all moieties -A- of a hydrogel.
In certain embodiments each -A- of formula (pA) has a molecular weight ranging
from 0.3
kDa to 40 kDa; e.g. from 0.4 to 30 kDa, from 0.4 to 25 kDa, from 0.4 to 20
kDa, from 0.4 to
15 kDa, from 0.4 to 10 kDa or from 0.4 to 5 kDa. In certain embodiments each -
A- has a
molecular weight from 0.4 to 5 kDa. In certain embodiments -A- has a molecular
weight of
about 0.5 kDa. In certain embodiments -A- has a molecular weight of about 1
kDa. In certain
embodiments -A- has a molecular weight of about 2 kDa. In certain embodiments -
A- has a
molecular weight of about 3 kDa. In certain embodiments -A- has a molecular
weight of
about 5 kDa.
In certain embodiments -A- of formula (pA) is of formula (pB-i)
-(CH2). i (OCH2CH2)nX- (0-0,
wherein
n1 is 1 or 2;
n is an integer ranging from 3 to 250, such as from 5 to 200, such as from 8
to 150 or
from 10 to 100; and
X is a chemical bond or a linkage covalently linking A and Hyp.
In certain embodiments -A- of formula (pA) is of formula (pB-ii)
-(CH2)ni(OCH2CH2)n-(CH2)n2X- (pB-ii),
wherein
n1 is 1 or 2;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
69
n is an integer ranging from 3 to 250, such as from 5 to 200, such as from 8
to 150 or
from 10 to 100;
n2 is 0 or 1; and
X is a chemical bond or a linkage covalently linking A and Hyp.
In certain embodiments -A- of formula (pA) is of formula (pB-i')
n3 (pB-i`),
wherein
the dashed line marked with the asterisk indicates attachment to B*,
the unmarked dashed line indicates attachment to -Hyp; and
n3 is an integer ranging from 10 to 50.
In certain embodiments n3 of formula (pB-i') is 25. In certain embodiments n3
of formula
(pB-i') is 26. In certain embodiments n3 of formula (pB-i') is 27. In certain
embodiments n3
of formula (pB-i') is 28. In certain embodiments n3 of formula (pB-i') is 29.
In certain
embodiments n3 of formula (pB-i') is 30.
In certain embodiments a moiety B*-(A)4 is of formula (pB-a)
n3 n3
n3 n3 (pB-a),
wherein
dashed lines indicate attachment to Hyp; and
each n3 is independently an integer selected from 10 to 50.
In certain embodiments n3 of formula (pB-a) is 25. In certain embodiments n3
of formula
(pB-a) is 26. In certain embodiments n3 of formula (pB-a) is 27. In certain
embodiments n3 of
formula (B-a) is 28. In certain embodiments n3 of formula (pB-a) is 29. In
certain
embodiments n3 of formula (pB-a) is 30.
A backbone moiety of formula (pA) may consist of the same or different
dendritic
moieties -Hyp and that each -Hyp can be chosen independently. In certain
embodiments all
moieties -Hyp present in a backbone moiety of formula (pA) have the same
structure.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments each -Hyp of formula (pA) has a molecular weight
ranging from 0.3
kDa to 5 kDa.
5 In certain embodiments -Hyb is be selected from the group consisting of a
moiety of formula
(PHYP-0
0
H NN
- - p2
N H 2
N H2 H
N
* - - P3 - - p4
0 0
(PHYP-0,
wherein
the dashed line marked with the asterisk indicates attachment to -A-,
10
the unmarked dashed lines indicate attachment to a spacer moiety -SP1-, a
crosslinker
moiety -CL"- or to -L2-; and
p2, p3 and p4 are identical or different and each is independently of the
others an
integer from 1 to 5;
15 .. a moiety of formula (pHyp-ii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
71
0 0
H
P-H - - p 6H
H N
H N
H
- P7
0
0
H NN
P 8H
H N-i,
H N
_ H
- P9 - - p io P11
0 0 0
(PHYP-ii),
wherein
the dashed line marked with the asterisk indicates attachment to -A-,
the unmarked dashed lines indicate attachment to a spacer moiety -SP'-, a
crosslinker
moiety -CL"- or to -L2-; and
p5 to pl 1 are identical or different and each is independently of the others
an integer
from 1 to 5;
a moiety of formula (pHyp-iii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
72
0 0 0
H
H N
P12
- - p 14
H N '
H
H N
0 - P15
OH
H
- P16
',NH
H N
H NNN
H - - P17 H - - P18
0 0 0 0
H -
N,11
H
- - P19
H N
H
H N
0- P21
0 H - - N
H N p24H
>NH HN
N
H - - P23 H - - P25 H - - P26
0 0 0 0
(pHyp-iii),
wherein
the dashed line marked with the asterisk indicates attachment to -A-,
the unmarked dashed lines indicate attachment to a spacer moiety -SP1-, a
crosslinker
moiety -CL"- or to -L2-; and
p12 to p26 are identical or different and each is independently of the others
an integer
from 1 to 5; and
a moiety of formula (pHyp-iv)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
73
H
[ d/N--4---,,'
P270
H - H
.,,,,,.NN.õ--------------N"
* - H - q
0
[ ¨HI\ls/
pH 28
(pHyp-iv),
wherein
the dashed line marked with the asterisk indicates attachment to -A-,
the unmarked dashed lines indicate attachment to a spacer moiety -SP1-, a
crosslinker
moiety -CLP- or to
p27 and p28 are identical or different and each is independently of the other
an integer
from 1 to 5; and
q is an integer from 1 to 8;
wherein the moieties (pHyp-i) to (pHyp-iv) may at each chiral center be in
either R- or S-
configuration.
In certain embodiments all chiral centers of a moiety (pHyp-i), (pHyp-ii),
(pHyp-iii) or
(pHyp-iv) are in the same configuration. In certain embodiments all chiral
centers of a moiety
(pHyp-i), (pHyp-ii), (pHyp-iii) or (pHyp-iv) are in R-configuration. In
certain embodiments
all chiral centers of a moiety (pHyp-i), (pHyp-ii), (pHyp-iii) or (pHyp-iv)
are in S-
configuration.
In certain embodiments p2, p3 and p4 of formula (pHyp-i) are identical. In
certain
embodiments p2, p3 and p4 of formula (pHyp-i) are 1. In certain embodiments
p2, p3 and p4
of formula (pHyp-i) are 2. In certain embodiments p2, p3 and p4 of formula
(pHyp-i) are 3. In
certain embodiments p2, p3 and p4 of formula (pHyp-i) are 4. In certain
embodiments p2, p3
and p4 of formula (pHyp-i) are 5.
In certain embodiments p5 to pll of formula (pHyp-ii) are identical. In
certain embodiments
p5 to pll of formula (pHyp-ii) are 1. In certain embodiments p5 to pll of
formula (pHyp-ii)
are 2. In certain embodiments p5 to pll of formula (pHyp-ii) are 3. In certain
embodiments

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
74
p5 to p11 of formula (pHyp-ii) are 4. In certain embodiments p5 to p11 of
formula (pHyp-ii)
are 5.
In certain embodiments p12 to p26 of formula (pHyp-iii) are identical. In
certain
embodiments p12 to p26 of formula (pHyp-iii) are 1. In certain embodiments p12
to p26 of
formula (pHyp-iii) are 2. In certain embodiments p12 to p26 of formula (pHyp-
iii) are 3. In
certain embodiments p12 to p26 of formula (pHyp-iii) are 4. In certain
embodiments p12 to
p26 of formula (pHyp-iii) are 5.
In certain embodiments q of formula (pHyp-iv) is 1. In certain embodiments of
formula
(pHyp-iv) is 2. In certain embodiments q of formula (pHyp-iv) is 3. In certain
embodiments q
of formula (pHyp-iv) is 4. In certain embodiments q of formula (pHyp-iv) is 5.
In certain
embodiments q of formula (pHyp-iv) is 6. In certain embodiments q of formula
(pHyp-iv) is
7. In certain embodiments q of formula (pHyp-iv) is 8. In certain embodiments
q of formula
(pHyp-iv) is 2 or 6.
In certain embodiments p27 and p28 of formula (pHyp-iv) are 4.
In certain embodiments -Hyp of formula (pA) comprises a branched polypeptide
moiety.
In certain embodiments -Hyp of formula (pA) comprises a lysine moiety. In
certain
embodiments each -Hyp of formula (pA) is independently selected from the group
consisting
of a trilysine moiety, tetralysine moiety, pentalysine moiety, hexalysine
moiety, heptalysine
moiety, octalysine moiety, nonalysine moiety, decalysine moiety, undecalysine
moiety,
dodecalysine moiety, tridecalysine moiety, tetradecalysine moiety,
pentadecalysine moiety,
hexadecalysine moiety, heptadecalysine moiety, octadecalysine moiety and
nonadecalysine
moiety.
In certain embodiments -Hyp comprises 3 lysine moieties. In certain
embodiments -Hyb
.. comprises 7 lysine moieties. In certain embodiments -Hyb comprises 15
lysine moieties. In
certain embodiments -Hyp comprises heptalysinyl.
In certain embodiments x of formula (pA) is 3. In certain embodiments x of
formula (pA) is 4.
In certain embodiments x of formula (pA) is 4. In certain embodiments x of
formula (pA) is 5.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
In certain embodiments x of formula (pA) is 6. In certain embodiments x of
formula (pA) is 4.
In certain embodiments x of formula (pA) is 7. In certain embodiments x of
formula (pA) is 8.
In certain embodiments the backbone moiety is of formula (pC)
0
NH
H N N
H 0
H N N"
0
0 NH
0 N NNN
0 0
NH
H N ss(
N'
0
_____________________________________________________________________________
4
5
(PC),
wherein
dashed lines indicate attachment to a spacer moiety -SP1-, a crosslinker
moiety -CL'- or
to -L2-; and
10 n ranges from 10 to 40.
In certain embodiments n of formula (pB) is about 28.
In certain embodiments there is no spacer moiety -SP'- between a backbone
moiety and a
15 crosslinker moiety -CL'-, i.e. -CL"- is directly linked to -Hyp.
The crosslinker -CLP- of the PEG-based hydrogel is in certain embodiments
poly(alkylene
glycol) (PAG)-based. In certain embodiments the crosslinker is poly(propylene
glycol)-based.
In certain embodiments the crosslinker -CL'- is PEG-based.
In certain embodiments such PAG-based crosslinker moiety -CLP- is of formula
(pD)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
76
_ _ ¨ ¨ ¨ El ¨ ¨ __o
Di
Gi
D2
Y2
."====., 2 D3 4
0
(PD),
wherein
dashed lines indicate attachment to a backbone moiety or to a spacer moiety -
SP1-;
-Y1- is of formula
- -
_ ss,
¨ r8
R R1 a
R2 R2a
r; r9
wherein the dashed line marked with the asterisk indicates attachment
to -D1- and the unmarked dashed line indicates attachment to -D2-;
-Y2- is of formula
6¨

ss *
_ = ss
-
rl 1
R3 R3 a
R4 R4a
r 1 0 r 1 2 s
2
wherein the dashed line marked with the asterisk indicates attachment
to -D4- and the unmarked dashed line indicates attachment to -D3-;
-El- is of formula
Di 2
G2
v 1
0 0
wherein the dashed line marked with the asterisk indicates attachment
to -(C=0)- and the unmarked dashed line indicates attachment to -0-;
-E2- is of formula

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
77
¨ ¨
*
D3
G3
D4
2/ s)
0 ss
- - r15 r16
0 0
wherein the dashed line marked with the asterisk indicates attachment to -Gl-
and the unmarked dashed line indicates attachment to -(C=0)-;

-G'- is of formula
R6 R6a
¨
*
0 ss,
R5 R5 r18a
r17
__________________________________________________ s3
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -E2-;
2 i -G - s of formula
R8 R8a
0 ss,
R7
R7a r20
r19
___________________________________________________ s4
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -(C=0)-;
-G3- is of formula

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
78
R9 R9a
ss
' 0
-r21 R10 R10a
- r22
____________________________________________________ s5
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -(C=0)-;
-Dl-, -D2-, -D3-,-D4-, -D5- and -D6- are identical or different and each is
independently
of the others selected from the group comprising -0-, -NR"-, -N+Ri2Ri2a_,
-(S=0)-, -(S(0)2)-, -C(0)-, -P(0)R13-, -P(0)(0R13) and -CRi4Ri4a_;
_Ria, _R2, _R2a, _R3, _R3a, _R4, _R4a, _R5, _R5a, _R6, _R6a, _R7, _R7a, _R8,
_Rsa, _R9,
_R9a, _Rlo, _Rioa, _RH, _R12, _Ri2a, _R13, _R14 and _ K14a
are identical or different and
each is independently of the others selected from the group consisting of -H
and C1_6
alkyl;
optionally, one or more of
the
pairs -R1/-R', -R2/_R2a, _R3/_R3a, _R4/_R4a, _R3/-R4,
_RiaiLR2a, _R3a/_R4a,
-R12/-R12',
and
form a chemical bond or are joined together with the atom to
which they are attached to form a C3_8 cycloalkyl or to form a ring A or are
joined
together with the atom to which they are attached to form a 4- to 7-membered
heterocyclyl or 8- to 11-membered heterobicyclyl or adamantyl;
A is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl
and
tetralinyl;
rl, r2, r5, r6, r13, r14, r15 and r16 are independently 0 or 1;
T3, T4, r7, r8, r9, rl 0, rl 1, r12 are independently 0, 1, 2, 3, or 4;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
79
r17, r18, r19, r20, r21 and r22 are independently 1, 2, 3, 4, 5, 6, 7, 8, 9 or
10;
sl, s2, s4, s5 are independently 1, 2, 3, 4, 5 or 6; and
s3 ranges from 1 to 900.
In certain embodiments s3 of formula (pD) ranges from 1 to 500. In certain
embodiments s3
of formula (pD) ranges from 1 to 200.
In certain embodiments rl of formula (pD) is 0. In certain embodiments rl of
formula (pD) is
1. In certain embodiments r2 of formula (pD) is 0. In certain embodiments r2
of formula (pD)
is 1. In certain embodiments r5 of formula (pD) is 0. In certain embodiments
r5 of formula
(pD) is 1.
In certain embodiments rl, r2, r5 and r6 of formula (pD) are 0.
In certain embodiments r6 of formula (pD) is 0. In certain embodiments r6 of
formula (pD) is
1. In certain embodiments r13 of formula (pD) is 0. In certain embodiments r13
of formula
(pD) is 1. In certain embodiments r14 of formula (pD) is 0. In certain
embodiments r14 of
formula (pD) is 1. In certain embodiments r15 of formula (pD) is 0. In certain
embodiments
r15 of formula (pD) is 1. In certain embodiments r16 of formula (pD) is 0. In
certain
embodiments r16 of formula (pD) is 1.
In certain embodiments r3 of formula (pD) is 1. In certain embodiments r3 of
formula (pD) is
2. In certain embodiments r4 of formula (pD) is 1. In certain embodiments r4
of formula (pD)
is 2. In certain embodiments r3 and r4 of formula (pD) are both 1. In certain
embodiments r3
and r4 of formula (pD) are both 2. In certain embodiments r3 and r4 of formula
(pD) are both
3.
In certain embodiments r7 of formula (pD) is 0. In certain embodiments r7 of
formula (pD) is
1. In certain embodiments r7 of formula (pD) is 2. In certain embodiments r8
of formula (pD)
is 0. In certain embodiments r8 of formula (pD) is 1. In certain embodiments
r8 of formula
(pD) is 2. In certain embodiments r9 of formula (pD) is 0. In certain
embodiments r9 of
formula (pD) is 1. In certain embodiments r9 of formula (pD) is 2. In certain
embodiments

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
r10 of formula (pD) is 0. In certain embodiments r10 of formula (pD) is 1. In
certain
embodiments r10 of formula (pD) is 2. In certain embodiments rll of formula
(pD) is 0. In
certain embodiments rll of formula (pD) is 1. In certain embodiments rll of
formula (pD) is
2. In certain embodiments r12 of formula (pD) is 0. In certain embodiments r12
of formula
5 (pD) is 1. In certain embodiments r12 of formula (pD) is 2.
In certain embodiments r17 of formula (pD) is 1. In certain embodiments r18 of
formula (pD)
is 1. In certain embodiments rl 9 of formula (pD) is 1. In certain embodiments
r20 of formula
(pD) is 1. In certain embodiments r21 of formula (pD) is 1. In certain
embodiments r22 of
10 formula (pD) is 1.
In certain embodiments sl of formula (pD) is 1. In certain embodiments sl of
formula (pD) is
2. In certain embodiments s2 of formula (pD) is 1. In certain embodiments s2
of formula (pD)
is 2. In certain embodiments s4 of formula (pD) is 1. In certain embodiments
s4 of formula
15 (pD) is 2. In certain embodiments s5 of formula (pD) is 1. In certain
embodiments s5 of
formula (pD) is 2.
In certain embodiments s3 of formula (pD) ranges from 5 to 500. In certain
embodiments s3
of formula (pD) ranges from 10 to 250. In certain embodiments s3 of formula
(pD) ranges
20 from 12 to 150. In certain embodiments s3 of formula (pD) ranges from 15
to 100. In certain
embodiments s3 of formula (pD) ranges from 18 to 75. In certain embodiments s3
of formula
(pD) ranges from 20 to 50.
In certain embodiments -1Z1 of formula (pD) is -H. In certain embodiments -RI
of formula
25 (pD) is methyl. In certain embodiments -R1 of formula (pD) is ethyl. In
certain
embodiments -Ria of formula (pD) is -H. In certain embodiments -Ria of formula
(pD) is
methyl. In certain embodiments -Rla of formula (pD) is ethyl. In certain
embodiments -R2 of
formula (pD) is -H. In certain embodiments -R2 of formula (pD) is methyl. In
certain
embodiments -R2 of formula (pD) is ethyl. In certain embodiments -R2a of
formula (pD)
30 is -H. In certain embodiments -R2a of formula (pD) is methyl. In certain
embodiments -R2a of
formula (pD) is ethyl. In certain embodiments -R3 of formula (pD) is -H. In
certain
embodiments -R3 of formula (pD) is methyl. In certain embodiments -R3 of
formula (pD) is
ethyl. In certain embodiments -R3a of formula (pD) is -H. In certain
embodiments -R3a of
formula (pD) is methyl. In certain embodiments -R3a of formula (pD) is ethyl.
In certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
81
embodiments -R4 of formula (pD) is -H. In certain embodiments -R4 of formula
(pD) is
methyl. In certain embodiments -R4 of formula (pD) is methyl. In certain
embodiments -R4a of
formula (pD) is -H. In certain embodiments -R4a of formula (pD) is methyl. In
certain
embodiments -R4a of formula (pD) is ethyl. In certain embodiments -R5 of
formula (pD) is -H.
In certain embodiments -R5 of formula (pD) is methyl. In certain embodiments -
R5 of formula
(pD) is ethyl. In certain embodiments -R5a of formula (pD) is -H. In certain
embodiments -R5a
of formula (pD) is methyl. In certain embodiments -R5a of formula (pD) is
ethyl. In certain
embodiments -R6 of formula (pD) is -H. In certain embodiments -R6 of formula
(pD) is
methyl. In certain embodiments -R6 of formula (pD) is ethyl. In certain
embodiments -R6a of
formula (pD) is -H. In certain embodiments -R6a of formula (pD) is methyl. In
certain
embodiments -R6a of formula (pD) is ethyl. In certain embodiments -R7 of
formula (pD) is -H.
In certain embodiments -R7 of formula (pD) is methyl. In certain embodiments -
R7 of formula
(pD) is ethyl. In certain embodiments -R7a of formula (pD) is -H. In certain
embodiments -R7a
of formula (pD) is methyl. In certain embodiments -R7a of formula (A) is
ethyl.In certain
embodiments -R8 of formula (pD) is -H. In certain embodiments -R8 of formula
(pD) is
methyl. In certain embodiments -R8 of formula (pD) is ethyl. In certain
embodiments -R8a of
formula (pD) is -H. In certain embodiments -R8a of formula (pD) is methyl. In
certain
embodiments -R8a of formula (pD) is ethyl. In certain embodiments -R9 of
formula (pD) is -H.
In certain embodiments -R9 of formula (pD) is methyl. In certain embodiments -
R9 of formula
(pD) is ethyl. In certain embodiments -R9a of formula (pD) is -H. In certain
embodiments -R9a
of formula (pD) is methyl. In certain embodiments -R9a of formula (pD) is
ethyl. In certain
embodiments -R1 of formula (pD) is -H. In certain embodiments -R1 of formula
(pD) is
methyl. In certain embodiments -R1 of formula (pD) is ethyl. In certain
embodiments -R1 a of
formula (pD) is -H. In certain embodiments -R1 a of formula (pD) is methyl. In
certain
embodiments -Rma of formula (pD) is ethyl. In certain embodiments -R11 of
formula (pD)
is -H. In certain embodiments -R11 of formula (pD) is methyl. In certain
embodiments -R11 of
formula (pD) is ethyl. In certain embodiments -R12 of formula (pD) is -H. In
certain
embodiments -R12 of formula (pD) is methyl. In certain embodiments -R12 of
formula (pD) is
ethyl. In certain embodiments -R12a of formula (pD) is -H. In certain
embodiments -R12a of
formula (pD) is methyl. In certain embodiments -R12a of formula (pD) is ethyl.
In certain
embodiments -R13 of formula (pD) is -H. In certain embodiments -R13 of formula
(pD) is
methyl. In certain embodiments -R13 of formula (pD) is ethyl. In certain
embodiments -R14 of
formula (pD) is -H. In certain embodiments -R14 of formula (pD) is methyl. In
certain
embodiments -R14 of formula (pD) is ethyl. In certain embodiments -R14a of
formula (pD)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
82
is -H. In certain embodiments -R14a of formula (pD) is methyl. In certain
embodiments -R14a
of formula (pD) is ethyl.
In certain embodiments -D1- of formula (pD) is -0-. In certain embodiments -D1-
of formula
(pD) is -NR11-. In certain embodiments -D1- of formula (pD) is _N+R12R12a_.
In certain
embodiments -DI- of formula (pD) is -S-. In certain embodiments -DI- of
formula (pD)
is -(S=0). In certain embodiments -Dl- of formula (pD) is -(S(0)2)-. In
certain
embodiments -D1- of formula (pD) is -C(0)-. In certain embodiments -D1- of
formula (pD) is
-P(0)R13-. In certain embodiments -D1- of formula (pD) is -P(0)(0R13)-. In
certain
embodiments -DI- of formula (pD) is -CR14R14a_.
In certain embodiments -D2- of formula (pD) is -0-. In certain embodiments -D2-
of formula
(pD) is -NR11-. In certain embodiments -D2- of formula (pD) is _N+R12R12a_.
In certain
embodiments -D2- of formula (pD) is -S-. In certain embodiments -D2- of
formula (pD)
is -(S=0). In certain embodiments -D2- of formula (pD) is -(S(0)2)-. In
certain
embodiments -D2- of formula (pD) is -C(0)-. In certain embodiments -D2- of
formula (pD) is
-P(0)R13-. In certain embodiments -D2- of formula (pD) is -P(0)(0R13)-. In
certain
_
embodiments -D2- of formula (pD) is -CRi4Ri4a.
In certain embodiments -D3- of formula (pD) is -0-. In certain embodiments -D3-
of formula
(pD) is -NR11-. In certain embodiments -D3- of formula (pD) is _N+R12R12a_.
In certain
embodiments -D3- of formula (pD) is -S-. In certain embodiments -D3- of
formula (pD)
is -(S=0). In certain embodiments -D3- of formula (pD) is -(S(0)2)-. In
certain
embodiments -D3- of formula (pD) is -C(0)-. In certain embodiments -D3- of
formula (pD)
is -P(0)R13-. In certain embodiments -D3- of formula (pD) is -P(0)(0R13)-. In
certain
_
embodiments -D3- of formula (pD) is -CRi4Ri4a.
In certain embodiments -D4- of formula (pD) is -0-. In certain embodiments -D4-
of formula
(pD) is -NR11-. In certain embodiments -D4- of formula (pD) is _N+R12R12a_.
In certain
embodiments -D4- of formula (pD) is -S-. In certain embodiments -D4- of
formula (pD)
is -(S=0). In certain embodiments -D4- of formula (pD) is -(S(0)2)-. In
certain
embodiments -D4- of formula (pD) is -C(0)-. In certain embodiments -D4- of
formula (pD) is
-P(0)R13-. In certain embodiments -D4- of formula (pD) is -P(0)(0R13)-. In
certain
i4R14a_.
embodiments -D4- of formula (pD) is -CR

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
83
In certain embodiments -D5- of formula (pD) is -0-. In certain embodiments -D5-
of formula
(pD) is -NR"-. In certain embodiments -D5- of formula (pD) is -N R12R12a_. In
certain
embodiments -D5- of formula (pD) is -S-. In certain embodiments -D5- of
formula (pD)
is -(S=0)-. In certain embodiments -D5- of formula (pD) is -(S(0)2)-. In
certain embodiments
-D5- of formula (pD) is -C(0)-. In certain embodiments -D5- of formula (pD) is
-P(0)R13-. In
certain embodiments -D5- of formula (pD) is -P(0)(0R13)-. In certain
embodiments -D5- of
formula (pD) is -CR i4R14a_.
In certain embodiments -D6- of formula (pD) is -0-. In certain embodiments -D6-
of formula
(pD) is -NR"-. In certain embodiments -D6- of formula (pD) is -N R12R12a_. In
certain
embodiments -D6- of formula (pD) is -S-. In certain embodiments -D6- of
formula (pD)
is -(S=0). In certain embodiments -D6- of formula (pD) is -(S(0)2)-. In
certain
embodiments -D6- of formula (pD) is -C(0)-. In certain embodiments -D6- of
formula (pD) is
-P(0)R13-. In certain embodiments -D6- of formula (pD) is -P(0)(0R13)-. In
certain
embodiments -D6- of formula (pD) is -CR14R14a_.
In one embodiment -CL'- is of formula (pE)
b2 b2a
0 0 0 0
0
0 0)LOV\/
Rb I Rb I a d
c2 Rb3 Rb3 a
c3
cl
Ra4 Ra4a 6Ra6a
c4 _ c6
0 0 R R 0 0
c5 (PE),
wherein
dashed lines marked with an asterisk indicate the connection point between the
upper
and the lower substructure,
unmarked dashed lines indicate attachment to a backbone moiety or to a spacer
moiety -SP1-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
84
_Rbt, _Rb I a, _Rb2, _Rb2a, _Rb3, _Rb3 a, _Rb4, _Rb4a, _Rb5, _Rb51, _R1'6
and -Rb6 are
independently selected from the group consisting of -H and C1_6 alkyl;
cl, c2, c3, c4, c5 and c6 are independently selected from the group consisting
of 1, 2,
3, 4, 5 and 6;
d is an integer ranging from 2 to 250.
In certain embodiments d of formula (pE) ranges from 3 to 200. In certain
embodiments d of
formula (pE) ranges from 4 to 150. In certain embodiments d of formula (pE)
ranges from 5
to 100. In certain embodiments d of formula (pE) ranges from 10 to 50. In
certain
.. embodiments d of formula (pE) ranges from 15 to 30. In certain embodiments
d of formula
(pE) is about 23.
In certain embodiments -Rbl and -Rbia of formula (pE) are -H. In certain
embodiments -Rb2
and -Rb2a of formula (pE) are -H. In certain embodiments -Rb3 and-Rb3a of
formula (pE)
are -H. In certain embodiments -Rb4 and -Rb4a of formula (pE) are -H. In
certain
embodiments -Rb5 and -Rb5a of formula (pE) are -H. In certain embodiments -
R1'6 and -Rb6a of
formula (pE) are -H.
In certain embodiments _Rb1, _Rbia, _Rb2, _Rb2a, _Rb3, _Rb3a, _Rb4, _Rb4a,
_R15, _Rb5a, _R16
and -R16 of formula (pE) are all -H.
In certain embodiments cl of formula (pE) is 1. In certain embodiments cl of
formula (pE) is
2. In certain embodiments cl of formula (pE) is 3. In certain embodiments cl
of formula (pE)
is 4. In certain embodiments cl of formula (pE) is 5. In certain embodiments
cl of formula
.. (pE) is 6.
In certain embodiments c2 of formula (pE) is 1. In certain embodiments c2 of
formula (pE) is
2. In certain embodiments c2 of formula (pE) is 3. In certain embodiments c2
of formula (pE)
is 4. In certain embodiments c2 of formula (pE) is 5. In certain embodiments
c2 of formula
(pE) is 6.
In certain embodiments c3 of formula (pE) is 1. In certain embodiments c3 of
formula (pE) is
2. In certain embodiments c3 of formula (pE) is 3. In certain embodiments c3
of formula (pE)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
is 4. In certain embodiments c3 of formula (pE) is 5. In certain embodiments
c3 of formula
(pE) is 6.
In certain embodiments c4 of formula (pE) is 1. In certain embodiments c4 of
formula (pE) is
5 2. In certain embodiments c4 of formula (pE) is 3. In certain embodiments
c4 of formula (pE)
is 4. In certain embodiments c4 of formula (pE) is 5. In certain embodiments
c4 of formula
(pE) is 6.
In certain embodiments c5 of formula (pE) is 1. In certain embodiments c5 of
formula (pE) is
10 2. In certain embodiments c5 of formula (pE) is 3. In certain
embodiments c5 of formula (pE)
is 4. In certain embodiments c5 of formula (pE) is 5. In certain embodiments
c5 of formula
(pE) is 6.
In certain embodiments c6 of formula (pE) is 1. In certain embodiments c6 of
formula (pE) is
15 2. In certain embodiments c6 of formula (pE) is 3. In certain
embodiments c6 of formula (pE)
is 4. In certain embodiments c6 of formula (pE) is 5. In certain embodiments
c6 of formula
(pE) is 6.
In certain embodiments a crosslinker moiety -CLP- is of formula (pE-i)
0 0 0 0
- 0
0 20 0 0 0
-
(pE-i),
wherein
dashed lines indicate attachment to a backbone moiety or to a spacer moiety -
SP',
25 In certain embodiments a crosslinker moiety -CLP- is selected from the
group consisting of
0 0 0 0
'
0 0 23 0
0 0 0 0 (pE-i2),
0 0 0 0
Y'r' 0...,..----.... ...IL...A .........õ...0
0........õ.........K.A.
0 0 23r 0
0 0 0 0 (pE-i3),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
86
0 0
00

O 0 0 0 (pE-i4),
O 0 00
ki kJ 23
0 0 0 0
(pE-i5),
O 0 00
k-7 23
O 0 0 0 (pE-i6),
0 0
00

00
00

(pE-i7),
0 0 00
O 0 0 0 (pE-i8),
0 0 00
23
fl'r()0)YL[0
0 0 0 0 (pE-i9),
0 0 00
rOci).)-L,F4051.r)r0()).
0 0 0 0 (pE-i10),
O 0 00
O 0 0 0 (pE-ill),
0 0
00

O 0 0 0
(pE-i12),
0 0 00
0.45 0c)
O 0 0 0
(pE-i13),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
87
0 0 0 0
y.(00)-yti,r10).(\r00).y.
vi 45
0 0 0 0 (pE-i14),
0 0
00

O0
I 00
(pE-i15),
0 0 00
0 0 0 0 (pE-i16),
0 0 0 0
,,,4051.r.r00)
O 0 0 0 (pE-i17),
0 0 0 0
).-.001.r)402031H.Loo
0 0 0 0
(pE418),
O 0 0 0
).H.r001.r.)40-2031.H"Loo.
O 0 0
0 (pE 419),
O 0 0 0
0 0 0 0
(pE 420),
0 0 0 0
-,:r.,)L0,---..,õ_,=-=,00,-203.1.r---)1,,,O.,.Ø...f,A.,',
0 0 0 0 (pE-i21)
O 0 0 0
.r0())=LI,(y.,-203)(r00)H.
O 0 0
0
(pE-i22),
0 0 0 0
O 0 0 0
(pE 423),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
88
O 0 0 0
H.r001.r.)L1,0,-203)(00)
0 0 0 0
(pE-124),
0 0 0 0
HrO0y.).Lcy.,-203 0)H=
0 0 0 0
(pE-i25),
0 0 0 0
).-.001.(A021H.Loo
0 0 0 0 (pE-126),
0 0 0 0
)-.001,Ht[0,4051H.Loo).
0 0 0 0 (pE-127),
0 0 0 0
Y)L001.4 51--r 01.H
O 0 0 0
(pE-i28),
0 0 0 0
0 0- '451r)r
O 0 0 0 (pE-i29),
O 0 0 0
>HrOc))..L[044051(00).H
0 0 0 0
(pE-i30),
0 0 0 0
O 0 0 0
(pE-13 1),
0 0 0 0
H.r001(Lky-,1-405).r..L00)*H.
0 0 0 0
(pE-i32),
O 0 0 0
-H.r()O-Lso405 0)H-
0 0 0 0
(pE-i33),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
89
0 0 0 0
O 0 0 0
(pE-i34),
O 0 0 0
0 0 0 0
(pE-i35),
)L0 0 0 0
001-L1,02031r)-LoOl
0 0 0 0 (pE-i36),
00 0 0 /
/ 0 0 0 0 (pE-i37),
O0 0 0 /
/ 0 0 00
(pE-i38),
O 0 0 0
>YLO It[02 31-r)LO 1?Y
0 0 0 0 (pE439),
0 0 0 0
,
,
0 0 0 0
(pE440),
O 0 0 0
tHjLO 1-02 31)LO
7 IrY
0 0 0 0 (pE441),
0 0 0 0
O 0 0 0
(pE-i42),
O 0 0 0
1.r)t[)0 04051.L00
0
0 0 0 0
(pE-i43),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
O 0 0 0
0 0 0 0 (pE-i44),
00 0 0 /
/ 0 0 0 0 (pE-i45),
00 0 0 /
))*L
/ 0 0 00
(pE-i46),
O 0 0 0
YLO It[04 51-r)LO 1?Y
0 0 0 0 (pE447),
0 0 0 0
'
,
0 0 0 0
(pE-i48),
0 0 0 0
ti,.A001.r-Lky,L051.r.).-(001.riV
7
0 0 0 0 (pE-i49),
0 0 0 0
rr0..,.,,,---,0).,...)-(0...--.-.40.1Ø,..õ..,--.0).,../===.,A,:,
0 0 0 0
(pE-150),
0 0 0 0
.r0())=*(01-401(0()).
O 0 0 0
(pE-151),
0 0 0 0
rri3.,..,,,-..0)-..,..õ..)*(0..--60-110.Ø-/1-=,.../====,A,
O 0 0 0
(pE-152),
0 0 0 0
0 0 0 0
(pE-153),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
91
0 0 0 0
r0())-tix40141(0ci
0 0 0 0
(pE-154),
0 0 0 0
0 0 0 0
(pE-15 5),
0 0 0 0
0 0 0 0
(pE-156),
0 0 0 0
0 0 0 0
(pE-157),
0 0
)-Lo 45)rs'y
0 o (pE-15 8),
0 Q 0
0
)- [01-45 IrrY
0 0 0 (pE-i59),
0 0
s =
0 0 (pE-60),
0 0
11 45
0 (pE-61
0 0 0
11 45
0 0 0 (pE-62),
0
A04 51.
0 (pE-63
0 0
Y)0)t[0 45y 0)
0 0 (pE-64),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
92
0 0
45 II
0 0 (pE-65),
0 0
45 II
O 0 (pE-66),
0 0
0 451reY,
O 0 (pE-67),
0 0 /
0 451r0
0 0 (pE-68),
O 0
,
.r==.r0c)).-.)L001.r.r,
0 0 0 0 (pE-69), and
0 0 0 0
0 0 0 0
(pE-70),
wherein
dashed lines indicate attachment to a backbone moiety or to a spacer moiety -
SP-.
In certain embodiments a crosslinker moiety -CL- is of formula (pE-i2). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i3). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i4). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i5). In certain embodiments a crosslinker moiety
-CL- is of
formula (pE-i6). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i7). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i8). In
certain embodiments
a crosslinker moiety -CL- is of formula (pE-i9). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i10). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-ill). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i12). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i13). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i14). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i15). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i16). In certain embodiments a crosslinker
moiety -CL- is of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
93
formula (pE-i17). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i18). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i19). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i20). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i21). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i22). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i23). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i24). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i25). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i26). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i27). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i28). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i29). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i30). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i31). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i32). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i33). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i34). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i35). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i36). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i37). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i38). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i39). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i40). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i41). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i42). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i43). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i44). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i45). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i46). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i47). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i48). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i49). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i50). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i51). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i52). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i53). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i54). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i55). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i56). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i57). In certain embodiments a
crosslinker

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
94
moiety -CL- is of formula (pE-i58). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i59). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i60). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i61). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i62). In certain
embodiments a
crosslinker moiety -CL- is of formula (pE-i63). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i64). In certain embodiments a crosslinker
moiety -CL- is of
formula (pE-i65). In certain embodiments a crosslinker moiety -CL- is of
formula (pE-i66). In
certain embodiments a crosslinker moiety -CL- is of formula (pE-i67). In
certain
embodiments a crosslinker moiety -CL- is of formula (pE-i68). In certain
embodiments a
.. crosslinker moiety -CL- is of formula (pE-i69). In certain embodiments a
crosslinker
moiety -CL- is of formula (pE-i70).
In certain embodiments a backbone moiety has a molecular weight ranging from 1
kDa to 20
kDa, such as from 1 to 18 kDa, from 2 to 15 kDa, from 4 to 13 kDa or from 5 to
12 kDa.
In certain embodiments a backbone moiety comprises at least one polymeric
moiety. In
certain embodiments a backbone moiety comprises a multi-arm polymer, such as a
polymer
having 3 to 8 polymeric arms, such as having three polymeric arms, four
polymeric arms, five
polymeric arms, six polymeric arms, seven polymeric arms or eight polymeric
arms. In
certain embodiments a backbone moiety comprises 3 to 6 polymeric arms.
In certain embodiments such polymeric arm comprises a polymer selected from
the group
consisting of the group consisting of 2-methacryloyl-oxyethyl phosphoyl
cholins, poly(acrylic
acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers,
poly(amides),
poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides),
poly(butyric
acids), poly(glycolic acids), polybutylene terephthalates,
poly(caprolactones),
poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides),
poly(esters),
poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl
phosphates),
poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates),
poly(hydroxyethyl-
oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides),
poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines),
poly(iminocarbonates),
poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides),
poly(methacrylates),
poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters),
poly(oxazolines),
poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl
alcohols), poly(vinyl

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones,
celluloses, carbomethyl
celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans,
dextrins, gelatins,
hyaluronic acids and derivatives, functionalized hyaluronic acids, alginate,
mannans, pectins,
rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches
and other
5 carbohydrate-based polymers, xylans, and copolymers thereof.
In certain embodiments such polymeric arm is a PEG-based polymer. In certain
embodiments
such polymeric moiety is a hyaluronic acid-based polymer.
10 In certain embodiments -Z is a hyaluronic acid-based hydrogel.
If -Z is a hyaluronic acid-based hydrogel, a conjugate of the present
invention is in certain
embodiments a conjugate comprising crosslinked hyaluronic acid strands to
which a plurality
of drug moieties are covalently and reversibly conjugated, wherein the
conjugate comprises a
15 plurality of connected units selected from the group consisting of
OB 3 OC 2 OD l
X L X L X L D
L4/
ORal \OA
ORa2
ORa2
0
0 H N 0 H N H
Z1 Z2
x0F
OE
ORa2
0
* 0 0 #
0 0
Z3
and
wherein
an unmarked dashed line indicates a point of attachment to an adjacent unit at
a
20 dashed line marked with # or to a hydrogen;
a dashed line marked with # indicates a point of attachment to an adjacent
unit at
an unmarked dashed line or to a hydroxyl;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
96
a dashed line marked with indicates a point of connection between at least
two
units Z3 via a moiety -CL-;
each -D is independently an antibiotic moiety;
each -L1- is independently a linker moiety to which -D is covalently and
reversibly conjugated;
each -L2-, -L3- and -L4- is independently either absent or a spacer moiety;
each -CL- is independently a moiety connecting at least two units Z3 and
wherein
there is at least one degradable bond in the direct connection between any two
carbon atoms marked with the * connected by a moiety -CL-;
each -SP- is independently absent or a spacer moiety;
each -Rai is independently selected from the group consisting of -H, C1_4
alkyl, an
ammonium ion, a tetrabutylammonium ion, a cetyl methylammonium ion, an
alkali metal ion and an alkaline earth metal ion;
each -Ra2 is independently selected from the group consisting of -H and C1_10
alkyl;
each -X A-, -X013_, _x0C _x013_, _x0E_
and -X"- is independently either absent or a
linkage;
optionally -X A- and/or -X B- form together with -L4- or parts of -L4- one or
more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8- to 11-membered heterobicyclyl and adamantyl;
optionally -X B- and/or -Xcc- form together with -L3- or parts of -L3- one or
more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8- to 11-membered heterobicyclyl and adamantyl;
optionally, -X()c- and/or -X D- form together with -L2- or parts of -L2- one
or more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8- to 11-membered heterobicyclyl and adamantyl;
optionally -X E- and/or -X"- form together with -SP- or parts of -SP- one or
more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8- to 11-membered heterobicyclyl and adamantyl;
wherein
all units Z1 present in the conjugate may be the same or different;
all units Z2 present in the conjugate may be the same or different;
all units Z3 present in the conjugate may be the same or different;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
97
at least one unit Z3 is present per hyaluronic acid strand which is connected
to at least
one unit Z3 on a different hyaluronic acid strand; and
the conjugate comprises at least one moiety -L1-D.
The presence of at least one degradable bond between the carbon atom marked
with the * of a
first moiety Z3 and the direct connection to the carbon atom marked with the *
of a second
moiety Z3 ensures that after cleavage of all such degradable bonds present in
the conjugates of
the present invention the hyaluronic acid strands present in said conjugate
are no longer
crosslinked, which allows clearance of the hyaluronic acid network
It is understood that in case a degradable bond is located in a ring structure
present in the
direct connection of the carbon atom marked with the * of a first moiety Z3
and the carbon
atom marked with the * of a second moiety Z3 such degradable bond is not
sufficient to allow
complete cleavage and accordingly one or more additional degradable bonds are
present in the
direct connection of the carbon atom marked with the * of a first moiety Z3
and the carbon
atom marked with the * of a second moiety Z3.
It is understood that the phrase "a dashed line marked with indicates a
point of connection
between at least two units Z3 via a moiety -CL-" refers to the following
structure
0 0,
ORa2
OE
,X
SP
I OF
CL
OF
X
OE
ORa2
* 0 0
0 0
Cir\
if -CL- is for example connected to two units Z3, which two moieties Z3 are
connected at the
position indicated with via a moiety -CL-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
98
It is understood that the phrase "-X E- and/or -X F- form together with -SP-
or parts
of -SP- one or more ring structure selected from the group consisting of 4- to
7-membered
heterocyclyl, 8- to 11-membered heterobicyclyl and adamantyl" refers to for
example
structures as shown below:
o
N11/3 0
SP' SP'
0
NY(,
N N
Y
Y Y
0. 0/
0./
Y 0.
Y
Y Y /
' '
Y SP'
SP SP
"iL-Nri 6
N N .
\/
______________________________________ and ;
wherein
the dashed line marked with the asterisk indicates attachment to -CL-;
the unmarked dashed line indicates attachment to the remainder of Z3, i.e. to
the
carbonyl of the hyaluronic acid moiety;
-SP'- refers to the remainder of -SP-;
each -Y- is independently absent or is selected from the group consisting
of -0-, -NR- and -S-; and
each -R is independently selected from the group consisting of is
independently selected
from the group consisting of -H and C1_6 alkyl; wherein C1_6 alkyl is
optionally
substituted with one or more halogen, which are the same or different.
This applies analogously to other variables.
It is understood that no three-dimensionally crosslinked hydrogel can be
formed if all
hyaluronic acid strands of the present conjugate comprise only one unit Z3,
which is
connected to only one unit Z3 on a different hyaluronic acid strand. However,
if a first unit Z3

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
99
is connected to more than one unit Z3 on a different strand, i.e. if -CL- is
branched, such first
unit Z3 may be crosslinked to two or more other units Z3 on two or more
different hyaluronic
acid strands. Accordingly, the number of units Z3 per hyaluronic acid strand
required for a
crosslinked hyaluronic acid hydrogel depends on the degree of branching of -CL-
. In certain
embodiments at least 30% of all hyaluronic acid strands present in the
conjugate are
connected to at least two other hyaluronic acid strands. It is understood that
it is sufficient if
the remaining hyaluronic acid strands are connected to only one other
hyaluronic acid strand.
It is understood that a moiety Z1 is an unmodified disaccharide of hyaluronic
acid, a moiety
Z2 is a disaccharide unit reversibly conjugated to a drug moiety and a moiety
Z3 is a
disaccharide unit that is crosslinked via a moiety -CL-.
The conjugate of the present invention may also comprise units selected from
the group
consisting of
YOB
[ y0A_LcL_x0F
SP
SP ***-X OE \ OE
ORa2 X ORa2
0 0 0 0 0 0 #
0 0 0 0
0 H N 0 H N
Z4 Z5
3/YOD
y c
1 4
OB 4
NX X ¨L\ A
"
ORa2
X ORa2
0 0
0 0 0 0
0 H N 0 H N
Z6

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
100
_.µ70C T 2 ITOE
3/
3/
OB 4 OB 4
X ¨L\ A
oRa2
OA 0 Ra2
/ 0 ,
0 0 0 # 0 0 0 #
0 0 0 0
Z8 Z9 and
YOH
ORa2
0 0 0 0
0 0
(1)-\
p
wherein
an unmarked dashed line indicates a point of attachment to an adjacent unit
Z1, Z2, Z3,
Z4, Z5, Z6, Z7, Z8, Z9 and Z10 at a dashed line marked with # or to a
hydrogen;
a dashed line marked with # indicates a point of attachment to an adjacent
unit Z1, Z2,
Z3, Z4, Z5, Z6, Z7, Z8, Z9 and Z10 at an unmarked dashed line or to a
hydroxyl;
a dashed line marked with @ indicates attachment to a moiety -X"- of a moiety
Z3;
a indicates the number of unreacted ends of -CL- and is a positive integer;
b indicates the number of ends of -CL- connected to a moiety -X F_ of a moiety
Z3 and
is 0 or a positive integer;
-L1-, -L2-, -L3-, -L4-, -SP-, -CL-, XOA,-x0 B _x0C_ , _x0 D_ , _x0 E_ , _x0 F_
and -Ra2 are
used as defined for Z1, Z2 and Z3;
each -Y A, - yOB yOC _y0D, _y0E, _yOF and Y _,,OH
is independently a functional group;
optionally, -Y A and/or -X"- forms together with -CL- or parts of -CL- one or
more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8-
to 11-membered heterobicyclyl and adamantyl;
optionally, -Y B and/or -X E- forms together with -SP- or parts of -SP- one or
more
ring structure selected from the group consisting of 4- to 7-membered
heterocyclyl, 8-
to 11-membered heterobicyclyl and adamantyl
optionally, -Y c and/or -X A- forms together with -L4- or parts of -L4- one or
more ring
structure selected from the group consisting of 4- to 7-membered heterocyclyl,
8- to
11-membered heterobicyclyl and adamantyl;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
101
optionally, -Y D and/or -X B- forms together with -L3- or parts of -L3- one or
more ring
structure selected from the group consisting of 4- to 7-membered heterocyclyl,
8- to
11-membered heterobicyclyl and adamantyl; and
optionally, -Y E and/or -X c- forms together with -L2- or parts of -L2- one or
more ring
structure selected from the group consisting of 4- to 7-membered heterocyclyl,
8- to
11-membered heterobicyclyl and adamantyl.
Units Z4, Z5, Z6, Z7, Z8, Z9 and Z1 represent partly reacted or unreacted
units. For example, a
unit Z4 represents a unit in which at least end of -CL- was not conjugated to
a unit Z3.
Depending on the order in which the elements of the conjugate of the present
invention are
assembled, different such partly reacted or unreacted units may be present. It
is understood
that the presence of such moieties cannot be avoided. In certain embodiments
the sum of units
Z4, Z5, Z6, Z7, Z8, Z9 and Z10 is no more than 25% of the total number of
units Z2, Z3, Z4, Z5,
Z6, Z7, Z8, Z9 and Zl present in the conjugate, such as no more than 10%,
such as no more
than 15% or such as no more than 10%.
In certain embodiments variable a of Z4 is selected from the group consisting
of 1, 2, 3, 4, 5,
6,7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19. In certain embodiments
variable a of Z4 is
a positive integer ranging from 20 to 200.
In certain embodiments b of Z4 is selected from the group consisting of 0, 1,
2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19. In certain embodiments b of Z4
is a positive
integer ranging from 20 to 200.
It is further understood that in addition to units Z1, Z2, Z3, Z4, Z5, Z6, Z7,
Z8, Z9 and Z10 a
conjugate may also comprise units that are the result of cleavage of the
reversible bond
between -D and -LI- or of one or more of the degradable bonds present in the
direct
connection between any two carbon atoms marked with the * connected by a
moiety -CL-, i.e.
units resulting from degradation of the conjugate.
In certain embodiments each strand present in the conjugates of the present
invention
comprises at least 20 units, such as from 20 to 2500 units, from 25 to 2200
units, from 50 to
2000 units, from 75 to 100 units, from 75 to 100 units, from 80 to 560 units,
from 100 to 250

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
102
units, from 200 to 800 units, from 20 to 1000, from 60 to 1000, from 60 to 400
or from 200 to
600 units.
In certain embodiments the moieties -CL- present in the conjugates of the
present invention
have different structures. In certain embodiments the moieties -CL- present in
the conjugates
of the present invention have the same structure.
In general, any moiety that connects at least two other moieties is suitable
for use as a
moiety -CL-, which may also be referred to as a "crosslinker moiety".
The at least two units Z3 that are connected via a moiety -CL- may either be
located on the
same hyaluronic acid strand or on different hyaluronic acid strands.
The moiety -CL- may be linear or branched. In certain embodiments -CL- is
linear. In certain
embodiments -CL- is branched.
In certain embodiments -CL- connects two units Z3. In certain embodiments -CL-
connects
three units Z3. In certain embodiments -CL- connects four unis Z3. In certain
embodiments -CL- connects five units Z3. In certain embodiments -CL- connects
six units Z3.
In certain embodiments -CL- connects seven units Z3. In certain embodiments -
CL- connects
eight units Z3. In certain embodiments -CL- connects nine units Z3.
If -CL- connects two units Z3 -CL- may be linear or branched. If -CL- connects
more than two
units Z3 -CL- is branched.
A branched moiety -CL- comprises at least one branching point from which at
least three
branches extend, which branches may also be referred to as "arms". Such
branching point
may be selected from the group consisting of
, - I- - , , - -I- - ,
1B : and
R
,
wherein
dashed lines indicate attachment to an arm; and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
103
-RB is selected from the group consisting of -H, C1_6 alkyl, C2_6 alkenyl and
C2_6
alkynyl; wherein C1_6 alkyl, C2_6 alkenyl and C2_6 alkynyl are optionally
substituted
with one or more -RBI, which are the same or different, and wherein C1_6
alkyl, C2_6
alkenyl and C2_6 alkynyl are optionally interrupted with -C(0)0-, -0-,
-C(0)-, -C(0)N(RB2)-, -S(0)2N(RB2)-, -S(0)N(RB2)-, -S(0)2-,
-S(0)-, -N(RB2)S(0)2N(RB2a)-,
-S-, -N(RB2)-, -oc(oRB2)(RB2a)_,
-N(RB2)C(0)N(RB2a)-, and -0C(0)N(RB2)-; wherein -RBI, -RB2 and -RB2a are
selected
from -H, C1_6 alkyl, C2_6 alkenyl and C2_6 alkynyl.
In certain embodiments -RB is selected from the group consisting of -H, methyl
and ethyl.
A branched moiety -CL- may comprise a plurality of branching points, such as
1, 2, 3, 4, 5, 6,
7 or more branching points, which may be the same or different.
If a moiety -CL- connects three units Z3, such moiety -CL- comprises at least
one branching
point from which at least three arms extend.
If a moiety -CL- connects four units Z3, such moiety -CL- may comprise one
branching point
from which four arms extend. However, alternative geometries are possible,
such as at least
two branching points from which at least three arms each extend. The larger
the number of
connected units Z3, the larger the number of possible geometries is.
In a first embodiment at least 70%, such as at least 75%, such as at least
80%, such as at least
85%, such as at least 90% or such as at least 95% of the number of hyaluronic
acid strands of
the conjugate of the present invention comprise at least one moiety Z2 and at
least one moiety
Z3. In such embodiment units Z2 and Z3 can be found in essentially all
hyaluronic acid strands
present in the conjugates of the present invention.
Accordingly, a conjugate of this first embodiment comprises crosslinked
hyaluronic acid
strands to which a plurality of drug moieties are covalently and reversibly
conjugated,
wherein the conjugate comprises a plurality of connected units selected from
the group
consisting of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
104
OB 3 OC 2 OD 1
X L X L X L D
4/
ORal ORa2 L \XOA
ORa2
0
________________________________ 0
0 H N 0 H N H
Z1 Z2
xOF
OE
X ORa2
___________________________________ 0
0 0
Z3
and
wherein
an unmarked dashed line indicates a point of attachment to an adjacent unit at
a
dashed line marked with # or to a hydrogen;
a dashed line marked with # indicates a point of attachment to an adjacent
unit at
an unmarked dashed line or to a hydroxyl;
a dashed line marked with indicates a point of connection between at least
two
units Z3 via a moiety -CL-;
-D, -Ll-, -L2-, -L3-, -L4-, -SP-, -CL-, XOA,-x0B_, _x0C_, _x0D_, _x0E_, _x0F_,
_Ral
and -Ra2 are used as defined for Z1, Z2 and Z3;
wherein
all units Z1 present in the conjugate may be the same or different;
all units Z2 present in the conjugate may be the same or different;
all units Z3 present in the conjugate may be the same or different;
the number of Z1 units ranges from 1% to 98% of the total number of units
present in
the conjugate;
the number of Z2 units ranges from 1% to 98% of the total number of units
present in
the conjugate, provided at least one unit Z2 is present in the conjugate;
the number of Z3 units ranges from 1% to 97% of the total number of units
present in
the conjugate, provided that at least one unit Z3 is present per strand; and
wherein at least 70% of all hyaluronic acid strands comprise at least one
moiety Z2 and
at least one moiety Z3.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
105
The conjugate according to this first embodiment may also comprise units
selected from the
group consisting of Z4, zs, z6, z7, -8,
L Z9 and Z10 as described above.
In a conjugate according to this first embodiment the number of units Z2
ranges from 1 to
70% of all units present in the conjugate, such as from 2 to 15%, from 2 to
10%, from 16 to
39, from 40 to 65%, or from 50 to 60% of all units present in the conjugate.
In a conjugate according to this first embodiment the number of units Z3
ranges from 1 to
30% of all units present in the conjugate, such as from 2 to 5%, from 5 to
20%, from 10 to
18%, or from 14 to 18% of all units present in the conjugate.
In a conjugate according to this first embodiment the number of units Z1
ranges from 10 to
97% of all units present in the conjugate, such as from 20 to 40%, such as
from 25 to 35%,
such as from 41 to 95%, such as from 45 to 90%, such as from 50 to 70% of all
units present
in the conjugate.
Each degradable bond present in the direct connection between any two carbon
atoms marked
with the * connected by a moiety -CL- may be different or all such degradable
bonds present
in the conjugate may be the same.
Each direct connection between two carbon atoms marked with the * connected by
a moiety -
-CL- may have the same or a different number of degradable bonds.
In certain embodiments the number of degradable bonds present in the conjugate
of the
present invention between all combinations of two carbon atoms marked with the
* connected
by a moiety -CL- is the same and all such degradable bonds have the same
structure.
In the first embodiment the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with the * connected by a moiety -CL- may
be
selected from the group consisting of ester, carbonate, sulfate, phosphate
bonds, carbamate
and amide bonds. It is understood that carbamates and amides are not
reversible per se, and
that in this context neighboring groups render these bonds reversible. In
certain embodiments
there is one degradable bond selected from the group consisting of ester,
carbonate, sulfate,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
106
phosphate bonds, carbamate and amide bonds in the direct connection between
any two
carbon atoms marked with the * connected by a moiety -CL-. In certain
embodiments there
are two degradable bonds selected from the group consisting of ester,
carbonate, sulfate,
phosphate bonds, carbamate and amide bonds in the direct connection between
any two
carbon atoms marked with the * connected by a moiety -CL-, which degradable
bonds may be
the same or different. In certain embodiments there are three degradable bonds
selected from
the group consisting of ester, carbonate, sulfate, phosphate bonds, carbamate
and amide bonds
in the direct connection between any two carbon atoms marked with the *
connected by a
moiety -CL-, which degradable bonds may be the same or different. In certain
embodiments
there are four degradable bonds selected from the group consisting of ester,
carbonate, sulfate,
phosphate bonds, carbamate and amide bonds in the direct connection between
any two
carbon atoms marked with the * connected by a moiety -CL-, which degradable
bonds may be
the same or different. In certain embodiments there are five degradable bonds
selected from
the group consisting of ester, carbonate, sulfate, phosphate bonds, carbamate
and amide bonds
in the direct connection between any two carbon atoms marked with the *
connected by a
moiety -CL-, which degradable bonds may be the same or different. In certain
embodiments
there are six degradable bonds selected from the group consisting of ester,
carbonate, sulfate,
phosphate bonds, carbamate and amide bonds in the direct connection between
any two
carbon atoms marked with the * connected by a moiety -CL-, which degradable
bonds may be
the same or different. It is understood that if more than two units Z3 are
connected
by -CL- there are more than two carbons marked with * that are connected and
thus there is
more than one shortest connection with at least one degradable bond present.
Each shortest
connection may have the same or different number of degradable bonds.
In certain embodiments the at least one degradable bond, such as one, two,
three, four, five,
six degradable bonds, are located within -CL-.
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
ester bond.
In other embodiments the at least one degradable bond are two ester bonds. In
other
embodiments the at least one degradable bond are three ester bonds. In other
embodiments the
at least one degradable bond are four ester bonds. In other embodiments the at
least one
degradable bond are five ester bonds. In other embodiments the at least one
degradable bond
are six ester bonds.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
107
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
carbonate
bond. In other embodiments the at least one degradable bond are two carbonate
bonds. In
other embodiments the at least one degradable bond are three carbonate bonds.
In other
embodiments the at least one degradable bond are four carbonate bonds. In
other
embodiments the at least one degradable bond are five carbonate bonds. In
other
embodiments the at least one degradable bond are six carbonate bonds.
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
phosphate
bond. In other embodiments the at least one degradable bond are two phosphate
bonds. In
other embodiments the at least one degradable bond are three phosphate bonds.
In other
embodiments the at least one degradable bond are four phosphate bonds. In
other
embodiments the at least one degradable bond are five phosphate bonds. In
other
embodiments the at least one degradable bond are six phosphate bonds.
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
sulfate
bond. In other embodiments the at least one degradable bond are two sulfate
bonds. In other
embodiments the at least one degradable bond are three sulfate bonds. In other
embodiments
the at least one degradable bond are four sulfate bonds. In other embodiments
the at least one
degradable bond are five sulfate bonds. In other embodiments the at least one
degradable
bond are six sulfate bonds.
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
carbamate
bond. In other embodiments the at least one degradable bond are two carbamate
bonds. In
other embodiments the at least one degradable bond are three carbamate bonds.
In other
embodiments the at least one degradable bond are four carbamate bonds. In
other
embodiments the at least one degradable bond are five carbamate bonds. In
other
embodiments the at least one degradable bond are six carbamate bonds.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
108
In certain embodiments the at least one degradable bond present in the direct
connection
between any two carbon atoms marked with * connected by a moiety -CL- is one
amide bond.
In other embodiments the at least one degradable bond are two amide bonds. In
other
embodiments the at least one degradable bond are three amide bonds. In other
embodiments
the at least one degradable bond are four amide bonds. In other embodiments
the at least one
degradable bond are five amide bonds. In other embodiments the at least one
degradable bond
are six amide bonds.
It was found that a high degree of derivatization of the disaccharide units of
hyaluronic acid,
.. meaning that the number of units Z1 is less than 80% of all units present
in the conjugate,
interferes with degradation of the hydrogel by certain hyaluronidases. This
has the effect that
less degradation by hyaluronidases occurs and that chemical cleavage of the
degradable bonds
becomes more relevant. This renders degradation of the conjugate more
predictable. The
reason for this is that the level of enzymes, such as hyaluronidases, exhibits
inter-patient
variability and may vary between different administration sites, whereas
chemical cleavage
predominantly depends on temperature and pH which are more stable parameters
and thus
chemical cleavage tends to be more predictable.
In some embodiments -CL- is C1_50 alkyl, which is optionally interrupted by
one or more
atoms or groups selected from the group consisting of -T-, -C(0)0-, -0-,
-C(0)-, _C(0)N(R)_, -S(0)2-, -S(0)-, -S-, _N(R)_, -0C(0Rci)(Rcia)- and
_0C(0)N(R)_;
wherein -T- is selected from the group consisting of phenyl, naphthyl,
indenyl, indanyl,
tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, and 8- to 11-
membered
heterobicyclyl; and
-Rci and -Rcia are selected from the group consisting of -H and C1_6 alkyl.
In certain embodiments such moiety -CL- comprises at least one (such as one,
two, three,
four, five or six) degradable bond, such as a degradable bond selected from
the group
consisting of ester, carbonate, sulfate, phosphate bonds, carbamate and amide
bonds.
In certain embodiments -CL- is a moiety of formula (A)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
109
0
D2
.."*\ 1,===="" -**-\ E -***\
rlY - T2 - r3 D
0
(A),
wherein
-Y1- is of formula
_ ss,
¨ r8
R la1 R R2 R2a
r7 r9
sl
wherein the dashed line marked with the asterisk indicates attachment
to -Dl- and the unmarked dashed line indicates attachment to -D2-;
-Y2- is of formula
ss *
D6
_ = ss
r11
R3 R3a
R4 R4a
r10
r12 s2
wherein the dashed line marked with the asterisk indicates attachment
to -D4- and the unmarked dashed line indicates attachment to -D3-;
-El- is of formula
- - - -
*,, 2
G2
0
r14
0 0
wherein the dashed line marked with the asterisk indicates attachment
to -(C=0)- and the unmarked dashed line indicates attachment to -0-;
-E2- is of formula
* 3 4 3
G
y2/ D
s)
0 ss
'15 r16 II
0 0

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
110
wherein the dashed line marked with the asterisk indicates attachment to -Gl-
and the unmarked dashed line indicates attachment to -(C=0)-;
-Gl- is of formula
R6 R6a
, ¨
*
0 s',
r18
R5
R5a
r17
____________________________________________ s3
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -E2-;
-G2- is of formula
R8
R8a
*
0 ss,
r
R7 R7a 20
r19
___________________________________________ s4
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -(C=0)-;
-G3- is of formula

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
111
R9 R9a
' 0
r21 0 R1 Oa
r22
(C-1/1), s5
wherein the dashed line marked with the asterisk indicates attachment to -0-
and the unmarked dashed line indicates attachment to -(C=0)-;
-D1-, -D2-, -D3-,-D4-, -D5-, -D6- and -D7- are identical or different and each
is
independently of the others selected from the group comprising -0-, -NR11-,
_N+R12 R12a_, -S-, -(S=0)-, -(S(0)2), -C(0)-, -13(0)R13 and -CR14R14a_;
_Ria, _R2, _R2a, _R3, _R3a, _R4, _R4a, _R5, _Rsa, _R6, _R6a, _R7a, _R8,
_Rsa, _R9, _R
9a, _R10, _R10a, _R11, _R12, _R12a, _R13, _R14 and K14a
are identical or different and each
is independently of the others selected from the group comprising -H and C1-6
alkyl;
optionally, one or more of
the
pairs -R1/-R', -R2/_R2a, _R3/_R3a, _R4/_R4a, _R1/_R2, _R3/-R4, -R/-R2',
_R3a/i_R4a,
_R121K_,- 12a,
and
form a chemical bond or are joined together with the atom to
which they are attached to form a C3_8 cycloalkyl or to form a ring A or are
joined
together with the atom to which they are attached to form a 4- to 7-membered
heterocyclyl or 8- to 11-membered heterobicyclyl or adamantyl;
A is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl
and
tetralinyl;
rl, r2, r5, r6, r13, r14, r15 and r16 are independently 0 or 1;
T3, T4, r7, r8, r9, rl 0, rl 1, r12 are independently 0, 1, 2, 3, or 4;
r17, r18, r19, r20, r21 and r22 are independently 1, 2, 3, 4, 5, 6, 7, 8, 9 or
10; and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
112
sl, s2, s4, s5 are independently 1, 2, 3, 4, 5 or 6.
s3 ranges from 1 to 200, preferably from 1 to 100 and more preferably from 1
to 50
In certain embodiments rl of formula (A) is 0. In certain embodiments rl of
formula (A) is 1.
In certain embodiments r2 of formula (A) is 0. In certain embodiments r2 of
formula (A) is 1.
In certain embodiments r5 of formula (A) is 0. In certain embodiments r5 of
formula (A) is 1.
In certain embodiments r6 of formula (A) is 0. In certain embodiments r6 of
formula (A) is 1.
In certain embodiments r13 of formula (A) is 0. In certain embodiments r13 of
formula (A) is
1. In certain embodiments r14 of formula (A) is 0. In certain embodiments r14
of formula (A)
is 1. In certain embodiments r15 of formula (A) is 0. In certain embodiments
r15 of formula
(A) is 1. In certain embodiments rl 6 of formula (A) is 0. In certain
embodiments r16 of
formula (A) is 1.
In certain embodiments r3 of formula (A) is 0. In certain embodiments r3 of
formula (A) is 1.
In certain embodiments r3 of formula (A) is 2. In certain embodiments r3 of
formula (A) is 3.
In certain embodiments r3 of formula (A) is 4. In certain embodiments r4 of
formula (A) is 0.
In certain embodiments r4 of formula (A) is 1. In certain embodiments r4 of
formula (A) is 2.
In certain embodiments r4 of formula (A) is 3. In certain embodiments r4 of
formula (A) is 4.
In certain embodiments r3 of formula (A) and r4 of formula (A) are both 0.
In certain embodiments r7 of formula (A) is 0. In certain embodiments r7 of
formula (A) is 1.
In certain embodiments r7 of formula (A) is 2. In certain embodiments r7 of
formula (A) is 3.
In certain embodiments r7 of formula (A) is 4. In certain embodiments r8 of
formula (A) is 0.
In certain embodiments r8 of formula (A) is 1. In certain embodiments r8 of
formula (A) of
formula (A) is 2. In certain embodiments r8 of formula (A) of formula (A) is
3. In certain
embodiments r8 of formula (A) of formula (A) is 4. In certain embodiments r9
of formula (A)
is 0. In certain embodiments r9 of formula (A) is 1. In certain embodiments r9
of formula (A)
is 2. In certain embodiments r9 of formula (A) is 3. In certain embodiments r9
of formula (A)
is 4. In certain embodiments r10 of formula (A) is 0. In certain embodiments
rl 0 of formula
(A) is 1. In certain embodiments r10 of formula (A) is 2. In certain
embodiments r10 of
formula (A) is 3. In certain embodiments rl 0 of formula (A) is 4. In certain
embodiments rll
of formula (A) is 0. In certain embodiments rll of formula (A) is 1. In
certain embodiments

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
113
r11 of formula (A) is 2. In certain embodiments r11 of formula (A) is 3. In
certain
embodiments rll of formula (A) is 4. In certain embodiments r12 of formula (A)
is 0. In
certain embodiments r12 of formula (A) is 1. In certain embodiments r12 of
formula (A) is 2.
In certain embodiments r12 of formula (A) is 3. In certain embodiments r12 of
formula (A) is
4.
In certain embodiments rl 7 of formula (A) is 1. In certain embodiments rl 7
of formula (A) is
2. In certain embodiments r17 of formula (A) is 3. In certain embodiments rl 8
of formula (A)
is 1. In certain embodiments r18 of formula (A) is 2. In certain embodiments
rl 8 of formula
.. (A) is 3. In certain embodiments rl 9 of formula (A) is 1. In certain
embodiments r19 of
formula (A) is 2. In certain embodiments r19 of formula (A) is 3. In certain
embodiments r20
of formula (A) is 1. In certain embodiments r20 of formula (A) is 2. In
certain embodiments
r20 of formula (A) is 3. In certain embodiments r21 of formula (A) is 1. In
certain
embodiments r21 of formula (A) is 2. In certain embodiments r21 of formula (A)
is 3. In
certain embodiments r22 of formula (A) is 1. In certain embodiments r22 of
formula (A) is 2.
In certain embodiments r22 of formula (A) is 3.
In certain embodiments sl of formula (A) is 1. In certain embodiments sl of
formula (A) is 2.
In certain embodiments sl of formula (A) is 3. In certain embodiments s2 of
formula (A) is 1.
In certain embodiments s2 of formula (A) is 2. In certain embodiments s2 of
formula (A) is 3.
In certain embodiments s4 of formula (A) is 1. In certain embodiments s4 of
formula (A) is 2.
In certain embodiments s4 of formula (A) is 3.
In certain embodiments s3 of formula (A) ranges from 1 to 100. In certain
embodiments s3 of
formula (A) ranges from 1 to 75. In certain embodiments s3 of formula (A)
ranges from 2 to
50. In certain embodiments s3 of formula (A) ranges from 2 to 40. In certain
embodiments s3
of formula (A) ranges from 3 to 30. In certain embodiments s3 of formula (A)
ranges from 3
to 20. In certain embodiments s3 of formula (A) ranges from 3 to 10. In
certain embodiments
s3 of formula (A) is about 2. In certain embodiments s3 of formula (A) is
about 3. In certain
embodiments s3 of formula (A) is about 4. In certain embodiments s3 of formula
(A) is about
5. In certain embodiments s3 of formula (A) is about 6. In certain embodiments
s3 of formula
(A) is about 7. In certain embodiments s3 of formula (A) is about 8. In
certain embodiments
s3 of formula (A) is about 9. In certain embodiments s3 of formula (A) is
about 10. In certain
embodiments s3 of formula (A) is 2. In certain embodiments s3 of formula (A)
is 3. In certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
114
embodiments s3 of formula (A) is 4. In certain embodiments s3 of formula (A)
is 5. In certain
embodiments s3 of formula (A) is 6. In certain embodiments s3 of formula (A)
is 7. In certain
embodiments s3 of formula (A) is 8. In certain embodiments s3 of formula (A)
is 9. In certain
embodiments s3 of formula (A) is 10. In certain embodiments s3 of formula (A)
is 20. In
certain embodiments s3 of formula (A) is 25.
In certain embodiments -Rl of formula (A) is -H. In certain embodiments -RI of
formula (A)
is methyl. In certain embodiments -R1 of formula (A) is ethyl. In certain
embodiments -Ria of
formula (A) is -H. In certain embodiments -Ria of formula (A) is methyl. In
certain
embodiments -Ria of formula (A) is ethyl. In certain embodiments -R2 of
formula (A) is -H. In
certain embodiments -R2 of formula (A) is methyl. In certain embodiments -R2
of formula (A)
is ethyl. In certain embodiments -R2a of formula (A) is -H. In certain
embodiments -R2a of
formula (A) is methyl. In certain embodiments -R2a of formula (A) is ethyl. In
certain
embodiments -R3 of formula (A) is -H. In certain embodiments -R3 of formula
(A) is methyl.
In certain embodiments -R3 of formula (A) is ethyl. In certain embodiments -
R3a of formula
(A) is -H. In certain embodiments -R3a of formula (A) is methyl. In certain
embodiments -R3a
of formula (A) is ethyl. In certain embodiments -R4 of formula (A) is -H. In
certain
embodiments -R4 of formula (A) is methyl. In certain embodiments -R4 of
formula (A) is
methyl. In certain embodiments -lea of formula (A) is -H. In certain
embodiments -R4a of
formula (A) is methyl. In certain embodiments -lea of formula (A) is ethyl. In
certain
embodiments -R5 of formula (A) is -H. In certain embodiments -R5 of formula
(A) is methyl.
In certain embodiments -R5 of formula (A) is ethyl. In certain embodiments -
R5a of formula
(A) is -H. In certain embodiments -R5a of formula (A) is methyl. In certain
embodiments -R5a
of formula (A) is ethyl. In certain embodiments -R6 of formula (A) is -H. In
certain
embodiments -R6 of formula (A) is methyl. In certain embodiments -R6 of
formula (A) is
ethyl. In certain embodiments -R6a of formula (A) is -H. In certain
embodiments -R6a of
formula (A) is methyl. In certain embodiments -R6a of formula (A) is ethyl. In
certain
embodiments -R7 of formula (A) is -H. In certain embodiments -R7 of formula
(A) is methyl.
In certain embodiments -R7 of formula (A) is ethyl. In certain embodiments -R8
of formula
(A) is -H. In certain embodiments -R8 of formula (A) is methyl. In certain
embodiments -R8
of formula (A) is ethyl. In certain embodiments -R8a of formula (A) is -H. In
certain
embodiments -R8a of formula (A) is methyl. In certain embodiments -R8a of
formula (A) is
ethyl. In certain embodiments -R9 of formula (A) is -H. In certain embodiments
-R9 of
formula (A) is methyl. In certain embodiments -R9 of formula (A) is ethyl. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
115
embodiments -R9a of formula (A) is -H. In certain embodiments -R9a of formula
(A) is methyl.
In certain embodiments -R9a of formula (A) is ethyl. In certain embodiments -
R9a of formula
(A) is -H. In certain embodiments -R9a of formula (A) is methyl. In certain
embodiments -R9a
of formula (A) is ethyl. In certain embodiments -R1 of formula (A) is -H. In
certain
embodiments -R1 of formula (A) is methyl. In certain embodiments -R1 of
formula (A) is
ethyl. In certain embodiments -R1 a of formula (A) is -H. In certain
embodiments _Rioa of
formula (A) is methyl. In certain embodiments -R1 a of formula (A) is ethyl.
In certain
embodiments -R11 of formula (A) is -H. In certain embodiments -R11 of formula
(A) is
methyl. In certain embodiments -R11 of formula (A) is ethyl. In certain
embodiments -R12 of
formula (A) is -H. In certain embodiments -R12 of formula (A) is methyl. In
certain
embodiments -R12 of formula (A) is ethyl. In certain embodiments -R12a of
formula (A) is -H.
In certain embodiments -R12a of formula (A) is methyl. In certain embodiments -
R12a of
formula (A) is ethyl. In certain embodiments -R13 of formula (A) is -H. In
certain
embodiments -R13 of formula (A) is methyl. In certain embodiments -R13 of
formula (A) is
ethyl In certain embodiments -R14 of formula (A) is -H. In certain embodiments
-R14 of
formula (A) is methyl. In certain embodiments -R14 of formula (A) is ethyl. In
certain
embodiments -R14a of formula (A) is -H. In certain embodiments -R14a of
formula (A) is
methyl. In certain embodiments -R14a of formula (A) is ethyl.
In certain embodiments -D1- of formula (A) is -0-. In certain embodiments -D1-
of formula
(A) is -NR11-. In certain embodiments -D1- of formula (A) is _N+R12R12a_. In
certain
embodiments -D1- of formula (A) is -S-. In certain embodiments -D1- of formula
(A)
is -(S=0). In certain embodiments -D1- of formula (A) is -(S(0)2)-. In certain

embodiments -D1- of formula (A) is -C(0)-. In certain embodiments -D1- of
formula (A)
is -P(0)R13-. In certain embodiments -D1- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D1- of formula (A) is -CR14R14a_.
In certain embodiments -D2- of formula (A) is -0-. In certain embodiments -D2-
of formula
(A) is -NR11-. In certain embodiments -D2- of formula (A) is _N+R12R12a_. In
certain
embodiments -D2- of formula (A) is -S-. In certain embodiments -D2- of formula
(A)
is -(S=0). In certain embodiments -D2- of formula (A) is -(S(0)2)-. In certain

embodiments -D2- of formula (A) is -C(0)-. In certain embodiments -D2- of
formula (A)
is -P(0)R13-. In certain embodiments -D2- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D2- of formula (A) is -CR14R14a_.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
116
In certain embodiments -D3- of formula (A) is -0-. In certain embodiments -D3-
of formula
(A) is -NR"-. In certain embodiments -D3- of formula (A) is -N+R12R12a_. In
certain
embodiments -D3- of formula (A) is -S-. In certain embodiments -D3- of formula
(A)
is -(S=0). In certain embodiments -D3- of formula (A) is -(S(0)2)-. In certain
embodiments -D3- of formula (A) is -C(0)-. In certain embodiments -D3- of
formula (A)
is -P(0)R13-. In certain embodiments -D3- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D3- of formula (A) is -CR14R14a_.
In certain embodiments -D4- of formula (A) is -0-. In certain embodiments -D4-
of formula
(A) is -NR11-. In certain embodiments -D4- of formula (A) is -N+R12R12a_. In
certain
embodiments -D4- of formula (A) is -S-. In certain embodiments -D4- of formula
(A)
is -(S=0). In certain embodiments -D4- of formula (A) is -(S(0)2)-. In certain

embodiments -D4- of formula (A) is -C(0)-. In certain embodiments -D4- of
formula (A)
.. is -P(0)R13-. In certain embodiments -D4- of formula (A) is -P(0)(0R13)-.
In certain
embodiments -D4- of formula (A) is -CR14R14a_.
In certain embodiments -D5- of formula (A) is -0-. In certain embodiments -D5-
of formula
(A) is -NR11-. In certain embodiments -D5- of formula (A) is -N+R12R12a_. In
certain
embodiments -D5- of formula (A) is -S-. In certain embodiments -D5- of formula
(A)
is -(S=0)-. In certain embodiments -D5- of formula (A) is -(S(0)2)-. In
certain
embodiments -D5- of formula (A) is -C(0)-. In certain embodiments -D5- of
formula (A)
is -P(0)R13-. In certain embodiments -D5- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D5- of formula (A) is -CR14R14a_.
In certain embodiments -D6- of formula (A) is -0-. In certain embodiments -D6-
of formula
(A) is -NR"-. In certain embodiments -D6- of formula (A) is -N+R12R12a_. In
certain
embodiments -D6- of formula (A) is -S-. In certain embodiments -D6- of formula
(A)
is -(S=0). In certain embodiments -D6- of formula (A) is -(S(0)2)-. In certain
embodiments -D6- of formula (A) is -C(0)-. In certain embodiments -D6- of
formula (A)
is -P(0)R13-. In certain embodiments -D6- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D6- of formula (A) is -CR14R14a_.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
117
In certain embodiments -D7- of formula (A) is -0-. In certain embodiments -D7-
of formula
(A) is -NR11-. In certain embodiments -D7- of formula (A) is -N+R12R12a_. In
certain
embodiments -D7- of formula (A) is -S-. In certain embodiments -D7- of formula
(A)
is -(S=0). In certain embodiments -D7- of formula (A) is -(S(0)2)-. In certain
embodiments -D7- of formula (A) is -C(0)-. In certain embodiments -D7- of
formula (A)
is -P(0)R13-. In certain embodiments -D7- of formula (A) is -P(0)(0R13)-. In
certain
embodiments -D7- of formula (A) is -CR14R14a_.
In certain embodiments -CL- is of formula (B)
0
0
(B),
wherein
al and a2 are independently selected from the group consisting of al and a2
are
independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12,
13 and 14; and
b is an integer ranging from 1 to 50.
In certain embodiments al and a2 of formula (B) are different. In certain
embodiments al and
a2 of formula (B) are the same.
In certain embodiments al of formula (B) is 1. In certain embodiments al of
formula (B) is 2.
In certain embodiments al of formula (B) is 3. In certain embodiments al of
formula (B) is 4.
In certain embodiments al of formula (B) is 5. In certain embodiments al of
formula (B) is 6.
In certain embodiments al of formula (B) is 7. In certain embodiments al of
formula (B) is 8.
In certain embodiments al of formula (B) is 9. In certain embodiments al of
formula (B) is
10.
In certain embodiments a2 of formula (B) is 1. In certain embodiments a2 of
formula (B) is 2.
In certain embodiments a2 of formula (B) is 3. In certain embodiments a2 of
formula (B) is 4.
In certain embodiments a2 of formula (B) is 5. In certain embodiments a2 of
formula (B) is 6.
In certain embodiments a2 of formula (B) is 7. In certain embodiments a2 of
formula (B) is 8.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
118
In certain embodiments a2 of formula (B) is 9. In certain embodiments a2 of
formula (B) is
10.
In certain embodiments al and a2 of formula (B) are both 1. In certain
embodiments al and
a2 of formula (B) are both 2. In certain embodiments al and a2 of formula (B)
are both 3. In
certain embodiments al and a2 of formula (B) are both 4. In certain
embodiments al and a2
of formula (B) are both 5. In certain embodiments al and a2 of formula (B) are
both 6. In
certain embodiments al and a2 of formula (B) are both 7. In certain
embodiments al and a2
of formula (B) are both 8. In certain embodiments al and a2 of formula (B) are
both 9. In
certain embodiments al and a2 of formula (B) are both 10.
In certain embodiments al and a2 of formula (B) are both 1 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 1 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 1 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 2 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 2 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 2 and b of formula (B) is 25.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
119
In certain embodiments al and a2 of formula (B) are both 3 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 3 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 6. In
certain
.. embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 7.
In certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 3 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 4 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 4 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 10. In
certain
.. embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 20.
In certain
embodiments al and a2 of formula (B) are both 4 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 5 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 5 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 5 and b of formula (B) is 25.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
120
In certain embodiments al and a2 of formula (B) are both 6 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 6 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 6 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 7 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 7 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 7 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 8 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 8 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 8 and b of formula (B) is 25.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
121
In certain embodiments al and a2 of formula (B) are both 9 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 9 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 10. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 20. In
certain
embodiments al and a2 of formula (B) are both 9 and b of formula (B) is 25.
In certain embodiments al and a2 of formula (B) are both 10 and b of formula
(B) is 3. In
certain embodiments al and a2 of formula (B) are both 10 and b of formula (B)
is 4. In certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 5. In
certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 6. In
certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 7. In
certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 8. In
certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 9. In
certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 10.
In certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 20.
In certain
embodiments al and a2 of formula (B) are both 10 and b of formula (B) is 25.
In certain embodiments b of formula (B) ranges from 1 to 500. In certain
embodiments b of
formula (B) ranges from 2 to 250. In certain embodiments b of formula (B)
ranges from 3 to
100. In certain embodiments b of formula (B) ranges from 3 to 50. In certain
embodiments b
of formula (B) ranges from 3 to 25. In certain embodiments b of formula (B) is
2. In certain
embodiments b of formula (B) is 3. In certain embodiments b of formula (B) is
4. In certain
embodiments b of formula (B) is 5. In certain embodiments b of formula (B) is
6. In certain
embodiments b of formula (B) is 7. In certain embodiments b of formula (B) is
8. In certain
embodiments b of formula (B) is 9. In certain embodiments b of formula (B) is
10. In certain
embodiments b of formula (B) is 20. In certain embodiments b of formula (B) is
25.
In certain embodiments -CL- is of formula (B-i)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
122
0
,
0..õ.....õ.......- :õ..i......õ..õ....õ,;õ(
0_ 3
0
(B-i).
In certain embodiments -CL- is of formula (C)
R11
0
I
N -
_ 0 ,
- al a2
0
(C),
wherein
al and a2 are independently selected from the group consisting of 1, 2, 3, 4,
5, 6, 7, 8,
9, 10, 11, 12, 13 and 14;
b is an integer ranging from 1 to 50; and
-R11 is selected from the group comprising -H and C1_6 alkyl.
In certain embodiments al and a2 of formula (C) are different. In certain
embodiments al and
a2 of formula (B) are the same.
In certain embodiments al of formula (C) is 1. In certain embodiments al of
formula (C) is 2.
In certain embodiments al of formula (C) is 3. In certain embodiments al of
formula (C) is 4.
In certain embodiments al of formula (C) is 5. In certain embodiments al of
formula (C) is 6.
In certain embodiments al of formula (C) is 7. In certain embodiments al of
formula (C) is 8.
In certain embodiments al of formula (C) is 9. In certain embodiments al of
formula (C) is
10.
In certain embodiments a2 of formula (C) is 1. In certain embodiments a2 of
formula (C) is 2.
In certain embodiments a2 of formula (C) is 3. In certain embodiments a2 of
formula (C) is 4.
In certain embodiments a2 of formula (C) is 5. In certain embodiments a2 of
formula (C) is 6.
In certain embodiments a2 of formula (C) is 7. In certain embodiments a2 of
formula (C) is 8.
In certain embodiments a2 of formula (C) is 9. In certain embodiments a2 of
formula (C) is
10.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
123
In certain embodiments al and a2 of formula (C) are both 1. In certain
embodiments al and
a2 of formula (C) are both 2. In certain embodiments al and a2 of formula (C)
are both 3. In
certain embodiments al and a2 of formula (C) are both 4. In certain
embodiments al and a2
of formula (C) are both 5. In certain embodiments al and a2 of formula (C) are
both 6. In
certain embodiments al and a2 of formula (C) are both 7. In certain
embodiments al and a2
of formula (C) are both 8. In certain embodiments al and a2 of formula (C) are
both 9. In
certain embodiments al and a2 of formula (C) are both 10.
In certain embodiments al and a2 of formula (C) are both 1 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 1 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 8. In
certain
.. embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 9.
In certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 1 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 2 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 2 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 2 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 3 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 3 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 6. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
124
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 3 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 4 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 4 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 4 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 5 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 5 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 5 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 6 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 6 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 7. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
125
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 6 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 7 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 7 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 7 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 8 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 8 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 8 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 9 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 9 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 8. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
126
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 10. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 20. In
certain
embodiments al and a2 of formula (C) are both 9 and b of formula (C) is 25.
In certain embodiments al and a2 of formula (C) are both 10 and b of formula
(C) is 3. In
certain embodiments al and a2 of formula (C) are both 10 and b of formula (C)
is 4. In certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 5. In
certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 6. In
certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 7. In
certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 8. In
certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 9. In
certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 10.
In certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 20.
In certain
embodiments al and a2 of formula (C) are both 10 and b of formula (C) is 25.
In certain embodiments b of formula (C) ranges from 1 to 500. In certain
embodiments b of
formula (C) ranges from 2 to 250. In certain embodiments b of formula (C)
ranges from 3 to
100. In certain embodiments b of formula (C) ranges from 3 to 50. In certain
embodiments b
of formula (C) ranges from 3 to 25. In certain embodiments b of formula (C) is
2. In certain
embodiments b of formula (C) is 3. In certain embodiments b of formula (C) is
4. In certain
embodiments b of formula (C) is 5. In certain embodiments b of formula (C) is
6. In certain
embodiments b of formula (C) is 7. In certain embodiments b of formula (C) is
8. In certain
embodiments b of formula (C) is 9. In certain embodiments b of formula (C) is
10. In certain
embodiments b of formula (C) is 20. In certain embodiments b of formula (C) is
25.
In certain embodiments -R" of formula (C) is -H. In certain embodiments -RH of
formula (C)
is methyl. In certain embodiments -RH of formula (C) is ethyl. In certain
embodiments -RH of
formula (C) is n-propyl. In certain embodiments -R11 of formula (C) is
isopropyl. In certain
embodiments -R11 of formula (C) is n-butyl. In certain embodiments -R11 of
formula (C) is
isobutyl. In certain embodiments -RH of formula (C) is sec-butyl. In certain
embodiments -RH of formula (C) is tert-butyl. In certain embodiments -RH of
formula (C) is
n-pentyl. In certain embodiments -R11 of formula (C) is 2-methylbutyl. In
certain
embodiments -R11 of formula (C) is 2,2-dimethylpropyl. In certain embodiments -
R11 of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
127
formula (C) is n-hexyl. In certain embodiments -R11 of formula (C) is 2-
methylpentyl. In
certain embodiments -R" of formula (C) is 3-methylpentyl. In certain
embodiments -R" of
formula (C) is 2,2-dimethylbutyl. In certain embodiments -R" of formula (C) is
2,3-
dimethylbutyl. In certain embodiments -R11 of formula (C) is 3,3-
dimethylpropyl.
In certain embodiments -CL- is of formula (C-i)
0
N
0
(C-i).
Specific
embodiments
for -Rai, -Ra2, _L1_, _L2_, _L3_, _L4_, _SP-, _x0A_, _x0B_, _x0C _x0D_, _x0E_,
ic _-0F_
and -D of the
first embodiment are as described elsewhere herein.
In certain embodimetns -CL- is of formula (D)
0 0
m2 m3 m4
0 0 (D),
wherein
the dashed lines indicate attachment to a moiety -X"-; and
m2, m3 and m4 are independently an integer selected from the group consisting
of 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24 and 25.
In certain embodiments m2 of formula (D) is an integer selected from the group
consisting of
2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m2 of formula (D) is an
integer selected
from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments m2 of
formula (D) is 3.
In certain embodiments m2 of formula (D) is 4. In certain embodiments m2 of
formula (D) is
5. In certain embodiments m2 of formula (D) is 6. In certain embodiments m2 of
formula (D)
is 7. In certain embodiments m3 of formula (D) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D) is an
integer selected from the group consisting of 1, 2, 3, 4, and 5. In certain
embodiments m3 of
formula (D) is 1. In certain embodiments m3 of formula (D) is 2. In certain
embodiments m3

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
128
of formula (D) is 3. In certain embodiments m3 of formula (D) is 4. In certain
embodiments
m4 of formula (D) is an integer selected from the group consisting of 2, 3, 4,
5, 6, 7, 8, 9 and
10. In certain embodiments m4 of formula (D) is an anteger selected from the
group
consisting of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula (D) is 3.
In certain
.. embodiments m4 of formula (D) is 4. In certain embodiments m4 of formula
(D) is 5. In
certain embodiments m4 of formula (D) is 6. In certain embodiments m4 of
formula (D) is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-i)
0 0
H
0N N ,
ml
m2 m3 m4 H m5 H 10 0 O (D-i);
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23,
24 and 25.
In certain embodiments ml of formula (D-i) is an integer selected from the
group consisting
of 2, 3, 4, 5, and 6. In certain embodiments ml of formula (D-i) is 3. In
certain embodiments
m2 of formula (D-i) is an integer selected from the group consisting of 2, 3,
4, 5, 6, 7, 8, 9 and
10. In certain embodiments m2 of formula (D-i) is an integer selected from the
group
consisting of 3, 4, 5, 6 and 7. In certain embodiments m2 of formula (D-i) is
3. In certain
embodiments m2 of formula (D-i) is 4. In certain embodiments m2 of formula (D-
i) is 5. In
certain embodiments m2 of formula (D-i) is 6. In certain embodiments m2 of
formula (D-i) is
7. In certain embodiments m3 of formula (D-i) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-i) is an
integer selected from the group consisting of 1, 2, 3, 4, and 5. In certain
embodiments m3 of
formula (D-i) is 1. In certain embodiments m3 of formula (D-i) is 2. In
certain embodiments
m3 of formula (D-i) is 3. In certain embodiments m3 of formula (D-i) is 4. In
certain
embodiments m4 of formula (D-i) is an integer selected from the group
consisting of 2, 3, 4,
5, 6, 7, 8, 9 and 10. In certain embodiments m4 of formula (D-i) is an anteger
selected from
the group consisting of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula
(D-i) is 3. In

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
129
certain embodiments m4 of formula (D-i) is 4. In certain embodiments m4 of
formula (D-i) is
5. In certain embodiments m4 of formula (D-i) is 6. In certain embodiments m4
of formula
(D-i) is 7. In certain embodiments m5 of formula (D-i) is an integer selected
from the group
consisting of 2, 3, 4, 5 and 6. In certain embodiments m5 of formula (D-1) is
3.
In certain embodiments -CL- is of formula (D-ii)
0
m3 H
0 o (D-ii),
wherein
dashed lines indicate attachment to a moiety -X F-;
m3, m4 and m5 are independently an integer selected from the group consisting
of 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24 and 25.
In certain embodiments m3 of formula (D-ii) is an integer selected from the
group consisting
of 1, 2, 3, 4 and 5. In certain embodiments m3 of formula (D-ii) is 2. In
certain embodiments
m4 of formula (D-ii) is an integer selected from the group consisting of 1, 2,
3, 4, 5, 6, 7, 8, 9
and 10. In certain embodiments m4 of formula (D-ii) is 1. In certain
embodiments m4 of
formula (D-ii) is 2. In certain embodiments m4 of formula (D-ii) is 3. In
certain embodiments
m4 of formula (D-ii) is 4. In certain embodiments m5 of formula (D-ii) is an
integer selected
from 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m5 of formula (D-
ii) is 3. In certain
embodiments m5 of formula (D-ii) is 4. In certain embodiments m5 of formula (D-
ii) is 5. In
certain embodiments m5 of formula (D-ii) is 6. In certain embodiments m5 of
formula (D-ii)
is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-iii)
0
= H 0
H,
S
m2 N
ml m4 m5
0 m3 H m6
0 0
0
(D-iii),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
130
ml, m2, m3, m4, m5 and m6 are independently an integer selected from the group

consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-iii) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-iii) is 3. In
certain embodiments
m2 is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments
m2 of formula (D-iii) is 2. In certain embodiments m3 of formula (D-iii) is an
integer selected
from the group consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 of
formula (D-iii) is
2. In certain embodiments m4 of formula (D-iii) is an integer selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 of
formula (D-iii) is 1.
In certain embodiments m4 of formula (D-iii) is 2. In certain embodiments m4
of formula (D-
iii) is 3. In certain embodiments m4 of formula (D-iii) is 4. In certain
embodiments m5 of
formula (D-iii) is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9 and 10. In
certain embodiments
m5 of formula (D-iii) is 3. In certain embodiments m5 of formula (D-iii) is 4.
In certain
embodiments m5 of formula (D-iii) is 5. In certain embodiments m5 of formula
(D-iii) is 6. In
certain embodiments m5 of formula (D-iii) is 7. In certain embodiments m6 of
formula (D-iii)
is an integer selected from the group consisting of 2, 3, 4, 5 and 6. In
certain embodiments m6
of formula (D-iiii) is 3.
In certain embodiments -CL- is of formula (D-iv):
0
,
0
,
m3 H
0 0 (D-iv),
wherein
dashed lines indicate attachment to a moiety -X"-;
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
m3, m4 and m5 are independently an integer selected from the group consisting
of 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24 and 25.
In certain embodiments m3 of formula (D-iv) is an integer selected from the
group consisting
of 1, 2, 3, 4 and 5. In certain embodiments m3 of formula (D-iv) is 2. In
certain embodiments
m4 of formula (D-iv) is an integer selected from the group consisting of 1, 2,
3, 4, 5, 6, 7, 8, 9

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
131
and 10. In certain embodiments m4 of formula (D-iv) is 1. In certain
embodiments m4 of
formula (D-iv) is 2. In certain embodiments m4 of formula (D-iv) is 3. In
certain
embodiments m4 of formula (D-iv) is 4. In certain embodiments m5 of formula (D-
iv) is an
integer selected from 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m5
of formula (D-
iv) is 3. In certain embodiments m5 of formula (D-iv) is 4. In certain
embodiments m5 of
formula (D-iv) is 5. In certain embodiments m5 of formula (D-iv) is 6. In
certain
embodiments m5 of formula (D-iv) is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-v)
0
N,.,.._.,,N..-------..õ H H
m2 S
0NNzi
, N
ml m4 m5
0 0 m3 H
0 0
m6 '
(D-v),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4, m5 and m6 are independently an integer selected from the group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-v) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-v) is 3. In
certain embodiments
m2 is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments
m2 of formula (D-v) is 2. In certain embodiments m3 of formula (D-v) is an
integer selected
from the group consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 of
formula (D-v) is
2. In certain embodiments m4 of formula (D-v) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 of
formula (D-v) is 1.
In certain embodiments m4 of formula (D-v) is 2. In certain embodiments m4 of
formula (D-
v) is 3. In certain embodiments m4 of formula (D-v) is 4. In certain
embodiments m5 of
formula (D-v) is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9 and 10. In
certain embodiments
m5 of formula (D-v) is 3. In certain embodiments m5 of formula (D-v) is 4. In
certain
embodiments m5 of formula (D-v) is 5. In certain embodiments m5 of formula (D-
v) is 6. In
certain embodiments m5 of formula (D-v) is 7. In certain embodiments m6 of
formula (D-v)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
132
is an integer selected from the group consisting of 2, 3, 4, 5 and 6. In
certain embodiments m6
of formula (D-v) is 3.
In certain embodiments -CL- is of formula (D-vi)
0
, N m4 m5
m3 H
0 0 (D-vi),
wherein
dashed lines indicate attachment to a moiety -X"-;
m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m3 of formula (D-vi) is an integer selected from the
group consisting
of 1, 2, 3, 4 and 5. In certain embodiments m3 of formula (D-vi) is 1. In
certain embodiments
m3 of formula (D-vi) is 2. In certain embodiments m4 of formula (D-vi) is an
integer selected
from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain
embodiments m4 of
formula (D-vi) is 1. In certain embodiments m4 of formula (D-vi) is 2. In
certain
embodiments m4 of formula (D-vi) is 3. In certain embodiments m4 of formula (D-
vi) is 4. In
certain embodiments m5 of formula (D-vi) is an integer selected from 2, 3, 4,
5, 6, 7, 8, 9 and
10. In certain embodiments m5 of formula (D-vi) is 3. In certain embodiments
m5 of formula
(D-vi) is 4. In certain embodiments m5 of formula (D-vi) is 5. In certain
embodiments m5 of
formula (D-vi) is 6. In certain embodiments m5 of formula (D-vi) is 7.
In certain embodiments a moiety -X"-SP-X"-CL-X"-SP-X"- has the structure of
formula
(D-vii)
0 0
< N
N
H ml H m2 m3 H m4 m5
m6"
0 0 (D-vii),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
133
ml, m2, m3, m4, m5 and m6 are independently an integer selected from the group

consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-vii) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-vii) is 3. In
certain embodiments
m2 of formula (D-vii) is an integer selected from the group consisting of 1,
2, 3, 4 and 5. In
certain embodiments m2 of formula (D-vii) is 1. In certain embodiments m2 of
formula (D-
vii) is 2. In certain embodiments m3 of formula (D-vii) is an integer selected
from the group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 of formula (D-vii)
is 1. In certain
embodiments m3 of formula (D-vii) is 2. In certain embodiments m4 of formula
(D-vii) is an
integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and
10. In certain
embodiments m4 of formula (D-vii) is 1. In certain embodiments m4 of formula
(D-vii) is 2.
In certain embodiments m4 of formula (D-vii) is 3. In certain embodiments m4
of formula (D-
vii) is 4. In certain embodiments m5 of formula (D-vii) is an integer selected
from 2, 3, 4, 5,
6, 7, 8, 9 and 10. In certain embodiments m5 of formula (D-vii) is 3. In
certain embodiments
m5 of formula (D-vii) is 4. In certain embodiments m5 of formula (D-vii) is 5.
In certain
embodiments m5 of formula (D-vii) is 6. In certain embodiments m5 of formula
(D-vii) is 7.
In certain embodiments m6 of formula (D-vii) is an integer selected from the
group consisting
.. of 2, 3, 4, 5 and 6. In certain embodiments m6 of formula (D-vii) is 3.
In certain embodiments -CL- is of formula (D-viii)
0
=
N 0
m3 m4
m2 H
0 O (D-viii),
wherein
dashed lines indicate attachment to a moiety -X"-;
m2, m3 and m4 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments ml of formula (D-viii) is an integer selected from the
group
consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-viii)
is 3. In certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
134
embodiments m2 is an integer selected from the group consisting of 1, 2, 3, 4
and 5. In certain
embodiments m2 of formula (D-viii) is 2. In certain embodiments m2 of formula
(D-viii) is 5.
In certain embodiments m3 of formula (D-viii) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-viii) is
an integer selected from the group consisting of 1, 2, 3 and 4. In certain
embodiments m3 of
formula (D-viii) is 1. In certain embodiments m3 of formula (D-viii) is 2. In
certain
embodiments m3 of formula (D-viii) is 3. In certain embodiments m3 of formula
(D-viii) is 4.
In certain embodiments m4 of formula (D-viii) is an integer selected from the
group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 of
formula (D-viii) is an
integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m4 of
formula (D-viii) is 3. In certain embodiments m4 of formula (D-viii) is 4. In
certain
embodiments m4 of formula (D-viii) is 5. In certain embodiments m4 of formula
(D-viii) is 6.
In certain embodiments m4 of formula (D-viii) is 7. In certain embodiments m5
of formula
(D-viii) is an integer selected from 2, 3, 4, 5 and 6. In certain embodiments
m5 of formula (D-
viii) is 3.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-ix)
0
.H H H H
'NNSNO-..,N N
-
m3 m4 i
ml m2 H m5'
0 0 0
(D-ix),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-ix) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-ix) is 3. In
certain embodiments
m2 is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments
m2 of formula (D-ix) is 2. In certain embodiments m2 of formula (D-ix) is 5.
In certain
embodiments m3 of formula (D-ix) is an integer selected from the group
consisting of 1, 2, 3,
4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of formula (D-ix) is an
integer selected

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
135
from the group consisting of 1, 2, 3 and 4. In certain embodiments m3 of
formula (D-ix) is 1.
In certain embodiments m3 of formula (D-ix) is 2. In certain embodiments m3 of
formula (D-
ix) is 3. In certain embodiments m3 of formula (D-ix) is 4. In certain
embodiments m4 of
formula (D-ix) is an integer selected from the group consisting of 2, 3, 4, 5,
6, 7, 8, 9 and 10.
In certain embodiments m4 of formula (D-ix) is an integer selected from the
group consisting
of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula (D-ix) is 3. In
certain embodiments
m4 of formula (D-ix) is 4. In certain embodiments m4 of formula (D-ix) is 5.
In certain
embodiments m4 of formula (D-ix) is 6. In certain embodiments m4 of formula (D-
ix) is 7. In
certain embodiments m5 of formula (D-ix) is an integer selected from 2, 3, 4,
5 and 6. In
certain embodiments m5 of formula (D-ix) is 3.
In certain embodiments -CL- is of formula (D-x)
o
m3 m4
(D-x),
dashed lines indicate attachment to a moiety -X"-;
m3 and m4 are independently an integer selected from the group consisting of
1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24
and 25.
In certain embodiments m3 of formula (D-x) is an integer selected from the
group consisting
of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of formula (D-
x) is an integer
selected from the group consisting of 1, 2, 3 and 4. In certain embodiments m3
of formula (D-
x) is 1. In certain embodiments m3 of formula (D-x) is 2. In certain
embodiments m3 of
formula (D-x) is 3. In certain embodiments m3 of formula (D-x) is 4. In
certain embodiments
m4 of formula (D-x) is an integer selected from the group consisting of 2, 3,
4õ5 ,6 ,7 ,8 , 9
and 10. In certain embodiments m4 of formula (D-x) is an integer selected from
the group
consisting of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula (D-x) is
3. In certain
embodiments m4 of formula (D-x) is 4. In certain embodiments m4 of formula (D-
x) is 5. In
certain embodiments m4 of formula (D-x) is 6. In certain embodiments m4 of
formula (D-x)
is 7.
In certain embodiments a moiety -X"-SP-X"-CL-X"-SP-X"- has the structure of
formula
(D-xi)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
136
0
= H H H H
m2S ....,..0,....,....,...----
,.......õõ
N
H m3 m4
ml 0
0 0 m5 "
(D-
xi),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
each ml, m2, m3, m4 and m5 is independently an integer selected from the group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xi) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-xi) is 3. In
certain embodiments
m2 is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments
m2 of formula (D-xi) is 2. In certain embodiments m2 of formula (D-xi) is 5.
In certain
embodiments m3 of formula (D-xi) is an integer selected from the group
consisting of 1, 2, 3,
4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of formula (D-xi) is an
integer selected
from the group consisting of 1, 2, 3 and 4. In certain embodiments m3 of
formula (D-xi) is 1.
In certain embodiments m3 of formula (D-xi) is 2. In certain embodiments m3 of
formula (D-
xi) is 3. In certain embodiments m3 of formula (D-xi) is 4. In certain
embodiments m4 of
formula (D-xi) is an integer selected from the group consisting of 2, 3, 4, 5,
6, 7, 8, 9 and 10.
In certain embodiments m4 of formula (D-xi) is an integer selected from the
group consisting
of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula (D-xi) is 3. In
certain embodiments
m4 of formula (D-xi) is 4. In certain embodiments m4 of formula (D-xi) is 5.
In certain
embodiments m4 of formula (D-xi) is 6. In certain embodiments m4 of formula (D-
xi) is 7. In
certain embodiments m5 of formula (D-xi) is an integer selected from 2, 3, 4,
5 and 6. In
certain embodiments m5 of formula (D-xi) is 3.
In certain embodiments -CL- is of formula (D-xii)
0
NICI , m5 m6
m4 H
0 0 (D-xii),
wherein

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
137
dashed lines indicate attachment to a moiety -X"-;
m4, m5 and m6 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m4 of formula (D-xii) is an integer selected from the
group consisting
of 1, 2, 3, 4 and 5. In certain embodiments m4 of formula (D-xii) is 1. In
certain
embodiments m4 of formula (D-xii) is 5. In certain embodiments m5 of formula
(D-xii) is an
integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments
m5 of formula (D-
xii) is an integer selected from the group consisting of 1, 2, 3 and 4. In
certain embodiments
m5 of formula (D-xii) is 1. In certain embodiments m5 of formula (D-xii) is 2.
In certain
embodiments m5 of formula (D-xii) is 3. In certain embodiments m5 of formula
(D-xii) is 4.
In certain embodiments m6 of formula (D-xii) is an integer selected from the
group consisting
of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m6 of formula (D-xii)
is an integer
selected from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments
m6 of formula
(D-xii) is 3. In certain embodiments m6 of formula (D-xii) is 4. In certain
embodiments m6 of
formula (D-xii) is 5. In certain embodiments m6 of formula (D-xii) is 6. In
certain
embodiments m6 of formula (D-xii) is 7.
In certain embodiments a moiety -X E-SP-X"-CL-X"-SP-X E- has the structure of
formula
(D-xiii)
H HNZN 0
H H
ml
0 m2 m3 m4 H m5
0 m6
0 m7
(D-xiii),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4, m5, m6 and m7 are independently an integer selected from the
group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xiii) is an integer selected from the
group
consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-xiii)
is 3. In certain
embodiments m2 of formula (D-xiii) is an integer selected from the group
consisting of 1, 2,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
138
3, 4 and 5. In certain embodiments m2 of formula (D-xiii) is 1. In certain
embodiments m3 of
formula (D-xiii) is an integer selected from the group consisting of 1, 2, 3,
4 and 5. In certain
embodiments m3 of formula (D-xiii) is 1. In certain embodiments m4 of formula
(D-xiii) is an
integer selected from the group consisting of 1, 2, 3, 4 and 5. In certain
embodiments m4 of
formula (D-xiii) is 1. In certain embodiments m4 of formula (D-xiii) is 5. In
certain
embodiments m5 of formula (D-xiii) is an integer selected from 1, 2, 3, 4, 5,
6, 7, 8, 9 and 10.
In certain embodiments m5 of formula (D-xiii) is an integer selected from the
group
consisting of 1, 2, 3 and 4. In certain embodiments m5 of formula (D-xiii) is
1. In certain
embodiments m5 of formula (D-xiii) is 2. In certain embodiments m5 of formula
(D-xiii) is 3.
In certain embodiments m5 of formula (D-xiii) is 4. In certain embodiments m6
of formula
(D-xiii) is an integer selected from the group consisting of 2, 3, 4, 5, 6, 7,
8, 9 and 10. In
certain embodiments m6 of formula (D-xiii) is an integer selected from the
group consisting
of 3, 4, 5, 6 and 7. In certain embodiments m6 of formula (D-xiii) is 3. In
certain
embodiments m6 of formula (D-xiii) is 4. In certain embodiments m6 of formula
(D-xiii) is 5.
In certain embodiments m6 of formula (D-xiii) is 6. In certain embodiments m6
of formula
(D-xiii) is 7. In certain embodiments m7 of formula (D-xiii) is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments m7 of formula (D-
xiii) is 3. In
certain embodiments m7 of formula (D-xiii) is 4.
In certain embodiments -CL- is of formula (D-xiv)
0 0
/0 N
m3 m4 m5 m6
(D-xiv),
wherein
dashed lines indicate attachment to a moiety -X F-;
m3, m4, m5 and m6 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m3 of formula (D-xiv) is an integer selected from the
group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 is 1. In certain
embodiments m3 of
.. formula (D-xiv) is 5. In certain embodiments m4 of formula (D-xiv) is an
integer selected
from the group consisting of 1, 2, 3, 4 and 5. In certain embodiments m4 of
formula (D-xiv) is

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
139
1. In certain embodiments m5 is an integer selected from the group consisting
of 1, 2, 3, 4, 5,
6, 7, 8, 9 and 10. In certain embodiments m5 of formula (D-xiv) is an integer
selected from
the group consisting of 1, 2, 3 and 4. In certain embodiments m5 of formula (D-
xiv) is 1. In
certain embodiments m5 of formula (D-xiv) is 2. In certain embodiments m5 of
formula (D-
xiv) is 3. In certain embodiments m5 of formula (D-xiv) is 4. In certain
embodiments m6 of
formula (D-xiv) is an integer selected from the group consisting of 2, 3, 4,
5, 6, 7, 8, 9 and 10.
In certain embodiments m6 of formula (D-xiv) is 3. In certain embodiments m6
of formula
(D-xiv) is 4. In certain embodiments m6 of formula (D-xiv) is 5. In certain
embodiments m6
of formula (D-xiv) is 6. In certain embodiments m6 of formula (D-xiv) is 7.
In certain embodiments a moiety -X0E_sp_xoF_cL_xoF_sp_xoE_ has the structure
of formula
(D-xv)
,H
>NN0 0
ml m21\11-
0 0 7N
m3 m4 m5
m6 H m H
0
(D-xv),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4, m5, m6 and m7 are independently an integer selected from the
group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xv) is an integer selected from the
group consisting
of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-xv) is 3. In
certain embodiments
of m2 of formula (D-xv) is an integer selected from the group consisting of 1,
2, 3, 4 and 5. In
certain embodiments m2 of formula (D-xv) is 1. In certain embodiments m3 of
formula (D-
xv) is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments
m3 is 1. In certain embodiments m3 of formula (D-xv) is 5. In certain
embodiments m4 of
formula (D-xv) is an integer selected from the group consisting of 1, 2, 3, 4
and 5. In certain
embodiments m4 of formula (D-xv) is 1. In certain embodiments m5 is an integer
selected
from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain
embodiments m5 of
formula (D-xv) is an integer selected from the group consisting of 1, 2, 3 and
4. In certain
embodiments m5 of formula (D-xv) is 1. In certain embodiments m5 of formula (D-
xv) is 2.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
140
In certain embodiments m5 of formula (D-xv) is 3. In certain embodiments m5 of
formula (D-
xv) is 4. In certain embodiments m6 of formula (D-xv) is an integer selected
from the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m6 of
formula (D-xv) is 3. In
certain embodiments m6 of formula (D-xv) is 4. In certain embodiments m6 of
formula (D-
xv) is 5. In certain embodiments m6 of formula (D-xv) is 6. In certain
embodiments m6 of
formula (D-xv) is 7. In certain embodiments m7 of formula (D-xv) is an integer
selected from
the group consisting of 2, 3, 4, 5 and 6. In certain embodiments m7 of formula
(D-xv) is 4.
In certain embodiments -CL- is of formula (D-xvi)
0
m2 m3 H m4 m5
0 0 (D-xvi),
wherein
dashed lines indicate attachment to a moiety -X"-;
m2, m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments of m2 of formula (D-xvi) is an integer selected from
the group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m2 of formula (D-xvi)
is 1. In certain
embodiments m3 of formula (D-xvi) is an integer selected from the group
consisting of 1, 2,
.. 3, 4 and 5. In certain embodiments m3 is 1. In certain embodiments m4 of
formula (D-xvi) is
an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and
10. In certain
embodimetns m4 of formula (D-xvi) is an integer selected from the group
consisting of 1, 2, 3
and 4. In certain embodiments m4 of formula (D-xvi) is 1. In certain
embodiments m4 of
formula (D-xvi) is 2. In certain embodiments m4 of formula (D-xvi) is 3. In
certain
embodiments m4 of formula (D-xvi) is 4. In certain embodiments m5 is an
integer selected
from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain
embodiments m5 of
formula (D-xvi) is an integer selected from the group consisting of 3, 4, 5,
6, and 7. In certain
embodiments m5 of formula (D-xvi) is 3. In certain embodiments m5 of formula
(D-xvi) is 4.
In certain embodiments m5 of formula (D-xvi) is 5. In certain embodiments m5
of formula
.. (D-xvi) is 6. In certain embodiments m5 of formula (D-xvi) is 7.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
141
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xvii)
0
N 0 N N
m2 m3 H m4 m5
m6'
0 0
ml
(D-
xvii),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4, m5 and m6 are independently an integer selected from the group

consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xvii) is an integer selected from the
group
consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-xvii)
is 3. In certain
embodiments ml of formula (D-xvii) is 4. In certain embodiments of m2 of
formula (D-xvii)
is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m2
of formula (D-xvii) is 1. In certain embodiments m3 of formula (D-xvii) is an
integer selected
from the group consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 is 1.
In certain
embodiments m4 of formula (D-xvii) is an integer selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7, 8, 9 and 10. In certain embodimetns m4 of formula (D-xvii) is
an integer selected
from the group consisting of 1, 2, 3 and 4. In certain embodiments m4 of
formula (D-xvii) is
.. 1. In certain embodiments m4 of formula (D-xvii) is 2. In certain
embodiments m4 of formula
(D-xvii) is 3. In certain embodiments m4 of formula (D-xvii) is 4. In certain
embodiments m5
of formula (D-xvii) is an integer selected from the group consisting of 2, 3,
4, 5, 6, 7, 8, 9 and
10. In certain embodiments m5 of formula (D-xvii) is an integer selected from
the group
consisting of 3, 4, 5, 6, and 7. In certain embodiments m5 of formula (D-xvii)
is 3. In certain
embodiments m5 of formula (D-xvii) is 4. In certain embodiments m5 of formula
(D-xvii) is
5. In certain embodiments m5 of formula (D-xvii) is 6. In certain embodiments
m5 of formula
(D-xvii) is 7. In certain embodiments m6 of formula (D-xvii) is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments m6 of formula (D-
xvii) is 3.
In certain embodiments -CL- is of formula (D-xviii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
142
0
0
m3 m4
m2 H
0 0 (D-xviii),
wherein
dashed lines indicate attachment to a moiety -X"-;
m2, m3 and m4 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m2 of formula (D-xviii) is an integer selected from the
group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m2 of formula (D-xviii)
is 1. In certain
embodiments m3 of formula (D-xviii) is an integer selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7,8, 9 and 10. In certain embodiments m3 of formula (D-xviii) is
an integer selected
from the group consisting of 1, 2, 3 and 4. In certain embodiments m3 of
formula (D-xviii) is
1. In certain embodiments m3 of formula (D-xviii) is 2. In certain embodiments
m3 of
formula (D-xix) is 3. In certain embodiments m3 of formula (D-xviii) is 4. In
certain
embodiments m4 of formula (D-xviii) is an integer selected from the group
consisting of 2, 3,
4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 of formula (D-xviii) is an
integer selected
from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments m4 of
formula (D-xviii)
is 3. In certain embodiments m4 of formula (D-xviii) is 4. In certain
embodiments m4 of
formula (D-xviii) is 5. In certain embodiments m4 of formula (D-xviii) is 6.
In certain embodiments a moiety -X"-SP-X"-CL-X"-SP-X"- has the structure of
formula
(D-xix)
NN 0
N I H H
ml m3 m4
m2 H m5
0 0 (D-xix),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
143
In certain embodiments ml of formula (D-xix) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments ml of formula
(D-xix) is 1. In
certain embodiments m2 of formula (D-xix) is an integer selected from the
group consisting
of 1, 2, 3, 4 and 5. In certain embodiments m2 of formula (D-xix) is 1. In
certain
embodiments m3 of formula (D-xix) is an integer selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7,8, 9 and 10. In certain embodiments m3 of formula (D-xix) is an
integer selected
from the group consisting of 1, 2, 3 and 4. In certain embodiments m3 of
formula (D-xix) is 1.
In certain embodiments m3 of formula (D-xix) is 2. In certain embodiments m3
of formula
(D-xix) is 3. In certain embodiments m3 of formula (D-xix) is 4. In certain
embodiments m4
of formula (D-xix) is an integer selected from the group consisting of 2, 3,
4, 5, 6, 7, 8, 9 and
10. In certain embodiments m4 of formula (D-xix) is an integer selected from
the group
consisting of 3, 4, 5, 6 and 7. In certain embodiments m4 of formula (D-xix)
is 3. In certain
embodiments m4 of formula (D-xix) is 4. In certain embodiments m4 of formula
(D-xix) is 5.
In certain embodiments m4 of formula (D-xix) is 6. In certain embodiments m4
of formula
(D-xix) is 7. In certain embodiments m5 of formula (D-xix) is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments m5 of formula (D-
xix) is 3.
In certain embodiments -CL- is of formula (D-xx)
0
m4 m5
m3 H
0 0 (D-xx),
wherein
dashed lines indicate attachment to a moiety -X"-;
m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m3 of formula (D-xx) is an integer selected from the
group consisting
of the group 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-xx) is an
integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m3 of
.. formula (D-xx) is 3. In certain embodiments m3 is 4. In certain embodiments
m3 of formula
(D-xx) is 5. In certain embodiments m3 of formula (D-xx) is 6. In certain
embodiments m3 of

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
144
formula (D-xxi is 7. In certain embodiments m4 of formula (D-xx) is an integer
selected from
the group consisting of 1, 2, 3,4 ,5, 6, 7, 8, 9 and 10. In certain
embodiments m4 of formula
(D-xx) is an integer selected from the group consisting of 1, 2, 3 and 4. In
certain
embodiments m4 of formula (D-xx) is 1. In certain embodiments m4 of formula (D-
xx) is 2.
In certain embodiments m4 of formula (D-xx) is 3. In certain embodiments m4 of
formula (D-
xx) is 4. In certain embodiments m5 of formula (D-xx) is an integer selected
from the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m5 of
formula (D-xx) is an
integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m5 of
formula (D-xx) is 3. In certain embodiments m5 of formula (D-xx) is 4. In
certain
embodiments m5 of formula (D-xx) is 5. In certain embodiments m5 of formula (D-
xx) is 6.
In certain embodiments m5 of formula (D-xx) is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xxi) or (D-xxi')
H H
N N
0 0
m2 N H H,
ml
m4 m5
m3 H m6
'
0 0
(D-xxi),
0 0
H H H H
N N
m2 N m4 m5
ml m3 H m6/
i
0 N\, 2 0 0
N
(D-
xxi`)
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
each ml, m2, m3, m4, m5 and m6 is independently an integer selected from the
group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
145
In certain embodiments ml of formula (D-xxi) or (D-xxi') is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-
xxi) or (D-
xxi') is 3. In certain embodiments ml of formula (D-xxi) or (D-xxi') is 4. In
certain
embodiments m2 of formula (D-xxi) or (D-xxi') is an integer selected from the
group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m2 of formula (D-xxi)
or (D-xxi') is 1.
In certain embodiments m3 of formula (D-xxi) or (D-xxi') is an integer
selected from the
group consisting of the group 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain
embodiments m3 of
formula (D-xxi) or (D-xxi') is an integer selected from the group consisting
of 3, 4, 5, 6 and 7.
In certain embodiments m3 of formula (D-xxi) or (D-xxi') is 3. In certain
embodiments m3 is
4. In certain embodiments m3 of formula (D-xxi) or (D-xxi') is 5. In certain
embodiments m3
of formula (D-xxi) or (D-xxi') is 6. In certain embodiments m3 of formula (D-
xxi) or (D-xxi')
is 7. In certain embodiments m4 of formula (D-xxi) or (D-xxi') is an integer
selected from the
group consisting of 1, 2, 3,4 ,5 6, 7, 8, 9 and 10. In certain embodiments m4
of formula (D-
xxi) or (D-xxi') is an integer selected from the group consisting of 1, 2, 3
and 4. In certain
embodiments m4 of formula (D-xxi) or (D-xxi') is 1. In certain embodiments m4
of formula
(D-xxi) or (D-xxi') is 2. In certain embodiments m4 of formula (D-xxi) or (D-
xxi') is 3. In
certain embodiments m4 of formula (D-xxi) or (D-xxi') is 4. In certain
embodiments m5 of
formula (D-xxi) or (D-xxi') is an integer selected from the group consisting
of 2, 3, 4, 5, 6, 7,
8, 9 and 10. In certain embodiments m5 of formula (D-xxi) or (D-xxi') is an
integer selected
from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments m5 of
formula (D-xxi)
or (D-xxi') is 3. In certain embodiments m5 of formula (D-xxi) or (D-xxi') is
4. In certain
embodiments m5 of formula (D-xxi) or (D-xxi') is 5. In certain embodiments m5
of formula
(D-xxi) or (D-xxi') is 6. In certain embodiments m5 of formula (D-xxi) or (D-
xxi') is 7. In
certain embodiments m6 of formula (D-xxi) or (D-xxi') is an integer selected
from the group
consisting of 2, 3, 4, 5 and 6. In certain embodiments m6 of formula (D-xxi)
or (D-xxi') is 3.
In certain embodiments m6 of formula (D-xxi) or (D-xxi') is 4.
In certain embodiments -CL- is of formula (D-xxii)
0
.,./.). .'=0----........_
N m3 m4
m2 H
0 0 (D-xxii),
wherein
dashed lines indicate attachment to a moiety -X F-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
146
m2, m3 and m4 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m2 (D-xxiii) or (D-xxiii') is an integer selected from
the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9, and 10. In certain embodiments m2 (D-
xxiii) or (D-xxiii') is
an integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m2
(D-xxiii) or (D-xxiii') is 3. In certain embodiments m2 (D-xxiii) or (D-
xxiii') is 4. In certain
embodiments m2 (D-xxiii) or (D-xxiii') is 5. In certain embodiments m2 (D-
xxiii) or (D-
xxiii') is 6. In certain embodiments m2 (D-xxiii) or (D-xxiii') is 7. In
certain embodiments
m3 (D-xxiii) or (D-xxiii') is an integer seleced from the group consisting of
1, 2, 3, 4, 5, 6, 7,
8, 9 and 10. In certain embodiments m3 (D-xxiii) or (D-xxiii') is is an
integer selected from
the group consisting of 1, 2, 3 and 4. In certain embodiments m3 (D-xxiii) or
(D-xxiii') is 1.
In certain embodiments m3 (D-xxiii) or (D-xxiii') is 2. In certain embodiments
m3 (D-xxiii)
or (D-xxiii') is 3. In certain embodiments m3 (D-xxiii) or (D-xxiii') is 4. In
certain
embodiments m4 (D-xxiii) or (D-xxiii') is an integer selected from the group
consisting of 2,
3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 (D-xxiii) or (D-xxiii')
is an integer
selected from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments
m4 (D-xxiii) or
(D-xxiii') is 3. In certain embodiments m4 is 4. In certain embodiments m4 (D-
xxiii) or (D-
xxiii') is 5. In certain embodiments m4 (D-xxiii) or (D-xxiii') is 6. In
certain embodiments
m4 (D-xxiii) or (D-xxiii') is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xxiii) or (D-xxiii')
0 0
N mi N m3 m4
= H N,, m2 H
0 0 m5
(D
xxiii),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
147
0 0
N mi N
H
N , N)Lj.-LN m3 m4 N
m2 H m5 '
0 0
(D-
xxiii`),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xxiii) or (D-xxiii') is an integer
selected from the
group consisting of 1, 2, 3, 4 and 5. In certain embodiments ml (D-xxiii) or
(D-xxiii') is 1. In
certain embodiments m2 (D-xxiii) or (D-xxiii') is an integer selected from the
group
consisting of 2, 3, 4, 5, 6, 7, 8, 9, and 10. In certain embodiments m2 (D-
xxiii) or (D-xxiii') is
an integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m2
(D-xxiii) or (D-xxiii') is 3. In certain embodiments m2 (D-xxiii) or (D-
xxiii') is 4. In certain
embodiments m2 (D-xxiii) or (D-xxiii') is 5. In certain embodiments m2 (D-
xxiii) or (D-
xxiii') is 6. In certain embodiments m2 (D-xxiii) or (D-xxiii') is 7. In
certain embodiments
m3 (D-xxiii) or (D-xxiii') is an integer seleced from the group consisting of
1, 2, 3, 4, 5, 6, 7,
8, 9 and 10. In certain embodiments m3 (D-xxiii) or (D-xxiii') is is an
integer selected from
the group consisting of 1, 2, 3 and 4. In certain embodiments m3 (D-xxiii) or
(D-xxiii') is 1.
In certain embodiments m3 (D-xxiii) or (D-xxiii') is 2. In certain embodiments
m3 (D-xxiii)
or (D-xxiii') is 3. In certain embodiments m3 (D-xxiii) or (D-xxiii') is 4. In
certain
embodiments m4 (D-xxiii) or (D-xxiii') is an integer selected from the group
consisting of 2,
3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 (D-xxiii) or (D-xxiii')
is an integer
selected from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments
m4 (D-xxiii) or
(D-xxiii') is 3. In certain embodiments m4 is 4. In certain embodiments m4 (D-
xxiii) or (D-
xxiii') is 5. In certain embodiments m4 (D-xxiii) or (D-xxiii') is 6. In
certain embodiments
m4 (D-xxiii) or (D-xxiii') is 7. In certain embodimens m5 (D-xxiii) or (D-
xxiii') is an integer
selected from the group consisting of 2, 3, 4, 5 and 6. In certain embodiments
m5 (D-xxiii) or
(D-xxiii') is 3. In certain embodiments m5 (D-xxiii) or (D-xxiii') is 4.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
148
In certain embodiments -CL- is of formula (D-xxiv)
0
, N
m3
m4 m5
H
0 0 (D-xxiv),
wherein
dashed lines indicate attachment to a moiety -X F-;
m3, m4 and m5 are independently an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20,
21, 22, 23, 24 and 25.
In certain embodiments m3 of formula (D-xxiv) is an integer seleced from the
group
consisting of 1, 2, 3, 4 and 5. In certain embodiments m3 of formula (D-xxiv)
is 1. In certain
embodiments m4 of formula (D-xxiv) is an integer selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m4 of formula (D-xxiv) is
an integer selected
from the group consisting of 1, 2, 3 and 4. In certain embodiments m4 of
formula (D-xxiv) is
1. In certain embodiments m4 of formula (D-xxiv) is 2. In certain embodiments
m4 of
formula (D-xxiv) is 3. In certain embodiments m4 of formula (D-xxiv) is 4. In
certain
embodimens m5 of formula (D-xxiv) is an integer selected from the group
consisting of 2, 3,
4, 5, 6, 7, 8, 9 and 10. In certain embodiments m5 of formula (D-xxiv) is an
integer selected
from the group consisting of 3, 4, 5, 6 and 7. In certain embodiments m5 of
formula (D-xxiv)
.. is 3. In certain embodiments m5 of formula (D-xxiv) is 4. In certain
embodiments m5 of
formula (D-xxiv) is 5. In certain embodiments m5 of formula (D-xxiv) is 6. In
certain
embodiments m5 of formula (D-xxiv) is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xxv) or (D-xxv')

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
149
H H
õ2 N N 0
H H ,
mi
0 0
m4 m5
m3 H m6
0 0
(D-xxv),
N,
= H H 'J\T 0
H H ,
NNN
m2 m4 m5
ml m3 H m6 '
0 0 0 0
(D-
xxvi),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3, m4. m5 and m6 are independently an integer selected from the group

consisting of 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xxv) or (D-xxv') is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-
xxv) or (D-
xxv') is 3. In certain embodiments ml of formula (D-xxv) or (D-xxv') is 4. In
certain
embodiments m2 of formula (D-xxv) or (D-xxv') is an integer selected from the
group
consisting of 2, 3, 4, 5, 6, 7, 8, 9, and 10. In certain embodiments m2 of
formula (D-xxv) or
(D-xxv') is an integer selected from the group consisting of 3, 4, 5, 6 and 7.
In certain
embodiments m2 of formula (D-xxv) or (D-xxv') is 3. In certain embodiments m2
of formula
(D-xxv) or (D-xxv') is 4. In certain embodiments m2 of formula (D-xxv) or (D-
xxv') is 5. In
certain embodiments m2 of formula (D-xxv) or (D-xxv') is 6. In certain
embodiments m2 of
formula (D-xxv) or (D-xxv') is 7. In certain embodiments m3 of formula (D-xxv)
or (D-xxv')
is an integer seleced from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m3
of formula (D-xxv) or (D-xxv') is 1. In certain embodiments m4 of formula (D-
xxv) or (D-
xxv') is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7,
8, 9 and 10. In
certain embodiments m4 of formula (D-xxv) or (D-xxv') is an integer selected
from the group
consisting of 1, 2, 3 and 4. In certain embodiments m4 of formula (D-xxv) or
(D-xxv') is 1. In

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
150
certain embodiments m4 of formula (D-xxv) or (D-xxv') is 2. In certain
embodiments m4 of
formula (D-xxv) or (D-xxv') is 3. In certain embodiments m4 of formula (D-xxv)
or (D-xxv')
is 4. In certain embodimens m5 of formula (D-xxv) or (D-xxv') is an integer
selected from the
group consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m5
of formula (D-
xxv) or (D-xxv') is an integer selected from the group consisting of 3, 4, 5,
6 and 7. In certain
embodiments m5 of formula (D-xxv) or (D-xxv') is 3. In certain embodiments m5
of formula
(D-xxv) or (D-xxv') is 4. In certain embodiments m5 of formula (D-xxv) or (D-
xxv') is 5. In
certain embodiments m5 of formula (D-xxv) or (D-xxv') is 6. In certain
embodiments m5 of
formula (D-xxv) or (D-xxv') is 7. In certain embdoments m6 of formula (D-xxv)
or (D-xxv')
is an integer selected from 2, 3,4 5 and 6. In certain embodiments m6 of
formula (D-xxv) or
(D-xxv') is 3. In certain embodiments m6 of formula (D-xxv) or (D-xxv') is 4.
In certain embodiments -CL- is of formula (D-xxvi)
,
> 0--------___
N m2 m3
H
0 0 (D-xxvi),
wherein
dashed lines indicate attachment to a moiety -X F-;
m2 and m3 are independently an integer selected from the group consisting of
1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24
and 25.
In certain embodiments m2 of formula (D-xxvi) is an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m2 of
formula (D-xxvi) is
an integer selected from the group consisting of 1, 2, 3 and 4. In certain
embodiments m2 of
formula (D-xxvi) is 1. In certain embodiments m2 of formula (D-xxvi) is 2. In
certain
embodiments m2 of formula (D-xxvi) is 3. In certain embodiments m2 of formula
(D-xxvi) is
4. In certain embodiments m3 of formula (D-xxvi) is an integer selected from
the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-xxvi) is an
integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m3 of
formula (D-xxvi) is 3. In certain embodiments m3 of formula (D-xxvi) is 4. In
certain
embodiments m3 of formula (D-xxvi) is 5. In certain embodiments m3 of formula
(D-xxvi) is
6. In certain embodiments m3 of formula (D-xxvi) is 7.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
151
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xxvii) or (D-xxvii')
0
H H H H
N N
m2 m3
ml m4 /
0 0 0
N,
(D-
xxvii),
0
H H
H H ON
m2 m3
0 0
ml
0
N,
(D-
xxvii`),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3 and m4 are independently an integer selected from the group
consisting of
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xxvii) or (D-xxvii') is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-
xxvii) or (D-
xxvii') is 3. In certain embodiments ml of formula (D-xxvii) or (D-xxvii') is
4. In certain
embodiments m2 of formula (D-xxvii) or (D-xxvii') is an integer selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m2 of
formula (D-xxvii)
or (D-xxvii') is an integer selected from the group consisting of 1, 2, 3 and
4. In certain
embodiments m2 of formula (D-xxvii) or (D-xxvii') is 1. In certain embodiments
m2 of
formula (D-xxvii) or (D-xxvii') is 2. In certain embodiments m2 of formula (D-
xxvii) or (D-
xxvii') is 3. In certain embodiments m2 of formula (D-xxvii) or (D-xxvii') is
4. In certain
embodiments m3 of formula (D-xxvii) or (D-xxvii') is an integer selected from
the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-xxvii) or
(D-xxvii') is an integer selected from the group consisting of 3, 4, 5, 6 and
7. In certain
embodiments m3 of formula (D-xxvii) or (D-xxvii') is 3. In certain embodiments
m3 of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
152
formula (D-xxvii) or (D-xxvii') is 4. In certain embodiments m3 of formula (D-
xxvii) or (D-
xxvii') is 5. In certain embodiments m3 of formula (D-xxvii) or (D-xxvii') is
6. In certain
embodiments m3 of formula (D-xxvii) or (D-xxvii') is 7. In certain embodiments
m4 of
formula (D-xxvii) or (D-xxvii') is an integer selected from the group
consisting of 2, 3, 4, 5
and 6. In certain embodiments m4 of formula (D-xxvii) or (D-xxvii') is 3. In
certain
embodiments m4 of formula (D-xxvii) or (D-xxvii') is 4.
In certain embodiments -CL- is of formula (D-xxviii)
0
m2 m3
0 0 (D-xxviii),
wherein
dashed lines indicate attachment to a moiety -X"-;
m2 and m3 are independently an integer selected from the group consisting of
1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24
and 25.
In certain embodiments m2 of formula (D-xxviii) is an integer selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m2 of
formula (D-xxviii)
is an integer selected from the group consisting of 1, 2, 3 and 4. In certain
embodiments m2 of
formula (D-xxviii) is 1. In certain embodiments m2 of formula (D-xxviii) is 2.
In certain
embodiments m2 of formula (D-xxviii) is 3. In certain embodiments m2 of
formula (D-xxviii)
is 4. In certain embodiments m3 of formula (D-xxviii) is an integer selected
from the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-xxviii) is
an integer selected from the group consisting of 3, 4, 5, 6 and 7. In certain
embodiments m3
of formula (D-xxviii) is 3. In certain embodiments m3 of formula (D-xxviii) is
4. In certain
embodiments m3 of formula (D-xxviii) is 5. In certain embodiments m3 of
formula (D-xxviii)
is 6. In certain embodiments m3 of formula (D-xxviii) is 7.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(D-xxix) or (D-xxix')

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
153
H
N.
N
1 I
0
H H H H ,
-,-
m2 m3
ml H m4 '
0 0 0
(D-
xxix),
H
N.
1 N
1
0
H H
H H NO--....,........-------
_____,N.,.,,N
m2 m3
' N N H m4
ml
0 (D-
xxix`),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
ml, m2, m3 and m4 are independently an integer selected from the group
consisting of
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24 and 25.
In certain embodiments ml of formula (D-xxix) or (D-xxix') is an integer
selected from the
group consisting of 2, 3, 4, 5 and 6. In certain embodiments ml of formula (D-
xxix) or (D-
xxix') is 3. In certain embodiments ml of formula (D-xxix) or (D-xxix') is 4.
In certain
embodiments m2 of formula (D-xxix) or (D-xxix') is an integer selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m2 of
formula (D-xxix) or
(D-xxix') is an integer selected from the group consisting of 1, 2, 3 and 4.
In certain
embodiments m2 of formula (D-xxix) or (D-xxix') is 1. In certain embodiments
m2 of
formula (D-xxix) or (D-xxix') is 2. In certain embodiments m2 of formula (D-
xxix) or (D-
xxix') is 3. In certain embodiments m2 of formula (D-xxix) or (D-xxix') is 4.
In certain
embodiments m3 of formula (D-xxix) or (D-xxix') is an integer selected from
the group
consisting of 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments m3 of
formula (D-xxix) or
(D-xxix') is an integer selected from the group consisting of 3, 4, 5, 6 and
7. In certain
embodiments m3 of formula (D-xxix) or (D-xxix') is 3. In certain embodiments
m3 of
formula (D-xxix) or (D-xxix') is 4. In certain embodiments m3 of formula (D-
xxix) or (D-
xxix') is 5. In certain embodiments m3 of formula (D-xxix) or (D-xxix') is 6.
In certain

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
154
embodiments m3 of formula (D-xxix) or (D-xxix') is 7. In certain embodiments
m4 of
formula (D-xxix) or (D-xxix') is an integer selected from the group consisting
of 2, 3, 4, 5 and
6. In certain embodiments m4 of (D-xxix) or (D-xxix') is 3. In certain
embodiments m4 of
formula (D-xxix) or (D-xxix') is 4.
In a second embodiment the moiety -CL- is selected from the group consisting
of
, 2 OD 1 1 OD T 2
¨L¨X
(C-0,
- I 2-
I OD
X
I
0D L OD
2X 2
L,
(C-ii),
wherein
each dashed line indicates attachment to a moiety -X"-; and
-L1-, -L2-, -X 13- and -D are used as defined for Z2.
It is understood that in formula (C-i) two functional groups of the drug are
conjugated to one
moiety -L1- each and that in formula (C-ii) three functional groups of the
drug are conjugated
to one moiety -L1- each. The moiety -CL- of formula (C-i) connects two
moieties Z3 and the
moiety -CL- of formula (C-ii) connects three moieties Z3, which may be on the
same or
different hyaluronic acid strand. In this embodiment -CL- comprises at least
two degradable
bonds, if -CL- is of formula (C-i) or at least three degradable bonds, if -CL-
is of formula (C-
ii), namely the degradable bonds that connect D with a moiety -LI-. A
conjugate may only
comprise moieties -CL- of formula (C-i), may only comprise moieties -CL- of
formula (C-ii)
or may comprise moieties -CL- of formula (C-i) and formula (C-ii).
Accordingly, a conjugate of this second embodiment comprises crosslinked
hyaluronic acid
strands to which a plurality of drug moieties are covalently and reversibly
conjugated,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
155
wherein the conjugate comprises a plurality of connected units selected from
the group
consisting of
OB 3 OC 2 OD
XL XL XD
L4/
ORal ORa2 \OA
ORa2
0 0 0 0
0 H N 0 H N H
(i)"\
Z2
O
' XF
OE
X--SP ORa2
/ 0
0 0
Z3
and
wherein
an unmarked dashed line indicates a point of attachment to an adjacent unit at
a
dashed line marked with # or to a hydrogen;
a dashed line marked with # indicates a point of attachment to an adjacent
unit at
an unmarked dashed line or to a hydroxyl;
a dashed line marked with indicates a point of connection between at least
two
units Z3 via a moiety -CL-;
each -CL- comprises at least one degradable bond between the two carbon atoms
marked with the * connected by a moiety -CL- and each -CL- is independently
selected from the group consisting of formula (C-i) and (C-ii)
, 2 OD 1 1 OD 2
¨L¨X ¨L¨D¨L¨X-
(C-i),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
156
- I 2-
I OD
X
I 1
1
L OD
OD 2
2X L,
,)(
(C-ii),
wherein
dashed lines indicate attachment to a moiety -X F- of a unit Z3;
_D, _L1_, _L2_, _L3_, _L4_, _SP-, _xoA_, _xos_, _xoc_, _xop_, _xoE_, _x0F_,
_Ral
and -Ra2 are used as defined for Z1, Z2 and Z3;
wherein
all units Z1 present in the conjugate may be the same or different;
all units Z2 present in the conjugate may be the same or different;
all units Z3 present in the conjugate may be the same or different;
the number of Z1 units ranges from 1% to 98% of the total number of units
present in
the conjugate;
the number of Z2 units ranges from 0% to 98% of the total number of units
present in
the conjugate;
the number of Z3 units ranges from 1% to 97% of the total number of units
present in
the conjugate, provided that at least one unit Z3 is present per strand which
is
connected to at least one unit Z3 on a different hyaluronic acid strand.
The conjugate according to this second embodiment may also comprise units
selected from
the group consisting of Z4, Z5, Z6, Z7, Z8, Z9 and Z10 as described above. For
Z4 variable a is 1
and b is 0 for a moiety -CL- of formula (C-i), and if -CL- is of formula (C-
ii) variable a may
be 1 with b being also 1 or variable a may be 2 with b being 0.
This embodiment has the effect that for synthesizing a conjugate of the
present invention
, 1_
there is no need to separate monoconjugates Y G_L2A0D_L D from bisconjugates Y
G-L2-
xop_,
L Y or even trisconjugates, in which three moieties Y G_L2_x0D_
1_
L are
conjugated to one moiety D. A mixture of both or all three can directly be
used for

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
157
, 1_
conjugation: Conjugation of a monoconjugate Y
G_C_x0D_L D to a unit Z7 results in the
formation of a unit Z2, whereas the his- and/or trisconjugate are conjugated
to units Z5 to thus
enable crosslinking and result in the formation of units Z3. -Y G is a
functional group, which
is used as defined as for -YOA, _y0B, _y0C and Y _, AMD
below. Such synthesis may also be done
with mixtures comprising higher conjugates, such as tetra-, penta-, hexa- or
heptaconjugates,
and such embodiments for -CL-, i.e. moieties -CL- in which one moiety D is
conjugated to
four, five, six or seven or more moieties -L1-, are also included in the
present invention.
Accordingly, also covered are conjugates comprising a moiety -CL- in the form
of tetra-,
penta-, hexa- and/or hepta- or higher conjugates.
In a conjugate according to this second embodiment the number of units Z2
ranges from 0 to
70% of all units present in the conjugate, such as from 2 to 15%, from 2 to
10%, from 16 to
39, from 40 to 65%, or from 50 to 60% of all units present in the conjugate.
In a conjugate according to this second embodiment the number of units Z3
ranges from 1 to
30% of all units present in the conjugate, such as from 2 to 5%, from 5 to
20%, from 10 to
18%, or from 14 to 18% of all units present in the conjugate.
In a conjugate according to this second embodiment the number of units Z1
ranges from 10 to
97% of all units present in the conjugate, such as from 20 to 40%, such as
from 25 to 35%,
such as from 41 to 95%, such as from 45 to 90%, such as from 50 to 70% of all
units present
in the conjugate.
More specific
embodiments
for -D, -L1-, -L2_, _L3_, _L4_, _sp_, -)coA_, _x013_, _x0C_, _x0D_, _x0E
_x0F_, _Ra 1 and _Ra2 of the
second embodiment are as described elsewhere herein.
In a third embodiment the moiety -CL- is a moiety

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
158
Ii
I OD
X
2
2 2
L
(D-i),
wherein
each dashed line indicates attachment to a moiety -X"- of a unit Z3.
It is understood that a moiety -CL- of formula (D-i) comprises at least one
branching point,
which branching point may be selected from the group consisting of
-I-
C--
1 B and - ]- -
wherein
dashed lines indicate attachment to an arm; and
i
B
-R s selected from the group consisting of -H, C16 alkyl, C2_6 alkenyl and
C2_6
alkynyl; wherein C1,6 alkyl, C2_6 alkenyl and C2,6 alkynyl are optionally
substituted
with one or more -RBI, which are the same or different, and wherein C1,6
alkyl, C2,6
alkenyl and C2_6 alkynyl are optionally interrupted with -C(0)0-, -0-,
-C(0)-, -C(0)N(RB2)-, -S(0)2N(RB2)-,
-S(0)N(RB2)-, -s(o)2-
- S (0)- , -N(RB2)S(0)2N(RB2a)-, -S-,
-N(RB2)C(0)N(RB2a)-, and -0C(0)N(RB2)-; wherein -RBI, -RB2 and -RB2a are
selected
from -H, C1_6 alkyl, C2_6 alkenyl and C2_6 alkynyl.
In certain embodiments -RB is selected from the group consisting of -H, methyl
and ethyl.
Accordingly, a conjugate of the third embodiment comprises crosslinked
hyaluronic acid
strands to which a plurality of drug moieties are covalently and reversibly
conjugated,
wherein the conjugate comprises a plurality of connected units selected from
the group
consisting of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
159
OB 3 OC 2 OD
X L X L X L1 D
L4/
ORal ORa2 \XOA
ORa2
0
0
-7L0 0
0 0
0 H N 0 H N H
Z1 Z2
OF
X
OE
x--SP
ORa2
0 0
Z3
and
wherein
an unmarked dashed line indicates a point of attachment to an adjacent unit at
a
dashed line marked with # or to a hydrogen;
a dashed line marked with # indicates a point of attachment to an adjacent
unit at
an unmarked dashed line or to a hydroxyl;
a dashed line marked with indicates a point of connection between two units
Z3
via a moiety -CL-;
each -CL- comprises at least one degradable bond between the two carbon atoms
marked with the * connected by a moiety -CL- and each -CL- is independently of
formula (D-i)
I
I OD
X
___________________________ LLL
(D-i),
wherein
dashed lines indicate attachment to a moiety -X F- of a unit Z3;
-D, -L1-, -L2_, _L3_, _L4_, _SP-, _xoA_, _xoB_, _xoc_, _xob_, _xoE_, _x0F_,
_Ral
and -Ra2 are used as defined for Z1, Z2 and Z3;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
160
wherein
all units Z1 present in the conjugate may be the same or different;
all units Z2 present in the conjugate may be the same or different;
all units Z3 present in the conjugate may be the same or different;
the number of units Z1 ranges from 1% to 99% of the total number of units
present in
the conjugate;
the number of units Z2 ranges from 0% to 98% of the total number of units
present in
the conjugate; and
the number of units Z3 ranges from 1% to 97% of the total number of units
present in
the conjugate, provided that at least one unit Z3 is present per strand.
The conjugate according to this third embodiment may also comprise units
selected from the
group consisting of Z4, Z5, Z6, Z7, Z8, Z9 and Z10 as described above. For Z4
variable a is 1 and
variable b is 0 in this third embodiment.
In a conjugate according to this third embodiment the number of units Z2
ranges from 0 to
70% of all units present in the conjugate, such as from 2 to 15%, from 2 to
10%, from 16 to
39, from 40 to 65%, or from 50 to 60% of all units present in the conjugate.
In a conjugate according to this third embodiment the number of units Z3
ranges from 1 to
30% of all units present in the conjugate, such as from 2 to 5%, from 5 to
20%, from 10 to
18%, or from 14 to 18% of all units present in the conjugate.
In a conjugate according to this third embodiment the number of units Z1
ranges from 10 to
97% of all units present in the conjugate, such as from 20 to 40%, such as
from 25 to 35%,
such as from 41 to 95%, such as from 45 to 90%, such as from 50 to 70% of all
units present
in the conjugate.
_
In this third embodiment -CL- comprises a moiety _cxoc_ L1_ D, so the presence
of units Z2
is optional in this embodiment. In certain embodiment no units Z2 are present
in the third
embodiment. In certain embodiments the conjugate according to the third
embodiment also
comprises units Z2. The presence of units Z2 may have the effect that in case
of a high drug
loading is desired, which in this embodiment also means a high degree of
crosslinking, an
undesired high degree of crosslinking can be avoided by the presence of units
Z2.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
161
More specific
embodiments
for -D, -LI-, -L2-, -L3-, -L4-, -SP-, -X A-, -x0B_, _x0C_, _x0D_, _x0E_,
_x0F_, _Ral and _Ra2 of the
second embodiment are as described elsewhere herein.
In certain embodiments each -X A- and -X E- is independently either absent or
selected from
the group consisting of
R01
R01
R01
I I
*
N'C)
* I oi * 101 0
(x-1), (x-2), (x-3), R (x-4), (x-5),
01 01a
ol 01a R 'R
R ' 1\i R RO1a
0 RO 1 a
N 1 I 1
* 0 I oi 101
(x-6), (x-7), (x-8), R (x-9), R
(x-10),
ol 01 01 a
R R R
S ROla
N N'
1
>; >
I I
R (x-11), R01 01a R (x-12), (x-13), R
01a (x-14), R 01b
01 01a
S NR
NN*
I (X-15) and R 01b (x-16);
wherein
unmarked dashed lines indicate attachment to -L4- for -X A- and to -SP- for -X
E-;
dashed lines marked with an asterisk indicate attachment to the carbonyl of
the
hyaluronic acid;
ol,
_R _R
each -R0 1 a and
olb is independently selected from the group consisting of
halogen, -H, -CN, -T , C1-50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -
T , Ci_so
alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally substituted with one or
more
which are the same or different, and wherein C1_50 alkyl, C2_50 alkenyl, and
C2_50 alkynyl
are optionally interrupted by one or more groups selected from the group
consisting
of -T -
,
-0-, -C(0)-, -C(0)N(R03)-,
-S(0)2N(R 3)-, -S(0)N(R 3)-, -S(0)2-,
-S(0)-, -N(R03)S(0)2N(R 3a)-, -S-, -N(R 3)-, -0C(OR 3)(Ro3a)_,
_N(R03)c(0)N(Ro3a)_,
and -0C(0)N(R 3)-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
162
each T is independently selected from the group consisting of phenyl,
naphthyl,
indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, and 8- to
11-membered heterobicyclyl; wherein each T is independently optionally
substituted
with one or more -R 2, which are the same or different; and
each _Ro2, _Ro3 and -lea is independently selected from the group consisting
of -H and
Ci_6 alkyl; wherein Ci_6 alkyl is optionally substituted with one or more
halogen, which
are the same or different.
In certain embodiments each -X A- and -X E- is independently a linkage
selected from the
group consisting of formula x-1, x-2, x-3, x-4, x-6, x-9, x-10, x-11, x-12, x-
13, x-14, x-15 and
x-16,
In certain embodiments each -X A- and -X E- is independently a linkage
selected from the
group consisting of formula x-1, x-2, x-3, x-4, x-6, x-9, x-10, x-12, x-13 and
x-15.
In certain embodiments each -X A- and -X E- is independently a linkage
selected from the
group consisting of formula x-1, x-2, x-9 and x-10.
In certain embodiments each -X A- and -X E- is independently a linkage
selected from the
group consisting of formula x-1, x-2 and x-10.
In certain embodiments -X A- is of formula x-1. In certain embodiments -X A-
is of formula x-
2. In certain embodiments -X A- is of formula x-3. In certain embodiments -X A-
is of formula
x-4. In certain embodiments -X A- is of formula x-5. In certain embodiments -X
A- is of
formula x-6. In certain embodiments -X A- is of formula x-7. In certain
embodiments -X A- is
of formula x-8. In certain embodiments -X A- is of formula x-9. In certain
embodiments -X A- is of formula x-10. In certain embodiments -X A- is of
formula x-11. In
certain embodiments -X A- is of formula x-12. In certain embodiments -X A- is
of formula x-
13. In certain embodiments -X A- is of formula x-14. In certain embodiments -X
A- is of
formula x-15. In certain embodiments -X A- is of formula x-16.
In certain embodiments -X E- is of formula x-1. In certain embodiments -X E-
is of formula x-
2. In certain embodiments -X E- is of formula x-3. In certain embodiments -X E-
is of formula
x-4. In certain embodiments -X E- is of formula x-5. In certain embodiments -X
E- is of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
163
formula x-6. In certain embodiments -X E- is of formula x-7. In certain
embodiments -X E- is
of formula x-8. In certain embodiments -X E- is of formula x-9. In certain
embodiments -X E- is of formula x-10. In certain embodiments -X E- is of
formula x-11. In
certain embodiments -X E- is of formula x-12. In certain embodiments -X E- is
of formula x-
13. In certain embodiments -X E- is of formula x-14. In certain embodiments -X
E- is of
formula x-15. In certain embodiments -X E- is of formula x-16.
_-_
In certain embodiments each -X
13_, _x0C 0D
x and -X F- is independently either absent
or
selected from the group consisting of
R04
, N ,
, => (x-17) 0 S 0 0
(x-18), (x-19), (x-20), < (x-21),
04
o
R04 R04 R04 R
I I I R04 0 I
0 s 0 0 ,N, 0
(x-22), (x-23), (x-24),
' ' (x-25), (x-26),
R04 0
R04
O
)Lo'

'll 0 104
R 0 I 04
R 0
(x-27), (x-28), (x-29),
(x-30),
04 04a
R04
R R
04 04a N'
R04
0y: ' R NR 1
, N '
,
1
LN-`);Z NI
(x-31), 0 >N< 0
(x-32), (x-33),
(x-34),
R04
R04a
0 R04a
I
1
I 04 I 04 II 'N ,
104a R 0 R 0 ' I 04 I 04a
R (x-35), (x-36), (x-37),
R R (x-38),
0 R04a
`,..õ.-
y
04 I 04a ' r 04 ' < 'NI , S 0
R R (x-39), R (x-40), (x-41), ' (x-42), (x-
, S 'y 0
>: ,
S
- - , oice
43), (x-44), (x-45), , s
s (x-46), (x-47),
0
0 0
< A
%`1\13LN)
I I
(X-48), , SS' 04 04 04a (x-49),
R (x-50), R R (x-51),

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
164
04a
04 R <N
< )kS S N R <N
0 N le µx ' µ
>I\1LNµ<
, \ > I 04a I
04 I 04a 04 I 04b
R (x-52), R R (x-53), (x-54), R R
(X-55),
04a 04a 04 04a 04 04a
R < R < R < R R < R
0 N 0 N 0 N' N' 0
14(04 404b I 04 I 04b I 04b I 04b
I-K (X-56), R R (x-57), R (x-58), R (X-59),
04 04a
S i\rR 0
A 0 0-R04
0 0-R04
0 / 0 R04
0 /
0 /
I 04b R (x-60) µ , (x-61), (x-
62), (x-63),
RO4 RO4a
RO4 RO4a O4b \ \
RO4 RO4a
\ X \ \R \ 0 0 0 0
0 , 0 ,
0 0 0 0 0 0 0 0 0 0 %'PP'0(=
< Iil \\F/ µ < Iil ID' Iil
O
`
, 0' '0' '0'(= , 0' '0' '0' '0< R04bX 0-R04c
(x-64), (x-65), (x-66),
RO4 O4a
\R \ R\O4 R \
O4a
RO4c O4a
\R \ 0 0 0 0 0000
0 0 0 0 < ID/ ID/ R1:)
O4c 0
%02µP/X\µP/' > i (Yo4iX 'CY 0'cP'O'R
RO4b =RO4P R 0-i- R 04b -
-
(x-67), (x-68), (x-69),
RO4 RO4a
\ \ R04
0 0 0 0 04
0 / 0 / 0IR R04 04c R <0 0 0 ..p 0 R04
9'1:)1:)''
I I 1 1
0 b = \ -
(x-70), ' (x-71), ' (x-72), >B' (x-73),
R04
R04
0 0
04 04
I =
R <o
0 0 S >0 0B
'
1 1
..L a
>O'B% ' B =
(x-74), (x-75), (x-76), (x-77), (x-
78),
04 04
<o
0 R04
0 R04 0 R OR 0
I
= 0 0 = 0' '0 ,
(x-79), . (x-80), (x-81), (x-
82),
R04
R04
R04
00 00 0
04
B1 S µ.,
B1 >0 0
0 0 0' '0 0' 'O'l
;<L1
O'B'0) (x-83), =
(x-84), C)
0 = (x-85), (x-86),

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
165
asp 0 0 0
0 0 0 0 0 0 o ,,
0 ,, 0 ,, \ S `,õ. 0 õ
`1\l'S'Oµ
`,.
104 = 0' '0 \ I 04
(x-87), (x-88), R (x-89), (x-90), R (x-
0 0
0 ,
N'S'Nµ<
104 I 04a 0 0 0 0
91), R R (x-92), (x-93), (x-
94),
R04
R04
1 I
`)SsN =.)Ø,......,,,,<s..õ--..,õ,,N;õ4:_.
1.,,,,S,...,...<sõ...-<õ,S;<
,, 0 ,, 0 ,, 0
0 0 0 0 0 0
(x-95), (x-96), (x-
97),
R04
R04a
1 I
0 00 0
0 õ 0 õ 0 00 0
0 õ 0 õ
0
0,, 0 \,,,S,0,5 %`O'S'O'S0>\
(x-98), (x-99), (x-
100),
,
0 0 R04 -S 0 ---S 0
\' 04
' --
0 0 0 0
(x-101), (x-102), (x- S R103),
R04a
R04
/
RN -N 0 `1\1/ 0 0
/
-\'s i\LRO4a =\'N----cN I ,
I 04
0 0 R 0
(x-104), (x-105), (x-106), (x-
107),
R04a
R04
04a 04 / 1 /
R -S 0 R -N 0 -1\1 0
'NN 1 'NN 1 ';N---cgN-R
4b
,
I 04 I 04b I 04a
R 0 R 0 R 0
(x-108), (x-109), (x-110),
R04a
Br /0 R04 -S 0 -4--S 0 R0-N" 0
,\s N_Rozi
0 0 0 0
(x-111), (x-112), (x-113),
Ro4
`1\1/ 0 Br 0 R 04
-S 0
\' __4g
, s RO4a
104 I 04a
0 R 0 R 0
(x-114), (x-115), (x-116), (x-
117),

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
166
R04a RO4
04 / I
R ¨N 0 -H\1 0
\
N ' ' , N N_Ro4b RN
S
,
I 04b I 04a 4
R 0 R 0 0
(x-118), (x-119), (x-120),
R04a 04
04a
Kr - .
Ni'

0 i
S
R04
:--- R04 1N-1,--
, ,
O 0 0
(x-121), (x-122), (x-123),
04 R04a
O4a
R - /.. R04
N 0
R04.)-4N , R04a_)-1.N
S S -II---
O 0 0
(x-124), (x-125), (x-126),
RO4a - /.., 0 R04
RO4b -/ .
N , 14 0 N 0
R01)-4 R R
04a 04a)-1./
/ N...L.
i
O R04b
0 RO4b
0
(x-127), (x-128), (x-129),
R04
4 -/ .
_..14 0 R
N 0
R04a
R04a
N-N--il--
R04131
O4b 0
0 R
0
(X-130), (X-131), (x-132),
HO
N - /
N, , N,
113 gr -;"--N"N -;"--N"N
H ¨/
, ""0 \ ¨c ')=
,
(x-133), (x-134), (x-135),
OH 0
,
I N-
, ¨ I - /-
1 R04 0 ' NiN
H N-Z:4 0 H
(x-136), R
(x-137), (x-138), R (x-
139),

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
167
04
0 RN'0
, 0
H NI
e R04 H NI
N N
04 jl >
R N 0 ,
(x-140), (x-141), (x-
142),
. Ft 4a . ,R04
1N' >:
, S , N-
)
N N N N N N
R
0 N 0 , 4 > R 04 N 0 , > 04 N
S a >
,
(x-143), (x- R144), (x-145),
. ,R04a
, N-
) CN
N N
,
_ 04
R 1\1 N< N
,
104b V,
R (x-146), (x-147), (x-
148),
N-
, -N ,N,-...,N
-11\1 N
Th
0 04 ,
R ¨N I 0 N
0( 0
(x-149), (x-150), (x-
04R RO4
\
'
, N-0 N-0
,
,
N R04 /
0 N-N
H
151), (x-152), (x-153), (x-
i 0 i 0
- -I- =
S
' 4
1
R RO4
/ /
' '
N-N N-N
H H
154), (x-155), (x-156), R (x-

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
168
RO4
)-
-IS S¨L S S
R04
¨2 0 0
N¨N
S .¨:- ,1\1¨N µ, ., \--
157), (x-158), R04 R
4a RO4a
(x-159), (x-
160),
0 sirt s
Si
,
RO4a
0 )¨N
S S 04 N H NI\l' R04 NH
0 ¨ 0 R Thl 0
el 0 H 0 0 H 0 H
N¨N , \
R04, -\--
(x-161), (x-162), ' (x-163), '
R04
001 01
' NH , ' NH 0
,
0 H 0 H N-I-
R04
0
D04
(x-164), ' (x-165), ' (x-166), (x-
167),
0
R im
,
R04
41.1N--"\<
R04
0 0
(x-168), (x-169), (x-
170),
0 0
,
0
' R 4a
,
R04a µ µ.
R04
R041
0 0
R04
(x-171), (x-172), (x-
173),
R04
R04
OH ,
sN-R04a 0
\ \ H 0
0 H
N N
OH
(x-174), (x-175) and , (x-
176);
wherein
Y is selected from the group consisting of -0-, -S-, -NR 5-, -cRo5Ro5a;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
169
each
_Ro4, _RO4a, _RO4b, _R04c, -R05 and _Rosa
is independently selected from the group
consisting of halogen, -H, -CN, -T , Ci_50 alkyl, C2_50 alkenyl, and C2_50
alkynyl;
wherein -T , C1-50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
substituted with
one or more -R 6, which are the same or different, and wherein C1_50 alkyl,
C2_50 alkenyl,
and C2_50 alkynyl are optionally interrupted by one or more groups selected
from the
group consisting of -T
-0-, -C(0)-, -C(0)N(R07)-, -S(0)2N(R 7)-,
-S(0)N(R 7)-, -S(0)2-,
-S(0)-, -N(R07)S(0)2N(R 7a)-, -S-, -N(R 7)-, -0C(OR 7)(1Ca)-, -N(R07)C(0)N(R
7a)-,
and -0C(0)N(R 7)-;
each T is independently selected from the group consisting of phenyl,
naphthyl,
indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, and 8- to
11-membered heterobicyclyl; wherein each T is independently optionally
substituted
with one or more -R 6, which are the same or different; and
each -R 6, -R 7 and -R 7a is independently selected from the group consisting
of -H and
C1_6 alkyl; wherein Ci_6 alkyl is optionally substituted with one or more
halogen, which
are the same or different.
In certain embodiments each -X B-, -X c-, -X D- and -X"- is independently a
linkage selected
from the group consisting of formula x-17, x-18, x-19, x-20, x-21, x-22, x-23,
x-25, x-26, x-
27, x-28, x-29, x-30, x-31, x-32, x-35, x-36, x-37, x-38, x-39, x-41, x-42, x-
43, x-45, x-46, x-
47, x-48, x-49, x-50, x-51, x-52, x-53, x-54, x-55, x-56, x-57, x-58, x-59, x-
60, x-61, x-62, x-
64, x-65, x-66, x-75, x-76, x-77, x-78, x-79, x-80, x-81, x-82, x-83, x-84, x-
85, x-87, x-88, x-
89, x-90, x-91, x-92, x-93, x-97, x-98, x-101, x-102, x-103, x-104, x-105, x-
106, x-107, x-
108, x-109, x-110, x-111, x-112, x-113, x-114, x-115, x-116, x-117, x-118, x-
119, x-132, x-
133, x-134, x-135, x-137, x-138, x-139, x-140, x-141, x-142, x-146, x-147, x-
148, x-150, x-
151, x-154, x-155, x-156, x-157, x-159, x-160, x-161, x-162, x-163, x-167, x-
170, x-174, x-
175 and x-176.
In certain embodiments each -X B-, -X c-, -X D- and -X"- is independently a
linkage selected
from the group consisting of formula x-17, x-18, x-21, x-22, x-23, x-26, x-28,
x-29, x-31, x-
32, x-36, x-37, x-38, x-41, x-42, x-43, x-45, x-47, x-48, x-49, x-50, x-51, x-
52, x-53, x-54, x-
56, x-57, x-59, x-60, x-61, x-62, x-64, x-65, x-66, x-75, x-77, x-79, x-80, x-
81, x-82, x-83, x-
87, x-88, x-89, x-90, x-91, x-92, x-93, x-97, x-98, x-101, x-102, x-103, x-
104, x-111, x-112,
x-113, x-132, x-133, x-134, x-135, x-137, x-138, x-139, x-140, x-141, x-142, x-
146, x-147, x-

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
170
148, x-150, x-151, x-154, x-155, x-156, x-157, x-159, x-160, x-161, x-162, x-
163, x-167, x-
170, x-174, x-175 and x-176.
In certain embodiments each -X 13_, _x0C _x0D_
and -X F- is independently a linkage selected
from the group consisting of formula x-17, x-18, x-21, x-22, x-31, x-36, x-37,
x-38, x-42, x-
45, x-47, x-50, x-51, x-54, x-56, x-59, x-88, x-89, x-90, x-91, x-92, x-93, x-
97, x-101, x-102,
x-104, x-113, x-132, x-135, x-147, x-148, x-150, x-151, x-154, x-155, x-156, x-
157, x-159, x-
163, x-167, x-170, x-174, x-175 and x-176.
_, _
In certain embodiments each _x013_, _x0C _x0D
and -X F- is independently a linkage selected
from the group consisting of formula x-18, x-22, x-37, x-45, x-47, x-50, x-51,
x-101, x-135,
x-148, x-150 and x-151.
In certain embodiments -X B- is of formula x-18. In certain embodiments -X B-
is of formula
x-22. In certain embodiments -X B- is of formula x-37. In certain embodiments -
X B- is of
formula x-45. In certain embodiments -X B- is of formula x-47. In certain
embodiments -X B- is of formula x-50. In certain embodiments -X B- is of
formula x-51. In
certain embodiments -X B- is of formula x-101. In certain embodiments -X B- is
of formula x-
135. In certain embodiments -X B- is of formula x-148. In certain embodiments -
X B- is of
formula x-150. In certain embodiments -X B- is of formula x-151.
In certain embodiments -X'Dc- is of formula x-18. In certain embodiments -X'Dc-
is of formula
x-22. In certain embodiments -X()c- is of formula x-37. In certain embodiments
-X()c- is of
formula x-45. In certain embodiments -X()c- is of formula x-47. In certain
embodiments -X c- is of formula x-50. In certain embodiments -X'Dc- is of
formula x-51. In
certain embodiments -X c- is of formula x-101. In certain embodiments -X c- is
of formula x-
135. In certain embodiments -X()c- is of formula x-148. In certain embodiments
-X()c- is of
formula x-150. In certain embodiments -X()c- is of formula x-151.
In certain embodiments -X D- is of formula x-18. In certain embodiments -X D-
is of formula
x-22. In certain embodiments -X D- is of formula x-37. In certain embodiments -
X D- is of
formula x-45. In certain embodiments -X D- is of formula x-47. In certain
embodiments -X D- is of formula x-50. In certain embodiments -X D- is of
formula x-51. In
certain embodiments -X D- is of formula x-101. In certain embodiments -X D- is
of formula x-

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
171
135. In certain embodiments -X 13- is of formula x-148. In certain embodiments
-X 13- is of
formula x-150. In certain embodiments -X D- is of formula x-151.
In certain embodiments -X"- is of formula x-18. In certain embodiments -X"- is
of formula
__ x-22. In certain embodiments -X"- is of formula x-37. In certain
embodiments -X"- is of
formula x-45. In certain embodiments -X"- is of formula x-47. In certain
embodiments -X"- is of formula x-50. In certain embodiments -X"- is of formula
x-51. In
certain embodiments -X"- is of formula x-101. In certain embodiments -X"- is
of formula x-
135. In certain embodiments -X"- is of formula x-148. In certain embodiments -
X"- is of
formula x-150. In certain embodiments -X"- is of formula x-151.
, , , .y OD In certain embodiments each -
Y
A _y0B _y0C _Y is individually selected from the group
consisting of
0 0
08
8 u
R08
R08
CYR
OAR 0 CY
>N,H
(y-l), (y-2), (y-3), (y-4),
(y-5),
0
A RO8a
H
0 N' ' Ny N H2 0 0 0 0
I I 08
µ N R
A H BF3K µ,JLoAR08
, 0
µ"..L
61-6), (y-7), (y-8), (y-9),
0 0 0 0 0
0
µ,,),r0 H , RO8a \ [ N A NRO8a
A 1 I 08 I I 108
Y 0 R H H R
(y-10), ` (y-11), (y-12), (y-13),
HO o
0 0
()S.
._. `0
0 0
0 N N A
, 0'N
(y-14), (y-15), (y-16), (y-
17),
NO2
0 40 Fri
NO2
0 0 0
1.
µ0
µ'0 NO2
'JLO
(y-18), (y-19), (y-
20),

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
172
F
F F
0
çNI,H
_N
F 'H NI-1
(y-21), (y-22) , (y-22a), (y-23),
R08
R08 R08 N
I I
>o \ 0 N Ny0 s Ny N.,.,
, y --
08a N H 0 0
(y-24), R (y-25), (y-26), (y-
2'7),
R08
R08
NO2
R08 I I
I 01 'N 0
`

N)r)( y 0
,
0 0
0 NO2 NO2
(Y-28), (y-29), (y-30),
R08
F
1
\ N 0 F
=r, y 0 R08
I Fr, r._-_N
0 \ N 0 0 Y01
F F ;(, y to ') y y
F 0 0 0
(y-31) (y-32), (Y-33), (y-
F
NO2 \ 0 0 F
0y 0 F 0 0
. y 0 0
0 0 F
NO2 NO2 F
34), (Y-35), (y-36),
F,-,
\ 0 0

>\ y ito \ 0 R08
µ
01 y =<(:)-s-
R08
0 Y , õ..
(y-37) µ,,
, (y-38), \ (Y-39) 0 , (y-40) 0
0, (y-41),
0 o H Rosa
,)1-111 , H
I 08a I 08
Ros <
µ N R
Y -. N N
)-L RO8
, ' \ N R
< 'N' < i\l'
1
0 H I 08 H
(y-42), (y-43), R (y-44), (y-45),
0
0 OH OH
'0 µ),/(R08b I 13
< NH A, H ' 08 08a <13'0 H , 0' OH
(y-46), (y-47), R R (y-48), (y-49), (y-
50),
0 OH 0 p o p o OH 0 OH
1 'S
S , .µ
.P $
0'130 H < '0 H ,( .
, 0' 0 H , 0 '0 H \< OH
(y-51), (y-52), (Y-53), (y-54), (Y-

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
173
H 0
02y
>
02a H
µ N 0
x µ)Ny
S H 0 0
55), s (y-56), (Y-57), (Y-58), \ (Y-
59),
CI
rCI
Ni\l H OJ
OH 0= 0
6 . N.----z( \xS
\ 08
(y-60), (y-61), (y-62), R (y-63), `
0
H
, -1- = H NO
I
' NrH H N
/0 H NI
---
H2N e RO8
-\ 08
0
(y-64), (y-65), R (y-66), (y-67),
Y03
CN
0
I\1 N ,
I
03a ,
, N Y
(y-68), (y-69), (y-70),
----
---- i 0
,
' =
N N¨N
0( 2:4 _RoEl
N=N
(y-71), (y-72), (Y-73), (y-74),
Br Br
0 _ 0
s)S 1$1 0==o 0 H
08 N
,, 0 N¨N R i\1 0
0 0 R08, -V (y-76), ' el
(Y-77) H,
0 = 0
08
R08
N , \,';0 ,
µ,,0%(:);(
)-rR08
N,
I 04 0 0
(y-78), (Y-79), Y (Y-80), (Y-81),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
174
R08

jR08
H N= 08a H
N¨R 0 OH
HO,
(Y-82), (Y-83), (y-84),
(y-85) and
0õ0
(y-86);
wherein
_Ros, _RO8a _RO8b
each and
is independently selected from the group consisting of
halogen, -H, -CN, -T , C1-50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -
T , Ci-so
alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally substituted with one or
more -R 9,
which are the same or different, and wherein C1_50 alkyl, C2_50 alkenyl, and
C2_50 alkynyl
are optionally interrupted by one or more groups selected from the group
consisting
of -T
-C(0)0-,
-0-, -C(0)-, -C(0)N(R 10)-, -S(0)2N(R 10)-, -S(0)N(R
10)-, -S(0)2-,
-S(0)-, -N(R 1 )S(0)2N(R 11)-,
-S-,
_N(Rolo) _ OC(OR 1 )(Ro _N(Roio)c(0)N(Roloas _
) , and -0C(0)N(R 1 )-;
each T is independently selected from the group consisting of phenyl,
naphthyl,
indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, and 8- to
11-membered heterobicyclyl; wherein each T is independently optionally
substituted
with one or more -R 9, which are the same or different;
each -R09, _R010 and K _-010a
is independently selected from the group consisting of -H and
C1_6 alkyl; wherein C1_6 alkyl is optionally substituted with one or more
halogen, which
are the same or different;
each TY is independently a ring comprising 5, 6 or 7 atoms of which at least
one is a
heteroatom;
each -Y 1 is independently selected from the group consisting of -F, -Cl, -Br
and -I;
each n is independently 1, 2, 3 or 4;
each -Y 2 and -Y 2a is independently selected from the group consisting of -H
and -Br;
each -Y 3 and -Y03a is independently selected from the group consisting
of -F, -Cl, -Br, -I, -OR, -Nellei la and -SR 11;
each -Y 4- is independently selected from -0-, -S-, -NR 11-, -CR 11Rma-; and
each -R 11 and -R 11a. is independently selected from the group consisting of
halogen, -H, -CN, -T , C1-50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -
T , Ci-so

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
175
alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or
more -R 12,
which are the same or different, and wherein C1_50 alkyl, C2_50 alkenyl, and
C2_50 alkynyl
are optionally interrupted by one or more groups selected from the group
consisting
of -T -, -C(0)0-, -0-, -C(0)-, -C(0)N(R 13)-, -S(0)2N(R 13)-, -S(0)N(R 13)-, -
S(0)2-,
-S(0)-, -N(R 13)S(0)2N(R 13a)-, -S-,
) _ OC(OR 13)(Roi3a)_, _N(Roo)c(0)N(Roi3a_
), and -0C(0)N(R 13)-;
each T is independently selected from the group consisting of phenyl,
naphthyl,
indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered
heterocyclyl, and 8- to
11-membered heterobicyclyl; wherein each T is independently optionally
substituted
with one or more -R 12, which are the same or different; and
_R12,o13 _R
each
and -R 13a is independently selected from the group consisting of -H and
C1_6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more
halogen, which
are the same or different.
In certain embodiments each -Y A, -y0B, _y0C, _y0D and - Y,OE
is independently a functional
group selected from the group consisting of formula y-1, y-2, y-3, y-7, y-8, y-
9, y-10, y-11, y-
12, y-13, y-14, y-15, y-16, y-17, y-18, y-21, y-22, y-22a, y-23, y-24, y-27, y-
28, y-29, y-31, y-
33, y-35, y-37, y-39, y-40, y-41, y-42, y-43, y-45, y-46, y-47, y-49, y-52, y-
53, y-54, y-55, y-
56, y-57, y-59, y-61, y-62, y-64, y-70, y-71, y-72, y-73, y-74, y-77, y-79, y-
80, y-85 and y-86.
In certain embodiments each -Y A, -Y B, -Y c, -Y D and -Y E is independently a
functional
group selected from the group consisting of formula y-1, y-2, y-3, y-7, y-8, y-
9, y-12, y-13, y-
14, y-15, y-16, y-17, y-18, y-21, y-22, y-22a, y-23, y-24, y-27, y-28, y-29, y-
31, y-39, y-45, y-
46, y-47, y-52, y-53, y-54, y-55, y-56, y-57, y-59, y-61, y-68, y-70, y-71, y-
72, y-73, y-74, y-
77, y-79, y-80, y-85 and y-86.
In certain embodiments each -Y A, -y0B, _y0C, _y0D and
-
Y is independently a functional
group selected from the group consisting of formula y-1, y-2, y-7, y-8, y-9, y-
13, y-14, y-15,
y-16, y-21, y-22, y-22a, y-24, y-39, y-56, y-57, y-60, y-70, y-71 and y-86.
In certain embodiments each -Y A, -y0B, _y0C, _y0D and
-
Y is independently a functional
group selected from the group consisting of formula y-1, y-2, y-8, y-9,y-13, y-
14, y-16, y-22,
y-22a, y-39, y-56, y-57, y-61, y-70, y-71 and y-86.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
176
In certain embodiments each -YOA, _y0B, _y0C, _y0D and Y _, ,DE
is independently a functional
group selected from the group consisting of formula y-1, y-2, y-8, y-9,y-16, y-
22, y-22a, y-39,
y-56, y-5'7, y-61, y-70, y-71 and y-86.
In certain embodiments -Y A is of formula y-1. In certain embodiments -Y A is
of formula y-
2. In certain embodiments -Y A is of formula y-8. In certain embodiments -Y A
is of formula
y-9. In certain embodiments -Y A is of formula y-16. In certain embodiments -Y
A is of
formula y-22. In certain embodiments -Y A is of formula y-22a. In certain
embodiments -Y A
is of formula y-39. In certain embodiments -Y A is of formula y-56. In certain
embodiments -Y A is of formula y-57. In certain embodiments -Y A is of formula
y-61. In
certain embodiments -Y A is of formula y-70. In certain embodiments -Y A is of
formula y-71.
In certain embodiments -Y A is of formula y-86.
In certain embodiments -Y B is of formula y-1. In certain embodiments -Y B is
of formula y-
2. In certain embodiments -Y B is of formula y-8. In certain embodiments -Y B
is of formula
y-9. In certain embodiments -Y B is of formula y-16. In certain embodiments -y
B is of
formula y-22. In certain embodiments -y B is of formula y-22a. In certain
embodiments -y B
is of formula y-39. In certain embodiments -Y B is of formula y-56. In certain

embodiments -Y B is of formula y-5'7. In certain embodiments -Y B is of
formula y-61. In
certain embodiments -Y B is of formula y-70. In certain embodiments -Y B is of
formula y-71.
In certain embodiments -y B is of formula y-86.
In certain embodiments -Y c is of formula y-1. In certain embodiments -Y c is
of formula y-
2. In certain embodiments -Y c is of formula y-8. In certain embodiments -Y c
is of formula
y-9. In certain embodiments -Y c is of formula y-16. In certain embodiments -Y
c is of
formula y-22. In certain embodiments -Y c is of formula y-22a. In certain
embodiments -Y c
is of formula y-39. In certain embodiments -Y c is of formula y-56. In certain

embodiments -Y c is of formula y-5'7. In certain embodiments -Y c is of
formula y-61. In
certain embodiments -Y c is of formula y-70. In certain embodiments -Y c is of
formula y-71.
In certain embodiments -Y c is of formula y-86.
In certain embodiments -Y D is of formula y-1. In certain embodiments -Y D is
of formula y-
2. In certain embodiments -Y D is of formula y-8. In certain embodiments -Y D
is of formula
y-9. In certain embodiments -Y D is of formula y-16. In certain embodiments -Y
D is of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
177
formula y-22. In certain embodiments -Y D is of formula y-22a. In certain
embodiments -Y D
is of formula y-39. In certain embodiments -Y D is of formula y-56. In certain

embodiments -Y D is of formula y-57. In certain embodiments -Y D is of formula
y-61. In
certain embodiments -Y D is of formula y-70. In certain embodiments -Y D is of
formula y-71.
In certain embodiments -Y 13 is of formula y-86.
In certain embodiments -Y E is of formula y-1. In certain embodiments -Y E is
of formula y-2.
In certain embodiments -Y" is of formula y-8. In certain embodiments -Y" is of
formula y-9.
In certain embodiments -Y" is of formula y-16. In certain embodiments -Y" is
of formula y-
22. In certain embodiments -YE is of formula y-22a. In certain embodiments -YE
is of
formula y-39. In certain embodiments -Y E is of formula y-56. In certain
embodiments -Y E is
of formula y-57. In certain embodiments -Y" is of formula y-61. In certain
embodiments -Y" is of formula y-70. In certain embodiments -Y" is of formula y-
71. In
certain embodiments -Y E is of formula y-86.
In certain embodiments -Y" is selected from the group consisting of
HO
0
S (
0 0
'0
NO2
0
(y-87), (y-88), (y-89), , (y-90),
is NO2
F, = F
NO2 >:
0
(y-91), (y-92) and (y-93);
wherein
each n is independently 1, 2, 3, or 4.
In certain embodiments each -Y" is independently a functional group selected
from the group
consisting of formula y-87, y-88, y-89, y-90 and y-91.
In certain embodiments each -Y" is independently a functional group selected
from the group
consisting of formula y-87, y-88 and y-93.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
178
In certain embodiments all -Y" present in the conjugates of the present
invention are of
formula y-87. In certain embodiments all -Y" present in the conjugates of the
present
invention are of formula y-88. In certain embodiments all -Y" present in the
conjugates of the
present invention are of formula y-93.
In certain embodiments each -Y" is independently a functional group selected
from the group
consisting of formula y-87 and y-88.
Each -Y H is independently selected from the group consisting of
0
0 ¨i L RO8a
NI\l'
' ' 1 ,......._
I
0 H BF3K 0 R08 , H1 R 08
(y -1), (y -2), (y -3), (y -4),
H 0
= 0
0 0 0.. 0
N N 1 N 1
' ______ O'I'R 0'
, T ,1 _ ,
ic.- - N'O 0 0
(y'-5), (y'-6), (y'-7),
40 NO2 Fn
40 NO2,
, ,
0 NO2 0 O
(y'-8), (y"-9) and (y"- 10).
In certain embodiments -Y H is of formula y'-1. In certain embodiments -Y H is
of formula y'-
2. In certain embodiments -Y 11 is of formula y'-3. In certain embodiments -Y
H is of formula
y'-4. In certain embodiments -Y 11 is of formula y'-5. In certain embodiments -
Y 1-1 is of
formula y'-6. In certain embodiments -Y 11 is of formula y'-7. In certain
embodiments -Y H is
of formula y'-8. In certain embodiments -Y 11 is of formula y'-9. In certain
embodiments -Y 11
is of formula y'-10.
The pharmaceutical compositions of the present invention comprise a conjugate
of the present
invention and at least one excipient. It is understood that more than one type
of conjugate of
the present invention may be present in such pharmaceutical composition.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
179
In certain embodiments all moieties -X D- of units Z2 und Z9 are identical. In
certain
embodiments a conjugate of the present invention comprises more than one type
of -X D-,
such as two, three or four different types of -X D-. In certain embodiment one
hyaluronic acid
strand comprises only one type of -X 13-. In certain embodiments the
conjugates comprise a
first type of hyaluronic acid strands with a first type of -X D- and a second
type of hyaluronic
acid strands with a second type of -X D- and optionally a third type of
hyaluronic acid strand
with a third type of -X D- and optionally a fourth type of hyaluronic acid
strand with a fourth
type of -X D-.
In certain embodiments -X D- of units Z2 und Z9 is a stable linkage, i.e -1.1-
and -X D-L2- are
connected through a stable linkage.
In certain embodiments -X 13- of units Z2 und Z9 is absent, in which case the
moiety -L2-X '--.-L 1-
is a moiety -L2-1.1-, wherein the bond between -L2- and -1.1- is a stable
bond.
-L2- of Z2, Z8 and Z9 is absent or a spacer moiety.
In certain embodiments -L2- of Z2, Z8 and Z9 is absent.
In certain embodiments -L2- of Z2, Z8 and Z9 is a spacer moiety.
In certain embodiments -L2- of Z2, Z8 and Z9 does not comprise a degradable
bond, i.e. all
bonds of -L2- are stable bonds.
In certain embodiments -L2- of Z2, Z8 and Z9 is a spacer moiety selected from
the group
consisting of -T-, C1-50 alkyl, C2_50 alkenyl, and C2-50 alkynyl; wherein -T-,
C1_50 alkyl, C2-50
alkenyl, and C2_50 alkynyl are optionally substituted with one or more -RY2,
which are the
same or different and wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl
are optionally
interrupted by one or more groups selected from the group consisting of -T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
180
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
Ci_50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -T, C1-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a._,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycycly1;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
each -RY2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -COORY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a,
-N(RY5)S(0)RY5a, -N(RY5)C(0)0RY5a,
-N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl
is optionally
substituted with one or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently selected from the group
consisting of -H, and C1_6 alkyl, wherein C1_6 alkyl is optionally substituted
with one or more
halogen, which are the same or different,
provided that -L2- is attached to -Xcc- and -X D- via a carbon atom of -L2-.
In certain embodiments -L2- of Z2, Z8 and Z9 is a spacer moiety selected from
the group
consisting of
C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C1_20 alkyl, C2-
20
alkenyl, and C2_20 alkynyl are optionally substituted with one or more -RY2,
which are the
same or different and wherein C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl
are optionally
interrupted by one or more groups selected from the group consisting of -T-, -
C(0)0-, -0-,
-C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -
N(RY3)S(0)2N(RY3a)-,
-S-, -N(RY3)-, -0C(0RY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
181
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
Ci_io alkyl, C2-10 alkenyl, and C2_10 alkynyl; wherein -T, Ci_io alkyl, C2_10
alkenyl, and C2-10
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein Chio alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(0)N(Ry4a,_,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
-RY2 is selected from the group consisting of halogen, -CN, oxo
(=0), -COORY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2R5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a, -N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a, -
N(RY5)C(0)N(RY5a
RY51), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with one
or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a, _RY5, -RY5a and -RY5b is independently of each
other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L2- is attached to -X()c- and -X D- via a carbon atom of -L2-.
In certain embodiments -L2- of Z2, Z8 and Z9 is a spacer moiety selected from
the group
consisting of -T-, C1-50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-,
C1_50 alkyl, C2-50
alkenyl, and C2_50 alkynyl are optionally substituted with one or more -RY2,
which are the
same or different and wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl
are optionally
interrupted by one or more groups selected from the group consisting of -T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
182
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RY1 a are independently selected from the group consisting of -H, -
T, Ci_io alkyl, C2_10
alkenyl, and C2_10 alkynyl;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
each -RY2 is independently selected from the group consisting of halogen and
Ci_6 alkyl; and
each -RY3, -Ry3a; _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L2- is attached to -Xcc- and -X D- via a carbon atom of -L2-.
In certain embodiments -L2- of Z2, Z8 and Z9 is a C1_20 alkyl chain, which is
optionally
interrupted by one or more groups independently selected from -0-, -T-, -N(R3)-

and -C(0)N(RY1)-; and which C1_20 alkyl chain is optionally substituted with
one or more
groups independently selected from -OH, -T, -N(RY3)- and -C(0)N(Ry6Ry6a);
wherein -WI, -RY6, -RY6a are independently selected from the group consisting
of H and C1_4
alkyl, wherein T is selected from the group consisting of phenyl, naphthyl,
indenyl, indanyl,
tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-
membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl,
provided that -L2- is attached to -X()c- and -X D- via a carbon atom of -L2-.
In certain embodiments -L2- of Z2, Z8 and Z9 has a molecular weight ranging
from 14 g/mol to
750 g/mol.
In certain embodiments -L2- of Z2, Z8 and Z9 has a chain length ranging from 1
to 20 atoms.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
183
In certain embodiments -L2- of Z2, Z8 and Z9 is a C1_10 alkyl. In certain
embodiments -L2- of
Z2, Z8 and Z9 is a CI alkyl. In certain embodiments -L2- of Z2, Z8 and Z9 is a
C2 alkyl. In
certain embodiments -L2- of Z2, Z8 and Z9 is a C3 alkyl. In certain
embodiments -L2- of Z2, Z8
and Z9 is a C4 alkyl. In certain embodiments -L2- of Z2, Z8 and Z9 is a C5
alkyl. In certain
embodiments -L2- of Z2, Z8 and Z9 is a C6 alkyl. In certain embodiments -L2-
of Z2, Z8 and Z9
is a C7 alkyl. In certain embodiments -L2- of Z2, Z8 and Z9 is a C8 alkyl. In
certain
embodiments -L2- of Z2, Z8 and Z9 is a C9 alkyl. In certain embodiments -L2-
of Z2, Z8 and Z9
is a C10 alkyl.
In certain embodiments all moieties -X c- are identical. In certain
embodiments the
conjugates comprise more than one type of -X c-, such as two, three or four
different types
of -X c-. In certain embodiment one hyaluronic acid strand comprises only one
type of -X c-.
In certain embodiments the conjugates comprise a first type of hyaluronic acid
strands with a
first type of -X c- and a second type of hyaluronic acid strands with a second
type
of -X c- and optionally a third type of hyaluronic acid strand with a third
type of -X c- and
optionally a fourth type of hyaluronic acid strand with a fourth type of -X c-
.
In certain embodiments -X c- is absent.
In certain embodiments -X c- is a stable linkage, i.e -L2- and -L3- are
connected through a
stable linkage.
In certain embodiments -X c- is a moiety selected from the group consisting of
0
,s-
¨:¨C¨N¨:-
0 I oc
and
wherein
-ROC selected from the group consisting of -H and C1_6 alkyl.
In certain embodiments -X c- is

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
184
0
S
N
/
0
wherein the dashed lines indicate attachment to -L2- and -L3-, respectively.
More specifically, in certain embodiments -X()c- is
0
*
N
//
0
wherein the dashed line marked with the asterisk indicates attachment to -L2-
and the
unmarked dashed line indicates attachment to -L3-.
-L3- is absent or a spacer moiety. In certain embodiments -L3- does not
comprise a reversible
linkage, i.e. all linkages in -L3- are stable linkages.
In certain embodiments -L3- is absent.
In certain embodiments -L3- is a spacer moiety.
In certain embodiments -L3- does not comprise a degradable bond, i.e. all
bonds of -L3- are
stable bonds.
In certain embodiments -L3- is a spacer moiety selected from the group
consisting of -T-,
C1-50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -T-, C1-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different and
wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
185
-RY1 and -RY1 a are independently of each other selected from the group
consisting of -H, -T,
C1_50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -T, C1-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a.
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
each -RY2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -COORY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a,
-N(RY5)S(0)RY5a, -N(RY5)C(0)0RY5a,
-N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl
is optionally
substituted with one or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently selected from the group
consisting of -H, and C1_6 alkyl, wherein C1_6 alkyl is optionally substituted
with one or more
halogen, which are the same or different,
provided that -L3- is attached to -X B- and -Xcc- via a carbon atom of -L3-.
In certain embodiments -L3- is a spacer moiety selected from the group
consisting of -T-, C 50
alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C120 alkyl, C2_20
alkenyl, and C2_20 alkynyl
are optionally substituted with one or more -RY2, which are the same or
different and wherein
C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally interrupted by
one or more groups
selected from the group consisting of -T-,
-C(0)0-, -0-,
-C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -
N(RY3)S(0)2N(RY3a)-,
-S-, -N(RY3)-, -0C(0RY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
186
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
Ci_io alkyl, C2-10 alkenyl, and C2_10 alkynyl; wherein -T, Ci_io alkyl, C2_10
alkenyl, and C2-10
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein Chio alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(0)N(Ry4a,_,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
-RY2 is selected from the group consisting of halogen, -CN, oxo
(=0), -COORY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2R5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a, -N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a, -
N(RY5)C(0)N(RY5a
RY51), -0C(0)N(RY5RY5a), and C1,6 alkyl; wherein C1,6 alkyl is optionally
substituted with one
or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a, _RY5, -RY5a and -RY5b is independently of each
other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1,6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L3- is attached to -X B- and -XI3c- via a carbon atom of -L3-.
In certain embodiments -L3- is a spacer moiety selected from the group
consisting of -T-, C1_50
alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C1_50 alkyl, C2_50
alkenyl, and C2_50 alkynyl
are optionally substituted with one or more -RY2, which are the same or
different and wherein
C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally interrupted by
one or more groups
selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
187
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RYla are independently selected from the group consisting of -H, -T,
Ci_io alkyl, C2_10
.. alkenyl, and C2_10 alkynyl;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
each -RY2 is independently selected from the group consisting of halogen and
Ci_6 alkyl; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L3- is attached to -X B- and -Xcc- via a carbon atom of -L3-.
In certain embodiments -L3- is a C1_213 alkyl chain, which is optionally
interrupted by one or
more groups independently selected from -0-, -T-, -N(RY3)- and -C(0)N(RY1)-;
and which
C1_20 alkyl chain is optionally substituted with one or more groups
independently selected
from -OH, -T, -N(RY3)- and -C(0)N(RY6RY6a); wherein -RY1, -RY6, -RY6a are
independently
selected from the group consisting of H and C1_4 alkyl, wherein T is selected
from the group
consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_113
cycloalkyl, 3- to
10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered
carbopolycyclyl, and 8- to 30-membered heteropolycyclyl, provided that -L3- is
attached
to -X B- and -X()c- via a carbon atom of -L3-.
In certain embodiments -L3- has a molecular weight ranging from 14 g/mol to
750 g/mol.
In certain embodiments -L3- has a chain length ranging from 1 to 20 atoms.
In certain embodiments -L3- is a Ci_io alkyl. In certain embodiments -L3- is a
C1 alkyl. In
certain embodiments -L3- is a C2 alkyl. In certain embodiments -L3- is a C3
alkyl. In certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
188
embodiments -L3- is a C4 alkyl. In certain embodiments -L3- is a C5 alkyl. In
certain
embodiments -L3- is a C6 alkyl. In certain embodiments -L3- is a C7 alkyl. In
certain
embodiments -L3- is a C8 alkyl. In certain embodiments -L3- is a C9 alkyl. In
certain
embodiments -L3- is a C10 alkyl.
In certain embodiments all moieties -X B- are identical. In certain
embodiments a conjugate or
the present invention comprises more than one type of -X B-, such as two,
three or four
different types of -X B-. In certain embodiment one hyaluronic acid strand
comprises only one
type of -X B-. In certain embodiments the conjugates comprise a first type of
hyaluronic acid
strands with a first type of -X B- and a second type of hyaluronic acid
strands with a second
type of -X B- and optionally a third type of hyaluronic acid strand with a
third type
of -X B- and optionally a fourth type of hyaluronic acid strand with a fourth
type of -X B-.
In certain embodiments -X B- is absent.
In certain embodiments -X B- is a stable linkage, i.e -L3- and -L4- are
connected through a
stable linkage.
In certain embodiments -X B- is a moiety selected from the group consisting of
0
, I I
¨:¨C¨N¨:-
0 I OB
and
wherein
-ROB selected from the group consisting of -H and C1_10 alkyl.
In certain embodiments -ROB is a -H. In certain embodiments -ROB is a Ci_10
alkyl. In certain
embodiments -ROB is a C1 alkyl. In certain embodiments -ROB is a C2 alkyl. In
certain
embodiments -ROB is a C3 alkyl. In certain embodiments -ROB is a C4 alkyl. In
certain
embodiments -ROB is a C5 alkyl. In certain embodiments -ROB is a C6 alkyl. In
certain
embodiments -ROB is a C7 alkyl. In certain embodiments -ROB is a C8 alkyl. In
certain
embodiments -ROB is a C9 alkyl. In certain embodiments -ROB is a C10 alkyl.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
189
In certain embodiments -X B- is
, 0
, -
,
----s ________________ C
N =
//
0
wherein the dashed lines indicate attachment to -L3- and -L4-, respectively.
In certain embodiments -X B- is
0
¨:¨C¨N¨:¨

I OB
R
wherein the dashed lines indicate attachment to -L3- and -L4-, respectively.
In certain embodiments -X B- is
0
õ , I I ,
¨hC¨N¨h
I OB
R ,
wherein the dashed line marked with the asterisk indicates attachment to -L3-
and the
unmarked dashed line indicates attachment to -L4-.
-L4- is absent or a spacer moiety. In certain embodiments -L4- does not
comprise a reversible
linkage, i.e. all linkages in -L4- are stable linkages.
In certain embodiments -L4- is absent.
In certain embodiments -L4- is a spacer moiety.
In certain embodiments -L4- does not comprise a degradable bond, i.e. all
bonds of -L4- are
stable bonds.
In certain embodiments -L4- is a spacer moiety selected from the group
consisting of -T-,
CI-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, CI-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different and

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
190
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
.. and -0C(0)N(RY3)-;
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T, C1_50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(0)N(Ry4a,_,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
each -RY2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -000RY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2R5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a,
-N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a,
.. -N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6
alkyl is optionally
substituted with one or more halogen, which are the same or different; and
each -R33, -Ry3a, _Ry4, _Ry4a, _RY5, -RY5a and -RY51 is independently selected
from the group
consisting of -H, and C1_6 alkyl, wherein C1_6 alkyl is optionally substituted
with one or more
halogen, which are the same or different,
provided that -L4- is attached to -X A- and -X B- via a carbon atom of -L4-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
191
In certain embodiments -L4- is a spacer moiety selected from the group
consisting of -T-, C1_50
alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C1_20 alkyl, C2_20
alkenyl, and C2_20 alkynyl
are optionally substituted with one or more -RY2, which are the same or
different and wherein
C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally interrupted by
one or more groups
selected from the group consisting of -T-, -C(0)0-, -0-,
-C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -
N(RY3)S(0)2N(RY3a)-,
-S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;
-RY1 and -RYla are independently of each other selected from the group
consisting of -H, -T,
Ci_io alkyl, C2-10 alkenyl, and C2_10 alkynyl; wherein -T, Ci_io alkyl, C2_10
alkenyl, and C2-10
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein Chio alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a._,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
-RY2 is selected from the group consisting of halogen, -CN, oxo
(=0), -COORY5, -ORY5, -c(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -SRY5, -N(RY5RY5a), -NO2, -
0C(0)R5
,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a, -N(RY5)S(0)RY5a, -N(RY5)C(0)0RY5a, -
N(RY5)C(0)N(RY5a
RY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with one
or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, K y4a,
RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L4- is attached to -X A- and -X B- via a carbon atom of -L4-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
192
In certain embodiments -L4- is a spacer moiety selected from the group
consisting of -T-, C1_50
alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C1_50 alkyl, C2_50
alkenyl, and C2_50 alkynyl
are optionally substituted with one or more -RY2, which are the same or
different and wherein
C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally interrupted by
one or more groups
selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RYla are independently selected from the group consisting of -H, -T,
Ci_io alkyl, C2_10
alkenyl, and C2_10 alkynyl;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
each -RY2 is independently selected from the group consisting of halogen and
C1_6 alkyl; and
each -RY3, -Ry3a, _Ry4, _Ry4a, _RY5, -RY5a and -RY5b is independently of each
other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -L4- is attached to -X A- and -X B- via a carbon atom of -L4-.
In certain embodiments -L4- is a C120 alkyl chain, which is optionally
interrupted by one or
more groups independently selected from -0-, -T-, -N(RY3)- and -C(0)N(RY1)-;
and which
C1_20 alkyl chain is optionally substituted with one or more groups
independently selected
from -OH, -T, -N(RY3)- and -C(0)N(RY6RY6a); wherein -RY1, -RY6, -RY6a are
independently
selected from the group consisting of H and C1_4 alkyl, wherein T is selected
from the group
consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_10
cycloalkyl, 3- to
10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered
carbopolycyclyl, and 8- to 30-membered heteropolycyclyl, provided that -L4- is
attached
to -X A- and -X B- via a carbon atom of -L4-.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
193
In certain embodiments -L4- has a molecular weight ranging from 14 g/mol to
750 g/mol.
In certain embodiments -L4- has a chain length ranging from 1 to 20 atoms.
In certain embodiments -L4- is a Ci_i 0 alkyl. In certain embodiments -L4- is
a Ci alkyl. In
certain embodiments -L4- is a C2 alkyl. In certain embodiments -L4- is a C3
alkyl. In certain
embodiments -L4- is a C4 alkyl. In certain embodiments -L4- is a C5 alkyl. In
certain
embodiments -L4- is a C6 alkyl. In certain embodiments -L4- is a C7 alkyl. In
certain
embodiments -L4- is a C8 alkyl. In certain embodiments -L4- is a C9 alkyl. In
certain
embodiments -L4- is a Cio alkyl.
In certain embodiments all moieties -X A- are identical. In certain
embodiments the
conjugates comprise more than one type of -X A-, such as two, three or four
different types
of -X A-. In certain embodiment one hyaluronic acid strand comprises only one
type of -X A-.
In certain embodiments the conjugates comprise a first type of hyaluronic acid
strands with a
first type of -X A- and a second type of hyaluronic acid strands with a second
type
of -X A- and optionally a third type of hyaluronic acid strand with a third
type of -X A- and
optionally a fourth type of hyaluronic acid strand with a fourth type of -X A-
.
In certain embodiments -X A- is absent.
In certain embodiments -X A- forms together with the carbonyl to which it is
attached a stable
linkage, i.e -L4- and the remainder of the unit Z2 are connected through a
stable linkage.
In certain embodiments -X A- is
¨LN¨

R1
I OA
,
wherein the dashed lines indicate attachment to -L4- and to the remainder of
Z2,
respectively; and
-R A selected from the group consisting of -H, methyl, ethyl, propyl,
isobutyl, n-butyl,
sec-butyl, isobutyl, tert-butyl, pentyl, 2-methylbutan-2-yl, 2,2-
dimethylpropyl, 3-
methylbutyl, pentan-2-yl, pentan-3-yl, 3-methylbutan-2-y1 and 2-methylbutyl.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
194
In certain embodiments -X A- is
wherein the dashed lines indicate attachment to -L4- and to the remainder of
Z2,
respectively.
In certain embodiments the only reversible bond in
a
moiety -xoA_L4_xos_L3_xoc_L2 _xop_.
L D is the bond that connects -Ll- and -D, which leads
to the drug being released in its free form.
In certain embodiments the moiety -X0A_L4A013_L3_x0C_C_-01130_
ic is of formula (i)
0
0
*S(VNNN<
- - n 111 H H
0
(0,
wherein
the dashed line marked with the asterisk indicates attachment to -L1-;
the unmarked dashed line indicates attachment to the remainder of Z2;
n is selected from the group consisting of 0, 1,2, 3,4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14,
15, 16, 17 and 18;
m is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15,
16, 17 and 18;
o is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15,
16, 17 and 18; and
wherein the moiety of formula (i) is optionally further substituted.
It is understood that in formula (i) -X D- is absent.
In certain embodiments n of formula (i) is selected from the group consisting
of 3, 4, 5, 6, 7,
8, and 9. In certain embodiments n of formula (i) is 3, 4, 5, 6, or 7. In
certain embodiments n
of formula (i) is 3. In certain embodiments n of formula (i) is 4. In certain
embodiments n of
formula (i) is 5. In certain embodiments n of formula (i) is 6.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
195
In certain embodiments m of formula (i) is selected from the group consisting
of 1, 2, 3, 4, 5,
6 or 7. In certain embodiments m of formula (i) is 1, 2, 3, 4 or 5. In certain
embodiments m of
formula (i) is 1. In certain embodiments m of formula (i) is 2. In certain
embodiments m of
formula (i) is 3. In certain embodiments m of formula (i) is 4.
In certain embodiments o of formula (i) is selected from the group consisting
of 1, 2, 3, 4, 5, 6
or 7. In certain embodiments o of formula (i) is 1, 2, 3, 4 or 5. In certain
embodiments o of
formula (i) is 1. In certain embodiments o of formula (i) is 2. In certain
embodiments o of
formula (i) is 3. In certain embodiments o of formula (i) is 4.
In certain embodiments the moiety -X0A_L4A0B_L3A0C_CAOD_-r 1_
L is selected from the group
consisting of
I 0
I
H* 0 0
0
N ------.s
N N-N1\1µ<
0 - - o
0
(Ia-i),
I 0
I
H* 0 0
0
N S
/
0
(Ia-ii)
I 0
NN"=/\,µ,!
I
H* 0 0
0
N-----s
/
0
(Ia-iii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
196
I 0
N
II
H* 0 0
0
N------__s ______________________
0
(Ia-iv),
I 0
N
I
H* 0 0
0
2\1-------s
O/ N'Ni\i
0
(Ib-i),
I 0
N
II
H* 0 y_O
c- 0
2\1------.s
/ NNI\T
0
(i)
(Ib-ii),
I 0
N
II
H* 0 y_O
c- 0
/ NNI\iµX
0
0
(Ib-iii),
I 0
N
N.=/\
I
H* 0 0
0
N----____ ______________________
s
0
o 2
(Ib-iv),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
197
0
H* 0 y_O
0
o/ NNV
0
(Ic-i),
0
N==/\!
H* 0
0
r - 4 s N
0
0
0
H* 0 y_O
0
/
0
0 3
(IC-iii),
0
H* 0 y_O
NS
0
/
0
0 3
0
H* 0
0
s N
0
O/
- o *
(Id-i),

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
198
0
H* 0 0
N 0
0
0/ 4 - - o *
(Id-ii),
0
H* 0 0
N s 0
N -
0 - 4
(Id-iii),
0
I I
H* 0 0
NS 0
N -
4
0
/ - - o *
0
(Id-iv);
wherein
5
the unmarked dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond;
o is selected from the group consisting of 1, 2, 3 and 4; and
the dashed line marked with the asterisk indicates attachment to the remainder
of Z2.
In certain embodiments the moiety -X0A_L4A0B_L3A0C_CAOD_, 1_
L
is of formula (Ia-i) with o
being 1. In certain embodiments the moiety -X0A_L4_)(0B_L3A0C_C_)(0D_ 1_
L
is of formula (Ia-
i) with o being 2. In certain embodiments the moiety -X0A_L4A013_L3A0C_CAOD_,
1_
L is of
formula (Ia-i) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2
L is of formula (Ia-i) with o being 4.
In certain embodiments the moiety -X0A_L4_)(0B_L3A0C_C_)(0D_ 1_
L is of formula (Ia-i) with
o being 1. In certain embodiments the moiety -X0A_L4A0B_L3A0C_CAOD_, 1_
L is of formula

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
199
(Ia-ii) with o being 2. In certain embodiments the moiety -
XoA_ct_xoB_c_xoc_c_xoD_Li _ is
of formula (Ia-ii) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Ia-ii) with o being 4.
In certain embodiments the moiety -X0A_C_x0B_L3_x0C_L2_x0D_, 1_
L
is of formula (Ia-iii) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ia-iii) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_L2_x0D_Ll_ is
of formula (Ia-iii) with o being 3. In certain embodiments the
moiety _ -x0A_L4A013_L3_x0C_L2_x0D_, 1
L is of formula (Ia-iii) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3A0C_CAOD_, 1_
L
is of formula (Ia-iv) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ia-iv) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_C_x0D_Ll _ is
of formula (Ia-iv) with o being 3. In certain embodiments the
moiety -XoA_o_xoB_c_xoc_c_xop_,
L - is of formula (Ia-iv) with o being 4.
In certain embodiments the moiety-X0A_Lzt_x0B_L3_x0C_C_x0D_, 1_
L
is of formula (Ib-i) with o
being 1. In certain embodiments the moiety _ -
X0A_L4_x0B_L3_x0C_C_x0D_ 1
L
is of formula (Ib-
i) with o being 2. In certain embodiments the moiety -
XoA_o_xoB_c_xoc_c_xoD_Li_ is of
formula (Ib-i) with o being 3 In certain embodiments the
moiety _ -x0A_L4A013_L3_x0C_L2_x0D_, 1
L is of formula (lb-i) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3A0C_CAOD_, 1_
L
is of formula (Ib-ii) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(lb-ii) with o being 2. In certain embodiments the moiety -
X0A_Lzt_x0B_L3_x0C_L2_x0D_Ll_ is
of formula (Ib-ii) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Ib-ii) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_ 1_
L
is of formula (Ib-iii) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ib-iii) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_L2_x0D_Ll_ is
of formula (Ib-iii) with o being 3. In certain embodiments the
moiety -x0A_L4A013_L3_x0C_L2_x0D_, 1_
L is of formula (Ib-iii) with o being 4.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
200
In certain embodiments the moiety -X0A_C_x0B_L3_x0C_L2_x0D_, 1_
L
is of formula (Ib-iv) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ib-iv) with o being 2. In certain embodiments the moiety-
X0A_L4_x0B_L3_x0C_C_x0D_Ll_ is
of formula (Ib-iv) with o being 3. In certain embodiments the
moiety _ -x0A_L4A013_L3_x0C_L2_x0D_, 1
L is of formula (Ib-iv) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3A0C_CAOD_, 1_
L
is of formula (Ic-i) with o
being 1. In certain embodiments the moiety _ -
X0A_L4_x0B_L3_x0C_C_x0D_ 1
L
is of formula (Ic-
i) with o being 2. In certain embodiments the moiety -
X0A_Lzt_x0B_L3_x0C_L2_x0D_, 1_
L is of
formula (Ic-i) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Ic-i) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_ 1_
L is of formula (Ic-i) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ic-i) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_C_x0D_Ll_ is
of formula (Ic-i) with o being 3. In certain embodiments the
moiety _ -x0A_L4A013_L3_x0C_L2_x0D_, 1
L is of formula (Ic-i) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3A0C_CAOD_, 1_
L
is of formula (Ic-iii) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ic-iii) with o being 2. In certain embodiments the moiety -
X0A_Lzt_x0B_L3_x0C_L2_x0D_Ll _ is
of formula (Ic-iii) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Ic-iii) with o being 4.
In certain embodiments the moiety -X0A_Lzt_x0B_L3_x0C_L2_x0D_, 1_
L
is of formula (Ic-iv) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_, 1_
L is of formula
(Ic-iv) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_C_x0D_Ll_ is
of formula (Ic-iv) with o being 3. In certain embodiments the
moiety-x0A_L4_x0B_L3_x0C_C_x0D_ 1_
L is of formula (Ic-iv) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_-.- 1_
L
is of formula (Id-i) with o
being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_C_x0D_-.- 1_
L
is of formula (Id-
i) with o being 2. In certain embodiments the moiety -
X0A_Lzt_x0B_L3_x0C_L2_x0D_, 1_
L is of

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
201
formula (Id-i) with o being 3. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Id-i) with o being 4.
In certain embodiments the moiety -X0A_LLI_x0B_L3_x0C_L2_x0D_, 1_
L
is of formula (Id-ii) with
.. o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_L2_x0D_, 1_
L is of formula
(Id-ii) with o being 2. In certain embodiments the moiety -
X0A_L4_x0B_L3_x0C_L2_x0D_Ll_ is
of formula (Id-ii) with o being 3. In certain embodiments the
moiety -x0A_L4A013_L3_x0C_L2_x0D_, 1_
L is of formula (Id-ii) with o being 4.
.. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_L2_x0D_-.- 1_
L
is of formula (Id-iii) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_L2_x0D_, 1_
L is of formula
(Id-iii) with o being 2. In certain embodiments the moiety -
X0A_LLI_x0B_L3_x0C_L2_x0D_Ll _ is
of formula (Id-iii) with o being 1. In certain embodiments the
moiety -xoA_o_xoB_c_xoc_L2 _xop_
L - is of formula (Id-iii) with o being 4.
In certain embodiments the moiety -X0A_C_x0B_L3_x0C_L2_x0D_, 1_
L
is of formula (Id-iv) with
o being 1. In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_L2_x0D_, 1_
L is of formula
(Id-iv) with o being 2. In certain embodiments the moiety -
X0A_LLI_x0B_L3_x0C_L2_x0D_Ll _ is
of formula (Id-iv) with o being 3. In certain embodiments the
moiety -XoA_o_xoB_c_xoc_c_xop_,
L - is of formula (Id-iv) with o being 4.
In certain embodiments the moiety -X0A_L4_x0B_L3_x0C_L2_x0D_ 1_
L is of formula (Ie-
i):
0
N N µ)
H* 0 0
0
- - 5 N -
/ N N
0
0 - 2 - 3
(Ie-i),
wherein
the unmarked dashed line indicates the attachment to a nitrogen of -D by
forming an
amide bond; and
the dashed line marked with the asterisk indicates attachment to the remainder
of Z2.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
202
In certain embodiments all moieties -X"- are identical. In certain embodiments
the conjugates
comprise more than one type of -X"-, such as two, three or four different
types of -X"-. In
certain embodiment one hyaluronic acid strand comprises only one type of -X"-.
In certain
embodiments the conjugates comprise a first type of hyaluronic acid strands
with a first type
of -X"- and a second type of hyaluronic acid strands with a second type of -X"-
and
optionally a third type of hyaluronic acid strand with a third type of -X"-
and optionally a
fourth type of hyaluronic acid strand with a fourth type of -X"-.
In certain embodiments -X"- is absent.
In certain embodiments -X"- is a stable linkage, i.e -SP- is connected to -CL-
through a stable
linkage.
In certain embodiments -X"- is an amide bond, in particular an amide of
formula (F)
0
(F),
wherein
the dashed line marked with the asterisk indicates attachment to -SP- and the
unmarked
dashed line indicates attachment to -CL-.
In certain embodiments the conjugate comprises a first type of hyaluronic acid
strand in
which -X"- is an amide bond, in particular an amide bond of formula (F), and a
second type
of hyaluronic acid strand in which -X"- is of formula (F-i)
V 0
04N -
(F-i),
wherein
dashed lines indicate attachment to -SP- and -CL-.
In particular, in the second type of hyaluronic acid strand -X"- is of formula
(F-ii)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
203
X * 0
4 0_
(F-ii),
wherein
the dashed line marked with the asterisk indicates attachment to -SP- and the
unmarked
dashed line indicates attachment to -CL-.
-SP- is absent or a spacer moiety. In certain embodiments -SP- does not
comprise a reversible
linkage, i.e. all linkages in -SP- are stable linkages.
In certain embodiments -SP- is absent.
In certain embodiments -SP- is a spacer moiety.
In certain embodiments -SP- does not comprise a degradable bond, i.e. all
bonds of -SP- are
stable bonds. In certain embodiments at least one of the at least one
degradable bond in the
direct connection between two carbon atoms marked with the * connected by a
moiety -CL- is
provided by -SP-.
In certain embodiments -SP- is a spacer moiety selected from the group
consisting of -T-,
C1_50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -T-, C1-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different and
wherein C1-50 alkyl, C2_50 alkenyl, and C2-50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RY1 a are independently of each other selected from the group
consisting of -H, -T,
C1_50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T, C1-50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
204
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a.
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
each -RY2 is independently selected from the group consisting of halogen, -CN,
oxo
(=0), -COORY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2R5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -SRY5, -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a,
-N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a,
-N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1,6 alkyl; wherein C1_6 alkyl
is optionally
substituted with one or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently selected from the group
consisting of -H, and C1_6 alkyl, wherein C1_6 alkyl is optionally substituted
with one or more
halogen, which are the same or different,
provided that -SP- is attached to -X"- and -X"- via a carbon atom of -SP-.
In certain embodiments -SP- is a spacer moiety selected from the group
consisting of -T-, Ci_
50 alkyl, C2-50 alkenyl, and C2_50 alkynyl; wherein -T-, C1-20 alkyl, C2_20
alkenyl, and C2-20
alkynyl are optionally substituted with one or more -RY2, which are the same
or different and
wherein C120 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of -T-, -C(0)0-, -0-,
-C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -
N(RY3)S(0)2N(RY3a)-,
-S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;
-RY1 and -R are are independently of each other selected from the group
consisting of -H, -T,
Ci_io alkyl, C2-10 alkenyl, and C2_10 alkynyl; wherein -T, C1_10 alkyl, C2_10
alkenyl, and C2-10
alkynyl are optionally substituted with one or more -RY2, which are the same
or different, and
wherein C1_10 alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally
interrupted by one or more

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
205
groups selected from the group consisting of -T-, -C(0)0-, -0-, -C(0)-,
-C(0)N(RY4)-, -S(0)2N(RY4)-, -S(0)N(RY4)-, -S(0)2-, -S(0)-, -
N(RY4)S(0)2N(RY4a)-, -S-,
-N(RY4)-, -0C(ORY4)(Ry4a)_, _N(Ry4)c(o)N(Ry4a._,
) and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
wherein each T is independently optionally substituted with one or more -RY2,
which are the
same or different;
-RY2 is selected from the group consisting of halogen, -CN, oxo
(=0), -000RY5, -ORY5, -C(0)R5, -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -
S(0)N(RY5RY5a),
-S(0)2RY5, -S(0)R5, -N(RY5)S(0)2N(RY5aRY5b), -N(RY5RY5a), -NO2, -0C(0)R5

,
-N(RY5)C(0)RY5a, -N(RY5)S(0)2RY5a, -N(RY5)S(0)RY5a, -N(RY5)C(0)ORY5a, -
N(RY5)C(0)N(RY5a
.. RY51), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with one
or more halogen, which are the same or different; and
each -RY3, -Ry3a, _Ry4, K y4a,
RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
.. one or more halogen, which are the same or different,
provided that -SP- is attached to -X"- and -X"- via a carbon atom of -SP-.
In certain embodiments -SP- is a spacer moiety selected from the group
consisting of -T-, Ci_
50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-, C1_50 alkyl, C2_50
alkenyl, and C2-50
alkynyl are optionally substituted with one or more -RY2, which are the same
or different and
wherein C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl are optionally
interrupted by one or more
groups selected from the group consisting of
-T-,
-C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-,
-S(0)-, -N(RY3)S(0)2N(RY3a)-, -S-, -N(RY3)-, -0C(ORY3)(RY3a)-, -
N(RY3)C(0)N(RY3a)-,
and -0C(0)N(RY3)-;
-RY1 and -RYla are independently selected from the group consisting of -H, -T,
Ci_io alkyl, C2_10
alkenyl, and C2_10 alkynyl;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
206
each T is independently selected from the group consisting of phenyl,
naphthyl, indenyl,
indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to
11-membered
heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered
heteropolycyclyl;
each -RY2 is independently selected from the group consisting of halogen and
Ci_6 alkyl; and
each -RY3, -Ry3a, _Ry4, _Ry4a,
RY5, -RY5a and -RY5b is independently of each other selected from
the group consisting of -H, and C1_6 alkyl; wherein C1_6 alkyl is optionally
substituted with
one or more halogen, which are the same or different,
provided that -SP- is attached to -X"- and -X"- via a carbon atom of -SP-.
In certain embodiments -SP- is a Ci_20 alkyl chain, which is optionally
interrupted by one or
more groups independently selected from -0-, -T-, -N(RY3)- and -C(0)N(RY1)-;
and which
C1_20 alkyl chain is optionally substituted with one or more groups
independently selected
from -OH, -T, -N(RY3)- and -C(0)N(RY6RY6a); wherein -RY1, -RY6, -RY6a are
independently
selected from the group consisting of H and C1_4 alkyl, wherein T is selected
from the group
consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_10
cycloalkyl, 3- to
10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered
carbopolycyclyl, and 8- to 30-membered heteropolycyclyl, provided that -SP- is
attached
to -X"- and -X"- via a carbon atom of -SP-.
In certain embodiments -SP- has a molecular weight ranging from 14 g/mol to
750 g/mol.
In certain embodiments -SP- has a chain lengths ranging from 1 to 20 atoms.
In certain embodiments all moieties -SP- of a conjugate are identical.
In certain embodiments -SP- is a Ci_io alkyl. In certain embodiments -SP- is a
C1 alkyl. In
certain embodiments -SP- is a C2 alkyl. In certain embodiments -SP- is a C3
alkyl. In certain
embodiments -SP- is a C4 alkyl. In certain embodiments -SP- is a C5 alkyl. In
certain
embodiments -SP- is a C6 alkyl. In certain embodiments -SP- is a C7 alkyl. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
207
embodiments -SP- is a C8 alkyl. In certain embodiments -SP- is a C9 alkyl. In
certain
embodiments -SP- is a Cio alkyl.
In certain embodiments -SP- is a moiety of formula (E)
0
P q
(E),
wherein
dashed lines indicate attachment to -X"- and -X"-;
p is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12,
13, 14 and 15; and
q is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12,
13, 14 and 15.
In certain embodiments -SP- is a moiety of formula (E-i)
0
(E-i),
wherein
dashed the dashed line indicate attachment to -X"- and the unmarked dashed
line
indicates attachment to
p is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12,
13, 14 and 15; and
q is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12,
13, 14 and 15.
In certain embodiments p of formula (E) or (E-i) is selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7 and 8. In certain embodiments p of formula (E) or (E-i) is
selected from the group
consisting of 2, 3, 4, 5, and 6. In certain embodiments p of formula (E) or (E-
i) is 2. In certain
embodiments p of formula (E) or (E-i) is 3. In certain embodiments p of
formula (E) or (E-i)
is 4. In certain embodiments p of formula (E) or (E-i) is 5.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
208
In certain embodiments q of formula (E) or (E-i) is selected from the group
consisting of 1, 2,
3, 4, 5, 6, 7 and 8. In certain embodiments q of formula (E) or (E-i) is
selected from the group
consisting of 1, 2, 3, 4 and 5. In certain embodiments q of formula (E) or (E-
i) is 1. In certain
embodiments q of formula (E) or (E-i) is 2. In certain embodiments q of
formula (E) or (E-i)
is 3. In certain embodiments q of formula (E) or (E-i) is 4. In certain
embodiments q of
formula (E) or (E-i) is 5.
In certain embodiments p of formula (E) or (E-i) is 3 and q of formula (E) or
(E-i) is 2.
In certain embodiments a conjugate comprises more than one type of -SP-, such
as two, three
or four different types of -SP-. In certain embodiment one hyaluronic acid
strand comprises
only one type of -SP-. In certain embodiments a conjugate comprise a first
type of hyaluronic
acid strands with a first type of -SP- and a second type of hyaluronic acid
strands with a
second type of -SP- and optionally a third type of hyaluronic acid strand with
a third type
of -SP- and optionally a fourth type of hyaluronic acid strand with a fourth
type of -SP-.
In certain embodiments the conjugate comprises a first type of hyaluronic acid
strand in
which -SP- is Chio alkyl, such as a methyl, ethyl, n-propyl, isopropyl, n-
butyl, isobutyl, sec-
butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-
methylpentyl, 3-
methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl or 3,3-dimethylpropyl. In
particular -SP- of the first type of hyaluronic acid is n-propyl. In certain
embodiments such
conjugate comprises a second type of hyaluronic acid strand in which -SP- is
of formula (E),
in particular of formula (E-i) and in particular of formula (E-i) in which p
is 3 and q is 2.
.. In certain embodiments all moieties -X E- are identical. In certain
embodiments the
conjugates comprise more than one type of -X E-, such as two, three or four
different types
of -X E-. In certain embodiment one hyaluronic acid strand comprises only one
type of -X E-.
In certain embodiments the conjugates comprise a first type of hyaluronic acid
strands with a
first type of -X E- and a second type of hyaluronic acid strands with a second
type
of -X E- and optionally a third type of hyaluronic acid strand with a third
type of -X E- and
optionally a fourth type of hyaluronic acid strand with a fourth type of -X E-
.
In certain embodiments -X E- is a stable linkage, i.e -SP- is connected to the
remainder of a
unit Z3 through a stable linkage.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
209
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(G-i)
- ml Th m3
y'----r .-----0 1\1"-----N"\-<-
-
m4 H - - m5 H
m2 -
- -
0 0
(G-i);
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
each ml, m2, m3, m4 and m5 is independently an integer selected from the group

consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23,
24 and 25.
In certain embodiments each ml of formula (G-i) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each ml of
formula (G-i) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments ml
of formula (G-i) is 1. In certain embodiments ml of formula (G-i) is 2. In
certain
embodiments ml of formula (G-i) is 3. In certain embodiments ml of formula (G-
i) is 4. In
certain embodiments ml of formula (G-i) is 5.
In certain embodiments each m2 of formula (G-i) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m2 of
formula (G-i) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m2
of formula (G-i) is 1. In certain embodiments m2 of formula (G-i) is 2. In
certain
embodiments m2 of formula (G-i) is 3. In certain embodiments m2 of formula (G-
i) is 4. In
certain embodiments m2 of formula (G-i) is 5.
In certain embodiments each m3 of formula (G-i) is individually selected from
the group
consisting of 0, 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m3 of
formula (G-i) is
individually selected from the group consisting of 0, 1, 2, 3, 4 and 5. In
certain embodiments
m3 of formula (G-i) is 0. In certain embodiments m3 of formula (G-i) is 1. In
certain
embodiments m3 of formula (G-i) is 2. In certain embodiments m3 of formula (G-
i) is 3. In
certain embodiments m3 of formula (G-i) is 4. In certain embodiments m3 of
formula (G-i) is
5.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
210
In certain embodiments each m4 of formula (G-i) is individually selected from
the group
consisting of 0, 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m4 of
formula (G-i) is
individually selected from the group consisting of 0, 1, 2, 3, 4 and 5. In
certain embodiments
.. m4 of formula (G-i) is 0. In certain embodiments m4 of formula (G-i) is 1.
In certain
embodiments m4 of formula (G-i) is 2. In certain embodiments m4 of formula (G-
i) is 3. In
certain embodiments m4 of formula (G-i) is 4. In certain embodiments m4 of
formula (G-i) is
5.
.. In certain embodiments each m5 of formula (G-i) is individually selected
from the group
consisting of 0, 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments m5 of
formula (G-i) is
selected from the group consisting of 0, 1, 2, 3, 4 and 5. In certain
embodiments m5 of
formula (G-i) is 0. In certain embodiments m5 of formula (G-i) is 1. In
certain embodiments
m5 of formula (G-i) is 2. In certain embodiments m5 of formula (G-i) is 3. In
certain
.. embodiments m5 of formula (G-i) is 4. In certain embodiments m5 of formula
(G-i) is 5.
In certain embodiments ml, m2, m3, m4 and m5 are 3.
In certain embodiments a moiety -X E-SP-X F-CL-X F-SP-X E- has the structure
of formula
(G-ii)
0 0
N N '
0
(G-ii),
wherein
dashed lines indicate attachment to the carbonyl of the hyaluronic acid; and
each ml, m2, m3, m4, m5 and m6 is independently an integer selected from the
group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23,
24 and 25.
In certain embodiments each ml of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each ml of
formula (G-ii) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments ml
of formula (G-ii) is 1. In certain embodiments ml of formula (G-ii) is 2. In
certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
211
embodiments ml of formula (G-ii) is 3. In certain embodiments ml of formula (G-
ii) is 4. In
certain embodiments ml of formula (G-ii) is 5.
In certain embodiments each m2 of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m2 of
formula (G-ii) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m2
of formula (G-ii) is 1. In certain embodiments m2 of formula (G-ii) is 2. In
certain
embodiments m2 of formula (G-ii) is 3. In certain embodiments m2 of formula (G-
ii) is 4. In
certain embodiments m2 of formula (G-ii) is 5.
In certain embodiments each m3 of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m3 of
formula (G-ii) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m3
of formula (G-ii) is 1. In certain embodiments m3 of formula (G-ii) is 2. In
certain
embodiments m3 of formula (G-ii) is 3. In certain embodiments m3 of formula (G-
ii) is 4. In
certain embodiments m3 of formula (G-ii) is 5.
In certain embodiments each m4 of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m4 of
formula (G-ii) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m4
of formula (G-ii) is 1. In certain embodiments m4 of formula (G-ii) is 2. In
certain
embodiments m4 of formula (G-ii) is 3. In certain embodiments m4 of formula (G-
ii) is 4. In
certain embodiments m4 of formula (G-ii) is 5.
In certain embodiments each m5 of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14. In certain
embodiments each m5 of
formula (G-ii) is individually selected from the group consisting of 1, 2, 3,
4, 5, 6, 7, 8, 9 and
10. In certain embodiments m5 of formula (G-ii) is 3. In certain embodiments
m5 of formula
(G-ii) is 4. In certain embodiments m5 of formula (G-ii) is 5. In certain
embodiments m5 of
formula (G-ii) is 6. In certain embodiments m5 of formula (G-ii) is 7. In
certain embodiments
m5 of formula (G-ii) is 8. In certain embodiments m5 of formula (G-ii) is 9.
In certain
embodiments m5 of formula (G-ii) is 10.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
212
In certain embodiments each m6 of formula (G-ii) is individually selected from
the group
consisting of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments each m6 of
formula (G-ii) is
individually selected from the group consisting of 1, 2, 3, 4 and 5. In
certain embodiments m6
of formula (G-ii) is 1. In certain embodiments m6 of formula (G-ii) is 2. In
certain
embodiments m6 of formula (G-ii) is 3. In certain embodiments m6 of formula (G-
ii) is 4. In
certain embodiments m6 of formula (G-ii) is 5.
In certain embodiments ml and m6 of formula (G-ii) are 3, m2, m3 and m4 of
formula (G-ii)
are 2 and m5 is 7.
In certain embodiments a moiety -X A-L4-x0B_L3A0C_L2A013_-.- 1_
L D is of formula (H-i)
D
0
I 0 0
Hr,N) S 0
..-- -......-
-
0 I 0 n3 H - n4 H
(H-i),
wherein
the dashed line indicates attachment to the carbonyl of the hyaluronic acid;
-D is used as defined above;
each n1 is independently an integer selected from the group consisting of 2 or
3; and
n2, n3 and n4 is independently an integer selected from the group consisting
of 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16.
In certain embodiments n1 of formula (H-i) is 2. In certain embodiments n1 of
formula (H-i)
is 3.
In certain embodiments n2 of formula (H-i) is an integer selected from the
group consisting of
1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments n2 of formula (H-i) is an
integer selected from
the group consisting of 2, 3, 4, 5, and 6. In certain embodiments n2 of
formula (H-i) is 2. In
certain embodiments n2 of formula (H-i) is 3. In certain embodiments n2 of
formula (H-i) is
4. In certain embodiments n2 of formula (H-i) is 5.
In certain embodiments n3 of formula (H-i) is an integer selected from the
group consisting of
1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments n3 of formula (H-i)
is an integer

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
213
selected from the group consisting of 1, 2, 3, 4, 5 and 6. In certain
embodiments n3 of formula
(H-i) is 1. In certain embodiments n3 of formula (H-i) is 2. In certain
embodiments n3 of
formula (H-i) is 3. In certain embodiments n3 of formula (H-i) is 4. In
certain embodiments
n3 of formula (H-i) is 5. In certain embodiments n3 of formula (H-i) is 6.
In certain embodiments n4 of formula (H-i) is an integer selected from the
group consisting of
1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments n4 of formula (H-i)
is an integer
selected from the group consisting of 1, 2, 3, 4, 5 and 6. In certain
embodiments n4 of formula
(H-i) is 1. In certain embodiments n4 of formula (H-i) is 2. In certain
embodiments n4 of
formula (H-i) is 3. In certain embodiments n4 of formula (H-i) is 4. In
certain embodiments
n4 of formula (H-i) is 5. In certain embodiments n4 of formula (H-i) is 6.
In certain embodiments n1 and n3 of formula (H-i) are 2, n2 of formula (H-i)
is 5 and n4 of
formula (H-i) is 3.
In certain embodiments a moiety -
L D is of formula (H-ii)
D
0
I H 0 0
0
H N - - n1 n2
0 I 0 - 113 H - - '4 H
(H-ii),
wherein
the dashed line indicates attachment to the carbonyl of the hyaluronic acid;
-D is used as defined above;
each n1 is independently an integer selected from the group consisting of 2 or
3; and
n2, n3 and n4 is independently an integer selected from the group consisting
of 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16.
In certain embodiments n1 of formula (H-ii) is 2. In certain embodiments n1 of
formula (H-ii)
is 3.
In certain embodiments n2 of formula (H-ii) is an integer selected from the
group consisting
of 1, 2, 3, 4, 5, 6, 7 and 8. In certain embodiments n2 of formula (H-ii) is
an integer selected
from the group consisting of 2, 3, 4, 5, and 6. In certain embodiments n2 of
formula (H-ii) is

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
214
2. In certain embodiments n2 of formula (H-ii) is 3. In certain embodiments n2
of formula (H-
ii) is 4. In certain embodiments n2 of formula (H-ii) is 5.
In certain embodiments n3 of formula (H-ii) is an integer selected from the
group consisting
of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments n3 of formula (H-
ii) is an integer
selected from the group consisting of 1, 2, 3, 4, 5 and 6. In certain
embodiments n3 of formula
(H-ii) is 1. In certain embodiments n3 of formula (H-ii) is 2. In certain
embodiments n3 of
formula (H-ii) is 3. In certain embodiments n3 of formula (H-ii) is 4. In
certain embodiments
n3 of formula (H-ii) is 5. In certain embodiments n3 of formula (H-ii) is 6.
In certain embodiments n4 of formula (H-ii) is an integer selected from the
group consisting
of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In certain embodiments n4 of formula (H-
ii) is an integer
selected from the group consisting of 1, 2, 3, 4, 5 and 6. In certain
embodiments n4 of formula
(H-ii) is 1. In certain embodiments n4 of formula (H-ii) is 2. In certain
embodiments n4 of
formula (H-ii) is 3. In certain embodiments n4 of formula (H-ii) is 4. In
certain embodiments
n4 of formula (H-ii) is 5. In certain embodiments n4 of formula (H-ii) is 6.
In certain embodiments n1 and n4 of formula (H-ii) are 3, n2 of formula (H-ii)
is 5 and n3 of
formula (H-ii) is 2.
If Z is a hyaluronic acid-based hydrogel, the present invention also relates
to a method of
preparing a pharmaceutical formulation comprising a conjugate of the first or
second aspect or
the compound of the third aspect comprising crosslinked hyaluronic acid
strands to which a
plurality of drug moieties are covalently conjugated, wherein the method
comprises the steps
of
(a) providing said conjugate or compound;
(b) subjecting the conjugate or compound of step (a) to a solution comprising
a
buffering agent, a surfactant and a salt comprising multivalent ions, to which
a
swelling agent is added after addition of said solution;
(c) homogenizing the admixture of step (b);
(d) deswelling the conjugate or compound of step (c) in a deswelling solution
comprising at least a deswelling agent;
(e) isolating the conjugate or compound from the admixture of step (d);

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
215
(f) subjecting the conjugate or compound of step (e) to a solution comprising
a
buffering agent, a surfactant, a salt comprising multivalent ions, a
hydrophilic
polymer of a molecular weight higher than 10 kDa, a density-modifying agent
and a polarity-modifying agent, to which a swelling agent is added after
addition
of said solution;
(g) homogenizing the admixture of step (f);
(h) deswelling the conjugate or compound of step (g) in a deswelling solution
comprising at least a deswelling agent;
(i) isolating the conjugate or compound from the admixture of step (h); and
wherein, there may be optional washing steps between steps (c) and (d), (f)
and (g), and (g)
and (h).
It was surprisingly found that this method allows for the formulation of such
conjugates and
compounds of the first, second and third embodiment.
It is understood that in step (b) the solution that comprises a buffering
agent, a surfactant and
a salt comprising multivalent ions may provide swelling to the conjugate,
before the addition
of the swelling agent.
.. It is also understood that in step (f) the solution that comprises a
buffering agent, a surfactant,
a salt comprising multivalent ions, a hydrophilic polymer of a molecular
weight higher than
10 kDa, a density-modifying agent and a polarity-modifying agent may provide
swelling to
the conjugate of step (e), before the addition of the swelling agent.
As used herein, the term "buffer" or "buffering agent" refers to a chemical
compound that
maintains the pH in a desired range. Physiologically tolerated buffers are,
for example acetate,
adipate, alanine, ammonium, arginine, ascorbate, aspartate, benzoate,
bicarbonate, carbonate,
citrate, diethanolamine, edetate, ethylenediamine, fumarate, gluconate,
glutamate, glycine,
guanidine, histidine, lactate, lysine, malate, metaphosphate, pentetate,
phosphate, pyruvate,
.. sorbate, succinate, tartrate, tromethamine and a-ketoglutarate. Antacids
such as CaCO3,
Mg(OH)2 or ZnCO3 may be also used.
As used herein, the term "surfactant" or "surfactant agent" refers to a
chemical compound that
reduces the surface tension of a liquid to which it is added.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
216
As used herein, the term "density-modifying agent" refers to a chemical
compound that
modifies the density of a liquid to which it is added. The density-modifying
agent may also
serve as a polarity-modifying agent.
As used herein, the term "polarity-modifying agent" refers to a chemical
compound that
modifies the polarity of a liquid to which it is added. The polarity-modifying
agent may also
serve as a density-modifying agent.
As used herein, the term "swelling agent" refers to a fluid used to swell a
gel, network or solid
so that the gel, network or solid may increase their volume after swelling
such as by at least
1.1, 1.5, 2, 5, 10, 50, 100 or 1000 times their volume in the non-swollen
state.
As used herein, the term "deswelling agent" refers to a fluid used to reduce
the swelling of a
gel, network or solid so that the gel, network or solid may decrease their
volume after
deswelling such as by at least 1.1, 1.5, 2, 5, 10, 50, 100 or 1000 times their
volume in the
swollen state.
As used herein, the term "polar protic solvent" refers to a solvent which
comprises bonds
between atoms with different electronegativities, has large dipole moments and
has at least
one hydrogen atom directly bound to an electronegative atom such as an oxygen,
nitrogen or
sulfur atom.
As used herein, the term "polar aprotic solvent" refers to a solvent which
comprises bonds
between atoms with different electronegativities, has large dipole moments and
has at least
one hydrogen atom directly bound to an electronegative atom such as an oxygen,
nitrogen or
sulfur atom.
As used herein, the term "homogenization" refers to any process that is used
to make a
mixture of two mutually non-miscible compounds the same throughout.
As used herein, the term "formulation", "pharmaceutical formulation",
"admixture" or
"composition" refers to a formulation containing one or more active
ingredients and one or
more excipients, as well as any product which results, directly or indirectly,
from

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
217
combination, complexation or aggregation of any two or more of the ingredients
of the
formulation, or from dissociation of one or more of the ingredients, or from
other types of
reactions or interactions of one or more of the ingredients. It is understood
that said active
ingredients may also be present in the form of inactive conjugates or
compounds, from which
the active ingredient is released.
As used herein, the term "reconstitution" means the addition of a liquid to a
dry
pharmaceutical formulation in order to bring back the original form of a
formulation, such as
a solution or suspension.
As used herein, the term "reconstituted formulation" refers to the formulation
obtained upon
reconstitution of a dry pharmaceutical formulation by addition of a
reconstitution solution.
As used herein, the term "reconstitution solution" refers to the liquid used
to reconstitute the
dry pharmaceutical formulation prior to administration to a patient in need
thereof
The conjugate or compound is subjected to a solution comprising a buffering
agent.
Exemplary buffering agents may be selected from the group consisting of
histidine, 1,3-
diaminopropane, 1,4-diaminopropane, 1,4-piperazinediethanesulfonic acid
(PIPES), 2-
(cyclohexylamino)ethanesulfonic acid (CHES), 2-(N-morpholino)ethanesulfonic
acid (MES),
2- [bis(2-hydroxyethypamino] -2-(hydroxymethyl)propane-1,3-diol[
(B TM), 2-amino-2-
methylpropan-1 - ol (AMP), 2-bis(2-hydroxyethypamino-2-(hydroxymethyl)-1,3-
propanediol
(BIS-TRIS), 2-hydroxy-3- [tris(hydroxymethyl)methylamino] -1 -propanesul
fonic acid
(TAP SO), 3 -(cyclohexylamino)-1 -propanesul foni c acid
(CAPS), 3 -(N,N-bi s [2-
hydroxyethyl] amino)-2-hydroxypropanesulfonic acid (DIP SO), 3 -(N-
morpholino)propanesul foni c acid (MOPS), 3- [4-(2-hydroxyethyl)piperazin-1 -
yl] propane-1-
sulfoni c acid (HEPP S), 3- { [1,3 -dihydroxy-2-(hydroxymethyl)propan-2-yl]
amino } propane-1-
sulfonic acid (TAPS), acetamidoglycine, acetic acid, aconitic acid, adipic
acid, alanine,
ammonia, arginine, ascorbic acid, aspartic acid, benzoic acid, besylic acid,
boric acid, butyric
acid, carbonic acid, cholamine, citraconic acid, citric acid, diethanolamine,
ethanolamine,
ethylenediamine, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric
acid,
gluconic acid, glutamic acid, glutaric acid, glycine, glycinamide,
glycylglycine, guanidine,
histamine, imidazole, isobutyric acid, lactic acid, lysine, maleic acid, malic
acid, malonic
acid, metaphosphoric acid, N-(2-acetamido)-2-aminoethanesulfonic acid (ACES),
N-(2-

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
218
acetamido)-iminodiacetic acid (ADA), N-(2-hydroxy-1,1-
bis(hydroxymethyl)ethyl)glycine
(TRICINE), N-(2-Hydroxyethyppiperazine-N-(4-butanesulfonic acid) (HEPBS), N-(2-

hydroxyethyppiperazine-Y-(2-ethanesulfonic acid) (HEPES),
N-
[tris(hydroxymethypmethy1]-2-aminoethanesulfonic acid (TES), nitrilotriacetic
acid (NTA),
oxalic acid, pentetic acid (DTPA), phosphoric acid, piperazine, piperidine,
pivalic acid,
propionic acid, pyridine, pyrrolidine, pyruvic acid, quinoline, sorbic acid,
spermidine,
spermine, squaric acid, succinic acid, tartronic acid, tetramic acid, tetronic
acid, tosylic acid,
triethanolamine (TEA), trimethylamine, tromethamine (TRIS), tryptamine,
tryptophan,
tyramine, tyrosine, a-ketoglutaric acid, P-hydroxy-4-morpholinepropanesulfonic
acid
(MOP SO) and mixtures thereof
It is clear to the person skilled in the art that the corresponding conjugate
acids, bases or salts
of the buffering agents and mixtures thereof are also included.
In certain embodiments, the buffering agent is selected from the group
consisting of histidine,
1,3-diaminopropane, 2-(N-morpholino)ethanesulfonic acid (MES),
2-bis(2-
hydroxyethypamino-2-(hydroxymethyl)-1,3-propanediol (BIS-TRIS), acetic acid,
adipic acid,
ammonia, arginine, boric acid, carbonic acid, citric acid, diethanolamine,
ethanolamine,
ethylenediamine, formic acid, gluconic acid, glutaric acid, glycine,
glycinamide, guanidine,
histamine, imidazole, lysine, malic acid, N-(2-hydroxy-1,1-
bis(hydroxymethyl)ethyl)glycine
(TRICINE), N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), N-
[tris(hydroxymethyDmethyl]-2-aminoethanesulfonic acid (TES), phosphoric acid,
piperazine,
propionic acid, pyruvic acid, spermidine, spermine, succinic acid, tartronic
acid,
triethanolamine (TEA), tromethamine (TRIS), tyrosine and mixtures thereof
In certain embodiments, the buffering agent is selected from the group
consisting of histidine,
acetic acid, ammonia, arginine, citric acid, diethanolamine, ethylenediamine,
gluconic acid,
glycine, guanidine, imidazole, lysine, N-(2-hydroxyethyl)piperazine-N'-(2-
ethanesulfonic
acid) (HEPES), phosphoric acid, piperazine, spermidine, spermine, succinic
acid, tartronic
acid, triethanolamine (TEA), tromethamine (TRIS) and mixtures thereof
In certain embodiments, the buffering agent is selected from the group
consisting of histidine,
arginine, diethanolamine, guanidine, spermidine and tromethamine (TRIS).

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
219
In certain embodiments, the buffering agent is selected from the group
consisting of histidine,
arginine and tromethamine (TRIS).
In certain embodiments, the buffering agent is histidine.
As defined herein, the term "histidine" is intended to encompass both D-
histidine and
L-histidine and mixtures thereof In certain embodiments, the term "histidine"
refers to
L-histidine. In certain embodiments, the term "histidine" refers to D-
histidine. In certain
embodiments, the term "histidine" refers to a mixture of L-histidine and D-
histidine.
In certain embodiments, the buffering agent is L-histidine.
The buffering agent maintains the pH of a solution within a desired range. In
certain
embodiments, the pH of the solutions of steps (b) and (f) is not higher than
9. In certain
embodiments, the pH of the solutions of steps (b) and (f) is from about pH 3
to about pH 9. In
certain embodiments, the pH of the solutions of steps (b) and (f) is from
about pH 4 to about
pH 8. In certain embodiments, the pH of the solutions of steps (b) and (f) is
from about pH 5
to about pH 7. In certain embodiments, the pH of the solutions of steps (b)
and (f) is about 6.
In certain embodiments, the pH of the solutions of steps (b) and (f) is 6Ø
The buffering agent may be added in an amount of about 0.01 mM to about 500
mM. In
certain embodiments, the buffering agent has a concentration ranging from
about 0.5 mM to
about 350 mM. In certain embodiments, the buffering agent has a concentration
ranging from
about 1 mM to about 250 mM. In certain embodiments, the buffering agent has a
concentration ranging from about 5 mM to 100 mM. In certain embodiments, the
buffering
agent has a concentration ranging from about 10 mM to 50 mM. In certain
embodiments, the
buffering agent has a concentration of about 20 mM. In certain embodiments,
the buffering
agent has a concentration of 20 mM.
The conjugate is subjected to a solution comprising a surfactant. Exemplary
surfactants may
be selected from the group consisting polyoxyethylenesorbitan monooleate
(Polysorbate 80,
Tween 80 and Tween 80R); alcohols such as propanol, butanol, pentanol,
hexanol, heptanol
or octanol; alkyl and aryl amine salts such as primary amine salts, quaternary
amine salts,
secondary amine salts or tertiary amine salts; alkyl dimethyl betaines; alkyl
ethoxylate

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
220
sulfates; alkyl phenyl polyoxyethylene ethers such as Octoxynol 9, Triton X-
100, IgepalTM or
Nonidet P40; alkyl phosphates such as monoalkylphosphates or
dialkylphosphates; alkyl
polyoxyethylene ethers such as Laureth-4, Laureth-9, Laureth-23, Ceteth-2,
Ceteth-10,
Ceteth-20, Ceteareth-6, Ceteareth-20, Ceteareth-25, Steareth-2, Steareth-10,
Steareth-20,
Oleth-2, Oleth-10, Oleth-20, Deceth-10 or Trideceth-10; alkyl sulfates such as
sodium
dodecylsulfate (SDS); alkyl xanthates; bile acid salts such as cholic acid
sodium salt or
deoxycholic acid sodium salt; cationic lipids such as cetyl trimethylammonium
bromide, cetyl
trimethylammonium chloride, dioctadecyl dimethyl ammonium bromide, dioctadecyl

dimethyl ammonium chloride, 1,2-diacy1-3-trimethylammonium propane, 1,2-diacy1-
3-
dimethyl ammonium propane, [2,3-bis(oleoyl)propyl] trimethyl ammonium chloride
or [N-
(N-dimethylaminoethane)-carbamoyl]cholesterol, dioleoyl); dialkyl
sulfosuccinate salts such
as Aerosol OT; Ethylenediamine tetrakis(ethoxylate-block-propoxylate) tetrols
such as
Tetronic 304, Tetronic 904, Tetronic 90R4 or Tetronic 1304; fatty acids such
as palmitic acid,
oleic acid, lauric acid, myristic acid, stearic acid, arachidic acid, behenic
acid, lignoceric acid,
palmitoleic acid, linoleic acid, linolenic acid or arachidonic acid and salts
thereof such as
sodium or potassium salts; glycosides such as octyl glucoside or dodecyl
maltoside; linear and
branched alkylbenzene sulfonates; poly(ethylene glycol)-block-poly(propylene
glycol)-block-
poly(ethylene glycol)s such as Poloxamer 101, Poloxamer 105, Poloxamer 108,
Poloxamer
122, Poloxamer 123, Poloxamer 124, Poloxamer 181, Poloxamer 182, Poloxamer
183,
Poloxamer 184, Poloxamer 185, Poloxamer 188 (Pluronic F68), Poloxamer 212,
Poloxamer
215, Poloxamer 217, Poloxamer 231, Poloxamer 234, Poloxamer 235, Poloxamer
237,
Poloxamer 238, Poloxamer 282, Poloxamer 284, Poloxamer 288, Poloxamer 331,
Poloxamer
333, Poloxamer 334, Poloxamer 335, Poloxamer 338, Poloxamer 401, Poloxamer
402,
Poloxamer 403, Poloxamer 407, Poloxamer 105 benzoate or Poloxamer 182
dibenzoate;
polyoxyethylenesorbitan esters such as polyethyleneoxy(40)-sorbitol hexaoleate
ester,
polyoxyethylenesorbitan monolaurate (Polysorbate 20, Tween 20 and Tween 21),
polyoxyethylenesorbitan monopalmitate (Polysorbate 40, Tween
40),
polyoxyethylenesorbitan monostearate (Polysorbate 60, Tween 60 and Tween
61),
polyoxyethylenesorbitan trioleate (Polysorbate 85, Tween 85) or
polyoxyethylenesorbitan
tristearate (Polysorbate 65, Tween 65); polyvinyl alcohol;
polyvinylpyrrolidone; sorbitan
esters such as sorbitan monolaurate (Span 20), sorbitan monooleate (Span
80), sorbitan
monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan
sequioleate (Span
83), sorbitan trioleate (Span 85) or sorbitan tristearate (Span 65); starch
and their
derivatives and mixtures thereof.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
221
In certain embodiments, the surfactant is selected from the group consisting
of
polyoxyethylenesorbitan monooleate (Polysorbate 80, Tween 80 and Tween 80R),
alkyl
phenyl polyoxyethylene ethers such as Octoxynol 9, Triton X-100, IgepalTM or
Nonidet P40;
alkyl polyoxyethylene ethers such as Laureth-9, Ceteth-10, Ceteareth-20,
Steareth-10, Oleth-
10, Deceth-10 or Trideceth-10; alkyl sulfates such as sodium dodecylsulfate
(SDS); bile acid
salts such as cholic acid sodium salt or deoxycholic acid sodium salt;
cationic lipids such as
cetyl trimethylammonium chloride, dioctadecyl dimethyl ammonium chloride, 1,2-
diacy1-3-
trimethylammonium propane, 1,2-diacy1-3-dimethyl ammonium propane or [2,3-
bis(oleoyl)propyl] trimethyl ammonium chloride; Ethylenediamine
tetrakis(ethoxylate-block-
propoxylate) tetrols such as Tetronic 90R4; glycosides such as octyl glucoside
or dodecyl
maltoside; poly(ethylene glycol)-block-poly(propylene glycol)-block-
poly(ethylene glycol)s
such as Poloxamer 101, Poloxamer 188 (Pluronic F68) or Poloxamer 288;
polyoxyethylenesorbitan esters such as polyethyleneoxy(40)-sorbitol hexaoleate
ester,
polyoxyethylenesorbitan monolaurate (Polysorbate 20, Tween 20 and Tween 21);
polyvinyl
alcohol; polyvinylpyrrolidone; sorbitan esters such as sorbitan monolaurate
(Span 20) or
sorbitan monooleate (Span 80) and mixtures thereof.
In certain embodiments, the surfactant is selected from the group consisting
of
polyoxyethylenesorbitan monooleate (Polysorbate 80, Tween 80 and Tween 80R),
alkyl
phenyl polyoxyethylene ethers such as Triton X-100; alkyl polyoxyethylene
ethers such as
Laureth-9 and Ceteth-10; alkyl sulfates such as sodium dodecylsulfate (SDS);
bile acid salts
such as cholic acid sodium salt; cationic lipids such as cetyl
trimethylammonium chloride;
Ethylenediamine tetrakis(ethoxylate-block-propoxylate) tetrols such as
Tetronic 90R4;
glycosides such as octyl glucoside; poly(ethylene glycol)-block-poly(propylene
glycol)-
block-poly(ethylene glycol)s such as Poloxamer 188 (Pluronic F68);
polyoxyethylenesorbitan esters such as polyoxyethylenesorbitan monolaurate
(Polysorbate 20,
Tween 20 and Tween 21) and mixtures thereof
In certain embodiments, the surfactant is selected from the group consisting
of
polyoxyethylenesorbitan monooleate (Polysorbate 80, Tween 80 and Tween 80R)
poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene
glycol)s such as
Poloxamer 188 (Pluronic F68) and polyoxyethylenesorbitan esters such as

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
222
polyoxyethylenesorbitan monolaurate (Polysorbate 20, Tween 20 and Tween 21)
and
mixtures thereof
In certain embodiments, the surfactant is a polyoxyethylenesorbitan
monooleate, such as
polysorbate 80.
The surfactant may be added in an amount of about 0.01% (w/w) to about 10%
(w/w). In
certain embodiments, the surfactant is added in an amount of about 0.1% (w/w)
to about 7%
(w/w). In certain embodiments, the surfactant is added in an amount of about
1% (w/w) to
about 5% (w/w). In certain embodiments, the surfactant is added in an amount
of about 1.5%
(w/w) to about 3.0% (w/w). In certain embodiments, the surfactant is added in
an amount of
about 2% (w/w). In certain embodiments, the surfactant is added in an amount
of 2% (w/w).
The conjugate or compound is subjected to a solution comprising a salt
comprising
multivalent ions. Exemplary salts may be selected from the group consisting of
calcium salts
and complexes such as calcium chloride, calcium acetate, calcium ascorbate,
calcium
bromide, calcium carbonate, calcium citrate, calcium dihydrogen phosphate,
calcium
disulfate, calcium fluoride, calcium formate, calcium fumarate, calcium
gluconate, calcium
hydrogen carbonate, calcium hydrogenphosphate, calcium hydrogen sulfate,
calcium
hydroxide, calcium iodide, calcium lactate, calcium levulinate, calcium
malate, calcium
malonate, calcium nitrate, calcium oxalate, calcium phosphate, calcium
propionate or calcium
sulfate; aluminium salts and complexes such as aluminium acetate, aluminium
ascorbate,
aluminium bromide, aluminium carbonate, aluminium chloride, aluminium citrate,
aluminium
dihydrogen phosphate, aluminium disulfate, aluminium fluoride, aluminium
formate,
aluminium fumarate, aluminium gluconate, aluminium hydrogen carbonate,
aluminium
hydrogenphosphate, aluminium hydrogen sulfate, aluminium hydroxide, aluminium
iodide,
aluminium lactate, aluminium levulinate, aluminium malate, aluminium malonate,
aluminium
nitrate, aluminium oxalate, aluminium phosphate, aluminium propionate or
aluminium
sulfate; barium salts and complexes such as barium acetate, barium ascorbate,
barium
bromide, barium carbonate, barium chloride, barium citrate, barium dihydrogen
phosphate,
barium disulfate, barium fluoride, barium formate, barium fumarate, barium
gluconate,
barium hydrogen carbonate, barium hydrogenphosphate, barium hydrogen sulfate,
barium
hydroxide, barium iodide, barium lactate, barium levulinate, barium malate,
barium malonate,
barium nitrate, barium oxalate, barium phosphate, barium propionate or barium
sulfate;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
223
copper(II) salts and complexes such as copper(II) acetate, copper(II)
ascorbate, copper(II)
bromide, copper(II) carbonate, copper(II) chloride, copper(II) citrate,
copper(II) dihydrogen
phosphate, copper(II) disulfate, copper(II) fluoride, copper(II) formate,
copper(II) fumarate,
copper(II) gluconate, copper(II) hydrogen carbonate, copper(II)
hydrogenphosphate,
.. copper(II) hydrogen sulfate, copper(II) hydroxide, copper(II) iodide,
copper(II) lactate,
copper(II) levulinate, copper(II) malate, copper(II) malonate, copper(II)
nitrate, copper(II)
oxalate, copper(II) phosphate, copper(II) propionate or copper(II) sulfate;
iron(II) salts and
complexes such as iron(II) acetate, iron(II) ascorbate, iron(II) bromide,
iron(II) carbonate,
iron(II) chloride, iron(II) citrate, iron(II) dihydrogen phosphate, iron(II)
disulfate, iron(II)
fluoride, iron(II) formate, iron(II) fumarate, iron(II) gluconate, iron(II)
hydrogen carbonate,
iron(II) hydrogenphosphate, iron(II) hydrogen sulfate, iron(II) hydroxide,
iron(II) iodide,
iron(II) lactate, iron(II) levulinate, iron(II) malate, iron(II) malonate,
iron(II) nitrate, iron(II)
oxalate, iron(II) phosphate, iron(II) propionate or iron(II) sulfate;
iron(III) salts and
complexes such as iron(III) acetate, iron(III) ascorbate, iron(III) bromide,
iron(III) carbonate,
.. iron(III) chloride, iron(III) citrate, iron(III) dihydrogen phosphate,
iron(III) disulfate, iron(III)
fluoride, iron(III) formate, iron(III) fumarate, iron(III) gluconate,
iron(III) hydrogen
carbonate, iron(III) hydrogenphosphate, iron(III) hydrogen sulfate, iron(III)
hydroxide,
iron(III) iodide, iron(III) lactate, iron(III) levulinate, iron(III) malate,
iron(III) malonate,
iron(III) nitrate, iron(III) oxalate, iron(III) phosphate, iron(III)
propionate and iron(III) sulfate;
lanthanum salts and complexes such as lanthanum acetate, lanthanum ascorbate,
lanthanum
bromide, lanthanum carbonate, lanthanum chloride, lanthanum citrate, lanthanum
dihydrogen
phosphate, lanthanum disulfate, lanthanum fluoride, lanthanum formate,
lanthanum fumarate,
lanthanum gluconate, lanthanum hydrogen carbonate, lanthanum
hydrogenphosphate,
lanthanum hydrogen sulfate, lanthanum hydroxide, lanthanum iodide, lanthanum
lactate,
.. lanthanum levulinate, lanthanum malate, lanthanum malonate, lanthanum
nitrate, lanthanum
oxalate, lanthanum phosphate, lanthanum propionate or lanthanum sulfate;
magnesium salts
and complexes such as magnesium acetate, magnesium ascorbate, magnesium
bromide,
magnesium carbonate, magnesium chloride, magnesium citrate, magnesium
dihydrogen
phosphate, magnesium disulfate, magnesium fluoride, magnesium formate,
magnesium
fumarate, magnesium gluconate, magnesium hydrogen carbonate, magnesium
hydrogenphosphate, magnesium hydrogen sulfate, magnesium hydroxide, magnesium
iodide,
magnesium lactate, magnesium levulinate, magnesium malate, magnesium malonate,

magnesium nitrate, magnesium oxalate, magnesium phosphate, magnesium
propionate or
magnesium sulfate; manganese(II) salts and complexes such as manganese(II)
acetate,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
224
manganese(II) ascorbate, manganese(II) bromide, manganese(II) carbonate,
manganese(II)
chloride, manganese(II) citrate, manganese(II) dihydrogen phosphate,
manganese(II)
disulfate, manganese(II) fluoride, manganese(II) formate, manganese(II)
fumarate,
manganese(II) gluconate, manganese(II) hydrogen carbonate, manganese(II)
hydrogenphosphate, manganese(II) hydrogen sulfate, manganese(II) hydroxide,
manganese(II) iodide, manganese(II) lactate, manganese(II) levulinate,
manganese(II) malate,
manganese(II) malonate, manganese(II) nitrate, manganese(II) oxalate,
manganese(II)
phosphate, manganese(II) propionate or manganese(II) sulfate; scandium salts
and complexes
such as scandium acetate, scandium ascorbate, scandium bromide, scandium
carbonate,
scandium chloride, scandium citrate, scandium dihydrogen phosphate, scandium
disulfate,
scandium fluoride, scandium formate, scandium fumarate, scandium gluconate,
scandium
hydrogen carbonate, scandium hydrogenphosphate, scandium hydrogen sulfate,
scandium
hydroxide, scandium iodide, scandium lactate, scandium levulinate, scandium
malate,
scandium malonate, scandium nitrate, scandium oxalate, scandium phosphate,
scandium
propionate and scandium sulfate; strontium salts and complexes such as
strontium acetate,
strontium ascorbate, strontium bromide, strontium carbonate, strontium
chloride, strontium
citrate, strontium dihydrogen phosphate, strontium disulfate, strontium
fluoride, strontium
formate, strontium fumarate, strontium gluconate, strontium hydrogen
carbonate, strontium
hydrogenphosphate, strontium hydrogen sulfate, strontium hydroxide, strontium
iodide,
strontium lactate, strontium levulinate, strontium malate, strontium malonate,
strontium
nitrate, strontium oxalate, strontium phosphate, strontium propionate or
strontium sulfate;
zinc salts and complexes such as zinc acetate, zinc ascorbate, zinc bromide,
zinc carbonate,
zinc chloride, zinc citrate, zinc dihydrogen phosphate, zinc disulfate, zinc
fluoride, zinc
formate, zinc fumarate, zinc gluconate, zinc hydrogen carbonate, zinc
hydrogenphosphate,
zinc hydrogen sulfate, zinc hydroxide, zinc iodide, zinc lactate, zinc
levulinate, zinc malate,
zinc malonate, zinc nitrate, zinc oxalate, zinc phosphate, zinc propionate,
zinc sulfate and
mixtures thereof
In certain embodiments, the salt is selected from the group consisting of
calcium salts and
complexes such as calcium chloride, calcium acetate, calcium ascorbate,
calcium bromide,
calcium carbonate, calcium citrate, calcium dihydrogen phosphate, calcium
disulfate, calcium
fluoride, calcium formate, calcium fumarate, calcium gluconate, calcium
hydrogen carbonate,
calcium hydrogenphosphate, calcium hydrogen sulfate, calcium hydroxide,
calcium iodide,
calcium lactate, calcium levulinate, calcium malate, calcium malonate, calcium
nitrate,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
225
calcium oxalate, calcium phosphate, calcium propionate or calcium sulfate;
iron(II) salts and
complexes such as iron(II) acetate, iron(II) ascorbate, iron(II) bromide,
iron(II) carbonate,
iron(II) chloride, iron(II) citrate, iron(II) dihydrogen phosphate, iron(II)
disulfate, iron(II)
fluoride, iron(II) formate, iron(II) fumarate, iron(II) gluconate, iron(II)
hydrogen carbonate,
iron(II) hydrogenphosphate, iron(II) hydrogen sulfate, iron(II) hydroxide,
iron(II) iodide,
iron(II) lactate, iron(II) levulinate, iron(II) malate, iron(II) malonate,
iron(II) nitrate, iron(II)
oxalate, iron(II) phosphate, iron(II) propionate or iron(II) sulfate;
lanthanum salts and
complexes such as lanthanum acetate, lanthanum ascorbate, lanthanum bromide,
lanthanum
carbonate, lanthanum chloride, lanthanum citrate, lanthanum dihydrogen
phosphate,
lanthanum disulfate, lanthanum fluoride, lanthanum formate, lanthanum
fumarate, lanthanum
gluconate, lanthanum hydrogen carbonate, lanthanum hydrogenphosphate,
lanthanum
hydrogen sulfate, lanthanum hydroxide, lanthanum iodide, lanthanum lactate,
lanthanum
levulinate, lanthanum malate, lanthanum malonate, lanthanum nitrate, lanthanum
oxalate,
lanthanum phosphate, lanthanum propionate or lanthanum sulfate; magnesium
salts and
complexes such as magnesium acetate, magnesium ascorbate, magnesium bromide,
magnesium carbonate, magnesium chloride, magnesium citrate, magnesium
dihydrogen
phosphate, magnesium disulfate, magnesium fluoride, magnesium formate,
magnesium
fumarate, magnesium gluconate, magnesium hydrogen carbonate, magnesium
hydrogenphosphate, magnesium hydrogen sulfate, magnesium hydroxide, magnesium
iodide,
magnesium lactate, magnesium levulinate, magnesium malate, magnesium malonate,

magnesium nitrate, magnesium oxalate, magnesium phosphate, magnesium
propionate or
magnesium sulfate; zinc salts and complexes such as zinc acetate, zinc
ascorbate, zinc
bromide, zinc carbonate, zinc chloride, zinc citrate, zinc dihydrogen
phosphate, zinc disulfate,
zinc fluoride, zinc formate, zinc fumarate, zinc gluconate, zinc hydrogen
carbonate, zinc
hydrogenphosphate, zinc hydrogen sulfate, zinc hydroxide, zinc iodide, zinc
lactate, zinc
levulinate, zinc malate, zinc malonate, zinc nitrate, zinc oxalate, zinc
phosphate, zinc
propionate, zinc sulfate and mixtures thereof
In certain embodiments, the salt is selected from the group consisting of
calcium salts and
complexes such as calcium chloride, calcium acetate, calcium ascorbate,
calcium bromide,
calcium carbonate, calcium citrate, calcium dihydrogen phosphate, calcium
disulfate, calcium
fluoride, calcium formate, calcium fumarate, calcium gluconate, calcium
hydrogen carbonate,
calcium hydrogenphosphate, calcium hydrogen sulfate, calcium hydroxide,
calcium iodide,
calcium lactate, calcium levulinate, calcium malate, calcium malonate, calcium
nitrate,

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
226
calcium oxalate, calcium phosphate, calcium propionate or calcium sulfate;
magnesium salts
and complexes such as magnesium acetate, magnesium ascorbate, magnesium
bromide,
magnesium carbonate, magnesium chloride, magnesium citrate, magnesium
dihydrogen
phosphate, magnesium disulfate, magnesium fluoride, magnesium formate,
magnesium
fumarate, magnesium gluconate, magnesium hydrogen carbonate, magnesium
hydrogenphosphate, magnesium hydrogen sulfate, magnesium hydroxide, magnesium
iodide,
magnesium lactate, magnesium levulinate, magnesium malate, magnesium malonate,

magnesium nitrate, magnesium oxalate, magnesium phosphate, magnesium
propionate,
magnesium sulfate and mixtures thereof.
In certain embodiments, the salt is selected from the group consisting of
calcium salts and
complexes such as calcium chloride, calcium acetate, calcium ascorbate,
calcium bromide,
calcium carbonate, calcium citrate, calcium dihydrogen phosphate, calcium
disulfate, calcium
fluoride, calcium formate, calcium fumarate, calcium gluconate, calcium
hydrogen carbonate,
calcium hydrogenphosphate, calcium hydrogen sulfate, calcium hydroxide,
calcium iodide,
calcium lactate, calcium levulinate, calcium malate, calcium malonate, calcium
nitrate,
calcium oxalate, calcium phosphate, calcium propionate and calcium sulfate.
In certain embodiments, the salt is selected from the group consisting of
calcium salts and
complexes such as calcium chloride, calcium acetate, calcium ascorbate,
calcium citrate,
calcium gluconate, calcium lactate, calcium levulinate, calcium malate and
calcium malonate.
In certain embodiments, the salt is calcium chloride.
The salt may be added in an amount of about 0.01 mM to about 500 mM. In
certain
embodiments, the salt has a concentration ranging from about 0.1 mM to about
350 mM. In
certain embodiments, the salt has a concentration ranging from about 1 mM to
about 250 mM.
In certain embodiments, the salt has a concentration ranging from about 5 mM
to 100 mM. In
certain embodiments, the salt has a concentration ranging from about 10 mM to
75 mM. In
certain embodiments, the salt has a concentration of about 50 mM. In certain
embodiments,
the salt has a concentration of 50 mM.
A swelling agent is added to the conjugate or compound after addition of a
solution
comprising a buffering agent, a surfactant and a salt comprising multivalent
ions.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
227
In certain embodiments, the swelling agent is a polar aprotic solvent.
Exemplary swelling
agents may be selected from the group consisting of dimethyl sulfoxide, 1,2-
dimethoxyether,
1,3-dimethyl-2-imidazolidinone, 1,3-dioxolane, 1,4-dioxane, 2,5-
dimethyltetrahydrofuran,
2-methyltetrahydrofuran, 4-acetyl morpholine, 4-propionyl morpholine, acetone,
acetonitrile,
diethyl carbonate, diethyl ether, dimethyl carbonate, ethyl acetate, ethyl
formate, ethyl lactate,
ethylene carbonate, gamma-butyrolactone, gamma-valerolactone,
hexamethylphosphoramide,
methyl acetate, methyl carbonate, monomethyl ether acetate, N,N-
dimethylpropyleneurea,
N,N-dimethylacetamide, N,N-dimethylformamide, N-formyl
morpholine,
N-methyl-2-pyrrolidone, propylene carbonate, sulfolane, tetrahydrofuran,
tetrahydropyran,
tripyrrolidinophosphoric acid triamide and mixtures thereof
In certain embodiments, the swelling agent may be selected from the group
consisting of
dimethyl sulfoxide, 1,3-dimethyl-2-imidazolidinone, 4-acetyl morpholine, 4-
propionyl
morpholine, hexamethylphosphoramide,
N,/V'-dimethylpropyleneurea,
N,N-dimethylacetamide, N,N-dimethylformamide, N-formyl
morpholine,
N-methyl-2-pyrrolidone, sulfolane, tripyrrolidinophosphoric acid triamide and
mixtures
thereof.
In certain embodiments, the swelling agent may be selected from the group
consisting of
dimethyl sulfoxide, N,N-dimethylacetamide, N,N-dimethylformamide, N-methy1-2-
pyrrolidone and sulfolane.
In certain embodiments, the swelling agent is dimethyl sulfoxide.
The swelling agent may be added in an amount of about 10% (v/v) to about 99%
(v/v). In
certain embodiments, the swelling agent is added in an amount of about 30%
(v/v) to about
97% (v/v). In certain embodiments, the swelling agent is added in an amount of
about 50%
(v/v) to about 95% (v/v). In certain embodiments, the swelling agent is added
in an amount of
about 80% (v/v) to about 90% (v/v). In certain embodiments, the swelling agent
is added in an
amount of about 87% (v/v). In certain embodiments, the swelling agent is added
in an amount
of about 85% (v/v). In certain embodiments, the swelling agent is added in an
amount of
about 83% (v/v). In certain embodiments, the swelling agent is added in an
amount of 87%

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
228
(v/v). In certain embodiments, the swelling agent is added in an amount of 85%
(v/v). In
certain embodiments, the swelling agent is added in an amount of 83% (v/v).
The conjugate or compound is subjected to a deswelling solution comprising at
least a
deswelling agent.
In certain embodiments, a deswelling agent is a polar protic solvent.
Exemplary deswelling agents may be selected from the group consisting of
ethanol, 1,4-
butanediol, acetic acid, cyclohexanol, diethylene glycol, diethylene glycol
monoethyl ether,
diethylene glycol monomethyl ether, ethylene diamine, ethylene glycol,
ethylene glycol
monoethyl ether, ethylene glycol monomethyl ether, formamide, formic acid,
glycerine,
isobutanol, isopropanol, methanesulfonic acid, methanol, n-butanol, n-hexanol,
n-pentanol, n-
propanol, propionic acid, propylene diamine, propylene glycol, propylene
glycol monoethyl
ether, propylene glycol monomethyl ether, sec-butanol, t-butanol, triethylene
glycol
monoethyl ether, triethylene glycol monomethyl ether, triethylene glycol,
trifluoroacetic acid,
water and mixtures thereof.
In certain embodiments, the deswelling agent may be selected from the group
consisting of
ethanol, 1,4-butanediol, diethylene glycol, ethylene glycol, formamide,
glycerine, isobutanol,
isopropanol, methanol, n-butanol, n-hexanol, n-pentanol, n-propanol, propylene
glycol,
sec-butanol, t-butanol and mixtures thereof.
In certain embodiments, the deswelling agent may be selected from the group
consisting of
ethanol, isopropanol, methanol and n-propanol.
In certain embodiments, the deswelling agent is ethanol.
The deswelling agent may be added in an amount of about 10% (v/v) to about 99%
(v/v). In
certain embodiments, the deswelling agent is added in an amount of about 30%
(v/v) to about
97% (v/v). In certain embodiments, the deswelling agent is added in an amount
of about 50%
(v/v) to about 95% (v/v). In certain embodiments, the deswelling agent is
added in an amount
of about 70% (v/v) to about 90% (v/v). In certain embodiments, the deswelling
agent is added
in an amount of about 87% (v/v). In certain embodiments, the deswelling agent
is added in an

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
229
amount of about 80% (v/v). In certain embodiments, the deswelling agent is
added in an
amount of about 74% (v/v). In certain embodiments, the deswelling agent is
added in an
amount of 87.5% (v/v). In certain embodiments, the deswelling agent is added
in an amount
of 80% (v/v). In certain embodiments, the deswelling agent is added in an
amount of 74%
(v/v).
In certain embodiments, the conjguate or compound is subjected to a solution
comprising a
hydrophilic polymer of a molecular weight higher than 10 kDa. Exemplary
hydrophilic
polymers may be selected from the group consisting of hyaluronic acids and
derivatives,
functionalized hyaluronic acids, 2-methacryloyl-oxyethyl phosphoryl cholins,
poly(acrylic
acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers,
poly(amides),
poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides),
poly(butyric
acids), poly(glycolic acids), polybutylene terephthalates,
poly(caprolactones),
poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides),
poly(esters),
poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl
phosphates),
poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates),
poly(hydroxyethyl-
oxazolines), poly(hydroxymethacrylates),
poly(hydroxypropylmethacrylamides),
poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines),
poly(iminocarbonates),
poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides),
poly(methacrylates),
poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters),
poly(oxazolines),
poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl
alcohols),
poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones),
silicones, celluloses,
carboxymethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans,
dextrans,
dextrins, gelatins, gellans, pullulans, mannans, pectins, rhamnogalacturonans,
starches,
hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based
polymers, xylans,
copolymers and mixtures thereof.
In certain embodiments, the hydrophilic polymer may be selected from the group
consisting
of hyaluronic acids and derivatives, functionalized hyaluronic acids,
poly(acrylic acids),
poly(ethylene glycol), poly(glycolic acids), poly(lactic acids), poly(lactic-
co-glycolic acids),
poly(propylene glycols), poly(vinyl alcohols), poly(vinylpyrrolidones),
carboxymethyl
celluloses, hydroxypropyl methylcelluloses, chitosans, dextrans, dextrins,
pullulans,
hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based
polymers, xylans,
copolymers and mixtures thereof.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
230
In certain embodiments, the hydrophilic polymer may be selected from the group
consisting
of hyaluronic acids, carboxymethyl celluloses, hydroxypropyl methylcelluloses,
chitosans,
dextrans, pullulans, hydroxyethyl starches and mixtures thereof.
In certain embodiments, the hydrophilic polymer is hyaluronic acid.
The hydrophilic polymer may be added in an amount of about 0.01 g/1 to about
100 g/l. In
certain embodiments, the hydrophilic polymer has a concentration ranging from
about 0.1 g/1
to about 50 g/l. In certain embodiments, the hydrophilic polymer has a
concentration ranging
from about 0.5 g/1 to about 10 g/l. In certain embodiments, the hydrophilic
polymer has a
concentration ranging from about 1 g/1 to about 5 g/l. In certain embodiments,
the hydrophilic
polymer has a concentration of about 2 g/l. In certain embodiments, the
hydrophilic polymer
has a concentration of 2 g/l.
In certain embodiments, the conjugate or compound may be subjected to a
solution
comprising a density-modifying agent.
Exemplary density-modifying agents may be selected from the group consisting
of trehalose,
arabitol, cellobiose, dextrose, erythritol, fructose, fucitol, fucose,
galactitol, gentiobiose,
iditol, inositol, isomalt, isomaltose, isomaltulose, lactitol, lactose,
lactulose, laminaribiose,
maltitol, maltose, maltotetraitol, maltotriitol, maltulose, mannitol, mannose,
melibiose,
neohesperidose, neotrehalose, nigerose, polyglycitol, potassium chloride,
potassium sulfate,
raffinose, ribitol, rutinose, sambubiose, sodium chloride, sodium sulfate,
sophorose, sorbitol,
sucrose, threitol, volemitol, xylitol and mixtures thereof.
In certain embodiments, the density-modifying agent may be selected from the
group
consisting of trehalose, erythritol, inositol, isomaltose, lactose, maltitol,
mannitol, sodium
chloride, sodium sulfate, sorbitol, sucrose, xylitol and mixtures thereof.
In certain embodiments, the density-modifying agent may be selected from the
group
consisting of trehalose, lactose, mannitol, sorbitol, sucrose and mixtures
thereof
In certain embodiments, the density-modifying agent is trehalose.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
231
As defined herein, the term "trehalose" is intended to encompass all salts and
hydration states
of trehalose, such as trehalose anhydrous or trehalose dihydrate. In certain
embodiments, the
term "trehalose" refers to trehalose anhydrous.
In certain embodiments, the term "trehalose" refers to trehalose dihydrate.
The density-modifying agent may be added in an amount of about 0.1% (w/w) to
about 25%
(w/w). In certain embodiments, the density-modifying agent is added in an
amount of about
1% (w/w) to about 20% (w/w). In certain embodiments, the density-modifying
agent is added
in an amount of about 2% (w/w) to about 10% (w/w). In certain embodiments, the
density-
modifying agent is added in an amount of about 5% (w/w). In certain
embodiments, the
density-modifying agent is added in an amount of 5% (w/w).
In certain embodiments, the conjugate or compound may be subjected to a
solution
comprising a polarity-modifying agent.
In certain embodiments, the polarity-modifying agent is selected from the
group consisting of
polar protic and polar aprotic solvents.
Exemplary polarity-modifying agents may be selected from the group consisting
of propylene
glycol, acetonitrile, dimethyl sulfoxide, ethanol, ethylene glycol, ethylene
glycol monomethyl
ether, glycerol, isopropanol, methanol, /V,N-dimethylformamide, n-propanol and
mixtures
thereof
In certain embodiments, the polarity-modifying agent may be selected from the
group
consisting of propylene glycol, dimethyl sulfoxide, ethanol, ethylene glycol,
glycerol and
mixtures thereof
In certain embodiments, the polarity-modifying agent may be selected from the
group
consisting of propylene glycol, ethanol, glycerol and mixtures thereof
In certain embodiments, the polarity-modifying agent is propylene glycol.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
232
As defined herein, the term "propylene glycol" is intended to encompass
(R)-1,2-dihydroxypropane, (S)-1,2-dihydroxypropane, (RS)-1,2-dihydroxypropane
and
mixtures thereof In certain embodiments, the term "propylene glycol" refers to

(R)-1,2-dihydroxypropane. In certain embodiments, the term "propylene glycol"
refers to
(S)-1,2-dihydroxypropane. In certain embodiments, the term "propylene glycol"
refers to
(RS)-1,2-dihydroxypropane.
In certain embodiments, the polarity-modifying agent is (RS)-1,2-
dihydroxypropane.
The polarity-modifying agent may be added in an amount of about 0.1% (w/w) to
about 75%
(w/w). In certain embodiments, the polarity-modifying agent is added in an
amount of about
1% (w/w) to about 50% (w/w). In certain embodiments, the polarity-modifying
agent is added
in an amount of about 2% (w/w) to about 35% (w/w). In certain embodiments, the
polarity-
modifying agent is added in an amount of about 5% (w/w) to about 20% (w/w). In
certain
embodiments, the polarity-modifying agent is added in an amount of about 10%
(w/w). In
certain embodiments, the polarity-modifying agent is added in an amount of 10%
(w/w).
In certain embodiments, homogenization may be achieved by mechanical methods
such as
extrusion, injection, atomization, shearing, molding or emulsion-templating,
sonication,
vortexing, manual grinding or combined procedures thereof
In certain embodiments, isolation of the conjugate may be achieved by
evaporation of a liquid
solution comprising the conjugate, lyophilization, filtration, centrifugation
or combined
procedures thereof
In certain embodiments, the method of preparing a pharmaceutical formulation
comprises the
steps of
(a) providing said conjugate or compound;
(b) subjecting the conjugate or compound of step (a) to a solution comprising
L-
histidine, polysorbate 80 and CaCl2 to which dimethyl sulfoxide is added after
addition of said solution;
(c) homogenizing the admixture of step (b);
(d) deswelling the conjugate or compound of step (c) in ethanol, acetic acid
and
polysorbate 80;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
233
(e) isolating the conjugate or compound from the admixture of step (d);
(f) subjecting the conjugate or compound of step (e) to a solution comprising
L-
histidine, polysorbate 80, CaCl2, hyaluronic acid of a molecular weight higher

than 10 kDa, trehalose dihydrate and (RS)-1,2-dihydroxypropane, to which
dimethyl sulfoxide is added after addition of said solution;
(g) homogenizing the admixture of step (f);
(h) deswelling the conjugate or compound dof step (g) in ethanol;
(i) isolating the conjugate or compound from the admixture of step (h); and
wherein, there may be optional washing steps between steps (c) and (d), (f)
and (g), and (g)
and (h).
In certain embodiments the pharmaceutical formulation obtained by the process
is dried, such
as by lyophilization or by treating the conjugate in a high vacuum.
Prior to applying such dry pharmaceutical formulation to a patient in need
thereof, the dry
pharmaceutical formulation is reconstituted. Reconstitution of the dry
pharmaceutical
formulation into a reconstituted formulation is done by adding a predefined
amount of
reconstitution solution to the dry pharmaceutical formulation. Therefore, a
further aspect of
the present invention is a method of reconstituting the dry pharmaceutical
formulation,
wherein the method comprises the step of
(a) contacting the dry pharmaceutical formulation with a reconstitution
solution.
The present invention also relates to a reconstituted pharmaceutical
formulation obtainable
from the method of reconstituting said dry pharmaceutical formulation.
Reconstitution may take place in the container in which the dry pharmaceutical
formulation
comprising the conjugate is provided, such as in a vial; syringe, such as a
dual-chamber syringe; ampoule; cartridge, such as a dual-chamber cartridge; or
the dry
pharmaceutical formulation may be transferred to a different container and is
then
.. reconstituted.
In certain embodiments, the container in which the reconstitution of the dry
pharmaceutical
formulation takes place is a vial. In certain embodiments, the container in
which the
reconstitution of the dry pharmaceutical formulation takes place is a syringe.
In certain

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
234
embodiments, the container in which the reconstitution of the dry
pharmaceutical formulation
takes place is a dual-chamber syringe. In certain embodiments, the container
in which the
reconstitution of the dry pharmaceutical formulation takes place is a
cartridge. In certain
embodiments, the container in which the reconstitution of the dry
pharmaceutical formulation
takes place is a dual-chamber cartridge. In certain embodiments, the dry
pharmaceutical
formulation is provided in a first chamber of the dual-chamber syringe and the
reconstitution
solution is provided in a second chamber of the dual-chamber syringe. In
certain
embodiments, the dry pharmaceutical formulation is provided in a first chamber
of the dual-
chamber cartridge and the reconstitution solution is provided in a second
chamber of the dual-
chamber cartridge.
The reconstitution solution is a sterile liquid, such as water or buffer,
which may comprise
further additives, such as preservatives and/or antimicrobials. In certain
embodiments, the
reconstituted solution comprises one or more preservative and/or
antimicrobial. In certain
embodiments, the reconstituted solution comprises one or more excipient. In
certain
embodiments, the reconstitution solution is sterile water. In certain
embodiments, the
reconstitution solution is sterile water comprising 0.7-1.1 % benzylalcohol.
In certain
embodiments, the reconstitution solution is sterile water comprising 0.9 %
benzylalcohol.
The buffering agent maintains the pH of the reconstituted formulation within a
desired range.
In certain embodiments, the pH of the reconstituted formulation is not higher
than 9. In
certain embodiments, the pH of the reconstituted formulation is from about pH
3 to about pH
9. In certain embodiments, the pH of the reconstituted formulation is from
about pH 4 to
about pH 6. In certain embodiments, the pH of the reconstituted formulation is
from about pH
4.5 to about pH 5.5.
In certain embodiments, the buffering agent has a concentration ranging from 1
to 50 mM in
the reconstituted formulation. In certain embodiments, the buffering agent has
a concentration
ranging from 2 to 30 mM in the reconstituted formulation. In certain
embodiments, the
buffering agent has a concentration ranging from 5 to 20 mM in the
reconstituted formulation.
In certain embodiments, the buffering agent has a concentration of about 10 mM
in the
reconstituted formulation.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
235
In general a pharmaceutical composition of the present invention has a pH
ranging from pH 3
to pH 8, such as ranging from pH 4 to pH 6 or ranging from pH 4 to pH 5. In
certain
embodiments the pharmaceutical composition has a pH of about 4. In certain
embodiments
the pharmaceutical composition has a pH of about 4.5. In certain embodiments
the
pharmaceutical composition has a pH of about 5.
In certain embodiments such pharmaceutical composition is a suspension
composition.
In certain embodiments such pharmaceutical is a dry composition. It is
understood that such
dry composition may be obtained by drying, such as lyophilizing, a suspension
composition.
Suitable excipients for the pharmaceutical may be categorized as, for example,
buffering
agents, isotonicity modifiers, preservatives, stabilizers, anti-adsorption
agents, oxidation
protection agents, viscosifiers/viscosity enhancing agents, anti-agglomeration
agents or other
auxiliary agents. However, in some cases, one excipient may have dual or
triple functions.
Excipient may be selected from the group consisting of
(i) Buffering agents: physiologically tolerated buffers to maintain pH in a
desired range,
such as sodium phosphate, bicarbonate, succinate, histidine, citrate and
acetate,
sulphate, nitrate, chloride, pyruvate; antacids such as Mg(OH)2 or ZnCO3 may
be also
used;
(ii) Isotonicity modifiers: to minimize pain that can result from cell
damage due to
osmotic pressure differences at the injection depot; glycerin and sodium
chloride are
examples; effective concentrations can be determined by osmometry using an
assumed
osmolality of 285-315 mOsmol/kg for serum;
(iii) Preservatives and/or antimicrobials: multidose parenteral
compositions benefit from
the addition of preservatives at a sufficient concentration to minimize risk
of patients
becoming infected upon injection and corresponding regulatory requirements
have
been established; typical preservatives include m-cresol, phenol,
methylparaben,
ethylparaben, propylparaben, butylparaben, chlorobutanol, benzyl alcohol,
phenylmercuric nitrate, thimerosol, sorbic acid, potassium sorbate, benzoic
acid,
chlorocresol, and benzalkonium chloride;

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
236
(iv) Stabilizers: Stabilisation is achieved by strengthening of the protein-
stabilising forces,
by destabilisation of the denatured state, or by direct binding of excipients
to the
protein; stabilizers may be amino acids such as alanine, arginine, aspartic
acid,
glycine, histidine, lysine, proline, sugars such as glucose, sucrose,
trehalose, polyols
such as glycerol, mannitol, sorbitol, salts such as potassium phosphate,
sodium
sulphate, chelating agents such as EDTA, hexaphosphate, ligands such as
divalent
metal ions (zinc, calcium, etc.), other salts or organic molecules such as
phenolic
derivatives; in addition, oligomers or polymers such as cyclodextrins,
dextran,
dendrimers, PEG or PVP or protamine or HSA may be used;
(v) Anti-adsorption agents: Mainly ionic or non-ionic surfactants or other
proteins or
soluble polymers are used to coat or adsorb competitively to the inner surface
of the
compoisition's container; e.g., poloxamer (Pluronic F-68), PEG dodecyl ether
(Brij
35), polysorbate 20 and 80, dextran, polyethylene glycol, PEG-polyhistidine,
BSA and
HSA and gelatins; chosen concentration and type of excipient depends on the
effect to
be avoided but typically a monolayer of surfactant is formed at the interface
just above
the CMC value;
(vi) Oxidation protection agents: antioxidants such as ascorbic acid,
ectoine, methionine,
glutathione, monothioglycerol, morin, polyethylenimine (PEI), propyl gallate,
and
vitamin E; chelating agents such as citric acid, EDTA, hexaphosphate, and
thioglycolic acid may also be used;
(vii) Viscosifiers or viscosity enhancers: retard settling of the particles
and are used in order
to facilitate mixing and resuspension of the particles and to make the
suspension easier
to inject (i.e., low force on the syringe plunger); suitable viscosifiers or
viscosity
enhancers are, for example, carbomer viscosifiers like Carbopol 940, Carbopol
Ultrez
10, cellulose derivatives like hydroxypropylmethylcellulose (hypromellose,
HPMC) or
diethylaminoethyl cellulose (DEAE or DEAE-C), colloidal magnesium silicate
(Veegum) or sodium silicate, hydroxyapatite gel, tricalcium phosphate gel,
xanthans,
carrageenans like Satia gum UTC 30, aliphatic poly(hydroxy acids), such as
poly(D,L-
or L-lactic acid) (PLA) and poly(glycolic acid) (PGA) and their copolymers
(PLGA),
terpolymers of D,L-lactide, glycolide and caprolactone, poloxamers,
hydrophilic

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
237
poly(oxyethylene) blocks and hydrophobic poly(oxypropylene) blocks to make up
a
triblock of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) (e.g.
Pluronic ),
polyetherester copolymer, such as a polyethylene glycol
terephthalate/polybutylene
terephthalate copolymer, sucrose acetate isobutyrate (SAIB), dextran or
derivatives
thereof, combinations of dextrans and PEG, polydimethylsiloxane, collagen,
chitosan,
polyvinyl alcohol (PVA) and derivatives, polyalkylimides, poly (acrylamide-co-
diallyldimethyl ammonium (DADMA)), polyvinylpyrrolidone (PVP),
glycosaminoglycans (GAGs) such as dermatan sulfate, chondroitin sulfate,
keratan
sulfate, heparin, heparan sulfate, hyaluronan, ABA triblock or AB block
copolymers
composed of hydrophobic A-blocks, such as polylactide (PLA) or poly(lactide-co-

glycolide) (PLGA), and hydrophilic B-blocks, such as polyethylene glycol (PEG)
or
polyvinyl pyrrolidone; such block copolymers as well as the abovementioned
poloxamers may exhibit reverse thermal gelation behavior, meaning they are
fluid
state at room temperature to facilitate administration and gel state above sol-
gel
transition temperature at body temperature after injection;
(viii) Spreading or diffusing agent: modifies the permeability of connective
tissue through
the hydrolysis of components of the extracellular matrix in the intrastitial
space such
as but not limited to hyaluronic acid, a polysaccharide found in the
intercellular space
of connective tissue; a spreading agent such as but not limited to
hyaluronidase
temporarily decreases the viscosity of the extracellular matrix and promotes
diffusion
of injected drugs;
(ix) Anti-agglomeration agents, such as propylene glycol; and
(x) Other auxiliary agents: such as wetting agents, viscosity modifiers,
antibiotics; acids
and bases such as hydrochloric acid and sodium hydroxide are auxiliary agents
necessary for pH adjustment during manufacture.
In certain embodiments the conjugate or the pharmaceutically acceptable salt
thereof or the
pharmaceutical composition comprising said conjugate or its pharmaceutically
acceptable salt
of the first aspect of the present invention are for use in a method of
preventing an infection.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
238
In certain embodiments the conjugate or the pharmaceutically acceptable salt
thereof or the
pharmaceutical composition comprising said conjugate or its pharmaceutically
acceptable salt
of the first aspect are for use in a method of treating an infection.
In certain embodiments such infection is in a body compartment. Such body
compartment
may be selected from the group consisting of body cavities, body spaces, brain
or parts
thereof, ear or parts thereof, nose, throat, sinuses, lung or parts thereof,
abdomen, bone, skin,
muscle, abscess, small intestine, large intestine, cyst, uterus, amniotic sac
and joint.
Such body compartment may be any cavity of the human body, such as the oral
cavity, cranial
cavity, spinal cavity, dorsal cavity, thoracic cavity, pericardial cavity,
abdominal cavity,
ventral cavity, retroperitoneal space, abdominopelvic cavity, pelvic cavity
and its enclosed
organs.
In certain embodiments such body compartment is selected from the group
consisting of the
retropharyngeal space, retropalatial space, mediastinal space, retrosternal
space, pleural space,
retroperitoneal space, prevesical space, paravesical space, vesicocervical
space, rectovaginal
space, pararectal space, presacral space, subphrenic space, subhepatic space,
supramesocolic
space and inframesocolic space.
In certain embodiments the body compartment is the brain or one or more parts
of it. In
certain embodiments the body compartment is the ear or one or more parts of
it, such as the
middle ear. In certain embodiments the body compartment is the nose, throat,
and sinuses. In
certain embodiments the body compartment is the lung or parts of it. In
certain embodiments
the body compartment is the abdomen. In certain embodiments the body
compartment is
bone, such as the pelvis. In certain embodiments the body compartment is the
skin. In certain
embodiments the body compartment is muscles.In certain embodiments the body
compartment is an abscess. In certain embodiments the body compartment is the
small
intestine, such as the duodenum, ileum and jejunum. In certain embodiments the
body
compartment is the large intestine, such as the colon, appendix and rectum. In
certain
embodiments the body compartment is a cyst. In certain embodiments the body
compartment
is the uterus. In certain embodiments the body compartment is the amniotic
sac. In certain
embodiments the body compartment is a joint.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
239
The present invention also relates to the use of the sustained-release
compound of the second
or third aspect as a medicament, such as a medicament for the prevention or
treatment of joint
infections. In certain embodiments the present invention relates to the use of
the sustained-
release compound of the second ot third aspect as a medicament for the
prevention of joint
infections. In certain embodiments the present invention relates to the use of
the sustained-
release compound of the second or third aspect as a medicament for the
treatment of joint
infections.
The present invention further relates to the conjugate of the second and the
compound of the
third aspect of present invention for use in a method of preventing or
treating a joint infection.
In certain embodiments the present invention relates to the conjugate of the
second and the
compound of the third aspect of present invention for use in a method of
preventing a joint
infection. In certain embodiments the present invention relates to the
conjugate of the second
and the compound of the third aspect of present invention for use in a method
of treating a
joint infection.
If the infection is in a joint, the conjugate according to the first and
second aspect and the
compound of the third aspect of the present invention may be administered via
intraarticular
injection.
In certain embodiments the volume of such an intraarticular injection is no
more than 12 ml,
such as no more than 11 ml, such as no more than 10 ml or such as no more than
9 ml such as
no more than 8 ml.
The joint of a joint infection may in certain embodiments be a synovial joint.
Such synovial
joint may be selected from the group consisting of hinge joints and ball and
socket joints. In
certain embodiments the joint is a hinge joint. In certain embodiments the
joint is a ball and
socket joint.
Examples for a synovial joint are knee, hip, shoulder, elbow, foot, hand,
sternoclavicular joint
and vertebral articulations.
Examples for a joint of the knee are tibiofemoral joint and patellofemoral
joint.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
240
Examples for a joint of the shoulder are glenohumeral joint and
acromioclavicular joint.
Examples for a joint of the elbow are humero-ulnar joint, humero-radial joint
and radio-ulnar
joint.
It is understood that the term "joints of the foot" also covers joints of the
toes. Examples for a
joint of the foot are ankle, subtalar and talocalcaneal joint.
It is understood that the term "joints of the hand" also covers joints of the
fingers. Example
for a joint of the hand are wrist, intercarpal joint, midcarpal joint,
carpometacarpal joint and
metacarpophalangeal joint.
Examples for a vertebral articulation are zygapophyseal joints,
temporomandibular joints and
sacroiliac joints.
In certain embodiments the joint is selected from the group consisting of
knee, hip, shoulder,
elbow and ankle. In certain embodiments the joint is a knee. In certain
embodiments the joint
is a hip. In certain embodiments the joint is a shoulder.
In certain embodiments the joint infection is a joint infection related to a
surgical implant.
Examples for such surgical implant are pins, rods, screws, artificial joints,
mesh, clips,
sutures, wires, tubes, catheters, pumps, filters, prostheses, plates,
fasteners, washers, bolts,
seeds, beads, staples, nails, shunts, cuffs, buttons, ports, cement, fixators,
stents, fillers, wax,
wraps, weights, stimulators, anchors, expanders, guidewires, fillers,
polymers, film, fixators,
drains, lines and cones.
In certain embodiments the surgical implant is an artificial joint. In certain
embodiments the
surgical implant is a prosthesis.
In certain embodiments surgical implants are at least partially made from one
or more
material selected from the group consisting of metals, ceramics, natural
polymers, artificial
polymers, bone cement, foreign organic material, artificial tissue and natural
tissue. Such

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
241
natural tissue may be selected from the group consisting of ligament, skin,
muscle and bone.
In certain embodiments the natural tissue is bone.
In certain embodiments the conjugate or the pharmaceutically acceptable salt
thereof or the
pharmaceutical composition comprising said conjugate or its pharmaceutically
acceptable salt
of the first and second aspect or the compound of the third aspect are for use
in a method of
preventing a joint infection, in particular a surgical implant-related joint
infection. In such
case the conjugate or the pharmaceutically acceptable salt thereof or the
pharmaceutical
composition comprising said conjugate or its pharmaceutically acceptable salt
of the first or
second aspect or the compound of the third aspect may be administered to the
joint prior,
during or after the implantation of the surgical implant. In certain
embodiments it is
administered prior to the implantation a surgical implant. In certain
embodiments it is
administered during the implantation of a surgical implant. In certain
embodiments it is
administered after the implantation of a surgical implant, such as for example
no more than 1
hour after the implantation, no later than 2 hours after the implantation, no
later than 5 hours
after the implantation, no later than 10 hours after the implantation, no
later than 24 hours
after the implantation, no later than 48 hours after the implantation or no
later than 72 hours
after the implantation, no later than 96 hours after the implantation, no
later than a week after
the implantation, no later than two weeks after the implantation, no later
than three weeks
after the implantation, no later than four weeks after the implantation, no
later than six weeks
after the implantation or no later than eight weeks after the implantation. In
certain
embodiments it may be administered later than two months after the
implantation.
In certain embodiments the joint infection, in particular a joint infection
related to surgical
implants, comprises the presence of a biofilm in said infected joint, in
particular a biofilm on
at least one surface of the surgical implant. Such biofilm may comprise
organisms selected
from the group consisting of bacteria, mycobacteria and fungi. Accordingly, in
certain
embodiments the method of preventing or treating a joint infection also
comprises the
preventing of biofilm formation or the eradication of an existing biofilm.
In certain embodiments such biofilm comprises bacteria. Such bacteria may be
gram-positive
or gram-negative. They may be aerobic or anaerobic bacteria. In certain
embodiments the
biofilm comprises multiple different species. In certain embodiments the
biofilm comprises
one predominant species, to which at least 80%, such as at least 85%, at least
90%, at least

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
242
92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%,
of all bacteria
present in the biofilm belong.
Examples for gram-positive bacteria are Staphylococcus, Streptococcus,
Enterococcus,
Clostridium, Bacillus, Listeria and lactic acid bacteria, such as
Staphylococcus aureus,
Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus
pneumoniae,
Streptococcus pyo genes, Streptococcus agalactiae, Streptococcus dysgalactiae,
Streptococcus
viridans, Enterococcus faecalis, Enterococcus faecium, Clostridium tetani,
Clostridium
botulinum, Clostridium perfringes, Clostridium difficile, Bacillus anthracis,
Listeria
monocyto genes and Propionibacterium acnes.
Examples for gram-negative bacteria are Enterobacteriaceae, Vibrionaceae,
Pseudomonadaceae, Bacteroidaceae, Actinomyces, Neisseria, Hemophilus,
Bordetella,
Legionella, Treponema, Borrelia, Chlamydia, Rickettsia, Ehrlichia, Mycoplasma
and
Burkholderia, such as Salmonella species, Shigella dysenteriae, Klebsiella
pneumoniae,
Escherichia coli, Escherichia faecalis, Vibrio cholera, Campylobacter jejuni,
Pseudomonas
aeruginosa, Bacteroides fragilis, Neisseria meningitidis, Neisseria
gonorrhoeae,
Haemophilus influenza, Actinomyces isrealli, Mycoplasma pneumoniae,
Acinetobacter
baumanii, Citrobacter, Achromobacter and Stenotrophomonas.
In certain embodiments the biofilm comprises mycobacteria.
In certain embodiments the biofilm comprises fungi. Such fungi may be molds or
yeasts.
Examples for fungi are Candida, Aspergillus, Cryptococcus, Trichosporon,
Coccidioides, and
Pneumocystis, such as Candida albicans, Candida parapsilosis, Candida
tropicalis, Candida
parapsilosis, Candida glabrata; Aspergillus fumigatus, Coccioides immitis,
Coccioides
neoformans, Trichosporon asahii, and Pneumocystis carinii.
Preferably, administration of the sustained-release compounds of the present
invention occurs
via intraarticular injection into the infected joint. Accordingly,
administration occurs via
intraarticular injection into the joints described above.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
243
Intraarticular injection allows the administration of significantly lower
doses of the antibiotic
compared to, for example, systemic administration of the same drug, which
reduces the risks
of side effects.
In certain embodiment administration of the conjugates of the present
invention, their
pharmaceutically acceptable salts or the pharmaceutical composition comprising
said
conjugates or their pharmaceutically acceptable salts occurs via external
application, injection
or infusion, including intraarticular, periarticular, intradermal,
subcutaneous, intramuscular,
intravenous, intraosseous, intraperitoneal, intrathecal, intracapsular,
intraorbital, intravitreal,
intratympanic, intravesical, intracardiac, transtracheal, subcuticular,
subcapsular,
subarachnoid, intraspinal, intraventricular, intrasternal injection and
infusion, direct delivery
to the brain via an implanted device allowing delivery of the conjugates of
the present
invention to brain tissue or brain fluids such as via an Ommaya Reservoir,
direct
intracerebroventricular injection or infusion, injection or infusion into
brain or brain
associated regions, injection into the subchoroidal space, retro-orbital
injection and ocular
instillation.
In certain embodiment administration occurs at the infection site. In certain
embodiments
administration occurs close to the infection site.
In certain embodiments administration of the conjugates of the present
invention, their
pharmaceutically acceptable salts or the pharmaceutical composition comprising
said
conjugates or their pharmaceutically acceptable salts occurs via
intraarticular injection into
the infected joint. Accordingly, administration occurs via intraarticular
injection into the
joints described above.
Such localized administration of a depot in the form of the conjugates of the
present invention
at or close to the infection site allows the administration of significantly
lower doses of the
antibiotic compared to, for example, systemic administration of the same drug,
which reduces
the risks of side effects.
In a further aspect the present invention relates to a method of preventing or
treating a patient
suffering from an infection, such as an infection of a body compartment, such
as a joint
infection and in particular a joint infection related to a surgical implant,
comprising

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
244
administering an effective amount of the conjugate of the present invention,
the
pharmaceutically acceptable salt thereof or the pharmaceutical composition
comprising said
conjugate or its pharmaceutically acceptable salt to the patient. Embodiments
are as described
above.
In a further aspect the present invention relates to the use of the conjugate
of the present
invention, the pharmaceutically acceptable salt thereof or the pharmaceutical
composition
comprising said conjugate or its pharmaceutically acceptable salt for the
manufacture of a
medicament for the prevention or treatment of an infection, such as an
infection in a body
compartment, such as a joint infection and in particular a joint infection
related to a surgical
implant. Embodiments are as described above.
Examples
Materials and Methods
All materials were commercially available except where stated otherwise.
RP-HP LC purification:
For preparative RP-HPLC a Waters 600 controller and a 2487 Dual Absorbance
Detector was
used, equipped with the following column: Waters XBridgeTM BEH300 Prep C18 10
pm, 150
x 30 mm, flow rate 40 mL/min. Gradients of solvent system A (water containing
0.1% TFA
v/v) and solvent system B (acetonitrile containing 0.1% TFA v/v) were used.
Products were
detected at 215 nm. HPLC fractions containing product were pooled and
lyophilized if not
stated otherwise.
Flash Chromatography:
Flash chromatography purifications were performed on an Isolera One system or
an Isolera
Four system from Biotage AB, Sweden, using Biotage KP-Sil silica cartridges
and
CH2C12/Me0H, CH2C12/ACN, CH2C12/THF, n-heptane/ethyl acetate or n-
heptane/methyl
acetate as eluents. Products were detected at 215 nm, 254 nm or 280 nm.
RP-LPLC purification:
Low pressure RP chromatography purifications were performed on an Isolera One
system or
an Isolera Four system from Biotage AB, Sweden, using Biotage SNAP C18
cartridges.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
245
Gradients of solvent system A (water containing 0.1 % TFA v/v) and solvent
system B
(acetonitrile containing 0.1 % TFA v/v) were used. Products were detected at
215 nm. LPLC
fractions containing product were pooled and lyophilized if not stated
otherwise.
Analytical methods
UPLC-MS analysis:
Analytical ultra-performance LC (UPLC)-MS was performed on a Waters Acquity
system or
an Agilent 1290 Infinity II equipped with a Waters BEH300 C18 column (2.1 x 50
mm,
1.7 gm particle size or 2.1 x 100 mm, 1.7 gm particle size; solvent A: water
containing 0.04%
TFA (v/v), solvent B: acetonitrile containing 0.05% TFA (v/v) or solvent A:
water containing
0.1% FA (v/v), solvent B: acetonitrile containing 0.1% FA (v/v)) coupled to an
LTQ Orbitrap
Discovery mass spectrometer from Thermo Scientific or coupled to a Waters
Micromass ZQ
or coupled to Single Quad MS System from Agilent or coupled to an Agilent
Triple Quad
6460 system.
SEC analysis:
Size-exclusion chromatography (SEC) was performed on an Agilent 1260 system,
equipped
with a Sepax Zenix SEC-150 column (150 A, 7.8 x 300 mm; isocratic: 60:40 v/v
mixture of
water containing 0.05% TFA and acetonitrile containing 0.04% TFA) with
detection at 215
nm and 280 nm.
OPA assay for amine content determination:
Amine content of the amine-HA was determined by reacting the free amino groups
with o-
phthalaldehyde (OPA) and N-acetylcysteine under alkaline conditions and
photometric
quantification of the formed chromophores, as methodically described by Molnar-
Perl (Ed.)
(2015), Journal of Chromatography Library 70: 405-444.
Amine content determination on the PEG-hydrogel beads:
Amino group content of the PEG-hydrogel was determined by conjugation of an
Fmoc-amino
acid to the free amino groups on the hydrogel and subsequent Fmoc-
determination as
described by Gude, M., J. Ryf, et al. (2002) Letters in Peptide Science 9(4):
203-206.
Maleimide content determination on the PEG-hydrogel beads:

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
246
Maleimide group content of the PEG-hydrogel was determined by conjugation of
Fmoc-
cysteine to the maleimide residues on the hydrogel and subsequent Fmoc-
determination
following a procedure, which is based on Gude, M., Ryf, J. et al. (2002)
Letters in Peptide
Science 9(4): 203-206 and Smyth, D. G., Blumenfeld, 0. 0., Konigsberg, W.
(1964)
Biochemical Journal 91: 589.
Quantitative amino acid analysis (QAAA):
Quantitative amino acid analysis was performed to determine the amount of
daptomycin in a
sample matrix with unknown content. For the content determination, a material
sample
containing daptomycin was hydrolysed using a TFA/HC1 mixture and microwave
irradiation.
The resulting single amino acids was dye labelled and analysed
chromatographically. The
contents of aspartic acid, alanine and ornithine were calculated using
calibration curves of the
respective amino acid standards. The amount of daptomycin was calculated using
the
averaged content values of aspartic acid, alanine and ornithine.
Daptomycin content by UV measurement:
For determination of the daptomycin content of a transient daptomycin-linker
HA-hydrogel
conjugate, the sample is completely hydrolyzed under strongly alkaline
conditions and the
UV absorption of the resulting sample at 360 nm is used to calculate the
daptomycin content.
Hydrogel degradation kinetics:
A hydro gel sample was incubated with degradation buffer of the desired pH in
a water bath at
the desired temperature. For each sampling time-point, the reaction mixture
was
homogenized, centrifuged, supernatant was withdrawn, filtered through a
syringe filter and
.. transferred into a sterile Eppendorf tube. Samples were further incubated
at the same
temperature. At the end of the incubation time, all samples were quenched with
acetic acid,
and analysed chromatographically. The obtained peak areas of the individual
samples were
used to calculate degradation kinetics.
Example 1
Synthesis of linker reagent if
Linker reagent if was synthesized according to the following scheme:

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
247
Tmob 0 Oxynna P ure, EDCõ
0
N H H 0 OBn collidine
NNOBn
TmobFmoc'N 0
-
Fnrioc'N 0
1 a lb
0 DBU
Tmob 0 N o 6-(Trt-mercapto)-
OBn
hexanoic acid, PyBOP, /NN
Id DIPEA Tmob HN 0
1 c
Trt'S
LiOH
0
0 0
0 H
Tmob /0 lc] 0 Tmob/ON 0
0
EDC, NHS
1e If
T
Trt rt'S
To a solution of /V,N-dimethylethylenediamine (2.00 g, 22.69 mmol) and NaCNBH3
(1.35 g,
21.55 mmol) in Me0H (40 mL) was added 2,4,6-trimethoxybenzaldehyde (4.23 g,
21.55
mmol) over two hours. After complete addition, the mixture was stirred at r.t.
for 1 hour,
acidified with 1 M HCl (60 mL) and stirred for further 30 min. To the reaction
mixture
saturated NaHCO3 solution (70 mL) was added and the solution was extracted
with CH2C12
(5x 150 mL). The combined organic phases were dried over Na2SO4, filtered and
the solvents
were evaporated in vacuo. The resulting N,N-dimethyl-N'-Tmob-ethylenediamine
la was
dried in high vacuum and used in the next reaction step without further
purification.
To a solution of Fmoc-N-Me-Asp(OBn)-OH (4.63 g, 10.07 mmol) in CH2C12 (108 mL)
EDC
(2.51 g, 13.09 mmol), OxymaPure (2.00 g, 14.09 mmol) and 2,4,6-collidine
(2.53 mL,
2.32 g, 19.13 mmol) were added and the mixture was stirred for 5 min. A
solution of crude la

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
248
(3.00 g, max. 11.18 mmol) in CH2C12 (27 mL) was added and the solution was
stirred at r.t.
for 1 hour. The reaction was quenched by addition of 0.1 M HCl (300 mL) and
the acidified
mixture was extracted with CH2C12 (5x 40 mL). The combined organic layers were
washed
with saturated NaHCO3 solution (2x 90 mL). The organic phase was dried over
Na2SO4,
filtered and the solvent was evaporated in vacuo. Crude lb was purified by
flash
chromatography.
Yield: 5.31 g (7.48 mmol, 74% over two steps)
MS: m/z 710.23 = [M+Hr, (calculated monoisotopic mass: [M] =
709.34.)
To a solution of lb (5.31 g, 7.48 mmol) in THF (53 mL) DBU (1.31 mL, 1.33 g,
8.75 mmol)
was added and the solution was stirred at r.t. for 12 min. The reaction
mixture was submitted
to flash chromatography and le was isolated from the product fractions by
evaporation of the
solvents in vacuo.
Yield: 3.16 g (6.48 mmol, 87%)
MS: m/z 488.13 = [M+H]+, (calculated monoisotopic mass: [M] = 487.27.)
To a solution of le (3.16 g, 6.48 mmol), PyBOP (4.05 g, 7.78 mmol) and DIPEA
(3.39 mL,
2.51 g, 19.44 mmol) in CH2C12 (32 mL), a solution of 6-tritylmercaptohexanoic
acid (3.04 g,
7.78 mmol) in CH2C12 (32 mL) was added and the mixture was stirred for 24
hours.
Additional 6-tritylmercaptohexanoic acid (633 mg, 1.62 mmol) and PyBOP (843
mg, 1.62
mmol) were added and the mixture was stirred for additional 5 hours. After
dilution with
CH2C12 (600 mL), the organic layer was washed with 0.1 M HC1 (3x 300 mL) and
brine (300
mL), dried over Na2SO4, filtered and the solvent was evaporated in vacuo.
Crude ld was
purified by flash chromatography.
Yield: 5.06 g (5.88 mmol, 91%)
MS: m/z 860.45 = [M+Hr, (calculated monoisotopic mass: [M] =
859.42.)
To a solution of id in a mixture of THF (61 mL) and water (61 mL) LiOH (423
mg,
17.66 mmol) was added and the solution was stirred at r.t. for six hours.
After dilution with
CH2C12 (500 mL), the organic layer was washed with a mixture of 0.1 M
HC1/brine (1:1 v/v,
3x 300 mL). The aqueous layers were re-extracted with CH2C12 (5x 100 mL). The
combined
organic layers were washed with brine (200 mL), dried over Na2SO4, filtered
and the solvents
were evaporated in vacuo. Crude le was dried in high vacuum and used without
further
purification in the next step.

CA 03114056 2021-03-24
WO 2020/064844 PCT/EP2019/075877
249
To a solution of crude le (5.05 g, max. 6.56 mmol) in CH2C12 (60 mL), NHS
(1.13 g,
9.85 mmol) and EDC (1.89 g, 9.85 mmol) were added and the mixture was stirred
at r.t. for
130 min. After evaporation of the solvent in vacuo, the residue was dissolved
in a mixture of
MeCN/water/TFA (8:2:0.002 v/v, 10 mL) and the resulting solution was purified
by
automated RP-LPLC to yield pure if after lyophilization.
Yield: 4.15 g (4.52 mmol, 76%, 96% purity by UV215)
MS: m/z 867.44 = [M+Hr, (calculated monoisotopic mass: [M] =
866.39.)
Example 2
Synthesis of cross-linker reagent 2b
Cross-linker reagent 2b was synthesized according to the following scheme:
0 0
HO 1-1OOH DCC, DMAP
03 ' 110 )ip.
0 0
0
u 3
0 0 0 2a
1
1) Pd/C, H2
2) TSTU, DIPEA
0
0 0 0
I\C())C)0)W0)1R
- 3
0 0 0
0 2b
To a cooled solution of triethylene glycol (5.00 g, 33.29 mmol), glutaric acid
monobenzyl
ester (22.20 g, 99.88 mmol) and DMAP (0.20 g, 1.66 mmol) in CH2C12 (100 mL)
DCC (20.61
g, 99.88 mmol) was added and the mixture was stirred at 0 C for 5 min, then
at r.t. for
additional 30 min. After filtration, the filtrate was diluted with CH2C12 (500
mL) and the
organic layer was washed with a mixture of saturated NaHCO3 solution/water
(1:1 v/v, 2x
500 mL) and brine (250 mL). The organic phase was dried over MgSO4, filtrated
and all
volatiles were evaporated in vacuo. Crude 2a was purified by flash
chromatography.
Yield: 13.64 g (24.42 mmol, 73%)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
250
MS: m/z 559.08 = [M+Hr, (calculated monoisotopic mass: [M] =
558.25.)
To a solution of 2a (13.64 g, 24.42 mmol) in THF (55 mL) palladium on charcoal
(10% Pd,
1.04 g) was added and the mixture was stirred under a hydrogen gas atmosphere
at 50 C for
two hours. The reaction mixture was filtered through a pad of Celite 503,
which was flushed
with additional THF (50 mL). The combined filtrates were split in half and to
each solution
TSTU (14.70 g, 48.84 mmol) and DIPEA (8.51 mL, 6.31 g, 48.84 mmol) were added
and
both reaction mixtures were stirred at r.t. for 16 hours. Both reaction
mixtures were combined
and filtered through a glass filter funnel, which was flushed with additional
THF (50 mL).
After removal of all volatiles from the combined organic layers, the residue
was dissolved in
CH2C12 (500 mL). The solution was washed with 0.5 M phosphate buffer pH 7.4
(2x 500
mL), 0.5 M HC1 (3x 250 mL) and brine (2x 250 mL). The organic phase was dried
over
MgSO4, filtered and all volatiles were evaporated in vacuo. Crude 2b was
purified by flash
chromatography.
Yield: 10.79 g (18.84 mmol, 77%, 98% purity by UV215)
MS: m/z 573.00 = [M+Hr, (calculated monoisotopic mass: [M] =
572.19.)
Example 3
Synthesis of amine-HAs 3, 3' and 3"
Synthesis of compound 3 in 1 g scale
To a solution of hyaluronic acid sodium salt (90-130 kDa, 1.00 g, 2.49 mmol
COOH eqv.) in
100 mM MES 400 mM 1,3-diaminopropane buffer pH 5.5 (125 mL) HOBt x H20 (1.15
g,
7.48 mmol) was added. EDC (2.87 g, 14.96 mmol) was added to the mixture and it
was stirred
at r.t. overnight. Sodium acetate trihydrate (16.97 g) was added to the
reaction mixture and
the solution was partitioned between twelve 50 mL Falcon tubes. To each tube
absolute Et0H
(ad 50 mL) was added, the tubes were shaken and centrifuged. The supernatants
were
decanted, and the pellets were washed with 80% v/v Et0H (40 mL each tube) and
absolute
Et0H (40 mL each tube). The residues were dried in high vacuum for 50 min. The
crude
material was dissolved in water (80 mL) and 4 M NaOH (26.67 mL) was added. The
resulting
mixture was stirred at r.t. for two hours before AcOH (6.10 mL) was added
while stirring. The
solution was partitioned between ten 50 mL Falcon tubes. To each tube absolute
Et0H (ad 50
mL) was added, the tubes were shaken and centrifuged. The supernatants were
decanted, and
the pellets were washed with 80% v/v Et0H (40 mL each tube) and absolute Et0H
(40 mL
each tube). The residues were dried in high vacuum overnight. The obtained
material was

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
251
dissolved in 10% TFA (w/w) in water (50 mL). The solution was partitioned
between ten 50
mL Falcon tubes. To each tube isopropanol (ad 50 mL) was added, the tubes were
shaken and
centrifuged. The supernatants were decanted, and the pellets were washed with
isopropanol
(40 mL each tube) and dried in high vacuum overnight to yield amine-HA 3 as
white solid.
The amine content of the material was determined by photometric measurement
after
chemical derivatization (OPA-assay).
Yield: 1.09 g (TFA salt, 87%, amine-content: 1.422 mmol/g, 71% DS)
Synthesis of compound 3' in 2 g scale
To a solution of hyaluronic acid sodium salt (90-130 kDa, 2.00 g, 4.99 mmol
COOH eqv.) in
100 mM MES 400 mM 1,3-diaminopropane buffer pH 5.5 (250 mL) HOBt x H20 (2.29
g,
14.96 mmol) was added. EDC (5.74 g, 29.93 mmol) was added to the mixture and
it was
stirred at r.t. overnight. Sodium acetate trihydrate (33.94 g) was added to
the reaction mixture
and the solution was partitioned between twenty-eight 50 mL Falcon tubes. To
each tube
absolute Et0H (ad 50 mL) was added, the tubes were shaken and centrifuged. The

supernatants were decanted, and the pellets were washed with 80% v/v Et0H (40
mL each
tube) and absolute Et0H (40 mL each tube). The residues were dried in high
vacuum for 60
min. The crude material was dissolved in water (160 mL) and 4 M NaOH (53.34
mL) was
added. The resulting mixture was stirred at r.t. for two hours before AcOH
(12.20 mL) was
added while stirring. The solution was partitioned between twenty-two 50 mL
Falcon tubes.
To each tube absolute Et0H (ad 50 mL) was added, the tubes were shaken and
centrifuged.
The supernatants were decanted, and the pellets were washed with 80% v/v Et0H
(40 mL
each tube) and absolute Et0H (40 mL each tube). The residues were dried in
high vacuum
overnight. 1.92 g of the obtained material were dissolved in 10% TFA (w/w) in
water (96.6
mL). The solution was partitioned between eighteen 50 mL Falcon tubes. To each
tube
isopropanol (ad 50 mL) was added, the tubes were shaken and centrifuged. The
supernatants
were decanted, and the pellets were washed with isopropanol (40 mL each tube)
and dried in
high vacuum for 65 hours to yield amine-HA 3". The amine content of the
material was
determined by photometric measurement after chemical derivatization (OPA-
assay).
Yield: 2.13 g (TFA salt, 86, amine-content: 1.400 mmol/g, 70% DS)
Synthesis of compound 3" in 2 g scale

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
252
The synthesis of amine-HA 3" was carried out as described for compound 3' to
yield
compound 3" as white solid. The amine content of the material was determined
by
photometric measurement after chemical derivatization (OPA-assay).
Yield: 2.06 g (TFA
salt, 83, amine-content: 1.413 mmol/g, 71% DS)
Example 4
Synthesis of daptomycin linker thiol 4b
Daptomycin linker thiol 4b was synthesized according to the following scheme:
H2N
N
/ \1-
10
V CONH2 ONH H I-1h ------
-----
0 0 2C H- HN
1 )1 HO C 0
2 .,µ,õ==
H 1 1 H
N H 0 --C 02 H 0 0 HO NH
0 j
I 1 H
0
0 Fi9N N0
I I H
lf, DIPEA I = 0
N H2 H 0 0
Tmob I
\NN
I
S
I
0 0
HN
H 11 [\-11 1 1
, N
/ r I Fr \ii
V CONH2 ONH --z---
-0
0 0 1-1B2C- H
1 NH 1 H 02 C
. 0
NI N
H ' H
N H 0 0 0 HO NH
II CO2 H 0 0 j
11
N0 NA
4a
H H
0
0 0
NH 2 HOO

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
253
HF IP, TES, TFA 1
I
HNN
I
Nõ )
HS
I ' 0
0 0
HN
/ II
V CONH2 ONH H
HN/-:-----
0 0 HIB2C H 0-
II H I
NNN HO2C.,,,,õ. =-0
H II H
N H 0 I --CO2H 0 HO N H 0
a
I H
0 N
N0
4b N9(
H II H
0
0 0
N H2 HOz0
To a mixture of daptomycin (1.08 g, approx. 0.63 mmol) and if (0.99 g, 1.01
mmol) in
DMSO (38 mL) DIPEA (0.97 mL, 0.72 g, 5.69 mmol) was added and it was stirred
for 380
min. After quenching with TFA (0.44 mL, 0.66 g, 5.69 mmol), the mixture was
added to
MTBE in 50 mL Falcon tubes (1 mL solution and 40 mL MTBE per tube) to
precipitate the
conjugate. The tubes were shaken and centrifuged. After decanting the
supernatants, the
residues were combined and dried in high vacuum overnight. Crude 4a was used
for the next
step without further purification.
Crude 4a (2.50 g, max. 0.63 mmol) was dissolved in a mixture of HFIP/TES (39:1
v/v, 57
mL) and the solution was stirred at r.t. for 5 min. TFA (4.01 mL) was added
and the reaction
mixture was stirred at r.t. for two hours. All volatiles were removed in vacuo
and the residue
was dissolved in a mixture of DCM/TFA (98:2 v/v, 3.0 mL). The solution was
added to
MTBE in 50 mL Falcon tubes (1 mL solution and 40 mL MTBE per tube) to
precipitate the
material. The tubes were shaken and centrifuged. After decanting the
supernatants, the
combined residues were dried in high vacuum overnight. Crude 4b was purified
by RP-LPLC
to afford pure and mixed product fractions. Pure product fractions were
lyophilized to afford a
first crop of pure linker thiol. The mixed fractions were additionally
purified by preparative

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
254
RP-HPLC to afford a second crop of pure linker thiol. Both product batches
were combined to
afford pure 4b.
Yield: 1.00 g (0.46 mmol, 72%, 99% purity at 215 nm)
MS: m/z 975.92 = [M+2H]2+, (calculated monoisotopic mass: [M] =
1948.89.)
Example 5
Synthesis of transient daptomycin-linker HA-hydrogel conjugates 5, 5', 5a, 5b,
5c and 5d
Synthesis of 5 (molar ratio of amines/maleimides/thiols/cross-linker =
1.3:1:1:0.3)
All reagent solutions in DMSO were separately filtered through sterile 0.22
1,1m PTFE syringe
filters before the actual hydrogel conjugate synthesis.
A solution of 3" in DMSO (50 mg/mL, 13.00 mL) was mixed with a solution of 4b
in DMSO
(200 mg/mL, 7.70 mL), a solution of N-succinimidyl 3-maleimidopropionate in
DMSO (50
mg/mL, 3.76 mL) and a solution of 2b in DMSO (50 mg/mL, 1.21 mL) in a 50 mL
Falcon
tube. The yellow solution was drawn into a 30 mL Luer Lock syringe. DIPEA
(1.20 mL) was
added to the mixture in the 30 mL syringe through the syringe tip, the syringe
was closed with
a sterile screw cap and vigorously shaken for 30 seconds. An 18G blunt cannula
was mounted
onto the syringe and the solidifying reaction mixture was transferred into
three 10 mL Luer
Lock syringes. Due to the increasing viscosity of the mixture, the 18G blunt
cannula was
exchanged for a 14G cannula after filling the first syringe. The three 10 mL
Luer Lock
syringes were closed with sterile caps and stored at r.t., in the dark
overnight. The gel portions
in the syringes were shred into particles by passing them through two
stainless steel mesh
plates (144 tim mesh size, 3.7 mm diameter) in row, which were fixed with PTFE
0-rings in
three LL connectors that were mounted on the syringes. The particulate gel
portions were
directly injected into three portions of Et0H/AcOH (98:2 v/v, 3x 35 mL) in 50
mL Falcon
tubes. The tubes were vigorously shaken until free-floating particle
suspension were obtained.
After a short settling time, the slightly turbid supernatants were removed
from the dense
particle suspensions. The solid conjugate was collected in two 20 mL syringe
reactors and
was washed with Et0H/AcOH (98:2 v/v, 5x 10 mL each) and absolute Et0H (5x 10
mL
each). After expelling the liquids completely from the suspensions, two
sterile 0.22 1,1m PTFE
syringe filters were attached and the materials were dried in high vacuum at
r.t. overnight to
yield 1642 mg intermediate 1 as yellow powder.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
255
Intermediate 1 (1642 mg) was briefly soaked in 20 mM histidine, 100 mM CaCl2,
2% Tween
80 buffer pH 6.0 (39.4 mL) in a sterile plastic bottle by gentle swirling. To
the pre-swollen
suspension, DMSO (200 mL) was added. After complete addition, the bottle was
vigorously
shaken, and the gel suspension was transferred into six Falcon tubes. After
gentle
centrifugation, the clear supernatants were removed. To each tube DMSO (20 mL
per tube)
was added, the tubes were shaken and centrifuged again gently. After removal
of the clear
supernatants, DMSO (4 mL per tube) was added and the tubes were gently
agitated to afford
homogeneous suspensions. The combined suspensions were injected in six
portions though a
25G nanoneedle (Japan Bio Products Co., Ltd.) into 2% v/v AcOH and 1% v/v
Tween 80 in
absolute Et0H (6x 35 mL) in six 50 mL Falcon tubes. The injected suspensions
were
distributed between twelve 50 mL Falcon tubes in 25 mL portions. To the tubes
2% v/v
AcOH and 1% v/v Tween 80 in absolute Et0H (25 mL per tube) was added. The
tubes were
vigorously shaken and left standing shortly. The slightly turbid supernatants
were removed
from the dense suspensions and the latter were combined in two 20 mL syringe
reactors. The
solids were washed with 2% v/v AcOH and 1% v/v Tween 80 in absolute Et0H (5x
10 mL
per syringe) and 2% v/v AcOH in absolute Et0H (5x 10 mL per syringe). After
expelling the
liquids completely from the suspensions without pressing the particles
together, two sterile
0.22 gm PTFE syringe filters were attached to the syringe reactors and the
materials were
dried in high vacuum at r.t. overnight to yield 1626 mg intermediate 2 as
yellow granules.
Intermediate 2 (1626 mg) was soaked in 20 mM histidine, 10% a,a-trehalose,
0.2% 1 MDa
native hyaluronic acid, 10% propylene glycol, 2% Tween 80 pH 6.0 (13.17 mL)
in two equal
portions in 50 mL Falcon tubes for 15 minutes. DMSO (40 mL per tube) was added
and the
tubes were shaken vigorously for approximately four hours. After dilution with
additional
DMSO (20 mL), the combined suspensions were subsequently injected through a 14
G and a
25G nanoneedle (Japan Bio Products Co., Ltd.) into absolute Et0H (10x 35 mL)
in equal
portions in ten 50 mL Falcon tubes. The tubes with the injected suspensions
were vigorously
shaken and left standing for sedimentation. The clear supernatants were
removed from the
dense suspensions and the latter were combined in a 20 mL syringe reactor. The
solid was
washed with absolute Et0H (10x 10 mL). After expelling the liquid completely
from the
suspension without pressing the particles together, a sterile 0.22 p.m PTFE
syringe filter was
attached to the syringe reactor and the material was dried in high vacuum at
r.t. overnight to
yield 1174 mg conjugate 5 as fine, yellow powder. The daptomycin content of 5
was
determined by QAAA.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
256
Yield: 1174 mg (51%, daptomycin content: 459 mg/g)
Synthesis of 5' (molar ratio of amines/maleimides/thiols/cross-linker =
1.3:1:1:0.3)
The synthesis of 5' was carried out as described for compound 5, using a
solution of 3' in
DMSO (50 mg/mL, 13.00 mL), a solution of 4b in DMSO (200 mg/mL, 7.62 mL), a
solution
of N-succinimidyl 3-maleimidopropionate in DMSO (50 mg/mL, 3.73 mL), a
solution of 2b
in DMSO (50 mg/mL, 1.20 mL) and DIPEA (1.21 mL) to give compound 5' as fine,
yellow
powder. The daptomycin content of 5' was determined by UV measurement after
total
hydrolysis.
Yield: 1262 mg (55%, daptomycin content: 483 mg/g)
Synthesis of 5a (molar ratio of amines/maleimides/thiols/cross-linker =
1.3:1:1:0.3)
A solution of 3 in DMSO (50 mg/mL, 2499 gL) was mixed with a solution of 4b in
DMSO
(200 mg/mL, 1490 gL), a solution of N-succinimidyl 3-maleimidopropionate in
DMSO (50
mg/mL, 728 gL) and a solution of 2b in DMSO (50 mg/mL, 235 gL) in a 50 mL
Falcon tube.
To test the mixture for filterability, an aliquot of approx. 1.2 mL was passed
through a sterile
0.22 gm PTFE syringe filter. The filtrate was combined with the remaining
portion of the
solution and the mixture was drawn into a 10 mL syringe. DIPEA (240 gL) was
added to the
solution, the syringe was closed and vigorously shaken for 30 seconds. The
syringe with the
reaction mixture was stored at r.t. in the dark overnight. The gel in the
syringe was shred into
particles by passing it through two stainless steel mesh plates (144 gm mesh
size, 3.7 mm
diameter) in row, which were fixed with PTFE 0-rings in three LL connectors
that were
mounted on the syringe. The particulate gel was directly injected into a
portion of
Et0H/AcOH (98:2 v/v, 40 mL) in a 50 mL Falcon tube. The syringe and the
shredding line
were flushed with a small portion of Et0H/Ac0H (98:2 v/v, 4 mL) and the
washing liquid
was combined with the suspension in the Falcon tube. The tube was vigorously
shaken until a
free-floating particle suspension was obtained. The suspension was transferred
into a 10 mL
syringe reactor with PP frit in portions until the whole material was present
in the syringe
reactor. The particles were washed with Et0H/Ac0H (98:2 v/v, 15x 8 mL). After
expelling
all liquids, hydrogel 5a was dried in high vacuum for 8 hours. The daptomycin
content of 5a
was determined by QAAA.
Yield: 301 mg (68%, daptomycin content: 489 mg/g)
Synthesis of 5b (molar ratio of amines/maleimides/thiols/cross-linker =
1.02:1:1:0.02)

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
257
A solution of 3 in DMSO (50 mg/mL, 240 !IL) was mixed with a solution of 4b in
DMSO
(200 mg/mL, 182 4), a solution of N-succinimidyl 3-maleimidopropionate in DMSO
(50
mg/mL, 89.1 L) and a solution of 2b in DMSO (50 mg/mL, 1.9 L) in a 2 mL
Eppendorf
tube. DIPEA (26.4 !IL) was added to the solution, the tube was shaken,
centrifuged and left
standing at r.t. in the dark for gelation overnight. The gel was transferred
into a 2 mL LL
syringe and passed through two stainless steel mesh plates (144 tim mesh size,
3.7 mm
diameter) in row, which were fixed with PTFE 0-rings in three LL connectors
that were
mounted on the syringe. The particulate gel was directly injected into a
portion of
Et0H/AcOH (98:2 v/v, 10 mL) in a 15 mL Falcon tube. The syringe and the
shredding line
were flushed with a small portion of Et0H/Ac0H (98:2 v/v, 2 mL) and the
washing liquid
was combined with the suspension in the Falcon tube. The tube was vigorously
shaken until a
free-floating particle suspension was obtained, then centrifuged. After
decanting the
supernatant, the particles were suspended in Et0H/AcOH (98:2 v/v, 10 mL) and
transferred
into a 10 mL syringe reactor with PP frit in portions until the whole material
was present in
the syringe reactor. The particles were washed with Et0H/AcOH (98:2 v/v, 5x 8
mL). After
expelling all liquids, hydrogel 5b was dried in high vacuum overnight. The
daptomycin
content of 5b was determined by QAAA.
Yield: 40 mg (81%, daptomycin content: 570 mg/g)
Synthesis of 5c (molar ratio of amines/maleimides/thiols/cross-linker = 1.05 :
1: 1:0.05)
A solution of 3 in DMSO (50 mg/mL, 240 !IL) was mixed with a solution of 4b in
DMSO
(200 mg/mL, 177 1,1L), a solution of N-succinimidyl 3-maleimidopropionate in
DMSO (50
mg/mL, 86.5 L) and a solution of 2b in DMSO (50 mg/mL, 4.7 L) in a 2 mL
Eppendorf
tube. DIPEA (25.9 L) was added to the solution, the tube was shaken,
centrifuged and left
standing at r.t. in the dark for gelation overnight. Work-up was carried out
as described for
compound 5b. The daptomycin content of 5c was determined by QAAA.
Yield: 40 mg (83%, daptomycin content: 564 mg/g)
Synthesis of 5d (molar ratio of ratio amines/maleimides/thiols/cross-linker =
1.1: 1: 1:0.1)
A solution of 3 in DMSO (50 mg/mL, 240 !IL) was mixed with a solution of 4b in
DMSO
(200 mg/mL, 168.9 4), a solution of N-succinimidyl 3-maleimidopropionate in
DMSO (50
mg/mL, 82.6 L) and a solution of 2b in DMSO (50 mg/mL, 8.9 L) in a 2 mL
Eppendorf
tube. DIPEA (25.2 !IL) was added to the solution, the tube was shaken,
centrifuged and left

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
258
standing at r.t. in the dark for gelation overnight. Work-up was carried out
as described for
compound 5b. The daptomycin content of 5d was determined by QAAA.
Yield: 37 mg (80%, daptomycin content: 476 mg/g)
Example 6
Synthesis of cross-linker reagent 6d
Cross-linker reagent 6d was synthesized according to the following scheme.
Theoretical
calculations of the Mw of the polydisperse PEG conjugates were exemplarily
performed for a
PEG 1000 with 23 ethylene glycol units that has a Mw of 1031.22 g/mol (exact
mass: 1030.61
g/mol):
0 0 DCC, 0 0
HO AP
H Bn0)1"------31"0 H DM
BnOOOH
6a
glutaric acid anhydride, 0 0
DIPEA, DMAP 0
BnO H)U.L"(3)-r-
r-3 - 3 Li
6b 0 0
PEG 1000,
DCC, DMAP
0 0 0 0
0
OBn
- 3 Li 3 'PEG 3
0 0 0 0 6c
1) Pd/C, H2
2) TSTU, DIPEA
0 0
0 0 0 0
cs-I(00o
'PEG 3
0 0 0 0 0 6d
0
Glutaric acid monobenzyl ester (40.0 g, 180 mmol), ethylene glycol (101 mL,
1.80 mol) and
DMAP (2.20 g; 18.0 mmol) were dissolved in CH2C12 (400 mL). DCC (44.6 g, 216
mmol)
was added to the solution, and the mixture was stirred at room temperature for
one hour. The
reaction mixture was filtered and the filter cake was washed with additional
CH2C12 (50 mL).
The filtrate was washed with 0.1 N hydrochloric acid (2x 250 mL) and brine (1x
250 mL).
The organic phase was dried over MgSO4, filtered and all volatiles were
evaporated in vacuo.
The residue was purified by flash chromatography to afford intermediate 6a.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
259
Yield: 41.9 g (157 mmol, 87%)
MS: m/z 267.00 = [M+H]+, (calculated monoisotopic mass: [M] =
266.16.)
Intermediate 6a (41.0 g, 154 mmol), glutaric acid anhydride (31.6 g, 277 mmol)
and DMAP
(3.76 g, 30.8 mmol) were dissolved in CH2C12 (164 mL). DIPEA, (53.8 mL, 308
mmol) was
added and the mixture was stirred at r.t. for two hours. The mixture was
washed with 1 M
hydrochloric acid (lx 400 mL, lx 200 mL) and brine (200 mL). The organic phase
was dried
over MgSO4, filtered and all volatiles were evaporated in vacuo. The residue
was purified by
flash chromatography to afford intermediate 6b.
Yield: 34.9 g (91.7 mmol, 60%)
MS: m/z 381.05 = [M+H]+, (calculated monoisotopic mass: [M] =
380.15.)
Poly(ethylene glycol) (PEG 1000, 19.0 g), intermediate 6b (25.3 g, 66.5 mmol)
and DMAP
(116 mg, 0.95 mmol) were dissolved in CH2C12 (95 mL). DCC (13.7 g, 66.50 mmol)
was
added at 0 C and the mixture was afterwards stirred at r.t. for 16 hours. The
mixture was
diluted with MTBE (95 mL), filtered and all volatiles of the filtrate were
evaporated in vacuo.
The residue was dissolved in CH2C12 (120 mL) and the solution was diluted with
MTBE
(1800 mL) and n-heptane (100 mL) and split in two halves. The mixtures were
cooled to -20
C for 20 h. The supernatants were decanted and the precipitates suspended in a
-20 C cold
mixture of MTBE/n-heptane (9:1 v/v, 2x approx. 900 mL). The mixtures were
stored at -20
C for one hour before supernatants were decanted. The precipitates were again
suspended in
a -20 C cold mixture of MTBE/n-heptane (9:1 v/v, 2x approx. 900 mL) and the
resulting
suspensions were combined and filtered. The filter cake was washed with a -20
C cold
mixture of MTBE/n-heptane (9:1 v/v, 500 mL) and was afterwards dried in high
vacuum to
afford pure intermediate 6c.
Yield: 28.2 g
MS: m/z 878.33 = [M+21-1]2 , (calculated monoisotopic mass: [M] =
1754.89.)
Compound 6c (28.1 g, 16.0 mmol) was dissolved in THF (281 mL) and palladium on
charcoal
(10% Pd, 0.68 g) was added. The reaction mixture was stirred at 50 C under a
hydrogen
atmosphere for one hour. The mixture was filtered through a pad of Celite 503,
which was
flushed with additional THF (50 mL). To the combined filtrates, TSTU (19.3 g,
64.0 mmol)
and DIPEA (11.2 mL, 64.0 mmol) were added and the reaction mixture was stirred
at r.t. for
three hours. The mixture was filtered and the filter cake was washed with THF
(50 mL). All

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
260
volatiles were removed from the combined filtrates in vacuo and the residue
was dissolved in
CH2C12 (1200 mL). The solution was washed with 0.5 M phosphate buffer pH 7.4
(2x 600
mL) and brine (2x 200 mL) and was afterwards dried over MgSO4. After
filtration, all
volatiles were removed in vacuo to afford crude NHS ester. The crude material
was dissolved
in toluene (1000 mL) and the solution was split in two halves. To each portion
MTBE (450
mL) was added and the resulting mixtures were stored at -20 C overnight. The
supernatants
were decanted and the solids were collected by filtration and washed with -20
C cold MTBE
(500 mL). The filter residue was transferred into a 100 mL flask and dried for
4 h in high
vacuum. The residue was dissolved in CH2C12 (600 mL) and the solution was
split in three
portions. To each portion MTBE (800 mL) was added and the resulting mixtures
were stored
at -20 C overnight. The supernatants were decanted from the precipitated oils
and all
volatiles were removed. The residues were combined with the precipitated oils
and the
combined crude material was dissolved in THF (1200 mL) and the solution was
split in four
portions. To each portion MTBE (700 mL) was added and the resulting mixtures
were stored
at -25 C overnight. The supernatants were decanted and the solids were
collected by
filtration and washed with -20 C cold MTBE (1000 mL). Pure cross-linker
reagent 6d was
obtained after drying in high vacuum.
Yield: 17.5 g
MS: m/z 885.25 = [M+2H]2 , (calculated monoisotopic mass: [M] =
1768.83.)
Example 7
Synthesis of backbone reagent 7
Backbone reagent 7 was synthesized as HC1 salt using L-lysine building blocks,
analogously
to an earlier described procedure (W02013/053856, example 1, compound lg
therein):

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
261
H H 2
HNO
H 2
H
H
CO0TN

0
H 0
N H 2 * 8 HCI
O=
n ¨ 28
0õN H NH2
H 2Nj1\1- H
H
N H 2
7
N H 2
4
Example 8
Synthesis of PEG-hydrogel beads 8a, 8b, and 8c containing free amino groups
The weights of the PEG-hydrogel beads 8a, 8b and 8c were estimated by the
volume of the
aqueous hydrogel bead suspensions, calculating with 1 g of the dry PEG-
hydrogel beads 8a,
8b or 8c swelling to a volume of approx. 20 mL under aqueous conditions. All
liquids,
solvents and reagent solutions were filtered through 0.2 1,1m PES filters (for
aqueous
solutions) or 0.2 p.m PTFE filters (all others) before use.
A cylindrical 250 mL reactor with bottom outlet, diameter 60 mm, equipped with
baffles, was
charged with an emulsion of CithrolTM DPHS (0.25 g) in heptane (75 mL). The
reactor
content was stirred with a pitch-blade stirrer, diameter 45 mm, at 520 rpm, at
r.t.. A solution
of cross-linker 6d (3129 mg) and backbone reagent 7 (2600 mg) in DMSO (22.92
g) was
added to the reactor and stirred for 10 min to form an emulsion. TMEDA (11.6
mL) was
added to effect polymerization and the mixture was stirred at r.t. for 16 h.
Acetic acid
(17.8 mL) was added while stirring. After 10 min, a sodium chloride solution
(15 wt%,
90 mL) was added under stirring. After 10 min, the stirrer was stopped and
phases were
allowed to separate. After 30 min, the aqueous phase containing the PEG-
hydrogel beads was
drained.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
262
For bead size fractionation, the water-hydrogel suspension was diluted with
ethanol (40 mL)
and wet-sieved on 125, 100, 75, 63, and 50 m (mesh opening) stainless steel
sieves, diameter
200 mm using a sieving machine for 15 min. Sieving amplitude was 1.5 mm,
liquid flow was
300 mL/min. First, a sodium chloride solution (20 wt%, 3000 mL), then water
(1000 mL) was
used as the liquid for wet-sieving. The bead fractions on the different sieves
were transferred
into 50 mL Falcon tubes (max. 14 mL bead suspension per tube) and successively
washed
with AcOH (0.1% v/v, 3x ¨40 mL) and ethanol (5-7x ¨40 mL) by addition,
shaking,
centrifugation and decantation. The bead fractions were transferred into 20 mL
syringes with
.. PE frits (max. z600 mg hydrogel beads per syringe) and dried in high vacuum
for 16 hours to
yield amine hydrogels 8a, 8b and 8c. The amine content of the hydrogels was
determined for
bead fraction 8a, representatively for all batches, by conjugation of an Fmoc-
amino acid to
the free amino groups on the hydrogel and subsequent Fmoc determination.
Yields: 8a (63 p.m sieve fraction): 125 mg
8b (75 p.m sieve fraction): 600 mg
8c (100 gm sieve fraction): 1400 mg
Amine content: 0.877 mmol/g
Example 9
.. Synthesis of transient daptomycin-linker PEG-hydrogel conjugate 9b
Amine hydrogel beads 8c (approx. 600 mg) were placed into a 20 mL syringe
reactor with PE
frit. The beads were washed with NMP (3x 12 mL) and NMP/DIPEA (98:2 v/v, 2x 12
mL)
and all solvents were expelled afterwards. N-succinimidyl 3-
maleimidopropionate (416 mg,
1.56 mmol) was dissolved in NMP (7.2 mL) and the resulting solution was drawn
to the
.. hydrogel in the syringe reactor. The suspension was allowed to incubate for
two hours at r.t.
under gentle agitation. The liquids were expelled and the hydrogel beads were
washed with
NMP (5x 12 mL), AcOH (0.1% v/v, 5x 12 mL) and ethanol (5x 12 mL). Maleimide
hydrogel
9a was obtained by drying in high vacuum for 5 days. The maleimide content of
the
functionalized PEG-hydrogel beads 9a was determined by conjugation of Fmoc-
cysteine to
the maleimide residues on the hydrogel and subsequent Fmoc determination.
Yield: not determined
Maleimide content: 0.7166 mmol/g

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
263
A suspension of the maleimide functionalized hydrogel beads 9a (346 mg, 0.248
mmol
maleimides) in buffer (100 mM succinate, 0.05% Tween 20, pH 5.5, 15.0 mL) in a
50 mL
Falcon tube was agitated for 5 min and then centrifuged. A part of the
supernatant (approx. 11
mL) was discarded and a solution of daptomycin linker thiol 4b (820 mg, 0.376
mmol) in
buffer (100 mM succinate, 0.05% Tween 20, pH 5.5, 32.8 mL) was added to the
hydrogel
suspension. The tube was agitated at r.t. and protected from light for 22
hours. The tube was
centrifuged and the supernatant was partially removed to leave approx. 2 mL
supernatant
above the dense bead suspension. The beads were transferred into a 20 ml
syringe reactor
with a PE fit. The hydrogel beads were successively washed with buffer (100 mM
succinate,
0.05% Tween 20, pH 5.5, 10x 10 mL), AcOH (0.1% v/v, 10x 10 mL), NMP/AcOH (97:3
v/v,
10x 10 mL) and ethanol (10x 10 mL). The transient daptomycin-linker PEG-
hydrogel
conjugate 9b was obtained after drying in high vacuum overnight. The
daptomycin content of
9b was determined by QAAA.
Yield: 821 mg (99%, daptomycin content: 470.1 mg/g)
Example 10
Linker release kinetics for transient daptomycin-linker hydrogel conjugates
The linker kinetics with respect to the daptomycin species release from
transient daptomycin-
linker hydrogel conjugates were investigated by incubation of transient
daptomycin-linker
HA-conjugate 5 and transient daptomycin-linker PEG-conjugate 9b at pH 7.4 and
37 C.
Daptomycin is prone to hydrolytic degradation and some minor different
degradation
pathways upon aqueous incubation. For determination of the linker kinetics on
the carriers,
the supernatants of the incubated suspensions were analyzed by UPLC at 215 nm
and all
daptomycin-related peaks were taken into account for the calculation of the
linker kinetics.
The half-lifes of the linker with respect to daptomycin species release have
been determined
to be two weeks for the transient daptomycin-linker PEG-hydrogel conjugate 9b
and eleven
days for the transient daptomycin-linker HA-conjugate 5.
Example 11
Stability of daptomycin in transient daptomycin-linker hydrogel conjugates
The relative stability of the covalently bound daptomycin in the transient
daptomycin-linker
hydrogel conjugates towards hydrolytic and other degradation pathways in
comparison to free
daptomycin was investigated. For that purpose, free daptomycin, transient
daptomycin-linker
HA-conjugate 5 and transient daptomycin-linker PEG-conjugate 9b were incubated
at pH 7.4

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
264
and 37 C. The supernatants of the carrier samples were exchanged five times
within a week
and the daptomycin purity in these samples was analyzed by UPLC. In parallel,
analytical
samples of the free daptomycin control solution were also analyzed by UPLC at
the same
incubation times. The purity of daptomycin in the samples was calculated as
the ratio of the
peak area of the intact daptomycin peak at 215 nm relative to the area sum of
all daptomycin-
related peaks identified at 215 nm. It was found that within the first 7 days
of incubation
under physiological conditions, the purity of the daptomycin, which was
continuously
released from transient daptomycin-linker hydrogel conjugates was constantly
at around 85%,
whereas the purity of the free daptomycin in the solution control sample
dropped to 72% at
day seven.
Example 12
Degradation study of transient daptomycin-linker hydrogel conjugates
The transient daptomycin-linker hydrogel conjugates were analyzed regarding
carrier
degradation. For that purpose, transient daptomycin-linker HA-conjugates 5,
5b, 5c, 5d and
transient daptomycin-linker PEG-conjugate 9b were incubated at pH 7.4 and 37
C. The
samples were visually checked for the presence of the solid carrier particles
daily. As soon as
no particles could be detected in the sample anymore, the material was deemed
to be fully
degraded to soluble products. It was found that the transient daptomycin-
linker PEG-hydrogel
conjugate 9b was fully degraded after about 40 days and the transient
daptomycin-linker HA-
hydrogel conjugate 5 was fully degraded after about 55 days. The less cross-
linked, transient
daptomycin-linker HA-conjugates 5b and 5c were fully degraded after about 36
days and
conjugate 5d needed more than 49 days for full degradation.
Example 13
In vitro biofilm eradication study
This study was performed to investigate the daptomycin concentration required
to fully
eradicate biofilms when constantly exposed to daptomycin for one or three
days. The
screening was done using a Calgary Biofilm Device (CBD) as described in Ceri,
H., et al.
(1999) Journal of Clinical Microbiology 37(6): 1771-1776. Biofilms were grown
in tryptic
soy broth (TSB) using a Methicillin-sensitive Staphylococcus aureus (MSSA) MN8
strain.
Aliquots of a diluted culture of this bacterial strain in TSB, obtained from
an inoculum of the
respective strain on trypticase soy agar plates (TSA), were transferred to all
but the negative
control wells of flat-bottom 96-well microtiter plates. The bacterial biofilms
were formed by

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
265
immersing lids with pegs into the 96-well microtiter plates, followed by
incubation for 24, 48
and 72 hours at 37 C. The differently aged biofilms were subsequently
transferred into new
microtiter plates using TSB media with addition of 12 mg/mL bovine serum
albumin (BSA)
and 50 g/mL calcium as CaCl2. Daptomycin was added to the media as required
to obtain
concentrations of 2-1458 idg/mL. The plates were incubated for one or three
days at 37 C.
The biofilms were detached from the pegs by centrifugation, generating
bacterial suspensions
in the wells of the microtiter plates. The optical densities of these
suspensions were measured
(0D600) to determine the biofilm eradication concentrations. All measurements
were
performed in triplicates. It was found that biofilms of all ages were
eradicated after 24 hours
exposure to 486 g/mL daptomycin. When biofilms were exposed for three days,
only 162
ps/mL daptomycin was needed to fully eradicate biofilms.
Example 14
Quantification of daptomycin concentrations in rabbit plasma
Daptomycin concentrations in rabbit plasma after IA administration of either
PEG-hydrogel
conjugate 9b or transient daptomycin-linker HA-hydrogel conjugate 5 and
different residence
times of the materials were determined after plasma protein precipitation via
liquid
chromatography separation and detection by LC-MS. As internal standard
deuterated
daptomycin-D5 peptide was used. LC-MS analysis was carried out by using an
UHPLC
system coupled to a triple quadrupole mass spectrometer via an ESI probe.
Chromatography
was performed on a C18 analytical UHPLC column. UPLC grade water containing
0.1%
formic acid (v/v) was used as mobile phase A and UPLC grade acetonitrile with
0.1% formic
acid as mobile phase B. The gradient system comprised a linear increase from
20% B to 45%
B in 10 min. Mass analysis was performed in MRM mode with the selected
transitions for
daptomycin and the internal standard daptomycin-D5.
Calibration standards of daptomycin in blank plasma were prepared as follows:
thawed K2-
EDTA rabbit plasma was homogenized. The daptomycin formulation was spiked into
blank
plasma at concentrations between 1000 ng/mL and 2 ng/mL. These solutions were
used for
the generation of a calibration curve. Calibration curves were weighted 1/x2.
For sample preparation, 70 L of rabbit plasma sample were spiked with 20 L
of internal
standard solution. Subsequently, the mixture was spiked with 40 1,IL of 0.5 M
citrate buffer
pH 4.0 and incubated for 30 min at room temperature. Protein precipitation was
carried out by

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
266
addition of 2701,IL of room temperature methanol. 2001,IL of the supernatant
were transferred
into a new well-plate and evaporated to dryness (under a gentle nitrogen
stream at 45 C). 50
tiL of reconstitution solvent (H20/Me0H 1:1 + 1.0% FA) were used to dissolve
the residue
by intensive shaking. 101,IL were injected into the LC-MS system.
Example 15
Pharmacokinetic profiles of daptomycin in New Zealand White rabbits after
intraarticular (IA) injections with transient daptomycin-linker hydrogel
conjugates
This study was performed in order to investigate the systemic pharmacokinetics
of
daptomycin in male New Zealand White (NZW) rabbits following intraarticular
administration of either transient daptomycin-linker PEG-hydrogel conjugate 9b
or transient
daptomycin-linker HA-hydrogel conjugate 5. Animals (n=9 per group) received a
single IA
injection of 300 1,IL transient daptomycin-linker PEG-hydrogel conjugate 9b
formulation (15
mg daptomycin nominal) or 300 IA of a formulation of transient daptomycin-
linker HA-
hydrogel conjugate (5; 15 mg daptomycin nominal) in the right knee and 300 tiL
vehicle in
the left knee. Three animals from each group were sacrificed three days, two
weeks, and six
weeks after dosing. Blood samples for PK analysis were collected and processed
to plasma at
predose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post
dose (PK blood
samples were only collected until 72 hours post dose from animals with three
days inlife).
Moreover, blood was collected for clinical chemistry and hematology at
predose, day three,
day seven*, week two*, and week six* (*in the appropriate groups). Visual
inspection and
palpation (such as reddening/swelling) were performed in the first seven days
after injection.
Hereafter, visual inspection and palpation was done once a week. Upon
sacrifice all knees
were sampled for histopathological examination.
Results: Dose administrations were well tolerated with no visible signs of
discomfort during
administration and following administration. No dose site reactions were
observed any time
throughout the study and all animals showed normal behavior and no knee
swelling or
warming. After intraarticular injection of either transient daptomycin-linker
PEG-hydrogel
conjugate 9b or transient daptomycin-linker HA-hydrogel conjugate 5, sustained
PK plasma
concentrations above 100 ng/mL were detected over the time course of one week
after
injection.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
267
Example 16
Quantification of daptomycin concentrations in rabbit synovial liquid
Rabbit synovial liquid was sampled after IA administration of transient
daptomycin-linker
HA-hydrogel conjugate 5' and different residence times of the materials from
incised rabbit
knee capsules with an Ecoflo perfusion catheter set after cutting of the
butterfly needle.
During collection the synovial fluid stayed in the catheter and did not enter
the syringe. The
fluid in the perfusion catheter was collected by flushing the perfusion
catheter vigorously with
air. 100 tit of the synovial liquid were transferred to a centrifugation
filter (PVDF membrane
with 5.0 1,1m pore size) and centrifuged for 4 min at 12,000 g. The filtrate
was diluted with
K2-EDTA rabbit plasma and after dilution analyzed for daptomycin content as
described for
plasma samples in example 14.
Example 17
Synovial liquid determination of daptomycin in New Zealand White rabbits after
intraarticular (IA) injections with transient daptomycin-linker hydrogel
conjugate 5'
This study was performed in order to investigate the synovial liquid
concentrations of
daptomycin in male New Zealand White (NZW) rabbits following intraarticular
administration of transient daptomycin-linker HA-hydrogel conjugate 5'.
Animals (n=3 per
group) received a single IA injection of 300 tiL of a formulation of transient
daptomycin-
linker HA-hydrogel conjugate 5' (15 mg daptomycin nominal) in the left knee.
The study
consisted of three groups with different in-life phases. Animals from group 1
were sacrificed
after three days, animals from group 2 were sacrificed after four days, and
animals from group
3 were sacrificed five days after dosing. At sacrifice, synovial liquid was
sampled from the
left knee and stored frozen until analysis.
Results: All animals showed a good clinical condition throughout the study
without local side
effects. After intraarticular injection of transient daptomycin-linker HA-
hydrogel conjugate
5', average synovial liquid concentrations of 58.1 g/mL daptomycin were
determined three
days after dosing in animals from group 1, average synovial liquid
concentrations of 111
ttg/mL daptomycin were determined four days after dosing in animals from group
2, and
average synovial liquid concentrations of 102 tig/mL daptomycin were
determined five days
after dosing in animals from group 3.

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
268
Two additional experiments indicate that the determined daptomycin levels can
be considered
as minimal values of daptomycin in rabbit synovial liquid. First, spiking
experiments with
bovine synovial fluid showed recovery values of around 50% using the same
sample
preparation method (centrifugation filter PVDF membrane with 5.0 1,1m pore
size). Second, in
an additional experiment, the extraction of one whole rabbit synovial fluid
sample with
organic solvent revealed significantly higher free daptomycin concentration in
this native,
unfiltered synovial fluid sample compared to the concentrations which have
been determined
in the filtered samples.
Abbreviations
ACN Acetonitrile
AcOH Acetic Acid
Asp Aspartic Acid
Bn Benzyl
BSA Bovine Serum Albumin
CBD Calgary Biofilm Device
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC Dicyclohexylcarbodiimide
DCM Dichloromethane
DIPEA /V,N-Diisopropylethylamine
DMAP 4-(Dimethylamino)pyridine
DMSO Dimethyl Sulfoxide
DPHS Dipolyhydroxystearate
DS Degree of Substitution
EDC N-(3-Dimethylaminopropy1)-N'-ethylcarbodiimide Hydrochloride
EDTA Ethylenediaminetetraacetic Acid
eqv. Equivalents
ESI Electrospray Ionization
Et0H Ethanol
FA Formic Acid
Fmoc Fluorenylmethyloxycarbonyl
HA Hyaluronic Acid
HFIP 1,1,1,3,3,3-Hexafluoro-2-propanol
HOBt 1-Hydroxybenzotriazole

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
269
HPLC High-Performance Liquid Chromatography
IA Intraarticular
LC Liquid Chromatography
LC-MS Mass Spectrometry Coupled Liquid Chromatography
LL Luer Lock
LPLC Low Pressure Liquid Chromatography
MeCN Acetonitrile
Me0H Methanol
MES 2-(N-Morpholino)ethanesulfonic acid
MRM Multiple Reaction Monitoring
MS SA Methicillin-sensitive Staphylococcus aureus
MTBE tert-Butyl Methyl Ether
Mw Molecular Weight
NHS N-Hydroxysuccinimide
NMP N-Methyl-2-pyrrolidone
NZW New Zealand White Rabbits
0D600 Optical Density Measured at 600 nm Wavelength
OPA o-Phthalaldehyde
OxymaPure Ethyl cyano(hydroxyimino)acetate
PE Polyethylene
PEG Poly(ethylene glycol)
PES Polyethersulfone
PK Pharmacokinetic/s
PP polypropylene
PTFE Polytetrafluoroethylene
PVDF Polyvinylidene Difluoride
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium
Hexafluorophosphate
QAAA Quantitative Amino Acid Analysis
RP Reversed Phase
RP-HPLC Reversed Phase High-Performance Liquid Chromatography
RP-LPLC Reversed Phase Low Pressure Liquid Chromatography
r.t. Room Temperature
SEC Size-exclusion chromatography
TES Triethylsilane

CA 03114056 2021-03-24
WO 2020/064844
PCT/EP2019/075877
270
TFA Trifluoroacetic Acid
THF Tetrahydrofurane
TMEDA /V,N, AP ,Arr -Tetramethylethylenediamine
Tmob 2,4,6-Trimethoxybenzyl
TSA Trypticase Soy Agar
TSB Tryptic Soy Broth
TSTU N,N,N ' ,N' -Tetramethy1-0-(N-succinimidypuronium
Tetrafluorborate
Tween 20 Polyethylene Glycol Sorbitan Monolaurate
Tween 80 Polyethylene Glycol Sorbitan Monooleate
UHPLC Ultra High Performance Liquid Chromatography
UPLC Ultra Performance Liquid Chromatography
UPLC-MS Mass Spectrometry Coupled Ultra Performance Liquid Chromatography
UV Ultraviolet